bioc-10q_20190930.htm

Large accelerated filer

Accelerated filer

Non-accelerated filer

Smaller reporting company

Emerging growth company

0001564590-19-043276.txt : 20191113 0001564590-19-043276.hdr.sgml : 20191113 20191113172423 ACCESSION NUMBER: 0001564590-19-043276 CONFORMED SUBMISSION TYPE: 10-Q PUBLIC DOCUMENT COUNT: 73 CONFORMED PERIOD OF REPORT: 20190930 FILED AS OF DATE: 20191113 DATE AS OF CHANGE: 20191113 FILER: COMPANY DATA: COMPANY CONFORMED NAME: BIOCEPT INC CENTRAL INDEX KEY: 0001044378 STANDARD INDUSTRIAL CLASSIFICATION: SERVICES-MEDICAL LABORATORIES [8071] IRS NUMBER: 800943522 FISCAL YEAR END: 1231 FILING VALUES: FORM TYPE: 10-Q SEC ACT: 1934 Act SEC FILE NUMBER: 001-36284 FILM NUMBER: 191215389 BUSINESS ADDRESS: STREET 1: 5810 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 BUSINESS PHONE: 858-320-8200 MAIL ADDRESS: STREET 1: 5810 NANCY RIDGE DR CITY: SAN DIEGO STATE: CA ZIP: 92121 10-Q 1 bioc-10q_20190930.htm 10-Q bioc-10q_20190930.htm

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

FORM 10-Q

☒	QUARTERLY REPORT UNDER SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the quarterly period ended September 30, 2019

☐	TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934

For the transition period from to .

Commission file number: 001-36284

Biocept, Inc.

(Exact name of registrant as specified in its charter)

Delaware

80-0943522

(State or other jurisdiction of

incorporation or organization)

(I.R.S. Employer

Identification No.)

5810 Nancy Ridge Drive, San Diego, California

(Address of principal executive offices)

92121

(Zip Code)

(858) 320-8200

(Registrant’s telephone number, including area code)

Not Applicable

(Former name, former address and former fiscal year, if changed since last report)

Securities registered pursuant to Section 12(b) of the Act:


Title of each class	Trading Symbol(s)	Name of each exchange on which registered
Common Stock, par value $.0001 per share	BIOC	The Nasdaq Stock Market LLC

Indicate by check mark whether the registrant (1) has filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that the registrant was required to file such reports), and (2) has been subject to such filing requirements for the past 90 days. Yes ☒ No ☐

Indicate by check mark whether the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T (§232.405 of this chapter) during the preceding 12 months (or for such shorter period that the registrant was required to submit such files). Yes ☒ No ☐

Indicate by check mark whether the registrant is a large accelerated filer, an accelerated filer, a non-accelerated filer, a smaller reporting company, or an emerging growth company. See the definitions of “large accelerated filer,” “accelerated filer,” “smaller reporting company” and “emerging growth company” in Rule 12b-2 of the Exchange Act.

If an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. ☒

Indicate by check mark whether the registrant is a shell company (as defined by Rule 12b-2 of the Exchange Act). Yes ☐ No ☒

As of November 8, 2019, there were 23,018,235 shares of the Registrant’s common stock outstanding.

BIOCEPT, INC.

FORM 10-Q

FOR THE QUARTERLY PERIOD ENDED

September 30, 2019

INDEX

		Page

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS		4

PART I.	FINANCIAL INFORMATION

Item 1.	Financial Statements	5

	Condensed Balance Sheets as of December 31, 2018 and September 30, 2019 (Unaudited)	5

	Condensed Statements of Operations and Comprehensive Loss for the three and nine months ended September 30, 2018 and 2019 (Unaudited)	6

	Condensed Statements of Shareholders’ Equity for the three and nine months ended September 30, 2018 and 2019 (unaudited)	7

	Condensed Statements of Cash Flows for the nine months ended September 30, 2018 and 2019 (Unaudited)	9

	Notes to Condensed Financial Statements (Unaudited)	12

Item 2.	Management’s Discussion and Analysis of Financial Condition and Results of Operations	28

Item 3.	Quantitative and Qualitative Disclosures about Market Risk	39

Item 4.	Controls and Procedures	39

PART II.	OTHER INFORMATION

Item 1.	Legal Proceedings	41

Item 1A.	Risk Factors	41

Item 2.	Unregistered Sales of Equity Securities and Use of Proceeds	67

Item 3.	Defaults Upon Senior Securities	67

Item 4.	Mine Safety Disclosures	67

Item 5.	Other Information	67

Item 6.	Exhibits	67

IMPORTANT NOTE REGARDING FORWARD-LOOKING STATEMENTS

This Quarterly Report on Form 10-Q, or Quarterly Report, contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements included or incorporated by reference in this Quarterly Report other than statements of historical fact, are forward-looking statements. You can identify these and other forward-looking statements by the use of words such as “may,” “will,” “could,” “anticipate,” “expect,” “intend,” “believe,” “continue” or the negative of such terms, or other comparable terminology. Forward-looking statements also include the assumptions underlying or relating to such statements.

Our actual results could differ materially from those anticipated in these forward-looking statements as a result of various factors, including those set forth in our other filings with the Securities and Exchange Commission, or the SEC. Moreover, we operate in an evolving environment. New risk factors and uncertainties emerge from time to time and it is not possible for us to predict all risk factors and uncertainties, nor can we assess the impact of all factors on our business or the extent to which any factor, or combination of factors, may cause actual results to differ materially from those contained in any forward-looking statements. Readers are cautioned not to place undue reliance on forward-looking statements. The forward-looking statements speak only as of the date on which they are made, and we undertake no obligation to update such statements to reflect events that occur or circumstances that exist after the date on which they are made except as required by law. Readers should, however, review the factors and risks we describe in the reports we file from time to time with the SEC. In addition, statements that “we believe” and similar statements reflect our beliefs and opinions on the relevant subject. These statements are based upon information available to us as of the date the statement is made, and while we believe such information forms a reasonable basis for such statements, such information may be limited or incomplete, and our statements should not be read to indicate that we have conducted an exhaustive inquiry into, or review of, all potentially available relevant information. These statements are inherently uncertain, and you are cautioned not to unduly rely upon these statements.

PART I. FINANCIAL INFORMATION

Item 1. Financial Statements

Biocept, Inc.

Condensed Balance Sheets

	December 31,			September 30,
	2018			2019
				(unaudited)
Current assets:
Cash	$	3,423,373		$	6,539,444
Accounts receivable, net		1,574,325			2,861,659
Inventories, net		587,222			687,186
Prepaid expenses and other current assets		425,961			497,121
Total current assets		6,010,881			10,585,410
Fixed assets, net		2,739,422			1,325,255
Lease right-of-use assets		—			2,610,249
Total assets	$	8,750,303		$	14,520,914
Current liabilities:
Accounts payable	$	2,039,718		$	1,834,020
Accrued liabilities		1,928,393			1,846,984
Supplier financings		—			132,924
Current portion of equipment financings		641,536			—
Current portion of lease liabilities		—			1,969,285
Total current liabilities		4,609,647			5,783,213
Non-current portion of equipment financings		985,015			—
Non-current portion of lease liabilities		—			1,032,243
Non-current portion of deferred rent		113,122			—
Total liabilities		5,707,784			6,815,456
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; 4,417 shares issued and outstanding at December 31, 2018; and 2,133 shares issued and outstanding at September 30, 2019.		—			—
Common stock, $0.0001 par value, 150,000,000 authorized; 4,629,174 issued and outstanding at December 31, 2018; 23,018,235 issued and outstanding at September 30, 2019.		463			2,302
Additional paid-in capital		223,499,634			247,685,038
Accumulated deficit		(220,457,578	)		(239,981,882	)
Total shareholders’ equity		3,042,519			7,705,458
Total liabilities and shareholders’ equity	$	8,750,303		$	14,520,914

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Operations and Comprehensive Loss

(Unaudited)

	For the three months ended September 30,						For the nine months ended September 30,
	2018			2019			2018			2019
Net revenues	$	761,591		$	1,529,262		$	2,390,772		$	3,744,824
Costs and expenses:
Cost of revenues		2,481,916			2,832,735			7,616,473			8,105,422
Research and development expenses		1,089,746			1,163,546			3,179,612			3,535,116
General and administrative expenses		1,793,720			1,700,380			5,441,354			5,058,525
Sales and marketing expenses		1,404,192			1,462,335			4,473,908			4,451,628
Total costs and expenses		6,769,574			7,158,996			20,711,347			21,150,691
Loss from operations		(6,007,983	)		(5,629,734	)		(18,320,575	)		(17,405,867	)
Other income/ (expense):
Interest expense		(63,764	)		(62,028	)		(230,677	)		(187,575	)
Warrant inducement and other income (expenses)		23,963			—			(6,037	)		(1,831,116	)
Total other income/ (expense):		(39,801	)		(62,028	)		(236,714	)		(2,018,691	)
Loss before income taxes		(6,047,784	)		(5,691,762	)		(18,557,289	)		(19,424,558	)
Income tax expense		—			—			(739	)		—
Net loss and comprehensive loss	$	(6,047,784	)	$	(5,691,762	)	$	(18,558,028	)	$	(19,424,558	)
Deemed dividend related to warrants down round provision		(636,370	)		—			(636,370	)		(99,743	)
Net loss attributable to common shareholders	$	(6,684,154	)	$	(5,691,762	)	$	(19,194,398	)	$	(19,524,301	)
Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:
Basic		2,767,440			23,018,235			2,322,749			17,807,298
Diluted		2,759,614			23,018,235			2,320,111			17,807,298
Net loss per common share:
Basic	$	(2.42	)	$	(0.25	)	$	(8.26	)	$	(1.10	)
Diluted	$	(2.42	)	$	(0.25	)	$	(8.27	)	$	(1.10	)

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Shareholders’ Equity

(Unaudited)

	Common Stock					Series A Convertible Preferred Stock					Additional			Accumulated
	Shares		Amount			Shares			Amount		Paid-in Capital			Deficit			Total
Balance at December 31, 2017		1,181,179	$	118			—		$	—	$	196,545,523		$	(195,249,607	)	$	1,296,034
Stock-based compensation expense		—		—			—			—		225,263			—			225,263
Shares and warrants issued for January 2018 financing transaction, net of issuance costs		1,095,153		110			—			—		13,342,711			—			13,342,821
Adjustment for presentation after reverse stock split		—		6,576			—			—		(6,576	)		—			—
Net loss		—		—			—			—		—			(6,357,143	)		(6,357,143	)
Balance at March 31, 2018		2,276,332	$	6,804			—		$	—	$	210,106,921		$	(201,606,750	)	$	8,506,975
Stock-based compensation expense		—		—			—			—		173,694			—			173,694
Shares issued for restricted stock units		5,834		19			—			—		(19	)		—			—
Net loss		—		—			—			—		—			(6,153,101	)		(6,153,101	)
Balance at June 30, 2018		2,282,166	$	6,823			—		$	—	$	210,280,596		$	(207,759,851	)	$	2,527,568
Stock-based compensation expense		—		—			—			—		113,072			—			113,072
Shares issued upon conversion of preferred stock		1,012,622		101			(4,582	)		—		(101	)		—			—
Preferred shares and warrants issued for August 2018 rights offering, net of issuance costs		—		—			11,587			1		10,097,877			—			10,097,878
Shares and warrant issued for September 2018 registered direct offering, net of issuance costs		642,438		64			—			—		2,247,610			—			2,247,674
Deemed dividends related to warrants downround provision		—		—			—			—		636,370			(636,370	)		—
Common stock reclassification		—		(6,594	)		—			—		6,594			—			—
Net loss		—		—			—			—		—			(6,047,784	)		(6,047,784	)
Balance at September 30, 2018		3,937,226	$	394			7,005		$	1	$	223,382,018		$	(214,444,005	)	$	8,938,408

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Shareholders’ Equity

(Unaudited)

	Common Stock				Series A Convertible Preferred Stock					Additional			Accumulated
	Shares		Amount		Shares			Amount		Paid-in Capital			Deficit			Total
Balance at December 31, 2018		4,629,174	$	463		4,417		$	—	$	223,499,634		$	(220,457,578	)	$	3,042,519
Stock-based compensation expense		—		—		—			—		102,459			—			102,459
Shares issued upon exercise of common stock warrants		5,985		1		—			—		4,747			—			4,748
Deemed dividends related to warrants downround provision		—		—		—			—		99,743			(99,743	)		—
Shares issued for January 2019 financing transaction, net of issuance costs		990,000		99		—			—		2,032,212			—			2,032,311
Shares and warrants issued for February 2019 financing transaction, net of issuance costs		6,250,000		625		—			—		6,602,110			—			6,602,735
Shares issued for January 2019 financing transaction overallotment, net of issuance costs		538,867		54		—			—		592,252			—			592,306
Shares and warrants issued for March 2019 financing transaction, net of issuance costs		5,950,000		595		—			—		7,553,198			—			7,553,793
Shares issued upon conversion of preferred stock		503,438		50		(2,278	)		—		(50	)		—			—
Net loss		—		—		—			—		—			(5,916,787	)		(5,916,787	)
Balance at March 31, 2019		18,867,464	$	1,887		2,139		$	—	$	240,486,305		$	(226,474,108	)	$	14,014,084
Stock-based compensation expense		—		—		—			—		224,641			—			224,641
Shares issued upon exercise of common stock warrants		4,149,445		415		—			—		4,845,307			—			4,845,722
Shares issued upon conversion of preferred stock		1,326		—		(6	)		—		—			—			—
Warrant inducement expense		—		—		—			—		1,831,116			—			1,831,116
Net loss		—		—		—			—		—			(7,816,012	)		(7,816,012	)
Balance at June 30, 2019		23,018,235	$	2,302		2,133		$	—	$	247,387,369		$	(234,290,120	)	$	13,099,551
Stock-based compensation expense		—		—		—			—		297,669			—			297,669
Net loss		—		—		—			—		—			(5,691,762	)		(5,691,762	)
Balance at September 30, 2019		23,018,235	$	2,302		2,133		$	—	$	247,685,038		$	(239,981,882	)	$	7,705,458

The accompanying notes are an integral part of these unaudited condensed financial statements.

Biocept, Inc.

Condensed Statements of Cash Flows

(Unaudited)

	For the nine months ended September 30,
	2018			2019
Cash Flows from Operating Activities
Net loss	$	(18,558,028	)	$	(19,424,558	)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization		580,366			691,191
Amortization of right-of-use assets		—			(113,419	)
Inventory reserve		(92,488	)		20,277
Stock-based compensation		512,029			624,769
Warrant inducement expense		—			1,831,116
Non-cash interest expense related to credit facility and other financing activities		29,425			—
Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net		(283,028	)		(1,287,334	)
Inventory		9,692			(120,241	)
Prepaid expenses and other current assets		277,720			322,299
Accounts payable		413,562			(198,400	)
Accrued liabilities		497,119			76,932
Accrued interest		(241,034	)		—
Deferred rent		(82,329	)		—
Net cash used in operating activities		(16,936,994	)		(17,577,368	)
Cash Flows from Investing Activities:
Purchases of fixed assets		(145,253	)		(297,877	)
Net cash used in investing activities		(145,253	)		(297,877	)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants		25,688,205			16,779,772
Proceeds from exercise of common stock warrants		—			2,513,172
Proceeds from warrant exercise inducement, net		—			2,337,298
Payments on finance leases		(160,111	)		(378,389	)
Payments on supplier and other third-party financings		(438,290	)		(260,537	)
Payments on credit facility		(1,197,968	)		—
Net cash provided by financing activities		23,891,836			20,991,316
Net increase in Cash		6,809,589			3,116,071
Cash at Beginning of Period		2,146,611			3,423,373
Cash at End of Period	$	8,956,200		$	6,539,444
Supplemental Disclosures of Cash Flow Information:
Cash paid during the period for:
Interest	$	379,587		$	187,574
Income taxes	$	739		$	-

Non-cash Investing and Financing Activities:

During the nine months ended September 30, 2018 and 2019, Biocept, Inc., or the Company, financed insurance premiums of approximately $488,000 and $393,000, respectively, through third-party financings. During the nine months ended September 30, 2019, the Company cancelled insurance premiums previously financed through third-parties with an aggregate remaining principal balance outstanding of approximately $31,000, and replaced them with insurance premiums financed through third parties totaling approximately $80,000.

Fixed assets purchased totaling approximately $270,000 and $583,000 during the nine months ended September 30, 2018 and 2019, respectively, were recorded as finance lease obligations and were excluded from cash purchases in the Company’s statements of cash flows (see Note 7).

The amount of unpaid fixed assets excluded from cash purchases in the Company’s statements of cash flows increased from approximately $31,000 at December 31, 2017 to approximately $55,000 at September 30, 2018. The amount of unpaid fixed assets excluded from cash purchases in the Company’s statements of cash flows increased from approximately $25,000 at December 31, 2018 to approximately $67,000 at September 30, 2019.

An offering of 1,095,153 shares of the Company’s common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit occurred on January 30, 2018. All warrants sold in this offering have an exercise price of $1.20 per share, subject to down round adjustment, are exercisable immediately and expire five years from the date of issuance. The estimated aggregate grant date fair value on a relative fair value basis of approximately $9.7 million associated with these warrants was recorded as an offset to additional paid-in-capital (see Note 4). Additionally, approximately $1.4 million of fees and costs directly associated with this offering were recorded as an offset to additional paid-in capital in accordance with applicable accounting guidance.

A rights offering for the Company’s Series A Preferred Stock and warrants was completed on August 13, 2018. Pursuant to the rights offering the Company sold 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock and 2,549,140 warrants, with each warrant exercisable for one share of common stock at an exercise price of $4.53 per share. The gross amount raised in the rights offering was $11.6 million. All warrants sold in this offering have an exercise price of $4.53 per share, are exercisable immediately and expire five years from the date of issuance. The estimated aggregate grant date fair value on a relative fair value basis of approximately $8.4 million associated with these warrants was recorded as an offset to additional paid-in-capital (see Note 4). Additionally, approximately $1.4 million of fees and costs directly associated with this offering were recorded as an offset to additional paid-in capital in accordance with applicable accounting guidance. During the three months ended September 30, 2018, 4,582 shares of Series A Preferred Stock were converted into 1,012,622 shares of common stock.

An offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock occurred on September 20, 2018. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The aggregate gross proceeds from the offering were approximately $2.5 million. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date. The estimated aggregate grant date fair value on a relative fair value basis of approximately $2.0 million associated with these warrants was recorded as an offset to additional paid-in-capital (see Note 4). Additionally, approximately $0.3 million of fees and costs directly associated with this offering were recorded as an offset to additional paid-in capital in accordance with applicable accounting guidance.

The issuance of warrants with an exercise price of $3.16 in the September 2018 financing transaction triggered the down round provision in the January 2018 warrants, resulting in recording a deemed dividend related to warrants down round provision in the amount of approximately $636,000 increasing the net loss attributable to common shareholders.

On January 1, 2019, the Company adopted the accounting rules in ASC Topic 842, Leases (ASC 842), and as a result, recorded net lease right-of-use assets of $1.9 million related to its operating lease, and recorded operating lease liabilities of $2.2 million. In addition, in accordance with the guidance, $1.4 million of assets under capital leases previously classified in the property, plant, and equipment section of the balance sheet were reclassified to lease right-of-use assets.

On January 18, 2019, the Company completed an offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses.

Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 offering price per share in the February 2019 financing transaction and it resulted in recording a deemed dividend of $99,000.

On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share purchased for cash in the offering. All warrants issued in this offering have an exercise price of $1.25 per share, are exercisable immediately upon issuance and expire 5.5 years following the date of issuance.

In May 2019, investors exercised warrants for 4.1 million shares of common stock at exercise prices ranging from $1.20 to $1.25 per share resulting in net cash proceeds to the Company totaling $4.8 million. Approximately 2.1 million shares of the warrants exercised was pursuant to a warrant inducement transaction raising approximately $2.3 million of net proceeds of the total $4.8 million raised.

The accompanying notes are an integral part of these unaudited condensed financial statements.

BIOCEPT, INC.

NOTES TO CONDENSED FINANCIAL STATEMENTS

(Unaudited)

1. The Company, Business Activities and Basis of Presentation

The Company and Business Activities

The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC^TM, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

Basis of Presentation

The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-thirty reverse stock split.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss.

Revenue Recognition and Accounts Receivable

copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes.

Contracts

For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows:


	•		Approval of a contract is established via the order and accession, which are submitted by the patient’s physician.
	•		The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.


	•		Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided.
	•		Once the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status.


	•		Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur.

The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations.

Transaction Price

The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services are established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management.

additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and nine months ended September 30, 2018 and 2019.

Allocate Transaction Price

For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed.

Point-in-time Recognition

The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service.

Contract Balances

The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable.

Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses.

The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses.

Disaggregation of Revenue and Concentration of Risk

The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net revenues from contracted payers*	$	325,097	$	476,101	$	1,019,857	$	1,447,421
Net revenues from non-contracted payers		373,018		956,140		1,201,869		2,080,018
Development services revenues		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

*Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net commercial revenues recognized upon delivery	$	698,115	$	1,432,241	$	2,221,726	$	3,527,439
Development services revenues recognized upon delivery		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types.

The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and nine months ended September 30, 2018 and 2019 were as follows:

	For the three months ended September 30,						For the nine months ended September 30,
	2018			2019			2018			2019
Medicare and Medicare Advantage		40	%		32	%		39	%		40	%
Blue Cross Blue Shield		9	%		25	%		14	%		20	%
United Healthcare		6	%		8	%		15	%		9	%

The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and September 30, 2019 were as follows:

	December 31, 2018			September 30, 2019
Blue Cross Blue Shield		22	%		25	%
Medicare and Medicare Advantage		17	%		17	%
United Healthcare		15	%		13	%

Recent Accounting Pronouncements

In February 2016, the FASB issued authoritative guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2018. Effective January 1, 2019, the Company adopted the guidance and elected the optional transition method to account for the impact of the adoption with a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company also elected the practical expedient package as permitted under the transition guidance. As of January 1, 2019, the Company recorded a right-of-use asset and liability upon adoption of the guidance (See Note 7).

In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity.

In February 2018, the FASB issued authoritative guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from a tax bill, “H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018,” or the Tax Cuts and Jobs Act, enacted on December 22, 2017. These amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act. However, because these amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This guidance also requires certain disclosures about stranded tax effects. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 which did not have a material impact on its financial statements or disclosures because the Company does not currently maintain any stranded tax effects in accumulated other comprehensive income.

In June 2018, the FASB issued authoritative guidance simplifying the accounting for nonemployee stock-based compensation and largely aligning such compensation with the accounting requirements for employee stock-based awards. For public companies, this guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures.

In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company currently intends to adopt this guidance upon the effective date and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures.

2. Liquidity and Going Concern Uncertainty

As of September 30, 2019, cash totaled $6.5 million and the Company had an accumulated deficit of $240.0 million. For the year ended December 31, 2018 and the nine months ended September 30, 2019, the Company incurred net losses of $24.6 million and $19.4 million. At September 30, 2019, the Company had aggregate net interest-bearing indebtedness of $1.9 million, of which $909,000 was due within one year, in addition to $3.0 million of other non-interest-bearing current liabilities. Additionally, in February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020, under which $154,000 remained outstanding at September 30, 2019 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. The accompanying financial statements and notes have been prepared assuming that the Company will continue as a going concern. The accompanying financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering, with approximately $1.3 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.20 per share, which is subject to down round adjustment, until their expiration in January 2023. Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 offering price per share in the February 2019 financing transaction.

In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as its public float is less than $75 million.

On August 13, 2018, the Company completed a rights offering pursuant to an effective registration statement. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock convertible into 471,393 shares of its common stock and 2,549,140 warrants, with each warrant exercisable for one share of its common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

On September 20, 2018, the Company completed a registered offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of

$3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from the offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers in the concurrent registered offering a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date.

On January 18, 2019, the Company completed a registered offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses.

On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million from the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering. On March 11, 2019, the underwriters exercised their overallotment option for 538,867 shares of the Company’s common stock related to the February 12, 2019 follow-on offering, purchasing shares at $1.20 per share for net cash proceeds of approximately $592,000.

In May 2019, the Company received net proceeds of approximately $2.3 million related to the May 2019 Warrant Exercise Inducement Offering as well as an additional $2.5 million from other warrant exercises. The warrants exercised had exercise prices ranging from $1.20 to $1.25 per share and the total number of shares of common stock issued upon exercises both in connection with the Warrant Exercise Inducement Offering and other warrant exercises was approximately 4.2 million shares.

Management’s Plan to Continue as a Going Concern

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

3. Sales of Equity Securities

On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit, with $1.4 million of costs directly associated with the offering recorded as an offset to additional paid-in capital under applicable accounting guidance. The warrants sold in this offering have an exercise price of $1.20 per share, which is subject to down round adjustment, are exercisable immediately and expire five years from the date of issuance. The aggregate estimated grant date fair value of $9.7 million was recorded as an offset to additional paid-in-capital upon the closing of this offering (see Note 4).

In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million.

On August 13, 2018, the Company completed a rights offering. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock and 2,549,140 warrants, with each warrant exercisable for one share of our common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. Each share of Series A Preferred Stock will be convertible, at the Company’s option at any time on or after the first anniversary of the closing of the Rights Offering or at the option of the holder at any time, into the number of shares of the Company’s common stock, par value $0.0001 per share determined by dividing the $1,000 stated value per share of the Series A Preferred Stock by a conversion price of $4.53 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Holders of Series A

Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock. The Series A Preferred Stock have no voting rights. Upon the Company’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series A Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series A Preferred Stock were fully converted (disregarding for such purpose any conversion limitations thereunder) to common stock, which amounts shall be paid pari passu with all holders of common stock. The Company is not obligated to redeem or repurchase any shares of Series A Preferred Stock.

On September 20, 2018, the Company completed an offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from this offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date.

On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million as a result of the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering. On March 11, 2019, the underwriters exercised their overallotment option for 538,867 shares of the Company’s common stock related to the February 12, 2019 follow-on offering, purchasing shares at $1.20 per share for net cash proceeds of approximately $592,000.

Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 price per share offering price in the February 2019 financing transaction.

In May 2019, the Company received cash proceeds of approximately $2.5 million from the exercise of 2,086,479 February 2019 warrants at $1.20 per share.

On May 28, 2019, the Company entered into Warrant Exercise Agreements, or the Exercise Agreements, with certain of the holders of its existing warrants, or the Exercising Holders. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that, subject to any applicable beneficial ownership limitations, the Exercising Holders would cash exercise up to 20% of their Existing Warrants, or the Investor Warrants, into shares of common stock underlying such Existing Warrants, or the Exercised Shares. In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date. The New Warrants have an exercise price per share of $1.31. A total of 2,062,966 Investor Warrants were exercised contemporaneously with the execution of the Exercise Agreements resulting in total proceeds to the Company of $2.3 million, net of investment banking fees. The warrants issued in connection with the Exercise Agreement were considered inducement warrants and are classified in equity. The fair value of the warrants issued was approximately $1.8 million (see valuation assumptions in Note 4). The fair value of the inducement warrants of $1.8 million was expensed as warrant inducement expense in the accompanying consolidated statements of operations for the nine months ended September 30, 2019.

On July 15, 2019, the Company entered into amendments (the “Amendments”) to the Exercise Agreements. Pursuant to the Amendments, the period during which the Exercising Holders may elect to exercise for cash the Existing Warrants in exchange for new warrants to purchase common stock to be issued in an amount equal to 75% of the number of shares of common stock exercised under the Existing Warrants was extended from July 15, 2019 to July 31, 2019. There were no additional warrants exercised under the Amendments during the second or third quarter of 2019.

4. Fair Value Measurement

The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $583,000 during the nine months ended September 30, 2019 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates. Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on the present value of future lease payments based on contractual payment amounts and estimated market rates in effect.

Other Fair Value Measurements

As of the closing of the Company’s January 30, 2018 offering, the grant date fair value of the warrants issued to purchase up to 1,095,153 shares of common stock were estimated to be approximately $8.82 per share, or a total of approximately $9.7 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering currently have an exercise price of $1.20 per share, which is subject to down round adjustment, and expire five years from the date of issuance. The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions:

Beginning stock price	$	10.17
Exercise price	$	15.00
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.48	%
Expected life (in years)		5.00
Expected volatility		99.00	%

As of the closing of the Company’s August 13, 2018 rights offering, the grant date fair value of the warrants issued to purchase up to 2,549,140 shares of common stock were estimated to be approximately $3.30 per share, or a total of approximately $8.4 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering have an exercise price of $4.53 per share and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:

Beginning stock price	$	3.89
Exercise price	$	4.53
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.75	%
Expected life (in years)		5.00
Expected volatility		128.69	%

As of the closing of the Company’s September 20, 2018 offering, the grant date fair value of the warrants issued to purchase up to 762,438 shares of common stock were estimated to be approximately $2.57 per share, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering have an exercise price of $3.16 per share and expire five years from the initial exercise date, which is the six month anniversary of the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:

Beginning stock price	$	2.92
Exercise price	$	3.16
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.77	%
Expected life (in years)		5.50
Expected volatility		130.7	%

Also, included in the September 20, 2018 offering the Company issued 120,000 pre-funded warrants. The pre-funded warrants had an intrinsic value of $350,000, were subsequently fully exercised and are no longer outstanding as of September 30, 2019.

As of the closing of the Company’s February 12, 2019 offering, the estimated grant date fair value of approximately $0.95 per share associated with the warrants to purchase up to 7,165,000 shares of common stock issued in this offering, or a total of approximately $6.8 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price	$	1.05
Exercise price	$	1.20
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.49	%
Expected life (in years)		5.00
Expected volatility		147.7	%

As of the closing of the Company’s March 19, 2019 offering, the estimated grant date fair value of approximately $1.01 per share associated with the warrants to purchase up to 5,950,000 shares of common stock issued in this offering, or a total of approximately $6.0 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.25 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price	$	1.12
Exercise price	$	1.25
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.44	%
Expected life (in years)		5.50
Expected volatility		140.0	%

As of the closing of the Company’s May 30, 2019 warrant inducement transaction, the estimated grant date fair value of approximately $1.18 per share associated with the warrants to purchase up to 1,547,226 shares of common stock issued in this offering, or a total of approximately $1.8 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $1.31 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price	$	1.29
Exercise price	$	1.31
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.05	%
Expected life (in years)		5.50
Expected volatility		145.9	%

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,			September 30,
	2018			2019
Fixed Assets
Machinery and equipment	$	2,818,583		$	2,845,053
Furniture and office equipment		157,391			156,987
Computer equipment and software		1,437,408			1,552,981
Leasehold improvements		570,173			570,174
Financed equipment		2,573,955			—
Construction in process		116,640			325,550
Total fixed assets, gross		7,674,150			5,450,745
Less accumulated depreciation and amortization		(4,934,728	)		(4,125,490	)
Total fixed assets, net	$	2,739,422		$	1,325,255
Accrued Liabilities
Accrued payroll		255,426			458,750
Accrued vacation		535,682			566,811
Accrued bonuses		712,574			636,167
Accrued sales commissions		62,767			81,101
Current portion of deferred rent		158,342			—
Accrued other		203,602			104,155
Total accrued liabilities	$	1,928,393		$	1,846,984

During the nine months ended September 30, 2019 there were no disposals and $350,000 of fixed assets were acquired. Upon adoption of the lease guidance in ASC Topic 842, Leases (ASC 842), equipment with a total cost of $2,574,000 and accumulated depreciation of $1,135,000 were reclassified to right-of-use lease assets on the Company’s balance sheet (see Note 7). Depreciation expense for the nine months ended September 30, 2018 and 2019 was $580,366 and $691,191, respectively. Depreciation expense for the three months ended September 30, 2018 and 2019 was $223,194 and $240,207, respectively.

6. April 2014 Credit Facility

On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility. Upon entering into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility was secured by substantially all of the Company’s personal property other than its intellectual property. The term loan under the April 2014 Credit Facility bore interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matured on July 1, 2018. Under the original terms of the underlying agreement, the Company was also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded. Upon maturity of the April 2014 Credit Facility on July 1, 2018, security interest in the Company’s personal property was released by the lender.

A warrant to purchase up to 588 shares of the Company’s common stock at an exercise price of $424.80 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of approximately $102,000 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of approximately $4,898,000. The estimated fair value of the warrant issued of approximately $233,000 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs were amortized to interest expense utilizing the effective interest method over the underlying term of the loan.

7. Leases

Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Property, Plant and Equipment on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an

estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet.

Finance Leases

The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $2,574,000 and $3,075,000 at December 31, 2018 and September 30, 2019, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $1,135,000 and $1,500,000 at December 31, 2018 and September 30, 2019, respectively. Total depreciation expense related to equipment under finance leases during the three months ended September 30, 2018 and 2019 was approximately $115,000 and $134,000, and during the nine months ended September 30, 2018 and 2019 was approximately $271,000 and $365,000, respectively.

On January 31, 2019, the Company executed an equipment financing commitment with a third-party lender for total amount of approximately $149,000, which was funded by the lender on February 1, 2019. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full after 36 monthly installments of $5,013 totaling approximately $180,000 through February 2022.

In July 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $100,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 48 monthly installments of $2,706 totaling approximately $130,000 through May 2023.

In August 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $245,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 36 monthly installments of $8,253 totaling approximately $297,000 through August 2022.

In September 2019, an additional equipment financing commitment was executed with a third-party lender for total additional amount of approximately $89,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 60 monthly installments of $1,770 totaling approximately $106,000 through September 2024.

Operating Lease

The Company leases its primary laboratory and office facilities in San Diego, California. This lease is classified as an operating lease in accordance with the ASC 842 guidance. The average monthly cash payment for the operating lease is approximately $120,000 per month, and the lease term ends on July 31, 2020. The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%.

In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments.

The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and September 30, 2019 as follows:

	December 31,		September 30,
	2018		2019
Lease right-of-use assets:
Operating	$	—	$	1,035,210
Finance		—		1,575,039
Total	$	—	$	2,610,249

The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

	December 31,		September 30,
	2018		2019
Current portion of lease liability:
Operating	$	—		1,193,255
Finance		—		776,030
Total	$	—	$	1,969,285

The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

	December 31,		September 30,
	2018		2019
Long-term portion of lease liability:
Operating	$	—	$	—
Finance		—		1,032,243
Total	$	—	$	1,032,243

The following schedule represents the components of lease expense for the three and nine months ended September 30, 2018 and 2019:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Lease cost
Finance lease cost
Amortization of right-of-use assets	$	—	$	134,472	$	—	$	364,401
Interest on lease liabilities		—		62,026		—		187,574
Operating lease cost		—		318,005		—		954,015
Total	$	—	$	514,503	$	—	$	1,505,990

The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments, as of September 30, 2019:

	Finance					Operating
	Minimum			Maintenance and		Minimum
	Lease			Sales Tax Obligation		Lease
	Payments			Payments		Payments
2019 (remaining)	$	222,245		$	27,016	$	362,929
2020		764,533			89,136		855,136
2021		517,927			67,974		—
2022		405,318			57,260		—
2023		263,274			56,799		—
Thereafter		58,448			8,241		—
Total payments		2,231,745			306,426		1,218,065
Less amount representing interest		(423,472	)		—		(24,810	)
Present value of payments	$	1,808,273		$	306,426	$	1,193,255

The following schedule sets forth supplemental cash flow information related to operating and finance leases as of September 30, 2019:

	For the three months ended		For the nine months ended
	September 30, 2019		September 30, 2019
Other information
Operating cash flows from financing leases	$	62,026	$	187,574
Operating cash flows from operating leases	$	355,813	$	1,067,437
Financing cash flows from finance leases	$	101,139	$	378,389

The aggregate weighted average remaining lease term was 3.14 years on finance leases and 0.84 years on operating leases as of September 30, 2019. The aggregate weighted average discount rate was 20.30% on finance leases and 4.5% on operating leases as of September 30, 2019. During the nine months ended September 30, 2019, the Company added $583,000 of right of use assets in exchange for finance lease liabilities. In addition, upon adoption of the accounting guidance in ASC 842, $1.4 million of net machinery and equipment was reclassified to lease right-of-use assets related to assets under finance leases and $1.9 million of right-of-use facility lease was recorded under operating lease.

8. Stock-Based Compensation

Equity Incentive Plans

The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan.

At the Company’s annual meeting of stockholders held on June 28, 2018, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 146,666 shares. At the Company’s annual meeting of stockholders held on June 17, 2019, the Company’s stockholders approved additional amendments to the 2013 Plan including the increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,800,000 shares. As of September 30, 2019, 124,211 shares of the Company’s common stock were authorized exclusively for the issuance of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules.

As of September 30, 2019, under all plans, a total of 3,064,098 non-inducement shares were authorized for issuance, 2,711,095 shares had been issued with 2,650,970 non-inducement stock options and restricted stock units, or RSUs, underlying outstanding awards, and 353,003 non-inducement shares were available for grant. As of September 30, 2019, 118,368 inducement shares were authorized for issuance, 118,368 inducement shares had been issued under the 2013 Plan, with 117,534 inducement stock options and RSUs underlying outstanding awards and no inducement shares available for grant.

Stock Options

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2018		195,820		$	41.41		9.20
Granted		2,664,129		$	0.91
Exercised		—			—
Cancelled/forfeited/expired		(62,293	)	$	6.43
Outstanding at September 30, 2019		2,797,656		$	3.62		9.52
Vested and unvested expected to vest at September 30, 2019		2,701,017		$	3.71		9.52

The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2018 and September 30, 2019 were each approximately zero.

The assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2019 were as follows:

Stock and exercise prices	$0.81 - $1.03
Expected dividend yield		0.00%
Discount rate-bond equivalent yield	1.58% – 2.55%
Expected life (in years)	5.00 – 5.96
Expected volatility	128% - 156%

On April 30, 2019, the Company’s Board of Directors approved the issuance of an aggregate of 2,578,229 options to be granted to the Company’s employees, executives and Board members pursuant to the 2013 Amended Plan, subject to shareholder approval of the increase of the options available under the 2013 Amended Plan at the Company’s annual meeting on June 17, 2019. On June 17, 2019 the Company’s shareholders approved the increase to the 2013 Amended Plan by 2.8 million shares.

Restricted Stock

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

			Weighted
	Number of		Average Grant
	Shares		Date Fair Value
Outstanding at December 31, 2018		360	$	415.80
Granted		—		—
Vested and issued		—		—
Forfeited		—		—
Outstanding at September 30, 2019		360	$	415.80
Vested and unvested expected to vest at September 30, 2019		360	$	415.80

At September 30, 2019, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were each approximately $400. Of the 360 RSUs outstanding at September 30, 2019, all were fully vested.

Stock-based Compensation Expense

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2018		2019		2018			2019
Stock Options
Cost of revenues	$	10,150	$	29,405	$	37,150		$	54,625
Research and development expenses		30,247		37,626		103,267			102,742
General and administrative expenses		57,162		168,484		243,593			361,102
Sales and marketing expenses		15,513		62,154		63,594			106,300
Total expenses related to stock options		113,072		297,669		447,604			624,769
RSUs
Cost of revenues		-		-		(18,802	)		-
Research and development expenses		-		-		13,576			-
General and administrative expenses		-		-		54,303			-
Sales and marketing expenses		-		-		15,348			-
Total stock-based compensation	$	113,072	$	297,669	$	512,029		$	624,769

Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during each of the three and nine months ended September 30, 2018 and 2019. As of September 30, 2019, total unrecognized share-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,545,000 and is expected to be recognized over a weighted-average period of approximately 3.2 years.

9. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2019 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2018		4,694,927		$	8.55		4.4
Issued		14,662,226		$	1.23
Exercised		(4,155,430	)		1.20
Expired		(4,474	)		953.06
Outstanding at September 30, 2019		15,197,249		$	3.08		4.5

Further information about equity-classified common stock warrants outstanding at September 30, 2019 is as follows:

				Weighted
Weighted				Average
Average		Total Shares		Contractual
Exercise Price		Outstanding		Life (in years)
$	1.24		11,601,949		4.7
$	4.21		3,311,578		3.9
$	25.50		8,208		3.2
$	33.00		96,999		2.1
$	45.00		47,821		2.9
$	75.00		71,995		3.0
$	117.00		38,772		1.6
$	140.00		19,339		0.4
$	424.80		588		4.6
			15,197,249

All warrants outstanding at September 30, 2019 are exercisable. The intrinsic value of equity-classified common stock warrants outstanding at September 30, 2019 was zero.

10. Net Loss per Common Share

Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and nine months ended September 30, 2018 and 2019, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive.

Based on applicable guidance, the 120,000 pre-funded warrants that were issued in the September 20, 2018 registered direct offering with an exercise price of $0.01 are considered common stock equivalents and are included in the calculation of basic and diluted loss per share. In other periods presented, the weighted-average shares used to calculate both basic and diluted loss per share are the same.

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and nine months ended
	September 30,
	2018		2019
Preferred warrants outstanding (number of common stock equivalents)		17		—
Common warrants outstanding		4,814,927		15,197,249
RSUs outstanding		360		360
Convertible preferred stock outstanding (number of common stock equivalents)		2,560,727		471,393
Common options outstanding		114,641		2,797,656
Total anti-dilutive common share equivalents		7,490,672		18,466,658

11. Commitments and Contingencies

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020. At September 30, 2019, a balance of approximately $154,000 remained outstanding under this purchase commitment.

During the three months ended September 30, 2018 and 2019, total expense recorded in the Company’s unaudited condensed statements of operations and comprehensive loss for sales tax and maintenance obligations associated with equipment financing

arrangements was approximately $25,000 and $35,000, respectively, with approximately $75,000 and $82,000 recorded during the nine months ended September 30, 2018 and 2019, respectively. At December 31, 2018 and September 30, 2019, approximately $69,000 and $71,000, respectively, of such sales tax and maintenance obligations incurred but not paid were recorded in accrued other liabilities in the Company’s balance sheet (see Note 5). Future amounts totaling approximately $306,426 for sales tax and maintenance obligations associated with financed equipment were due under equipment financing arrangements at September 30, 2019, which will be expensed as incurred (see Note 7).

12. Related Party Transactions

A member of the Company’s management is the controlling person of Aegea Biotechnologies, Inc., or Aegea. On September 2, 2012, the Company entered into an Assignment and Exclusive Cross-License Agreement, or the Cross-License Agreement, with Aegea. The Company received no payments from during the three months ended September 30, 2018 and 2019, and approximately $19,000 and $26,000 was received during the nine months ended September 30, 2018 and 2019, respectively, from Aegea as reimbursements for shared patent costs under the Cross-License Agreement.

Item 2. Management’s Discussion and Analysis of Financial Condition and Results of Operations

The following discussion and analysis of our financial condition and results of operations should be read in conjunction with our unaudited condensed financial statements and related notes included in this Quarterly Report on Form 10-Q and the audited financial statements and notes thereto as of and for the year ended December 31, 2018 and the related Management’s Discussion and Analysis of Financial Condition and Results of Operations, both of which are contained in our Annual Report on Form 10-K for the year ended December 31, 2018, filed with the Securities and Exchange Commission on March 29, 2019. Past operating results are not necessarily indicative of results that may occur in future periods.

Company Overview

We are an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or “liquid biopsy.” Our current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, show progression or be used for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. Our assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging.

Our current assays and our planned future assays focus on key solid tumor indications utilizing our Target-Selector^TM liquid biopsy technology platform for the biomarker analysis of CTCs and ctDNA from a standard blood sample. Our patented Target-Selector CTC offering is based on an internally developed microfluidics-based cell capture and analysis platform, with enabling features that change how information provided by CTC testing is used by clinicians. Our CTC technology also could be validated on cerebral spinal fluid in order to provide information for patients with central nervous system tumors both primary and metastatic. Our patented Target-Selector ctDNA technology enables detection of mutations and genome alterations with enhanced sensitivity and specificity, and is applicable to nucleic acid from ctDNA, could potentially be validated for interrogating other sample types such as bone marrow, tissue (surgical resections and/or biopsies) or cerebrospinal fluid. Our Target-Selector CTC and ctDNA platforms provide both biomarker detection as well as monitoring capabilities and require only a patient blood sample. In January 2019, we began offering Research Use Only, or RUO, liquid biopsy kits containing our ctDNA Target Selector ctDNA technology to laboratories worldwide.

At our corporate headquarters facility located in San Diego, California, we operate a clinical laboratory that is certified under the Clinical Laboratory Improvement Amendments of 1988, or CLIA, and accredited by the College of American Pathologists, or CAP. We also performed the research and development that led to our current assays and continue to perform research and development for our planned assays, at this same facility. In addition, we currently manufacture our microfluidic channels and various chemistries utilized in our testing process, however, we have identified and have been working with a manufacturer to outsource certain manufacturing activities in the near term to reduce costs and improve efficiency. The assays we offer and intend to offer are classified as laboratory developed tests, or LDTs, under CLIA regulations. CLIA certification is required before any clinical laboratory, including ours, may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, or treatment of disease or the assessment of health. In addition, we participate in and have received CAP accreditation, which includes rigorous bi-annual laboratory inspections and requires adherence to specific quality standards.

Our primary sales strategy is to engage medical oncologists and other physicians in the United States at private and group practices, hospitals, laboratories and cancer centers. In addition, we market our clinical trial and research services to pharmaceutical and biopharmaceutical companies and clinical research organizations. Additionally, our pathology partnership program, branded as Empower TC^TM, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of our patented blood collection tubes, or BCTs, commenced in June 30, 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.

Our revenue generating efforts are focused in three areas:

•

providing laboratory services to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians who use the biomarker information we provide in order to determine the best treatment plan for their patients;

•

providing laboratory services utilizing both our CTC and ctDNA testing in order to help pharmaceutical and biopharmaceutical companies developing drug candidate therapies to treat cancer; and

•

licensing and/or selling our proprietary testing and/or technologies, including our BCTs, to partners in the United States and abroad.

We plan to grow our business by directly offering medical oncologists, surgical oncologists, pulmonologists, pathologists and other physicians our Target-Selector liquid biopsy CTC and ctDNA assays. Based on our product development data, as well as discussions with our collaborators, we believe that our planned future assays should provide important information and clinical value to physicians. In particular, CTC and ctDNA assays could deliver important, actionable information not provided by other assays. For example, the historic clinical CTC test is the United States Food and Drug Administration, or FDA, approved CellSearch^® test, which provides CTC enumeration, but is not FDA approved to perform biomarker analysis. We believe our ability to rapidly translate research insights about the utility of cytogenetic, immunocytochemical and molecular biomarkers to provide information to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians for treatment decisions in the clinical setting will improve patient treatment and management, and that these assays will become a key component of the standard of care for personalized cancer treatment.

Assays, Products and Services

We currently offer and conduct our commercialized diagnostic assays and offer our clinical studies services at our CLIA-certified, CAP-accredited and state-licensed laboratory. We have commercialized our Target-Selector assays for a number of solid tumor indications such as: breast cancer, NSCLC, gastric cancer, colorectal cancer, prostate cancer, melanoma, pancreaticobiliary cancer, and ovarian cancer. These assays utilize our dual CTC and ctDNA technology platforms and provide biomarker analysis from a patient’s blood sample.

Our current assays and clinical trial services include:


•	CTC and ctDNA Testing. Our current assays and our other planned cancer diagnostic assays are based on our Target-Selector technologies and are currently intended to be performed only in our clinical laboratory. After completing testing, we or our partners provide our customers with an easy to understand report that describes the results of the analyses performed, which is designed to help medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians make better decisions about the treatment of their patients.
•	Clinical Studies Services. We plan to utilize our clinical laboratory and translational research capabilities to provide clinical studies and research services to pharmaceutical and biopharmaceutical companies and clinical research organizations to improve the efficiency and economic viability of their clinical studies. Our clinical studies and translational research services could leverage our knowledge of CTCs and ctDNA and our ability to develop and implement new cytogenetic, immunocytochemical and molecular diagnostic assays. Our current assays can, and our other planned cancer diagnostic assays and biomarker assays are anticipated to be able to, help optimize clinical trial patient selection and/or monitor cancer drivers during the course of treatment or disease progression. Demonstration of clinical utility of our assays would more easily enable these tests to be adopted in standard clinical practice, helping physicians select the most appropriate therapy for their patients.

In the case of our breast and gastric cancer offerings, biomarker analysis involves fluorescence in situ hybridization, or FISH, for the detection and quantitation of the human epidermal growth factor receptor 2, or HER2, gene copy number as well as immunocytochemical, or ICC, analysis to evaluate protein expression of the of estrogen receptor, or ER, protein, progesterone receptor, or PR, protein, and androgen receptor, or AR, protein; all of these tests are currently available commercially. A patient’s HER2 status provides the physician with information about the appropriateness of therapies such as Herceptin^® or Tykerb^®. ER and PR status provides the physician with information to guide decisions related to endocrine therapies such as tamoxifen and aromatase inhibitors.

Our lung cancer biomarker analysis offering currently includes FISH testing for ALK, ROS1, RET, MET and FGFR1 gene rearrangements, as well as analysis for the T790M, Deletion 19, and L858R mutations of the epidermal growth factor receptor, or EGFR gene, as well as BRAF, KRAS and NRAS. The L858R mutation of the EGFR gene and Exon 19 deletions are activators of EGFR kinase activity. For lung cancer, we also offer a resistance profile assay consisting of the biomarkers MET, HER2 (both of which we perform using our technology for CTCs), KRAS, and T790M (both of which are performed using ctDNA in plasma). These assays can be used by physicians to identify the mechanism causing disease progression for patients with NSCLC who are being treated with tyrosine kinase inhibitor, or TKI, therapy and therefore may qualify patients for inclusion in a clinical trial.

Fibroblast growth receptor 1, or FGFR1, gene amplification is offered using our CTC technology. FGFR1 amplification is present in several tumor types, including both NSCLC and small cell lung cancer, or SCLC, and has been shown to be a prognostic indicator of progression. FGFR1 is also a key target for several drugs undergoing clinical development.

We analytically validated PD-L1 testing utilizing our CTC technology in 2016. PD-L1 is a biomarker that is informative for immuno-oncology therapies currently marketed for lung cancer and melanoma, as well as therapies in development for multiple tumor types. We collaborated with David Rimm, M.D., Ph.D., a pathologist at Yale Medical School and a scientific advisor to us, on the analytical development of this assay.

We plan to release additional blood-based biomarker assays, such as those that test for ESR1 mutations, to our current menu of liquid biopsy assays using blood samples. In addition, we plan to complete the development and offer multiplexed biomarker tests, which will allow the detection and quantitative monitoring of multiple biomarkers in a single assay.

In August 2017, we announced that we had executed a distribution agreement for our patented blood collection tubes with VWR International, LLC which can preserve intact cells (such as CTCs) for up to 96 hours and ctDNA for up to 8 days, allowing for the transport of RUO liquid biopsy samples from regions around the world.

In October 2017, we launched our pathology partnership initiative, branded as Empower TC, expanding access of our proprietary liquid biopsy testing to community pathologists and hospitals throughout the United States. The aim of this program is to incorporate community pathologists into the review of biomarkers found in liquid biopsy for patients diagnosed with cancer. Pathologists are now enabled to interpret our liquid biopsy results locally, while patient specimens will continue to be sent to us for processing in our CLIA-certified, CAP-accredited high complexity laboratory. In February 2019 we launched Version 2 of Empower TC which is intended to expand the capabilities of the program to allow for more tests to be interpreted by local pathologists.

We intend to continue to commercialize cancer diagnostic assays in the United States as LDTs performed in our CLIA-certified, CAP-accredited, and state-licensed laboratory. We plan to evaluate potential opportunities for the commercialization of our products in other countries. We believe the Target-Selector technology can be used for molecular biomarker screening, marked as RUO test kits.

We launched the first of our RUO Target Selector kit products, ctDNA EGFR, in January 2019. Additionally, we plan to evaluate opportunities for licensing of our products and proprietary technologies to partners in the United States and abroad.

In December 2018, we entered into a Software License and Laboratory Data Supply Agreement with Prognos, Inc., an innovator in predicting disease by applying artificial intelligence, or AI to clinical laboratory diagnostics. Under the agreement, we will supply de-identified data from its liquid biopsy testing to Prognos, which will leverage its AI capabilities to help its pharmaceutical clients ensure that the right patients receive the right therapies. This agreement could provide revenue sharing opportunities in future periods.

In May 2019 we announced launch of the Oncomine NGS lung cancer panel in collaboration with Thermo Fisher Scientific. This panel requires a local coverage determination, or LCD, for reimbursement and we started that process with a meeting with MOLDx in November 2018. In the absence of a national coverage policy, an item or service may be covered at the discretion of the Medicare contractors based on an LCD. We have applied for LCD’s in several categories as the initial step for national coverage.

In June 2019 we announced launch of the Oncomine NGS breast cancer panel, a multi-gene liquid biopsy panel specifically developed for breast cancer, in collaboration with Thermo Fisher Scientific. This panel is being marketed to physicians and researches for the detection and monitoring of actionable genomic biomarkers associated with breast cancer.

We also expanded our prostate panel offerings as a key element for growing the demand for our testing among urologists, including the AR-V7 assay which helps physicians determine if patient should stay on hormone therapy or switch to chemotherapy, as well as PTEN, MET, MYC, and EGFR FISH assays which provide valuable prognostic information to the aggressiveness of a patient’s prostate cancer.

Pharmaceutical Research and Health Economic Collaborations

We continue to execute on our strategies intended to expand our business globally, as well as to engage with pharmaceutical companies on clinical trials and assay development. We have preferred provider agreements in place in Mexico with Quest Diagnostics to support testing for Astra Zeneca. In addition, we have distribution agreements in place in Mexico, Uruguay, Turkey, Columbia, Israel and Canada.

As a follow up to the CTC findings published in Cancer Medicine, we were involved in a clinical study led by investigators at the Dana-Farber Cancer Institute. Study enrollment was completed. During the screening phase of this study, our CLIA-certified, CAP accredited laboratory tested blood samples from a cohort of patients with HER2 negative tissue status, with the aim to identify individuals with HER2 amplified CTCs. These patients were then assigned to chemotherapy plus Herceptin^®. Additional CTC testing with HER2 FISH biomarker analyses were performed at subsequent time points. At the December 2014 San Antonio Breast Cancer Symposium, we presented findings of 311 patients tested with HER2 negative tissue status, where 22% had CTCs with HER2 gene amplification at disease progression. HER2 gene amplification subsequently categorized these patients as potential candidates for anti-HER2 therapy as the cancer evolved. Moreover, our multi-antibody CTC capture method identified a substantial subset of patients who would not likely have had detectable CTCs with commonly used CTC capture technologies. This added 10% (included in the 22%) to the number of women who were candidates for this highly specific targeted therapy.

With our cooperation, researchers at Columbia University published a study in the journal Clinical and Translational Oncology in January 2015. The study demonstrated the high correlation (79%) of circulating tumor cells, primary tumor tissue biopsy and

metastatic tumor tissue biopsy in the determination of hormone receptor status, or ER/PR, of breast cancer patients. The investigators also found that this high correlation was strongest when comparing metastatic tissue biopsy to CTCs (83%). The conclusion of the study was that determining ER/PR status in CTCs using our platform is feasible, with high concordance in ER/PR between tumor tissue (as determined with immunohistochemistry, or IHC) and CTCs (as determined with immunocytochemistry, or ICC). The authors suggest a larger trial to determine the prognostic significance of these findings.

In September 2015, we presented the clinical validation data of our ctDNA assay in collaboration with the University of California, San Diego. The results demonstrated a very high level of concordance to tissue results (88%), together with >95% analytical sensitivity and 99% analytical specificity, supporting our offering of a validated, robust non-invasive solution for mutation identification and monitoring in patients with lung cancer. Subsequent FDA approval of Tagrisso^® , a third-generation tyrosine kinase inhibitor, presented an opportunity for patients to be monitored using a ctDNA assay.

During 2016, we announced a pharmaceutical collaboration agreement that provides testing for a clinical trial, which includes metastatic lung cancer patients with leptomeningeal or brain metastases. In this exploratory trial, we tested both cerebrospinal fluid and blood for molecular alterations that could be impacted by treatment. A second pharmaceutical collaboration was announced in 2016, which entails a milestone-based assay development project focused on hepatocellular carcinoma, or HCC, or liver cancer. Custom assays utilizing both our CTC and ctDNA technologies were developed for identifying specified biomarkers and capturing HCC CTCs for potential clinical trial use.

In April 2016, we announced a study collaboration with Dr. Giuseppe Giaccone at the MedStar Georgetown University Hospital to assess resistance biomarkers in non-small cell lung cancer, or NSCLC, patients treated with EGFR inhibitors or chemotherapy. Later in 2016, we announced another collaboration involving a study presented at the European Society for Medical Oncology, or ESMO, Annual Congress in October 2016, evaluating the detection of EGFR alterations (del19, L858R and T790M) by our Target-Selector liquid biopsy. Subsequent to this study, we have earned business in both Mexico and Columbia for EGFR gene mutation testing in blood to qualify patients for a pharmaceutical company’s targeted therapy. The relationship also resulted in a study initiated during the following year that includes peripheral blood CTC assessment of PD-L1 protein expression in patients undergoing chemotherapy as a monotherapy or in combination with a checkpoint inhibitor. In December 2016, we announced a clinical study agreement with Columbia University Medical Center to evaluate the clinical utility of our Target-Selector platform to diagnose leptomeningeal metastases, or LM, in breast cancer patients. This work was expanded in the fourth quarter of 2018 to include patients with other primary solid tumor types. Dr. Kevin Kalinsky leads this study to test CTCs in cerebrospinal fluid and blood, where CTC analysis will be compared to standard methods for confirming LM diagnosis.

In May 2017, we entered into a clinical study agreement with the University of Texas Southwestern Medical Center. Led by recognized oncologist and ALK alteration researcher, Dr. Saad Khan, the study is designed to evaluate the clinical utility of our Target-Selector platform for patients diagnosed with ALK-positive NSCLC and treated with ALK-inhibitor therapy. A second arm of the study evaluated patients with rare cancers such as anaplastic thyroid cancer to determine if genetic drivers such as ALK gene rearrangements can be identified and treated with targeted therapy to improve patient outcomes.

In November 2017, we announced a collaboration involving 100 patients in a clinical study with the University of California, San Diego. The study entails clinical validation of specified PD-L1 antibody clones on our Target-Selector CTC platform. Concordance of PD-L1 protein expression in tissue biopsy versus liquid biopsy, as well as correlation of therapeutic response with PD-L1 liquid biopsy status, are the study objectives.

Two complementary posters on the highly sensitive Target Selector ctDNA assays were presented in 2018. The first poster entitled “Biocept Study Shows Incorporation of Thermo Fisher QuantStudio 5 PCR Instrument into Target Selector Platform Improves Sensitivity and Specificity in Detection of Lung Cancer Biomarkers” was presented in January 2018 at the Fifth AACR-IASLC International Joint Conference: Lung Cancer Translational Science from the Bench to the Clinic. The related poster, entitled “Validation of highly sensitive TargetSelector™ ctDNA assays for EGFR, BRAF, and KRAS mutations” was presented at the April 2018 American Association for Cancer Research annual meeting. Together, these posters highlight improvements to the Target Selector ctDNA platform, enabling more sensitive mutation detection down to a single copy, thereby increasing the likelihood of identifying actionable molecular drivers towards guiding targeted therapy decisions and better management of a patient’s cancer.

In collaboration with Dr. Shilpa Gupta from the Masonic Cancer Center at the University of Minnesota, a poster was presented at the April 2018 American Association for Cancer Research annual meeting. The results demonstrated proof-of-concept use of our Target-Selector CTC platform, correlating CTC count with clinical responses in refractory testicular cancer patients undergoing therapy. This work is part of a Phase 2 clinical trial of brentuximab vedontin (an anti-CD-30 antibody) with bevacizumab in refractory CD-30 + germ cell tumors. The capability for our Target-Selector CTC platform to monitor this rare cancer type presents the potential for a precision medicine-based approach to guide treatment decisions for these patients.

During the first half of 2018, three key case studies were published in peer-reviewed journals. In April, the 2018 Spring issue of Oncology & Hematology Review featured a case report demonstrating the clinical utility of our CTC platform whereby identification of an ALK rearrangement enabled sequential targeted therapy and improved quality of life in a patient with NSCLC. This case illustrated the use of our technology to monitor therapeutic response and early detection of drug resistance to manage patient disease through the course of treatment with various ALK inhibitors. A Letter to the Editor in the May 2018 issue of Journal of Thoracic Oncology described the identification of a ROS1 rearrangement by Biocept CTC analysis using FISH (fluorescent in situ hybridization). The ROS1 translocation was concordant with tissue biopsy. In contrast, next-generation sequencing analysis of plasma by another vendor failed to detect the genetic alteration in the patient with lung cancer. Also, in May 2018, a case report describing the application of our CTC technology in the management of metastatic breast cancer was published in Clinics in Oncology. This work described a patient with recurrent breast cancer where numerous tissue-based evaluations of the individual’s bone-only metastases had repeated challenges or inclusive results. HER2 amplification detected in CTCs from blood provided crucial information towards changing treatment strategies to include anti-HER therapy, consequently extending and improving the patient’s quality of life. Each of the three published cases provide real-life examples in lung and breast cancer towards establishing the importance of liquid biopsy to identify and monitor clinically actionable biomarkers to improve outcomes of patients with cancer.

In July 2018, we announced a collaboration involving two studies with the University of California, San Diego. Each of the two studies will enroll 100 patients with solid tumors, for a total of 200 patients. One study will assess the feasibility of using our CTC and ctDNA methodologies to predict post-resection disease recurrence in patients with Stage II or III cancer, and the other study will use our technology to predict response to therapy in patients with metastatic disease. Dr. Rebecca Shatsky and Dr. Razelle Kurzrock are the investigators key to both studies.

In August 2018, we announced a Quality Improvement Initiative with Highmark Health to help improve molecular testing rates of NCCN Category I Guidelines for NSCLC. The Initiative aims to improve health outcomes by using liquid biopsy to more rapidly assess a patient's actionable biomarker status towards selecting appropriate therapy, while reducing the overall cost of care. The project will evaluate at least 100 patients in the Highmark Health-affiliated Allegheny Health Network, or AHN, Cancer Institute. Patients will receive our CTC and ctDNA testing in addition to tissue biopsy with the goal of obtaining biomarker status results for a higher percentage of patients compared to standard testing.

Two scientific posters featuring the Target Selector™ CTC and ctDNA platforms were presented in September 2018 at the International Association for the Study of Lung Cancer, or IASLC, 19^th World Conference on Lung Cancer. Data from these clinical studies demonstrate the ability of our technology to detect and monitor CTC counts and actionable biomarkers in both blood and cerebrospinal fluid, or CSF, of patients with advanced NSCLC. The first poster described interim results of a collaboration with Dr. Janakiraman Subramanian at the Saint Luke’s Cancer Institute in Kansas City, Missouri. This study evaluates CTC enumeration in advanced stage NSCLC patients before and during the course of chemotherapy. Interim data suggest that CTC counts may have prognostic and predictive potential to assess therapeutic benefit. The second poster was in collaboration with Kadmon Corporation, featuring CTC and ctDNA analyses and monitoring in the CSF of NSCLC patients with leptomeningeal metastases who were treated with tesevatib in Kadmon’s clinical trial KD019-206. In this study, alterations detected in the CSF of patients were concordant with original tissue biopsies, and serial monitoring of CTCs and ctDNA biomarkers in CSF were consistent with the overall clinical.

A case series was published in January 2019 issue of the peer reviewed journal, Clinics in Oncology. The work highlights the clinical utility of liquid biopsy to stratify patients who may benefit from targeted therapy, describing three patients with metastatic NSCLC for whom tissue biopsy was insufficient for molecular profiling. In all three cases, our ctDNA liquid biopsy analyses detected an activating EGFR mutation. EGFR tyrosine kinase inhibitor therapy subsequently was initiated. Complete response lasting approximately two years was observed in one patient. For two patients, our ctDNA testing was performed at signs of clinical progression and Osimertinib was administered upon our liquid biopsy identification of the EGFR T790M resistance marker. In sum, patient survival was dramatically extended in all cases presented where targeted therapies were prescribed based on liquid biopsy results.

In April 2019, we presented a poster at the annual meeting of the American Association for Cancer Research. The work describes analytical validation of Target Selector ESR1 Next Generation Sequencing, or NGS, ctDNA assays with single copy mutant detection. The assays have a limit of detection, or LOD, 0.03% or better, with >99% sensitivity for mutant allele fractions, or MAF, ranging from greater than 5% down to 0.03%. ESR1 gene mutations are associated with acquired drug resistance in up to 55% of patients with estrogen receptor, or ER, positive metastatic breast cancer, or mBC, who received anti-estrogen treatment. Detection of ESR1 mutations may enable the prediction of treatment failure and disease progression in these patients. As new therapies are developed that antagonize ER activity by mechanisms that differ from current drug treatments, ESR1 mutation testing can be a helpful tool to identify patients who may benefit from these alternative agents.

Provider Agreements

In January 2017, we announced that we had secured an in-network provider agreement with Blue Cross Blue Shield of Texas, the largest provider of health benefits in Texas. In addition, we entered into a national master business agreement with the Blue Cross Blue Shield Association, a not-for-profit trade association that provides multiple services for its 38-member Blue Cross and Blue Shield health plan companies across the U.S., including forming national strategic vendor partnerships. We were selected by the Blue Cross Blue Shield Association based on a rigorous request-for-proposal progress. This agreement establishes pricing for our Target-Selector liquid biopsy testing service through the Blue Cross Blue Shield Association’s group purchasing organization, CareSourcing Workgroup. The pricing offered by the CareSourcing Workgroup group purchasing organization is available to those Blue Cross and Blue Shield member health plans that have, or may seek, in-network agreements with us.

In June 2017, we entered into a participating provider agreement with MediNcrease Health Plans, LLC and a preferred provider agreement with Scripps Health Plan Services, Inc., both establishing pricing for our Target-Selector liquid biopsy testing service.

In December 2017, we signed an agreement with Wellmark, Inc., the largest health insurer in Iowa and South Dakota. The agreement marks our third Blue Cross Blue Shield contract and enables patients diagnosed with cancer the ability to access our proprietary testing services in-network under their Wellmark health plan.

In August 2018, we entered into a quality initiative program with Highmark and Alleghany Health Network as a result of the Caresourcing Workgroup. The focus is to improve access to molecular testing to members with a diagnosis of lung cancer. Enrollment begin in August 2018 and has been steadily increasing.

In July 2019 we announced that we entered into a Laboratory Services Provider Agreement with Beacon Laboratory Benefit Solutions, Inc., a nationally recognized premier provider of laboratory benefit management technology solutions to health and managed care companies in the United States.

We are currently contracted with nine preferred provider organization networks, three large health plans, and five regional independent physician associations, and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans.

Patents and Technology

The proprietary nature of, and protection for, our products, services, processes, and know-how are important to our business. Our success depends in part on our ability to protect the proprietary nature of our products, services, technology, and know-how, to operate without infringing on the proprietary rights of others, and to prevent others from infringing our proprietary rights. We seek patent protection in the United States and internationally for our products, services and other technology. Our policy is to patent or in-license the technology, inventions and improvements that we consider important to the development of our business.

We also rely on trade secrets, know-how, and continuing innovation to develop and maintain our competitive position. We cannot be certain that patents will be granted with respect to any of our pending patent applications or with respect to any patent applications filed by us in the future, nor can we be sure that any of our existing patents or any patents granted to us in the future will be commercially useful in protecting our technology.

Our success depends on an intellectual property portfolio that supports our future revenue streams and erects barriers to our competitors. We are maintaining and building our patent portfolio through filing new patent applications, prosecuting existing applications, and licensing and acquiring new patents and patent applications.

Despite these measures, any of our intellectual property and proprietary rights could be challenged, invalidated, circumvented, infringed or misappropriated, or such intellectual property and proprietary rights may not be sufficient to permit us to take advantage of current market trends or otherwise to provide competitive advantages. For more information, see the section entitled “Risk Factors – Intellectual Property Risks Related to Our Business.”

We have issued patents with broad claims covering our blood collection tube, antibody cocktail approach, microchannel, CTC detection methodologies, and ctDNA analysis. In addition to issued patents in the U.S., we have patents for our proprietary microchannel in China, South Korea, Europe, Hong Kong, Canada and Japan, and for our antibody cocktail in Australia, Europe, Hong Kong and Japan. Our patent estate continues to evolve, and in addition to the broad patent estate around our CTC platform, we also have issued patents in the U.S., Australia, Europe, Japan, China and South Korea for our novel switch blocker technology, solidifying our proprietary enrichment methodology for detecting ctDNA with very high sensitivity. Our CTC platform patents were filed from 2005 through 2012, and we expect to have patent protection into the 2030s. Our CTC patents and applications cover not only cancer as a target, but also prenatal and other rare cells of interest. Recently allowed patents in the U.S. cover the capture of “any

target of interest on any solid surface” using our antibody capture approach. The patent for our proprietary specimen collection tubes expire in 2031, and the patents for our ctDNA technology expire in the early 2030’s.

As of September 30, 2019, we owned 36 issued patents and 13 patents pending related to our current technologies. Of these, 9 were issued and 4 were pending patents in the U.S., while 27 were issued and 11 were pending patents in non-U.S. territories. Separately, we also owned 7 issued patents related to our earlier microarray and cell analysis technology.

Results of Operations

Three Months Ended September 30, 2018 and 2019

The following table sets forth certain information concerning our results of operations for the periods shown:

	Three months ended September 30,						Change
	2018			2019			$			%
(dollars in thousands)
Net revenues	$	762		$	1,529		$	767			101	%
Cost of revenues		2,482			2,833			351			14	%
Research and development expenses		1,089			1,164			75			7	%
General and administrative expenses		1,794			1,700			(94	)		(5	%)
Sales and marketing expenses		1,404			1,462			58			4	%
Loss from operations		(6,007	)		(5,630	)		377			(6	%)
Interest expense		(64	)		(62	)		2			(3	%)
Other income		24			—			(24	)		100	%
Loss before income taxes		(6,047	)		(5,692	)		355			(6	%)
Income tax expense		—			—			—			0	%
Net loss	$	(6,047	)	$	(5,692	)	$	355			(6	%)

Net Revenues

Net revenues were approximately $1,529,000 for the three months ended September 30, 2019, compared with approximately $762,000 for the same period in 2018, an increase of $767,000, or 101%, which is primarily due to an increase in accession volume over the same period in the prior year. The increase in net revenues is due to an increase in accession volumes, which is partially attributable to the increase in the urology business specifically targeted as part of our growth strategy. In addition, we had an increase in the number of tests ordered per accession which is partially attributable to the launching of new assays in 2019.

The net estimated revenue per commercial accession delivered during the three months ended September 30, 2019 was $1,189, based on 1,107 commercial accessions delivered, while during the three months ended September 30, 2018 it was approximately $717, based on 691 commercial accessions delivered. In the three months ended September 30, 2019 there were approximately $1,432,000 in corresponding commercial net revenues.

The following table sets forth certain information regarding commercial accessions received during the three months ended September 30, 2018 and 2019:

	Three months ended September 30,				Change
	2018		2019		# / $		%
# Commercial accessions received		717		1,189		472		66	%
$ Value estimated per commercial accession received	$	1,235	$	1,251	$	16		1	%

Additionally, overall development revenues decreased by $25,000 as compared to the same period in the prior year. The net revenue per accession decreased due to lower number of development services accessions delivered and lower value per development case delivered during period as compared to the same period in the prior year as follows:

	Three months ended September 30,				Change
	2018		2019		# / $			%
# Development services accessions delivered		176		135		(41	)		(23	%)
$ Value per development services accession delivered	$	361	$	281	$	(79	)		(22	%)

Costs and Expenses

Cost of Revenues. Cost of revenues was approximately $2,833,000 for the three months ended September 30, 2019, compared with approximately $2,482,000 for the same period in 2018 as we continued to leverage the fixed components of our costs. As a result, cost of revenues as a percentage of net revenues decreased by 140.4% over the three months ended September 30, 2019 as compared to the same period in the prior year. Cost of revenues are comprised of, but not limited to, expenses related to personnel costs, materials, shipping and other direct costs, as well as equipment depreciation and software amortization expenses.

Research and Development Expenses. Research and development expenses were approximately $1,164,000 for the three months ended September 30, 2019, compared with approximately $1,089,000 for the same period in 2018, an increase of $75,000, or 7%. The increase was primarily attributable to development and validation costs related to additional tests. Research and development expenses are comprised of, but not limited to, personnel costs, material, shipping and other direct costs, computer and laboratory equipment maintenance and facility related costs.

General and Administrative Expenses. General and administrative expenses were approximately $1,700,000 for the three months ended September 30, 2019, compared with approximately $1,794,000 during the same period in 2018, a decrease of $94,000, or 5%. The decrease was primarily attributable to a lower consulting, outside service and legal and patent costs compared to the same period in the prior year. General and administrative expenses are comprised of, but not limited to, personnel costs, facilities, depreciation, repairs and maintenance costs, stock-based compensation expenses, patent and legal costs, accounting and audit fees, as well as insurance, office and other expenses.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $1,462,000 for the three months ended September 30, 2019 compared with approximately $1,404,000 for the same period in 2018, an increase of $58,000, or 4%. The increase was primarily attributable to higher volume and revenues during the period. Sales and marketing expenses are comprised of, but not limited to, personnel costs, trade show and other marketing related expenses, as well as office and other costs.

Interest Expenses. Interest expenses stayed relatively flat at approximately $62,000 for the three months ended September 30, 2019 compared with approximately $64,000 for the same period in 2018.

Income Tax Expense

Over the past several years we have generated operating losses in all jurisdictions in which we may be subject to income taxes. As a result, we have accumulated significant net operating losses and other deferred tax assets. Because of our history of losses and the uncertainty as to the realization of those deferred tax assets, a full valuation allowance has been recognized. We do not expect to report a provision for income taxes until we have a history of earnings, if ever, that would support the realization of our deferred tax assets.

We have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, we believe ownership changes likely occurred in each year from 2015 through 2018. As a result, we have estimated that the use of our net operating loss is limited and the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future remain fully offset by a valuation allowance to reduce the net asset to zero.

Results of Operations

Nine Months Ended September 30, 2018 and 2019

The following table sets forth certain information concerning our results of operations for the periods shown:

	Nine months ended September 30,						Change
	2018			2019			$			%
(dollars in thousands)
Net revenues	$	2,391		$	3,745		$	1,354			57	%
Cost of revenues		7,616			8,105			489			6	%
Research and development expenses		3,180			3,535			355			11	%
General and administrative expenses		5,441			5,059			(382	)		(7	%)
Sales and marketing expenses		4,474			4,452			(22	)		(0	%)
Loss from operations		(18,320	)		(17,406	)		914			(5	%)
Interest expense		(231	)		(188	)		43			(19	%)
Warrant inducement and other expenses		(6	)		(1,831	)		(1,825	)		30,417	%
Loss before income taxes		(18,557	)		(19,425	)		(868	)		5	%
Income tax expense		(1	)		-			1			(100	%)
Net loss	$	(18,558	)	$	(19,425	)	$	(867	)		5	%

Net Revenues

Net revenues were approximately $3,745,000 for the nine months ended September 30, 2019 compared with approximately $2,391,000 for the same period in 2018, an increase of $1,354,000, or 57%, which is primarily due to an increase in accession volume over the same period in the prior year. The increase in accession volume is partially attributable to the increase in the urology business specifically targeted as part of our growth strategy. In addition, we had an increase in the number of tests ordered per accession which is partially attributable to the launching of new assays in 2019.

The net estimated revenue per commercial accession delivered during the nine months ended September 30, 2019 was $1,123, based on 3,142 commercial accessions delivered, while during the nine months ended September 30, 2018 it was approximately $955, based on 2,326 commercial accessions delivered. In the nine months ended September 30, 2019 there were approximately $3,527,000 in corresponding commercial net revenues.

The following table sets forth certain information regarding commercial accessions received during the nine months ended September 30, 2018 and 2019:

	Nine months ended September 30,				Change
	2018		2019		# / $		%
# Commercial accessions received		2,478		3,266		788		32	%
$ Value estimated per commercial accession received	$	1,162	$	1,170	$	8		1	%

Additionally, revenues for development services decreased approximately $35,000 during the nine months ended September 30, 2019 as compared to the same period in 2018, due to a decrease in development cases delivered and in the value per development case delivered as follows:

	Nine months ended September 30,				Change
	2018		2019		# / $			%
# Development services cases delivered		474		399		(75	)		(16	%)
$ Value per development services accession delivered	$	337	$	314	$	(23	)		(7	%)

Costs and Expenses

Cost of Revenues. Cost of revenues was approximately $8,105,000 for the nine months ended September 30, 2019, compared with approximately $7,616,000 for the same period in 2018 as we continue to leverage the fixed components of our costs. As a result, cost

of revenues as a percentage of net revenues decreased by 102.1% over the nine months ended September 30, 2019 as compared to the same period in the prior year. Cost of revenues are comprised of, but not limited to, expenses related to personnel costs, materials, shipping and other direct costs, as well as equipment depreciation and software amortization expenses.

Research and Development Expenses. Research and development expenses were approximately $3,535,000 for the nine months ended September 30, 2019, compared with approximately $3,180,000 for the same period in 2018, an increase of $355,000, or 11%, with the increase being primarily due to development and validation costs of new liquid biopsy tests and panels year to date. The increase was attributable to an increase of $443,000 in materials and supplies costs, partially offset by other lower expenses compared to the same period in the prior year.

General and Administrative Expenses. General and administrative expenses were approximately $5,059,000 for the nine months ended September 30, 2019, compared with approximately $5,441,000 during the same period in 2018, a decrease of $382,000, or 7%, primarily attributable to our ongoing cost containment efforts. General and administrative expenses are comprised of, but not limited to personnel costs, facilities, depreciation, repairs and maintenance costs, stock-based compensation expenses, patent and legal costs, accounting and audit fees, as well as insurance, office and other expenses.

Sales and Marketing Expenses. Sales and marketing expenses were approximately $4,452,000 for the nine months ended September 30, 2019 compared with approximately $4,474,000 for the same period in 2018, a decrease of $22,000 or 0%. During the period there was a decrease in personnel costs partially offset by costs related to increased sales and marketing efforts related to higher revenues compared to the same period in the prior year.

Interest Expenses. Interest expenses were approximately $188,000 for the nine months ended September 30, 2019 compared with approximately $231,000 for the same period in 2018, a decrease of $43,000 or 19%. The decrease was primarily due to the term loan having been paid off during 2018.

Warrant Inducement and Other Expense. Warrant inducement and other expenses were approximately $1,831,000 for the nine months ended September 30, 2019 compared with approximately $6,000 for the same period in 2018, an increase of $1,825,000. The increase was due to recognizing the fair value of the inducement warrants issued in May 2019 in connection with the warrant exercise offering of $1.8 million as equity and recognizing as a warrant inducement expense.

Income Tax Expense

Liquidity and Capital Resources

Cash Flows

Our net cash flow from operating, investing and financing activities for the periods below were as follows:

	Nine months ended September 30,
	2018			2019
(dollars in thousands)
Cash provided by/ (used in):
Operating activities	$	(16,937	)	$	(17,577	)
Investing activities		(145	)		(298	)
Financing activities		23,892			20,991
Net increase in cash	$	6,810		$	3,116

Cash Used in Operating Activities. Net cash used in operating activities was $17.6 million for the nine months ended September 30, 2019, compared to net cash used in operating activities of $16.9 million for the same period in 2018. The net increase of $640,000 million in cash used was primarily related to an increase in cash used to fund our net loss. During the nine months ended September 30, 2019 we recorded a non-cash warrant inducement expense of $1.8 million related to the May 2019 warrant inducement transaction.

Cash Used in Investing Activities. Net cash used in investing activities of approximately $298,000 and $145,000 during the nine months ended September 30, 2019 and 2018, respectively, was related to purchases of fixed assets.

Cash Provided by Financing Activities. Net cash provided by financing activities was $21.0 million for the nine months ended September 30, 2019, compared to net cash provided by financing activities of $23.9 million for the same period in 2018. Our primary sources of cash from financing activities during the nine months ended September 30, 2019 consisted of $2.0 million in net proceeds from our offering of common stock in January 2019, $6.6 million in net proceeds from our sale of common stock and warrants in February 2019, $0.6 million in net proceeds from the exercise of the placement agent’s overallotment option from the January 2019 transaction, $7.6 million in net proceeds from our sale of common stock and warrants in March 2019, and $4.9 million in proceeds from exercise of common stock warrants. Our primary sources of cash from financing activities during the nine months ended September 30, 2018 consisted of $25.7 million in net proceeds from our common stock and warrant financing transaction in January 2018, rights offering completed in August 2018, and registered direct financing transaction completed in September of 2018, which was partially offset by $1.2 million of principal payments made on indebtedness.

Liquidity, Capital Resources and Expenditure Requirements

We expect to continue to incur substantial operating losses in the future. It may take several years to achieve positive operational cash flow, or we may not ever achieve positive operational cash flow. We expect that we will use the net proceeds from our sale of equity securities, if any, cash received from the licensing of our technology, if any, and our revenues from operations to hire sales and marketing personnel, support increased sales and marketing activities, fund further research and development, clinical utility studies and future enhancements of our assays, acquire equipment, implement automation and scale our capabilities to prepare for significant assay volume, for general corporate purposes and to fund ongoing operations and the expansion of our business, including the increased costs associated with expanded commercial activities. We may also use the net proceeds from our sale of equity securities, if any, cash received from the licensing of our technology, if any, and our revenues from operations to acquire or invest in businesses, technologies, services or products, although we do not have any current plans to do so. On January 18, 2019, we completed an offering of 990,000 shares of our common stock at a purchase price of $2.25 per share raising net proceeds of approximately $2.0 million. On February 12, 2019, we completed an offering of 6,250,000 shares of our common stock and warrants at a combined offering price of $1.20 per unit, raising approximately $6.6 million, and on March 11, 2019, the underwriters exercised their overallotment option under the February 2019 transaction and purchased 538,867 shares from us for total proceeds of $592,000. In addition, on March 19, 2019, we completed an offering of 5,950,000 shares of common stock and warrants at an offering price of $1.37 per share raising approximately $7.6 million in net proceeds. In May 2019, investors exercised warrants for 4.1 million shares of common stock at exercise prices ranging from $1.20 to $1.25 per share resulting in net cash proceeds to the Company totaling $4.8 million. Approximately 2.1 million shares of the warrants exercised was pursuant to a warrant inducement transaction raising approximately $2.3 million of net proceeds of the total $4.8 million raised.

As of September 30, 2019, our cash totaled $6.5 million, and our outstanding net indebtedness totaled $1.9 million. While we currently are in the commercialization stage of operations, we have not yet achieved profitability and anticipate that we will continue to incur net losses for the foreseeable future. We have determined that there is substantial doubt about our ability to continue as a going concern for the one-year period following the date that our unaudited condensed financial statements for the three and nine months ended September 30, 2019 were issued, and we expect that we will need additional financing to execute on our current or future business strategies beyond December 2019.

We expect that we will need additional financing to execute on our current or future business strategies. Until we can generate significant cash from operations, including assay revenues, we expect to continue to fund operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. For example, we have an effective shelf registration statement on file with the SEC which allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time until expiry on May 21, 2021, subject to certain restrictions that apply for so long as our public float is less than $75 million. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. If we are unable to raise a sufficient amount of financing in a timely manner, we would likely need to scale back our general and administrative activities and certain of our research and development activities. Our forecast pertaining to our current financial resources and the costs to support our general and administrative and research and development activities are forward-looking statements and involve risks and uncertainties. Actual results could vary materially and negatively as a result of a number of factors, including:

•

our ability to secure financing and the amount thereof;

•

the costs of operating and enhancing our laboratory facilities;

•

the costs of developing our anticipated internal sales and marketing capabilities;

•

the scope, progress and results of our research and development programs, including clinical utility studies;

•

the scope, progress, results, costs, timing and outcomes of the clinical utility studies for our diagnostic assays;

•

our ability to manage the costs for manufacturing our microfluidic channels;

•

the costs of maintaining, expanding and protecting our intellectual property portfolio, including potential litigation costs and liabilities;

•

our ability to obtain adequate reimbursement from governmental and other third-party payers for our assays and services;

•

the costs of additional general and administrative personnel, including accounting and finance, legal and human resources, as a result of becoming a public company;

•

our ability to collect revenues; and

•

other risks discussed in our other filings with the SEC.

We may raise additional capital to fund our current operations and to fund expansion of our business to meet our long-term business objectives through public or private equity offerings, debt financings, borrowings or strategic partnerships coupled with an investment in our company or a combination thereof. If we raise additional funds through the issuance of convertible debt securities, or other debt securities, these securities could be secured and could have rights senior to those of our common stock. In addition, any new debt incurred by us could impose covenants that restrict our operations. The issuance of any new equity securities will also dilute the interest of our current stockholders. Given the risks associated with our business, including our unprofitable operating history and our ability or inability to develop additional assays, additional capital may not be available when needed on acceptable terms, or at all. If adequate funds are not available, we will need to curb our expansion plans or limit our research and development activities, which would have a material adverse impact on our business prospects and results of operations.

Off-Balance Sheet Arrangements

We have not engaged in any off-balance sheet arrangements as defined in Item 303(a)(4) of Regulation S-K.

Critical Accounting Policies and Significant Judgments and Estimates

For a discussion of accounting policies that we consider critical to our business operations and understanding of our results of operations, and that affect the more significant judgments and estimates used in the preparation of our financial statements, please see the information listed in Part II, Item 7, “Management’s Discussion and Analysis of Financial Condition and Results of Operations—Critical Accounting Policies and Significant Judgments and Estimates” contained in our Annual Report on Form 10-K for the year ended December 31, 2018. There have been no material changes to our critical accounting policies and estimates from the information provided in our Annual Report on Form 10-K for the year ended December 31, 2018.

Item 3. Quantitative and Qualitative Disclosures about Market Risk

We are a smaller reporting company as defined by Rule 12b-2 of the Exchange Act and are not required to provide the information otherwise required under this item.

Item 4. Controls and Procedures

We maintain disclosure controls and procedures that are designed to ensure that information required to be disclosed in our periodic and current reports that we file with the SEC is recorded, processed, summarized and reported within the time periods specified in the SEC’s rules and forms, and that such information is accumulated and communicated to our management, including our principal executive officer and principal financial officer, as appropriate, to allow timely decisions regarding required disclosure. In designing and evaluating the disclosure controls and procedures, management recognized that any controls and procedures, no matter how well designed and operated, can provide only reasonable and not absolute assurance of achieving the desired control objectives. In reaching a reasonable level of assurance, management necessarily was required to apply its judgment in evaluating the cost-benefit relationship of possible controls and procedures. In addition, the design of any system of controls also is based in part upon certain assumptions about the likelihood of future events, and there can be no assurance that any design will succeed in achieving its stated goals under all potential future conditions; over time, control may become inadequate because of changes in conditions, or the degree of compliance with policies or procedures may deteriorate. Because of the inherent limitations in a cost-effective control system, misstatements due to error or fraud may occur and not be detected.

As of September 30, 2019, we carried out an evaluation, under the supervision and with the participation of our management, including our principal executive officer and principal financial officer, of the effectiveness of the design and operation of our disclosure controls and procedures, as defined in Rules 13a-15(e) and 15d-15(e) under the Exchange Act. Based on this evaluation, our principal executive officer and principal financial officer concluded that our disclosure controls and procedures were effective at the reasonable assurance level as of September 30, 2019.

An evaluation was performed under the supervision and with the participation of our management, including our principal executive officer and our principal financial officer, of any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting. That evaluation did not identify any change in our internal control over financial reporting that occurred during our last fiscal quarter that has materially affected, or is reasonably likely to materially affect, our internal control over financial reporting.

PART II. OTHER INFORMATION

Item 1. Legal Proceedings

None.

Item 1A. Risk Factors

An investment in shares of our common stock involves a high degree of risk. You should carefully consider the following risk factors, as well as the other information contained elsewhere in this report, before deciding whether to purchase, hold or sell shares of our common stock. The occurrence of any of the following risks could harm our business, financial condition, results of operations and/or growth prospects or cause our actual results to differ materially from those contained in forward-looking statements we have made in this report and those we may make from time to time. You should consider all of the risk factors described when evaluating our business. We have marked with an asterisk (*) those risk factors that reflect changes from the risk factors included in our Annual Report on Form 10-K for the year ended December 31, 2018 filed with the Securities and Exchange Commission on March 29, 2019.

Risks Relating to Our Financial Condition and Capital Requirements

*We are an early commercial stage molecular oncology diagnostics company with a history of net losses; we expect to incur net losses in the future, and we may never achieve sustained profitability.

We have historically incurred substantial net losses, including net losses of $24.6 million for the year ended December 31, 2018 and $19.4 million for the nine months ended September 30, 2019, and we have never been profitable. At September 30, 2019, our accumulated deficit was $240.0 million. Before 2008, we were pursuing a business plan relating to fetal genetic disorders and other fields, all of which were unrelated to cancer diagnostics. The portion of our accumulated deficit that relates to the period from inception through December 31, 2007 is $66.5 million.

We expect our losses to continue as a result of costs relating to our laboratory operations as well as increased sales and marketing costs and ongoing research and development expenses. These losses have had, and will continue to have, an adverse effect on our working capital, total assets and stockholders’ equity. Because of the numerous risks and uncertainties associated with our commercialization efforts, we are unable to predict when we will become profitable, and we may never become profitable. Even if we do achieve profitability, we may not be able to sustain or increase profitability on a quarterly or annual basis. Our inability to achieve and then maintain profitability would negatively affect our business, financial condition, results of operations and cash flows.

We need to raise additional capital to continue as a going concern.

We expect to continue to incur losses for the foreseeable future and will have to raise additional capital to fund our planned operations and to meet our long-term business objectives. As a result, there is substantial doubt about our ability to continue as a going concern unless we are able to successfully raise additional capital. Until we can generate significant cash from operations, including product and assay revenues, we expect to continue to fund our operations with the proceeds from offerings of our equity securities or debt, or transactions involving product development, technology licensing or collaboration. We can provide no assurances that any sources of a sufficient amount of financing will be available to us on favorable terms, if at all. Failure to raise additional capital in sufficient amounts would significantly impact our ability to continue as a going concern. The actual amount of funds that we will need and the timing of any such investment will be determined by many factors, some of which are beyond our control.

Risks Relating to Our Business and Strategy

If we are unable to increase sales of our current products, assays and services or successfully develop and commercialize other products, assays and services, our revenues will be insufficient for us to achieve profitability.

We currently derive substantially all of our revenues from sales of diagnostic assays. We began offering our assays through our Clinical Laboratory Improvement Amendments of 1988, or CLIA, certified, CAP accredited, and state-licensed laboratory in 2014. Additionally, the sale of our proprietary blood collection tubes, or BCTs, commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. We are in varying stages of research and development for other products and diagnostic assays that we may offer. If we are unable to increase sales of our existing products and diagnostic assays or successfully develop and commercialize other products and diagnostic assays, we will not produce sufficient revenues to become profitable.

If we are unable to execute our sales and marketing strategy for our products and diagnostic assays and are unable to gain acceptance in the market, we may be unable to generate sufficient revenue to sustain our business.

We are an early stage molecular oncology diagnostics company and have engaged in only limited sales and marketing activities for the diagnostic assays we currently offer through our CLIA-certified, CAP accredited, and state-licensed laboratory. To date, our revenue has been insufficient to fund operations.

Although we believe that our current assays and our planned future assays, as well as our BCT product, represent a promising commercial opportunity, our products or assays may never gain significant acceptance in the marketplace and therefore may never generate substantial revenue or profits for us. We will need to establish a market for our products and diagnostic assays and build that market through physician education, awareness programs and the publication of clinical trial results. Gaining acceptance in medical communities requires, among other things, publications in leading peer-reviewed journals of results from studies using our current products, assays and services and/or our planned future products, assays and services. The process of publication in leading medical journals is subject to a peer review process and peer reviewers may not consider the results of our studies sufficiently novel or worthy of publication. Failure to have our studies published in peer-reviewed journals would limit the adoption of our current products, assays and services and our planned future products, assays and services.

Our ability to successfully market the products and diagnostic assays that we have developed, and may develop in the future, will depend on numerous factors, including:

•	conducting clinical utility studies of such assays in collaboration with key thought leaders to demonstrate their use and value in important medical decisions such as treatment selection;

•	whether our current or future partners, vigorously support our offerings;

•	the success of our sales force;

•	whether healthcare providers believe such diagnostic assays provide clinical utility;

•	whether the medical community accepts that such diagnostic assays are sufficiently sensitive and specific to be meaningful in-patient care and treatment decisions;

•	our ability to continually source raw materials, BCTs, shipping kits and other products that we sell or consume in our manufacturing process that are of sufficient quality and supply;

•	our ability to continue to fund planned sales and marketing activities; and

•	whether private health insurers, government health programs and other third-party payers will adopt liquid biopsy-based assays in their guidelines, or cover such diagnostic assays and, if so, whether they will adequately reimburse us.

Failure to achieve widespread market acceptance of our current products, assays and services, as well as our planned future products, assays and services, would materially harm our business, financial condition and results of operations.

If we cannot develop products, assays and services to keep pace with rapid advances in technology, medicine and science, our operating results and competitive position could be harmed.

In recent years, there have been numerous advances in technologies relating to the diagnosis and treatment of cancer. Several new cancer drugs have been approved, and a number of new drugs in clinical development may increase patient survival time. There have also been advances in methods used to identify patients likely to benefit from these drugs based on analysis of biomarkers. We must continuously develop new products and diagnostic assays and enhance any existing products, assays and services to keep pace with evolving standards of care. Our current products, assays and services and our planned future products, assays and services could become obsolete unless we continually innovate and expand them to demonstrate benefit in the diagnosis, monitoring or prognosis of patients with cancer. New cancer therapies typically have only a few years of clinical data associated with them, which limits our ability to develop products and diagnostic assays based on, for example, biomarker analysis related to the appearance or development of resistance to those therapies. If we cannot adequately demonstrate the applicability of our current products, assays and services and our planned future products, assays and services to new treatments, by incorporating important biomarker analysis, sales of our products, assays and services could decline, which would have a material adverse effect on our business, financial condition and results of operations.

If our current products, assays and services and our planned future products, assays and services do not continue to perform as expected, our operating results, reputation and business will suffer.

Our success depends on the market’s confidence that we can continue to provide reliable, high-quality products and assay results. We believe that our customers are likely to be particularly sensitive to product or assay defects and errors. As a result, the failure of our current or planned future products or assays to perform as expected, including with respect to our ability to maintain the sensitivity,

specificity, concordance or reproducibility of such assays, would significantly impair our reputation and the public image of our products and cancer assays, and we may be subject to legal claims arising from any defects or errors.

If our sole laboratory facility becomes damaged or inoperable, or we are required to vacate the facility, our ability to sell and provide our products and diagnostic assays and pursue our research and development efforts may be jeopardized.

We currently derive our revenues from our diagnostic assays conducted in our CLIA-certified, CAP accredited, and state-licensed laboratory. We do not have any clinical reference laboratory facilities other than our facility in San Diego, California. Our facilities and equipment could be harmed or rendered inoperable by natural or man-made disasters, including fire, earthquake, flooding and power outages, which may render it difficult or impossible for us to sell our products or perform our diagnostic assays for some period of time. The inability to sell our current or planned future products, or to perform our current assays and our planned future assays, or the backlog of assays that could develop if our facility is inoperable for even a short period of time, may result in the loss of customers or harm to our reputation or relationships with scientific or clinical collaborators, and we may be unable to regain those customers or repair our reputation in the future. Furthermore, our facilities and the equipment we use to perform our research and development work could be costly and time-consuming to repair or replace.

The San Diego area has recently experienced serious fires and power outages and is considered to lie in an area with earthquake risk.

Additionally, a key component of our research and development process involves using biological samples as the basis for our diagnostic assay development. In some cases, these samples are difficult to obtain. If the parts of our laboratory facility where we store these biological samples were damaged or compromised, our ability to pursue our research and development projects, as well as our reputation, could be jeopardized. We carry insurance for damage to our property and the disruption of our business, but this insurance may not be sufficient to cover all of our potential losses and may not continue to be available to us on acceptable terms, if at all.

Further, if our CLIA-certified, CAP accredited, and state-licensed laboratory became inoperable we may not be able to license or transfer our technology to another facility with the necessary qualifications, including state licensure and CLIA certification, under the scope of which our current assays and our planned future assays could be performed. Even if we find a facility with such qualifications to perform our assays, it may not be available to us on commercially reasonable terms.

*If we cannot compete successfully with our competitors, we may be unable to increase or sustain our revenues or achieve and sustain profitability.

Our principal competition comes from mainstream diagnostic methods, used by medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians for many years, which focus on tumor tissue analysis. The methods or behavior of medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians may be difficult to change regarding the use of our CTC and ctDNA assays, including molecular diagnostic assays, in their practices in conjunction with or instead of tissue biopsies and analysis. In addition, companies offering capital equipment, BCTs, and kits or reagents to local pathology laboratories or laboratory supply distributors represent another source of potential competition. These kits are used directly by the pathologist, which can facilitate adoption. Historically, we have focused our marketing and sales efforts on medical oncologists rather than pathologists, our Empower TC offering provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States.

We also face competition from companies that offer products or are conducting research to develop products for CTC or ctDNA assays in various cancers. CTC and ctDNA products, assays and services represent a new area of science and we cannot predict what products or assays others will develop that may compete with or provide results similar or superior to the results we are able to achieve with the products or assays we develop. Competitors include but are not limited to companies such as Qiagen, Roche, Guardant Health, Cancer Genetics, Agena Bioscience, Precipio, Illumina, Grail, Precision for Medicine, EPIC Sciences, Clearbridge Biomedics, Biodesix, Thermo Fisher Scientific, Foundation Medicine, Cynvenio Biosystems, Genomic Health, Fluxion Biosciences, RareCells Diagnostics, ScreenCell, Menarini Silicon Biosystems, Sysmex, Natera, Circulogen, Angle PLC, Caris Life Sciences, Archer DX, DiaCarta and Tempus. Some of these groups, in addition to operating research and development laboratories, are establishing CLIA-certified testing laboratories while others are focused on selling equipment and reagents.

There are a number of companies which are focused on the oncology diagnostic market, who while not currently offering CTC or ctDNA assays are selling to the medical oncologists and pathologists and could develop or offer CTC or ctDNA assays. Large laboratory services companies such as Quest, LabCorp and NeoGenomics provide more generalized cancer diagnostic assays and testing but could also offer a CTC or ctDNA assay service. Companies like Abbott, Danaher and others could develop equipment or reagents in the future as well. Currently, companies like Streck, Roche and Exact Sciences offer blood collection tubes, or BCTs, and in the future, companies like Covidien, Beckton Dickinson, Thermo Fisher, and other large medical device companies may develop BCTs as well.

There are a number of companies that are focused on the oncology diagnostic market such as Illumina, Biorad, Sysmex, Qiagen and Thermo Fisher Scientific that are selling equipment and reagents kits for ctDNA assays and assay panels to laboratories that are developing tests that are marketed to medical oncologists and pathologists.

Some of our present and potential competitors have widespread brand recognition and substantially greater financial and technical resources and development, production and marketing capabilities than we do. Others may develop lower-priced, less complex assays that payers, medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians could view as functionally equivalent to our current or planned future assays, which could force us to lower the list price of our assays and impact our operating margins and our ability to achieve and maintain profitability. In addition, technological innovations that result in the creation of enhanced products or diagnostic tools that are more sensitive or specific than ours may enable other clinical laboratories, hospitals, physicians or medical providers to provide specialized products or diagnostic assays similar to ours in a more patient-friendly, efficient or cost-effective manner than is currently possible. If we cannot compete successfully against current or future competitors, we may be unable to increase or create market acceptance and sales of our current or planned future products or assays, which could prevent us from increasing or sustaining our revenues or achieving or sustaining profitability.

We expect that biopharmaceutical companies will increasingly focus attention and resources on the personalized cancer diagnostic sector as the potential and prevalence of molecularly targeted oncology therapies approved by the FDA along with companion diagnostics increases. For example, the FDA has approved three such agents: Xalkori^® from Pfizer Inc. along with its companion anaplastic lymphoma kinase FISH test from Abbott Laboratories, Inc., Zelboraf^® from Daiichi-Sankyo/Genentech/Roche along with its companion BRAF kinase V600 mutation test from Roche Molecular Systems, Inc. and Tafinlar^® from GlaxoSmithKline along with its companion BRAF kinase V600 mutation test from bioMerieux. Since companion diagnostic tests are part of FDA labeling, non-FDA cleared tests such as ours would be considered an off-label use and this may limit our access to this market segment.

Additionally, projects related to cancer diagnostics and particularly genomics have received increased government funding, both in the United States and internationally. As more information regarding cancer genomics becomes available to the public, we anticipate that more products aimed at identifying targeted treatment options will be developed and that these products may compete with ours. In addition, competitors may develop their own versions of our current or planned future products or assays in countries where we did not apply for patents or where our patents have not issued and compete with us in those countries, including encouraging the use of their product or assay by physicians or patients in other countries.

*We expect to continue to incur significant expenses to develop and market products and diagnostic assays, which could make it difficult for us to achieve and sustain profitability.

In recent years, we have incurred significant costs in connection with the development of our products and diagnostic assays. For the year ended December 31, 2018 and the nine months ended September 30, 2019, our research and development expenses were $4.5 million and $3.5 million, respectively, and our sales and marketing expenses were $5.9 million and $4.5 million, respectively. We expect our expenses to continue to increase for the foreseeable future as we conduct studies of our current products, assays and services and our planned future products, assays and services, continue to establish our sales and marketing organization, drive adoption of and reimbursement for our products and diagnostic assays and develop new products, assays and services. As a result, we need to generate significant revenues in order to achieve sustained profitability.

If medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians decide not to order our current or planned future assays, or if laboratory supply distributors or their customers decide not to order our current or planned future products, we may be unable to generate sufficient revenue to sustain our business.

To generate demand for our current products, assays and services and our planned future products, assays and services, we will need to educate medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, and other physicians and other health care professionals, as well as laboratory and medical equipment suppliers, on the clinical utility, benefits and value of the products, assays and services we provide through published papers, presentations at scientific conferences, educational programs and one-on-one education sessions by members of our sales force. In addition, we need to educate medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians of our ability to obtain and maintain coverage and adequate reimbursement from third-party payers. We need to hire additional commercial, scientific, technical and other personnel to support this process. Unless an adequate number of medical practitioners order our current assays and our planned future assays, or unless an adequate number of laboratory supply distributors order our current and planned future products, we will likely be unable to create demand in sufficient volume for us to achieve sustained profitability.

Clinical utility studies are important in demonstrating to both customers and payers an assay’s clinical relevance and value. If we are unable to identify collaborators willing to work with us to conduct clinical utility studies, or the results of those studies do not demonstrate that an assay provides clinically meaningful information and value, commercial adoption of such assay may be slow, which would negatively impact our business.

Clinical utility studies show when and how to use a clinical test or assay and describe the particular clinical situations or settings in which it can be applied and the expected results. Clinical utility studies also show the impact of the test or assay results on patient care and management. Clinical utility studies are typically performed with collaborating oncologists or other physicians at medical centers and hospitals, analogous to a clinical trial, and generally result in peer-reviewed publications. Sales and marketing representatives use these publications to demonstrate to customers how to use a clinical test or assay, as well as why they should use it. These publications are also used with payers to obtain coverage for a test or assay, helping to assure there is appropriate reimbursement.

We need to conduct additional studies for our assays, increase assay adoption in the marketplace and obtain coverage and adequate reimbursement. Should we not be able to perform these studies, or should their results not provide clinically meaningful data and value for medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians, adoption of our assays could be impaired, and we may not be able to obtain coverage and adequate reimbursement for them.

The loss of key members of our executive management team could adversely affect our business.

Our success in implementing our business strategy depends largely on the skills, experience and performance of key members of our executive management team and others in key management positions, including Michael W. Nall, our Chief Executive Officer and President, Lyle J. Arnold, Ph.D., our Senior Vice-President of Research & Development and Chief Scientific Officer, Michael Terry, our Senior Vice President Corporate Development, Edwin Hendrick, our Senior Vice President Chief Commercial Officer, and Timothy C. Kennedy, our Chief Financial Officer, Senior Vice President of Operations and Secretary. The collective efforts of each of these persons and others working with them as a team are critical to us as we continue to develop our technologies, products, services, assays and research and development and sales programs. As a result of the difficulty in locating qualified new management, the loss or incapacity of existing members of our executive management team could adversely affect our operations. If we were to lose one or more of these key employees, we could experience difficulties in finding qualified successors, competing effectively, developing our technologies and implementing our business strategy. Our executive management team each have employment agreements, however, the existence of an employment agreement does not guarantee retention of members of our executive management team and we may not be able to retain those individuals for the duration of or beyond the end of their respective terms. We do not maintain “key person” life insurance on any of our employees.

In addition, we rely on collaborators, consultants and advisors, including scientific and clinical advisors, to assist us in formulating our research and development and commercialization strategy. Our collaborators, consultants and advisors are generally employed by employers other than us and may have commitments under agreements with other entities that may limit their availability to us.

The loss of a key employee, the failure of a key employee to perform in his or her current position or our inability to attract and retain skilled employees could result in our inability to continue to grow our business or to implement our business strategy.

There is a scarcity of experienced professionals in our industry. If we are not able to retain and recruit personnel with the requisite technical skills, we may be unable to successfully execute our business strategy.

The specialized nature of our industry results in an inherent scarcity of experienced personnel in the field. Our future success depends upon our ability to attract and retain highly skilled personnel, including scientific, technical, commercial, business, regulatory and administrative personnel, necessary to support our anticipated growth, develop our business and perform certain contractual obligations. Given the scarcity of professionals with the scientific knowledge that we require and the competition for qualified personnel among life science businesses, we may not succeed in attracting or retaining the personnel we require to continue and grow our operations.

Our failure to continue to attract, hire and retain a sufficient number of qualified sales professionals would hamper our ability to increase demand for our products and diagnostic assays, to expand geographically and to successfully commercialize any other products or assays we may develop.

To succeed in selling our products and diagnostic assays and any other products or assays that we are able to develop, we must expand our sales force in the United States and/or internationally by recruiting additional sales representatives with extensive experience in oncology and established relationships with medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, oncology nurses, and other physicians and hospital personnel, as well as laboratory supply distributors. To achieve our marketing and sales goals, we will need to continue to build our sales and commercial infrastructure. Sales professionals with the necessary technical and business qualifications are in high demand, and there is a risk that we may be unable to attract, hire and retain the number of sales professionals with the right qualifications, scientific backgrounds and relationships with decision-makers at potential customers needed to achieve our sales goals. We expect to face competition from other companies in our industry, some of whom are much larger than us and who can pay greater compensation and benefits than we can, in seeking to attract and retain qualified sales and marketing employees. If we are unable to hire and retain qualified sales and marketing personnel, our business will suffer.

Our dependence on commercialization partners for sales of products, assays and services could limit our success in realizing revenue growth.

We intend to grow our business through the use of commercialization partners for the sales, marketing and commercialization of our current products, assays and services, as well as our planned future products, assays and services, and to do so we must enter into agreements with these partners to sell, market or commercialize our products, assays and services. These agreements may contain exclusivity provisions and generally cannot be terminated without cause during the term of the agreement. We may need to attract additional partners to expand the markets in which we sell products or assays. These partners may not commit the necessary resources to market and sell our products and diagnostics assays to the level of our expectations, and we may be unable to locate suitable alternatives should we terminate our agreement with such partners or if such partners terminate their agreement with us.

If current or future commercialization partners do not perform adequately, or we are unable to locate commercialization partners, we may not realize revenue growth.

We depend on third parties for the supply of blood samples and other biological materials that we use in our research and development efforts. If the costs of such samples and materials increase or our third-party suppliers terminate their relationship with us, our business may be materially harmed.

We have relationships with suppliers and institutions that provide us with blood samples and other biological materials that we use in developing and validating our current assays and our planned future assays. If one or more suppliers terminate their relationship with us or are unable to meet our requirements for samples, we will need to identify other third parties to provide us with blood samples and biological materials, which could result in a delay in our research and development activities and negatively affect our business. In addition, as we grow, our research and academic institution collaborators may seek additional financial contributions from us, which may negatively affect our results of operations.

We currently rely on third-party suppliers for our BCTs, shipping kits, and critical materials needed to perform our current assays, as well as our planned future products, assays and services, and any problems experienced by them could result in a delay or interruption of their supply to us.

We currently purchase our BCTs and raw materials for our microfluidic channels and assay reagents under purchase orders and do not have long-term contracts with most of the suppliers of these materials. If suppliers were to delay or stop producing our BCTs, shipping kits, materials or reagents, or if the prices they charge us were to increase significantly, or if they elected not to sell to us, we would need to identify other suppliers. We could experience delays in obtaining BCTs and shipping kits, manufacturing the microfluidic channels, or performing assays while finding another acceptable supplier, which could impact our results of operations. The changes could also result in increased costs associated with qualifying the new BCTs, shipping kits, materials or reagents and in increased operating costs. Further, any prolonged disruption in a supplier’s operations could have a significant negative impact on our ability to perform diagnostic assays in a timely manner and sell our products.

Some of the components used in our current or planned future products are currently sourced from a supplier for which alternative suppliers exist but we have not validated the products of such alternative suppliers, and substitutes for these components might not be able to be obtained easily or may require substantial design or manufacturing modifications. Any significant problem experienced by any one of our suppliers may result in a delay or interruption in the supply of components to us until that supplier cures the problem or an alternative source of the component is located and qualified. Any delay or interruption would likely lead to a delay or interruption in our manufacturing operations or product sales. The inclusion of substitute components must meet our product specifications and could require us to qualify the new supplier with the appropriate government regulatory authorities.

If we were sued for product liability or professional liability, we could face substantial liabilities that exceed our resources.

The marketing, sale and use of our products and current assays, as well our planned future products, assays and services, could lead to the filing of product liability claims against us if someone alleges that our products or assays failed to perform as designed. We may also be subject to liability for errors in the assay results we provide to physicians or for a misunderstanding of, or inappropriate reliance upon, the information we provide. A product liability or professional liability claim could result in substantial damages and be costly and time-consuming for us to defend.

Although we believe that our existing product and professional liability insurance is adequate, our insurance may not fully protect us from the financial impact of defending against product liability or professional liability claims. Any product liability or professional liability claim brought against us, with or without merit, could increase our insurance rates or prevent us from securing insurance coverage in the future. Additionally, any product liability lawsuit could damage our reputation, result in the recall of products or assays, or cause current partners to terminate existing agreements and potential partners to seek other partners, any of which could impact our results of operations.

If we use biological and hazardous materials in a manner that causes injury, we could be liable for damages.

Our activities currently require the controlled use of potentially harmful biological materials and chemicals. We cannot eliminate the risk of accidental contamination or injury to employees or third parties from the use, storage, handling or disposal of these materials. In the event of contamination or injury, we could be held liable for any resulting damages, and any liability could exceed our resources or any applicable insurance coverage we may have. Additionally, we are subject to, on an ongoing basis, federal, state and local laws and regulations governing the use, storage, handling and disposal of these materials and specified waste products. The cost of compliance with these laws and regulations may become significant and could have a material adverse effect on our financial condition, results of operations and cash flows. In the event of an accident or if we otherwise fail to comply with applicable regulations, we could lose our permits or approvals or be held liable for damages or penalized with fines.

We may acquire other businesses or form joint ventures or make investments in other companies or technologies that could harm our operating results, dilute our stockholders’ ownership, increase our debt or cause us to incur significant expense.

As part of our business strategy, we may pursue acquisitions of businesses and assets. We also may pursue strategic alliances and joint ventures that leverage our core technology and industry experience to expand our offerings or distribution. We have no experience with acquiring other companies and limited experience with forming strategic alliances and joint ventures. We may not be able to find suitable partners or acquisition candidates, and we may not be able to complete such transactions on favorable terms, if at all. If we make any acquisitions, we may not be able to integrate these acquisitions successfully into our existing business, and we could assume unknown or contingent liabilities. Any future acquisitions also could result in significant write-offs or the incurrence of debt and contingent liabilities, any of which could have a material adverse effect on our financial condition, results of operations and cash flows. Integration of an acquired company also may disrupt ongoing operations and require management resources that would otherwise focus on developing our existing business. We may experience losses related to investments in other companies, which could have a material negative effect on our results of operations. We may not identify or complete these transactions in a timely manner, on a cost-effective basis, or at all, and we may not realize the anticipated benefits of any acquisition, technology license, strategic alliance or joint venture.

To finance any acquisitions or joint ventures, we may choose to issue shares of our common stock as consideration, which would dilute the ownership of our stockholders. If the price of our common stock is low or volatile, we may not be able to acquire other companies or fund a joint venture project using our stock as consideration. Alternatively, it may be necessary for us to raise additional funds for acquisitions through public or private financings. Additional funds may not be available on terms that are favorable to us, or at all.

If we cannot support demand for our current products, assays and services, as well as our planned future products, assays and services, including successfully managing the evolution of our laboratory service, our business could suffer.

As our product and assay volume grows, we will need to increase our assay capacity, implement automation, increase our scale and related processing, customer service, billing, collection and systems process improvements and expand our internal quality assurance program and technology to support assays on a larger scale. Examples of challenges we may face include, but are not limited to, maintaining the same validated sensitivity in our assays for both CTC and ctDNA analysis as our assay volume increases. We will also need additional clinical laboratory scientists and other scientific and technical personnel to process these additional assays. Any increases in scale, related improvements and quality assurance may not be successfully implemented and appropriate personnel may not be available. As additional products, assays and services are commercialized, we may need to bring new equipment on line, implement new systems, technology, controls and procedures and hire personnel with different qualifications. Failure to implement or maintain necessary procedures or to hire the necessary personnel could result in a higher cost of processing or an inability to meet market demand. We cannot assure you that we will be able to perform assays on a timely basis, or procure BCTs, shipping kits or other materials we sell, at a level consistent with demand, that our efforts to scale our commercial operations will not negatively affect the quality of our assay results, or that we will respond successfully to the growing complexity of our operations. If we encounter difficulty meeting market demand or quality standards for our current products, assays and services and our planned future products, assays and services, including with respect to our assays our ability to maintain the sensitivity, specificity, concordance and reproducibility of such assays, our reputation could be harmed, and our future prospects and business could suffer, which may have a material adverse effect on our financial condition, results of operations and cash flows.

Billing for our diagnostic assays is complex, and we must dedicate substantial time and resources to the billing process to be paid.

Billing for clinical laboratory assay services is complex, time-consuming and expensive. Depending on the billing arrangement and applicable law, we bill various payers, including Medicare, insurance companies and patients, all of which have different billing requirements. We generally bill third-party payers for our diagnostic assays and pursue reimbursement on a case-by-case basis where pricing contracts are not in place. To the extent laws or contracts require us to bill patient co-payments or co-insurance, we must also comply with these requirements. We may also face increased risk in our collection efforts, including potential write-offs of doubtful accounts and long collection cycles, which could adversely affect our business, results of operations and financial condition.

Several factors make the billing process complex, including:

•

differences between the list price for our assays and the reimbursement rates of payers;

•

compliance with complex federal and state regulations related to billing Medicare;

•

risk of government audits related to billing Medicare;

•

disputes among payers as to which party is responsible for payment;

•

differences in coverage and in information and billing requirements among payers, including the need for prior authorization and/or advanced notification;

•

the effect of patient co-payments or co-insurance;

•

changes to billing codes and/or coverage policies that apply to our assays;

•

incorrect or missing billing information; and

•

the resources required to manage the billing and claims appeals process.

We use standard industry billing codes, known as Current Procedural Terminology, or CPT, codes, to bill for our diagnostic assays. These codes can change over time. When codes change, there is a risk of an error being made in the claim adjudication process. These errors can occur with claims submission, third-party transmission or in the processing of the claim by the payer. Claim adjudication errors may result in a delay in payment processing or a reduction in the amount of the payment received. Coding changes, therefore, may have an adverse effect on our revenues. There can be no assurance that payers will recognize these codes in a timely manner or that the process of transitioning to such a code and updating their billing systems and ours will not result in errors, delays in payments and a related increase in accounts receivable balances.

As we introduce new assays, we will need to add new codes to our billing process as well as our financial reporting systems. Failure or delays in effecting these changes in external billing and internal systems and processes could negatively affect our collection rates, revenue and cost of collecting.

Additionally, our billing activities require us to implement compliance procedures and oversight, train and monitor our employees, challenge coverage and payment denials, assist patients in appealing claims, and undertake internal audits to evaluate compliance with applicable laws and regulations as well as internal compliance policies and procedures. Payers also conduct external audits to evaluate payments, which add further complexity to the billing process. If the payer makes an overpayment determination, there is a risk that we may be required to return some portion of prior payments we have received. These billing complexities, and the related uncertainty in obtaining payment for our assays, could negatively affect our revenue and cash flow, our ability to achieve profitability, and the consistency and comparability of our results of operations.

We rely on third-party billing provider software, and an in-house billing function, to transmit claims to payers, and any delay in transmitting claims could have an adverse effect on our revenue.

While we manage the overall processing of claims, we rely on third-party billing provider software to transmit the actual claims to payers based on the specific payer billing format. We have previously experienced delays in claims processing when our third-party provider made changes to its invoicing system. Additionally, coding for diagnostic assays may change, and such changes may cause short-term billing errors that may take significant time to resolve. If claims are not submitted to payers on a timely basis or are erroneously submitted, or if we are required to switch to a different software provider to handle claim submissions, we may experience delays in our ability to process these claims and receipt of payments from payers, or possibly denial of claims for lack of timely submission, which would have an adverse effect on our revenue and our business.

We may encounter manufacturing problems or delays that could result in lost revenue.

We currently manufacture our proprietary microfluidic channels at our San Diego facility and intend to continue to do so. We believe we currently have adequate manufacturing capacity for our microfluidic channels. If demand for our current products, assays and services and our planned future products, assays and services increases significantly, we will need to either expand our manufacturing capabilities or outsource to other manufacturers. If we or third-party manufacturers engaged by us fail to manufacture and deliver our microfluidic channels or certain reagents in a timely manner, our relationships with our customers could be seriously harmed. We cannot assure you that manufacturing, or quality control problems will not arise as we attempt to increase the production of our microfluidic channels or reagents or that we can increase our manufacturing capabilities and maintain quality control in a timely manner or at commercially reasonable costs. If we cannot manufacture our microfluidic channels consistently on a timely basis because of these or other factors, it could have a significant negative impact on our ability to perform assays and generate revenues.

International expansion of our business would expose us to business, regulatory, political, operational, financial and economic risks associated with doing business outside of the United States.

Our business strategy is to pursue increased international expansion, including partnering with academic and commercial testing laboratories, and introducing our technology outside the United States as part of IVD test kits and/or testing systems utilizing our technologies. Doing business internationally involves a number of risks, including:

•	multiple, conflicting and changing laws and regulations such as tax laws, export and import restrictions, employment laws, regulatory requirements and other governmental approvals, permits and licenses;

•	failure by us or our distributors to obtain regulatory approvals for the sale or use of our current products or assays and our planned future products or assays in various countries;

•	difficulties in managing foreign operations;

•	complexities associated with managing government payer systems, multiple payer-reimbursement regimes or self-pay systems;

•	logistics and regulations associated with shipping blood samples, including infrastructure conditions and transportation delays;

•	limits on our ability to penetrate international markets if our current products or assays and our planned future products or assays cannot be processed by an appropriately qualified local laboratory;

•	financial risks, such as longer payment cycles, difficulty enforcing contracts and collecting accounts receivable and exposure to foreign currency exchange rate fluctuations;

•	reduced protection for intellectual property rights, or lack of them in certain jurisdictions, forcing more reliance on our trade secrets, if available;

•	natural disasters, political and economic instability, including wars, terrorism and political unrest, outbreak of disease, boycotts, curtailment of trade and other business restrictions; and

•	failure to comply with the Foreign Corrupt Practices Act, including its books and records provisions and its anti-bribery provisions, by maintaining accurate information and control over sales activities and distributors’ activities.

Any of these risks, if encountered, could significantly harm our future international expansion and operations and consequently, have a material adverse effect on our financial condition, results of operations and cash flows.

General economic or business conditions may have a negative impact on our business.

Continuing concerns over United States health care reform legislation and energy costs, geopolitical issues, the availability and cost of credit and government stimulus programs in the United States and other countries have contributed to increased volatility and diminished expectations for the global economy. These factors, combined with low business and consumer confidence and high unemployment, precipitated an economic slowdown and recession. If the economic climate deteriorates, our business, including our access to patient samples and the addressable market for products or diagnostic assays that we may successfully develop, as well as the financial condition of our suppliers and our third-party payers, could be adversely affected, resulting in a negative impact on our business, financial condition and results of operations.

Intrusions into our computer systems could result in compromise of confidential information.

Despite the implementation of security measures, our technology or systems that we interface with, including the Internet and related systems, may be vulnerable to physical break-ins, hackers, improper employee or contractor access, computer viruses, programming errors, or similar problems. Any of these might result in confidential medical, business or other information of other persons or of ourselves being revealed to unauthorized persons.

There are a number of state, federal and international laws protecting the privacy and security of health information and personal data. The Health Information Technology for Economic and Clinical Health Act of 2009, or HITECH, amended the privacy and security provisions of the Health Insurance Portability and Accountability Act, or HIPAA. HIPAA imposes limitations on the use and disclosure of an individual’s healthcare information by certain healthcare providers, healthcare clearinghouses, and health insurance plans, collectively referred to as covered entities, and also grants individuals rights with respect to their health information. HIPAA also imposes compliance obligations and corresponding penalties for non-compliance on individuals and entities that provide services to healthcare providers and other covered entities, collectively referred to as business associates. HITECH also made significant increases in the penalties for improper use or disclosure of an individual’s health information under HIPAA and extended enforcement authority to state attorneys general. As amended by HITECH and subsequently by the final omnibus rule adopted in 2013, or Final Omnibus Rule, HIPAA also imposes notification requirements on covered entities in the event that certain health information has been inappropriately accessed or disclosed: notification requirements to individuals, federal regulators, and in some cases, notification to local and national media. Notification is not required under HIPAA if the health information that is improperly used or disclosed is

deemed secured in accordance with encryption or other standards developed by the U.S. Department of Health and Human Services, or HHS. Most states have laws requiring notification of affected individuals and/or state regulators in the event of a breach of personal information, which is a broader class of information than the health information protected by HIPAA. Many state laws impose significant data security requirements, such as encryption or mandatory contractual terms to ensure ongoing protection of personal information. Activities outside of the United States implicate local and national data protection standards, impose additional compliance requirements and generate additional risks of enforcement for non-compliance. For example, if we obtain certain personal information regarding residents in the European Union, we may be subject to the European Union General Data Protection Regulation. We may be required to expend significant capital and other resources to ensure ongoing compliance with applicable privacy and data security laws, to protect against security breaches and hackers or to alleviate problems caused by such breaches.

We depend on our information technology and telecommunications systems, and any failure of these systems could harm our business.

We depend on information technology and telecommunications systems for significant aspects of our operations. In addition, our third-party billing software provider depends upon telecommunications and data systems provided by outside vendors and information we provide on a regular basis. These information technology and telecommunications systems support a variety of functions, including assay processing, sample tracking, quality control, customer service and support, billing and reimbursement, research and development activities and our general and administrative activities. Information technology and telecommunications systems are vulnerable to damage from a variety of sources, including telecommunications or network failures, malicious human acts and natural disasters. Moreover, despite network security and back-up measures, some of our servers are potentially vulnerable to physical or electronic break-ins, computer viruses and similar disruptive problems. Despite the precautionary measures we have taken to prevent unanticipated problems that could affect our information technology and telecommunications systems, failures or significant downtime of our information technology or telecommunications systems or those used by our third-party service providers could prevent us from processing assays, providing assay results to medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists, other physicians, billing payers, processing reimbursement appeals, handling patient or physician inquiries, conducting research and development activities and managing the administrative aspects of our business. Any disruption or loss of information technology or telecommunications systems on which critical aspects of our operations depend could have an adverse effect on our business.

Regulatory Risks Relating to Our Business

Healthcare policy changes, including recently enacted legislation reforming the U.S. health care system, may have a material adverse effect on our financial condition, results of operations and cash flows.

The Patient Protection and Affordable Care Act, as amended by the Health Care and Education Reconciliation Act, or collectively the ACA, enacted in March 2010, makes a number of substantial changes in the way health care is financed by both governmental and private insurers. Among other things, the ACA requires each certain medical device manufacturer to pay an excise tax equal to 2.3%, or Medical Device Excise Tax, of the price for which such manufacturer sells its medical devices that are listed with the FDA. We believe that at this time this tax does not apply to our current diagnostic assays or to our products that are currently sold or in development; nevertheless, this could change in the future if either the FDA or the Internal Revenue Service, which regulates the payment of this excise tax, changes its position.

Although some of these provisions may negatively impact payment rates for clinical laboratory tests, the ACA also extends coverage to over 30 million previously uninsured people, which may result in an increase in the demand for our current assays and our planned future assays. Since January 2017, the President of the United States has signed two executive orders and other directives designed to delay, circumvent, or loosen certain requirements mandated by the ACA. Concurrently, Congress has considered legislation that would repeal or repeal and replace all or part of the ACA. While Congress has not passed repeal legislation, it has enacted laws that modify certain provisions of the ACA such as removing penalties starting January 1, 2019, for not complying with the ACA’s individual mandate to carry health insurance and delaying the implementation of certain ACA-mandated fees, including but not limited the Medical Device Excise Tax. On December 14, 2018, a Texas U.S. District Court Judge ruled that the ACA is unconstitutional in its entirety because the “individual mandate” was repealed by Congress as part of the Tax Cuts and Jobs Act of 2017. While the Texas U.S. District Court Judge, as well as the Trump administration and CMS, have stated that the ruling will have no immediate effect pending appeal of the decision, it is unclear how this decision, subsequent appeals, and other efforts to repeal and replace the ACA will impact the ACA.

In addition, other legislative changes have been proposed and adopted since the ACA was enacted. The Protecting Access to Medicare Act of 2014, or PAMA, was signed to law, which, among other things, significantly alters the current payment methodology under the CLFS. Under the new law, issued in 2016 and the reporting period beginning in 2017 and every three years thereafter (or annually in the case of advanced diagnostic laboratory tests), clinical laboratories must report laboratory test payment data for each Medicare-covered clinical diagnostic laboratory test that it furnishes during a time period. The reported data must include the payment rate

(reflecting all discounts, rebates, coupons and other price concessions) and the volume of each test that was paid by each private payer (including health insurance issuers, group health plans, Medicare Advantage plans and Medicaid managed care organizations). Beginning in 2018, the Medicare payment rate for each clinical diagnostic laboratory test is equal to the weighted median amount for the test from the most recent data collection period. The payment rate will apply to laboratory tests furnished by a hospital laboratory if the test is separately paid under the hospital outpatient prospective payment system. The PAMA rate changes to our tests that were impacted did not materially affect our payments beginning in 2018; however, we cannot predict how this may change future payment in coming years. Also, under PAMA, the Centers for Medicare & Medicaid Services, or CMS, is required to adopt temporary billing codes to identify new tests and new advanced diagnostic laboratory tests that have been cleared or approved by the FDA. For an existing test that is cleared or approved by the FDA and for which Medicare payment is made as of April 1, 2014, CMS is required to assign a unique billing code if one has not already been assigned by the agency. In addition to assigning the code, CMS was required to publicly report payment for the tests no later than January 1, 2016. Further, under PAMA, CMS is required to adopt temporary billing codes to identify new tests and new advanced diagnostic laboratory tests that have been cleared or approved by the FDA. We cannot determine at this time the full impact of PAMA on our business, financial condition and results of operations.

Additionally, the Budget Control Act of 2011, among other things, created the Joint Select Committee on Deficit Reduction to recommend proposals in spending reductions to Congress. The Joint Select Committee did not achieve its targeted deficit reduction of at least $1.2 trillion for the years 2013 through 2021, triggering the legislation’s automatic reduction to several government programs. This includes aggregate reductions to Medicare payments to providers and suppliers of up to 2% per fiscal year, starting in 2013, and, due to subsequent legislative amendments to the statute, will remain in effect through 2027 unless additional congressional action is taken. The full impact on our business the sequester law is uncertain. In addition, the Middle-Class Tax Relief and Job Creation Act of 2012, or MCTRJCA, mandated an additional change in Medicare reimbursement for clinical laboratory tests.

Some of our laboratory assay business is subject to the Medicare Physician Fee Schedule and, under the current statutory formula, the rates for these services are updated annually. For the past several years, the application of the statutory formula would have resulted in substantial payment reductions if Congress failed to intervene. In the past, Congress passed interim legislation to prevent the decreases. If Congress fails to intervene to prevent the negative update factor in future years, the resulting decrease in payment may adversely affect our revenue and results of operations. If in future years Congress does not adopt interim legislation to block or offset, and/or CMS does not moderate, any substantial CMS-proposed reimbursement reductions, the resulting decrease in payments from Medicare could adversely impact our revenues and results of operations.

We cannot predict whether future health care initiatives will be implemented at the federal or state level, or how any future legislation or regulation may affect us. The expansion of government’s role in the U.S. health care industry, and changes to the reimbursement amounts paid by Medicare and other payers for our current assays and our planned future assays, may reduce our profits, if any, and have a materially adverse effect on our business, financial condition, results of operations and cash flows. Moreover, Congress has proposed on several occasions to impose a 20% coinsurance payment requirement on patients for clinical laboratory tests reimbursed under the Medicare Clinical Laboratory Fee Schedule, which would require us to bill patients for these amounts. In the event that Congress were to ever enact such legislation, the cost of billing and collecting for our assays could often exceed the amount actually received from the patient.

Our commercial success could be compromised if hospitals or other clients do not pay our invoices or if third-party payers, including managed care organizations and Medicare, do not provide coverage and reimbursement, breach, rescind or modify their contracts or reimbursement policies or delay payments for our current assays and our planned future assays.

Medical oncologists, surgical oncologists, urologists, pulmonologists, pathologists and other physicians may not order our current assays and our planned future assays unless third-party payers, such as managed care organizations and government payers (e.g., Medicare and Medicaid), pay a substantial portion of the assay price. Coverage and reimbursement by a third-party payer may depend on a number of factors, including a payer’s determination that assays using our technologies are:

•	not experimental or investigational;

•	medically necessary;

•	appropriate for the specific patient;

•	cost-effective;

•	supported by peer-reviewed publications; and

•	included in clinical practice guidelines.

Uncertainty surrounds third-party payer coverage and adequate reimbursement of any test incorporating new technology, including tests developed using our technologies. Technology assessments of new medical tests conducted by research centers and other entities may be disseminated to interested parties for informational purposes. Third-party payers and health care providers may use such

technology assessments as grounds to deny coverage for a test or procedure. Technology assessments can include evaluation of clinical utility studies, which define how a test is used in a particular clinical setting or situation.

Because each payer generally determines for its own enrollees or insured patients whether to cover or otherwise establish a policy to reimburse our diagnostic assays, seeking payer approvals is a time-consuming and costly process. We cannot be certain that coverage for our current assays and our planned future assays will be provided in the future by additional third-party payers or that existing agreements, policy decisions or reimbursement levels will remain in place or be fulfilled under existing terms and provisions. If we cannot obtain coverage and adequate reimbursement from private and governmental payers such as Medicare and Medicaid for our current assays, or new assays or assay enhancements that we may develop in the future, our ability to generate revenues could be limited, which may have a material adverse effect on our financial condition, results of operations and cash flow. Further, we may experience delays and interruptions in the receipt of payments from third-party payers due to missing documentation and/or other issues, which could cause delay in collecting our revenue.

In addition, to the extent that our assays are ordered for Medicare inpatients and outpatients, only the hospital may receive payment from the Medicare program for the technical component of pathology services and any clinical laboratory services that we perform, unless the testing is ordered at least 14 days after discharge and certain other requirements are met. We therefore must look to the hospital for payment for these services under these circumstances. If hospitals refuse to pay for the services or fail to pay in a timely manner, our ability to generate revenues could be limited, which may have a material adverse effect on our financial condition, results of operations and cash flow.

*We expect to depend on Medicare and a limited number of private payers for a significant portion of our revenues and if these or other payers stop providing reimbursement or decrease the amount of reimbursement for our current assays and our planned future assays, our revenues could decline.

Approximately 39% and 40% of total net revenues during the year ended December 31, 2018 and the nine months ended September 30, 2019, respectively, were associated with Medicare reimbursement. Approximately 11% and 20% of total net revenues during the year ended December 31, 2018 and the nine month period ended September 30, 2019, respectively, were associated with Blue Cross Blue Shield reimbursement, and approximately 17% and 8% of total net revenues during the year ended December 31, 2018 and the nine month period ended September 30, 2019, respectively, were associated with United Healthcare reimbursement. We cannot assure you that, even if our current assays and our planned future assays are otherwise successful, reimbursement for the currently Medicare, Blue Cross Blue Shield, and United Healthcare covered-portions of our current assays and our planned future assays would, without such contracted payer reimbursement for the capture/enumeration portion, produce sufficient revenues to enable us to reach profitability and achieve our other commercial objectives.

Medicare and other third-party payers may change their coverage policies or cancel future contracts with us at any time, review and adjust the rate of reimbursement or stop paying for our assays altogether, which would reduce our total revenues. Payers have increased their efforts to control the cost, utilization and delivery of health care services. In the past, measures have been undertaken to reduce payment rates for and decrease utilization of clinical laboratory testing generally. Because of the cost-trimming trends, third-party payers that currently cover and provide reimbursement for our current assays and our planned future assays may suspend, revoke or discontinue coverage at any time, or may reduce the reimbursement rates payable to us. Any such action could have a negative impact on our revenues, which may have a material adverse effect on our financial condition, results of operations and cash flows.

In addition, we are currently considered a “non-contracted provider” by many private payers because we have not entered into a specific contract to provide diagnostic assays to their insured patients at specified rates of reimbursement. Additionally, a significant amount of our non-Medicare business (private payers) has historically not been contracted, and reimbursement for this business has historically not been at “in network” rates and has therefore been inconsistent. We first began to contract private payer networks in 2015, and since then our number of accessions treated as “in network” has increased as we continue to execute additional contracts, and reimbursement is improving. We are currently contracted with nine preferred provider organization networks, three large health plans, and five regional independent physician associations, and expect to continue to gain contracts in order to be considered as an “in-network” provider with additional plans. If we were to become a contracted provider with additional payers in the future, the amount of overall reimbursement we receive would likely decrease because we could be reimbursed less money per assay performed at a contracted rate than at a non-contracted rate, which could have a negative impact on our revenues. Further, we typically are unable to collect payments from patients beyond that which is paid by their insurance and will continue to experience lost revenue as a result.

*Because of certain Medicare billing policies, we may not receive complete reimbursement for assays provided to Medicare patients. Medicare reimbursement revenues are an important component of our business model, and private payers sometimes look to Medicare determinations when making their own payment determinations; therefore, incomplete or inadequate reimbursement from Medicare would negatively affect our business.

Medicare has coverage policies that can be national or regional in scope. Coverage means that assay is approved as a benefit for Medicare beneficiaries. If there is no coverage, neither the supplier nor any other party, such as a reference laboratory, may receive

reimbursement from Medicare for the service. There is currently no national coverage policy regarding the CTC enumeration portion of our assays. Because our laboratory is in California, the regional Medicare Administrative Contractor, or MAC, for California is the relevant MAC for all our assays. The previous MAC for California, Palmetto, which is contracted with CMS to administer the Molecular Diagnostic Services, or MolDx, program that sets guidelines for coding, coverage and reimbursement of molecular diagnostic assays, adopted a negative coverage policy for CTC enumeration. The current MAC for California, Noridian Healthcare Solutions, LLC, is adopting the coverage policies from Palmetto. Therefore, the enumeration portion of our assays is not currently covered, and we will receive no payment from Medicare for this portion of the service unless and until the coverage policy is changed. Although approximately 76% and 78% of all billable cases received during the year-ended December 31, 2018 and the nine month period ended September 30, 2019, respectively, relate to our Target-Selector biomarker assays, we continue to receive orders for traditional enumeration testing, which counts disease burden, and therefore the enumeration testing receives no payment from Medicare based upon the existing coverage decision. The CTC enumeration counts disease burden and is a prognostic assay, and although valuable, it does not meet many of the medical necessity requirements of Medicare and the payers. We intend to pursue payment for the capture portion of our CTC technology that allows us to run our diagnostic testing for some of our Target-Selector assays.

We cannot assure you that, even if our current assays and our planned future assays are otherwise successful, reimbursement for the currently Medicare, Blue Cross Blue Shield, and United Healthcare-covered portions of our current assays and our planned future assays would, without such contracted payer reimbursement for the capture/enumeration portion, produce sufficient revenues to enable us to reach profitability and achieve our other commercial objectives.

The processing of Medicare claims is subject to change at CMS’ discretion at any time. Cost containment initiatives may be a threat to Medicare reimbursement levels (including for the covered components of our current assays and our planned future assays, including FISH analysis and molecular assays) for the foreseeable future.

Long payment cycles of Medicare, Medicaid and/or other third-party payers, or other payment delays, could hurt our cash flows and increase our need for working capital.

Medicare and Medicaid have complex billing and documentation requirements that we must satisfy in order to receive payment, and the programs can be expected to carefully audit and monitor our compliance with these requirements. We must also comply with numerous other laws applicable to billing and payment for healthcare services, including, for example, privacy laws. Failure to comply with these requirements may result in, among other things, non-payment, refunds, exclusion from government healthcare programs, and civil or criminal liabilities, any of which may have a material adverse effect on our revenues and earnings. In addition, failure by third-party payers to properly process our payment claims in a timely manner could delay our receipt of payment for our products and services, which may have a material adverse effect on our cash flows.

Complying with numerous regulations pertaining to our business is an expensive and time-consuming process, and any failure to comply could result in substantial penalties.

We are subject to CLIA, a federal law regulating clinical laboratories that perform testing on specimens derived from humans for the purpose of providing information for the diagnosis, prevention or treatment of disease. Our clinical laboratory must be certified under CLIA in order for us to perform testing on human specimens. CLIA is intended to ensure the quality and reliability of clinical laboratories in the United States by mandating specific standards in the areas of personnel qualifications, administration, and participation in proficiency testing, patient test management, quality control, quality assurance and inspections. We have a current certificate of accreditation under CLIA to perform high complexity testing, and our laboratory is accredited by the College of American Pathologists, or CAP, one of six CLIA-approved accreditation organizations. To renew this certificate, we are subject to survey and inspection every two years. Moreover, CLIA and CAP inspectors may make periodic inspections of our clinical laboratory outside of the renewal process. The failure to comply with CLIA or CAP requirements can result in enforcement actions, including the revocation, suspension, or limitation of our CLIA and/or CAP certificate of accreditation, as well as a directed plan of correction, state on-site monitoring, civil money penalties, civil injunctive suit and/or criminal penalties. We must maintain CLIA compliance and certification to be eligible to bill for assays provided to Medicare beneficiaries. If we were to be found out of compliance with CLIA program requirements and subjected to sanctions, our business and reputation could be harmed. Even if it were possible for us to bring our laboratory back into compliance, we could incur significant expenses and potentially lose revenue in doing so.

In addition, our laboratory is located in California and is required by state law to have a California state license; as we expand our geographic focus, we may need to obtain laboratory licenses from additional states. California laws establish standards for operation of our clinical laboratory, including the training and skills required of personnel and quality control. In addition, we hold licenses from the states of Pennsylvania, Maryland and Rhode Island to test specimens from patients in those states or received from ordering physicians in those states. In addition, our clinical reference laboratory is required to be licensed on a product-specific basis by New York as an out of state laboratory and our products, as LDTs, must be approved by the New York State Department of Health before they are offered in New York. As part of this process, the State of New York requires validation of our assays. We currently do not have the necessary New York license, but we are in the process of addressing the requirements for licensure in New York. Other states

may have similar requirements or may adopt similar requirements in the future. Finally, we may be subject to regulation in foreign jurisdictions if we seek to expand international distribution of our assays outside the United States.

If we were to lose our CLIA certification or California laboratory license, whether as a result of a revocation, suspension or limitation, we would no longer be able to offer our assays, which would limit our revenues and harm our business. If we were to lose, or fail to obtain, a license in any other state where we are required to hold a license, we would not be able to test specimens from those states. If we were to lose our CAP accreditation, our reputation for quality, as well as our business, financial condition and results of operations, could be significantly and adversely affected.

If the FDA were to begin requiring approval or clearance of our current products or assays and our planned future products or assays, we could incur substantial costs and time delays associated with meeting requirements for pre-market clearance or approval or we could experience decreased demand for, or reimbursement of, our assays.

We provide our assays as LDTs. Historically; the FDA has exercised enforcement discretion with respect to most LDTs and has not required laboratories that offer LDTs to comply with the agency’s requirements for medical devices (e.g., establishment registration, device listing, quality systems regulations, premarket clearance or premarket approval, and post-market controls). In recent years, however, the FDA has stated it intends to end its policy of enforcement discretion and regulate certain LDTs as medical devices. To this end, on October 3, 2014, the FDA issued two draft guidance documents, entitled “Framework for Regulatory Oversight of Laboratory Developed Tests (LDTs)” and “FDA Notification and Medical Device Reporting for Laboratory Developed Tests (LDTs)”, respectively, that set forth a proposed risk-based regulatory framework that would apply varying levels of FDA oversight to LDTs. The FDA has indicated that it does not intend to modify its policy of enforcement discretion until the draft guidance documents are finalized. In January 2017, the FDA announced that final guidance on the oversight of LDTs would allow for further public discussion. On January 13, 2017 the FDA issued a “Discussion Paper on Laboratory Developed Tests (LDTs),” which states that the material in the document does not represent a final version of the LDT draft guidance documents that were published in 2014 or position of the FDA; rather, the document is a method to encourage additional dialogue. The timing of when, if at all, the draft guidance documents will be finalized is unclear, and even then, the new regulatory requirements are proposed to be phased-in consistent with the schedule set forth in the guidance. Nevertheless, the FDA may decide to regulate certain LDTs on a case-by-case basis at any time. LDTs with the same intended use as a cleared or approved companion diagnostic are defined in FDA’s draft guidance as “high-risk LDTs (Class III medical devices)” for which premarket review would be first to occur.

FDA review, if required and successfully accomplished, would be expected to have some advantages. Certain health insurance payers have paid higher amounts over LDT prices for FDA approved or cleared tests, recognizing the additional costs of bringing a test through regulatory review. Some payers also accept FDA approval or clearance as a presumptive evidence of an assay’s analytic validity and clinical validity, which can reduce the barriers to coverage since the payer can focus its review on clinical utility.

The container we provide for collection and transport of blood samples from a health care provider to our clinical laboratory, as well as our BCTs, may be medical devices subject to the FDA regulation but are currently exempt from pre-market review by the FDA. While we believe that we are currently in material compliance with applicable laws and regulations, we cannot assure you that the FDA or other regulatory agencies would agree with our determination, and a determination that we have violated these laws, or a public announcement that we are being investigated for possible violations of these laws, could adversely affect our business, prospects, results of operations or financial condition.

Some of the materials we use for our current products, assays and services and may use in our planned future products, assays and services are labeled for RUO. In November 2013, the FDA finalized guidance regarding the sale and use of products labeled for research or investigational use only. Among other things, the guidance advises that the FDA continues to be concerned about distribution of research or investigational use only products intended for clinical diagnostic use and that the manufacturer’s objective intent for the product’s intended use will be determined by examining the totality of circumstances, including advertising, instructions for clinical interpretation, presentations that describe clinical use, and specialized technical support, surrounding the distribution of the product in question. The FDA has advised that if evidence demonstrates that a product is inappropriately labeled for research or investigational use only, the device would be misbranded and adulterated within the meaning of the Federal Food, Drug and Cosmetic Act. Some of the materials and reagents obtained by us from suppliers for use in our current products, assays and services and our planned future products, assays and services are currently labeled as research or investigational use only products. If the FDA were to undertake enforcement actions, some of our suppliers might cease selling research or investigational use products to us, and any failure to obtain an acceptable substitute could significantly and adversely affect our business, financial condition and results of operations, including increasing the cost of materials or reagents used in our current products, assays and services or planned future products, assays and services or delaying, limiting or prohibiting the purchase of materials or reagents necessary to sell our current products or planned future products or to perform our current assays or our planned future assays.

Our BCTs and Target Selector kits are marketed for RUO and distributed and sold to end users, some of which will be researchers and institutions while other end users could be labs performing clinical testing that will create their own LDTs. Some end users may assert

that our ROU products caused their assays to perform inadequately or give erroneous results. If that was the case, we could potentially incur additional liabilities.

Further, HHS requested that its Advisory Committee on Genetics, Health and Society make recommendations about the oversight of genetic testing. A final report was published in April 2008. If the report’s recommendations for increased oversight of genetic testing were to result in further regulatory burdens, they could negatively affect our business and delay the commercialization of assays in development.

Additionally, on March 16, 2018 CMS issued a final determination decision memo for Next-Generation Sequencing, or NGS, tests for Medicare Beneficiaries with Advanced Cancer (CAG-00450N). Under this final determination, NGS tests that gain FDA approval or clearance as a companion diagnostic will receive coverage, and the final determination of coverage for NGS tests that are LDTs will be left up to the local MAC. Currently, only 1 of our 15 CLIA validated assays is NGS-based; however, we plan to offer additional NGS assays in the future. To gain coverage for those assays, we will need to apply to Palmetto, which is the MAC that evaluates and recommends payment coverage or denial for molecular testing in our jurisdiction. Historically, Palmetto has offered a path to reimbursement by providing coverage while data is being gathered known as Coverage with Data Development, or CDD. Going forward, the extent to which CDD will be continued, if at all, or to the extent that a process will be available in its place, if any, are unclear.

The requirement of pre-market review could negatively affect our business until such review is completed and clearance to market or approval is obtained. The FDA could require that we stop selling our products or diagnostic assays pending pre-market clearance or approval. If the FDA allows our products or assays to remain on the market but there is uncertainty about our products or assays, if they are labeled investigational by the FDA or if labeling claims the FDA allows us to make are very limited, orders from laboratory supply distributors and physicians, or reimbursement from third-party payers, may decline. The regulatory approval process may involve, among other things, successfully completing additional clinical trials and making a 510(k) submission or filing a pre-market approval application with the FDA. If the FDA requires pre-market review, our products or assays may not be cleared or approved on a timely basis, if at all. We may also decide voluntarily to pursue FDA pre-market review of our products or assays if we determine that doing so would be appropriate.

If we were required to conduct additional clinical studies or trials before continuing to offer assays that we have developed or may develop as LDTs, those studies or trials could lead to delays or failure to obtain necessary regulatory approval, which could cause significant delays in commercializing any future products and harm our ability to achieve sustained profitability.

If the FDA decides to require that we obtain clearance or approvals to commercialize our current assays or our planned future assays, we may be required to conduct additional pre-market clinical testing before submitting a regulatory notification or application for commercial sales. In addition, as part of our long-term strategy we may plan to seek FDA clearance or approval, so we can sell our assays outside our CLIA laboratory; however, we would need to conduct additional clinical validation activities on our assays before we can submit an application for FDA approval or clearance. Clinical trials must be conducted in compliance with FDA regulations or the FDA may take enforcement action or reject the data. The data collected from these clinical trials may ultimately be used to support market clearance or approval for our assays. It may take two years or more to conduct the clinical studies and trials necessary to obtain approval from the FDA to commercially launch our current assays and our planned future assays outside of our clinical laboratory. Even if our clinical trials are completed as planned, we cannot be certain that their results will support our assay claims or that the FDA or foreign authorities will agree with our conclusions regarding our assay results. Success in early clinical trials does not ensure that later clinical trials will be successful, and we cannot be sure that the later trials will replicate the results of prior clinical trials and studies. If we are required to conduct pre-market clinical trials, whether using prospectively acquired samples or archival samples, delays in the commencement or completion of clinical testing could significantly increase our assay development costs and delay commercialization. Many of the factors that may cause or lead to a delay in the commencement or completion of clinical trials may also ultimately lead to delay or denial of regulatory clearance or approval. The commencement of clinical trials may be delayed due to insufficient patient enrollment, which is a function of many factors, including the size of the patient population, the nature of the protocol, the proximity of patients to clinical sites and the eligibility criteria for the clinical trial. Moreover, the clinical trial process may fail to demonstrate that our current assays and our planned future assays are effective for the proposed indicated uses, which could cause us to abandon an assay candidate and may delay development of other assays.

We may find it necessary to engage contract research organizations to perform data collection and analysis and other aspects of our clinical trials, which might increase the cost and complexity of our trials. We may also depend on clinical investigators, medical institutions and contract research organizations to perform the trials properly. If these parties do not successfully carry out their contractual duties or obligations or meet expected deadlines, or if the quality, completeness or accuracy of the clinical data they obtain is compromised due to the failure to adhere to our clinical protocols or for other reasons, our clinical trials may have to be extended, delayed or terminated. Many of these factors would be beyond our control. We may not be able to enter into replacement arrangements without undue delays or considerable expenditures. If there are delays in testing or approvals as a result of the failure to perform by third parties, our research and development costs would increase, and we may not be able to obtain regulatory clearance or approval for our current assays and our planned future assays. In addition, we may not be able to establish or maintain relationships

with these parties on favorable terms, if at all. Each of these outcomes would harm our ability to market our assays or to achieve sustained profitability.

We are subject to federal and state healthcare fraud and abuse laws and regulations and could face substantial penalties if we are unable to fully comply with such laws.

We are subject to health care fraud and abuse regulation and enforcement by both the federal government and the states in which we conduct our business. These health care laws and regulations include, for example:

•

the federal Anti-Kickback Statute, which prohibits, among other things, persons or entities from soliciting, receiving, offering or providing remuneration, directly or indirectly, overtly or covertly, in cash or in kind, in return for or to induce either the referral of an individual for, or the purchase, lease, order or recommendation of, any good, facility, item or services for which payment may be made under a federal health care program such as the Medicare and Medicaid programs;

•

the federal physician self-referral prohibition, commonly known as the Stark Law, which prohibits physicians from referring Medicare or Medicaid patients to providers of “designated health services” with whom the physician or a member of the physician’s immediate family has an ownership interest or compensation arrangement, unless a statutory or regulatory exception applies;

•

HIPAA, which established additional federal civil and criminal liability for, among other things, knowingly and willfully executing a scheme to defraud any health care benefit program or making false statements in connection with the delivery of or payment for health care benefits, items or services;

•	HIPAA, as amended by HITECH, and its implementing regulations, which imposes certain requirements relating to the privacy, security and transmission of individually identifiable health information;

•	federal false claims and civil monetary penalties laws, which, prohibit, among other things, individuals or entities from knowingly presenting, or causing to be presented, false or fraudulent claims for payment to the federal government;

•

the federal Physician Payments Sunshine Act requirements under the ACA, which require certain manufacturers of drugs, devices, biologics and medical supplies to report to CMS information related to payments and other transfers of value made to or at the request of covered recipients, such as physicians and teaching hospitals, and certain physician ownership and investment interests held by physicians and their immediate family members; and

•	state law equivalents of each of the above federal laws, such as anti-kickback and false claims laws, which may apply to items or services reimbursed by any third-party payer, including commercial insurers.

Further, the ACA, among other things, amends the intent requirement of the federal Anti-Kickback Statute and certain criminal health care fraud statutes. Where the intent requirement has been lowered, a person or entity no longer needs to have actual knowledge of this statute or specific intent to violate it in order to have committed a violation. In addition, the government may now assert that a claim including items or services resulting from a violation of the federal Anti-Kickback Statute constitutes a false or fraudulent claim for purposes of the false claims statutes. Any action brought against us for violation of these laws or regulations, even if we successfully defend against it, could cause us to incur significant legal expenses and divert our management’s attention from the operation of our business. If our operations are found to be in violation of any of these laws and regulations, we may be subject to any applicable penalty associated with the violation, including, among others, significant administrative, civil and criminal penalties, damages and fines, imprisonment, integrity oversight and reporting obligations, and exclusion from participation in government funded healthcare programs such as Medicare, Medicaid programs, including the California Medical Assistance Program (Medi-Cal-the California Medicaid program) or other state or federal health care programs. Additionally, we could be required to refund payments received by us, and we could be required to curtail or cease our operations. Any of the foregoing consequences could seriously harm our business and our financial results.

We are required to comply with laws governing the transmission, security and privacy of health information that require significant compliance costs, and any failure to comply with these laws could result in material criminal and civil penalties.

Under the administrative simplification provisions of HIPAA, HHS has issued regulations which establish uniform standards governing the conduct of certain electronic health care transactions and protecting the privacy and security of protected health information used or disclosed by health care providers and other covered entities.

The privacy regulations regulate the use and disclosure of protected health information by covered entities engaging in certain electronic transactions or “standard transactions.” They also set forth certain rights that an individual has with respect to his or her protected health information maintained by a covered entity, including the right to access or amend certain records containing

protected health information or to request restrictions on the use or disclosure of protected health information. The HIPAA security regulations establish administrative, physical and technical standards for maintaining the confidentiality, integrity and availability of protected health information in electronic form. These standards apply to covered entities and also to “business associates” or third parties providing services to covered entities involving the use or disclosure of protected health information. The HIPAA privacy and security regulations establish a uniform federal “floor” and do not supersede state laws that are more stringent or provide individuals with greater rights with respect to the privacy or security of, and access to, their records containing protected health information. As a result, we may be required to comply with both HIPAA privacy regulations and varying state privacy and security laws.

Moreover, HITECH, among other things, established certain health information security breach notification requirements, which were later further modified by the Final Omnibus Rule. In the event of a breach of unsecured protected health information, a covered entity must notify each individual whose protected health information is breached, federal regulators and in some cases, must publicize the breach in local or national media. Breaches affecting 500 individuals or more may be publicized by federal regulators who publicly identify the breaching entity, the circumstances of the breach and the number of individuals affected.

These laws contain significant fines and other penalties for wrongful use or disclosure of protected health information. Given the complexity of HIPAA and HITECH and their overlap with state privacy and security laws, and the fact that these laws are rapidly evolving and are subject to changing and potentially conflicting interpretation, our ability to comply with the HIPAA, HITECH and state privacy requirements is uncertain and the costs of compliance are significant. Adding to the complexity is that our operations are evolving, and the requirements of these laws will apply differently depending on such things as whether or not we bill electronically for our services. The costs of complying with any changes to the HIPAA, HITECH and state privacy restrictions may have a negative impact on our operations. Noncompliance could subject us to criminal penalties, civil sanctions and significant monetary penalties as well as reputational damage.

Clinical research is heavily regulated and failure to comply with human subject protection regulations may disrupt our research program leading to significant expense, regulatory enforcement, private lawsuits and reputational damage.

Clinical research is subject to federal, state and, for studies conducted outside of the United States, international regulation. At the federal level, the FDA imposes regulations for the protection of human subjects and requirements such as initial and ongoing institutional review board review; informed consent requirements, adverse event reporting and other protections to minimize the risk and maximize the benefit to research participants. Many states impose human subject protection laws that mirror or in some cases exceed federal requirements. HIPAA also regulates the use and disclosure of protected health information in connection with research activities. Research conducted overseas is subject to a variety of national protections such as mandatory ethics committee review, as well as laws regulating the use, disclosure and cross-border transfer of personal data. For example, if we obtain certain personal information regarding residents in the European Union, we may be subject to the European Union General Data Protection Regulation. The costs of compliance with these laws may be significant and compliance with regulatory requirements may result in delay. Noncompliance may disrupt our research and result in data that is unacceptable to regulatory authorities, data lock or other sanctions that may significantly disrupt our operations.

Violation of a state’s prohibition on the corporate practice of medicine could result in a material adverse effect on our business.

A number of states, including California, do not allow business corporations to employ physicians to provide professional services. This prohibition against the “corporate practice of medicine” is aimed at preventing corporations such as us from exercising control over the medical judgments or decisions of physicians. The state licensure statutes and regulations and agency and court decisions that enumerate the specific corporate practice rules vary considerably from state to state and are enforced by both the courts and regulatory authorities, each with broad discretion. If regulatory authorities or other parties in any jurisdiction successfully assert that we are engaged in the unauthorized corporate practice of medicine, we could be required to restructure our contractual and other arrangements. In addition, violation of these laws may result in significant civil, criminal and administrative penalties imposed against us and/or the professional through licensure proceedings, and exclusion from state and federal health care programs.

Intellectual Property Risks Related to Our Business

If we are unable to obtain and maintain effective patent rights for our products or services, we may not be able to compete effectively in our markets.

We rely upon a combination of patents, trade secret protection, and confidentiality agreements to protect the intellectual property related to our technologies, products and services. Our success depends in large part on our ability to obtain and maintain patent and other intellectual property protection in the United States and in other countries with respect to our proprietary technology and products.

We have sought to protect our proprietary position by filing patent applications in the United States and abroad related to our novel technologies and products that are important to our business. This process is expensive and time consuming, and we may not be able

to file and prosecute all necessary or desirable patent applications at a reasonable cost or in a timely manner. The possibility exists that we will fail to identify patentable aspects of our research and development output before it is too late to obtain patent protection.

The patent position of diagnostic companies generally is highly uncertain and involves complex legal and factual questions for which legal principles remain unsolved. The patent applications that we own, or in-license, may fail to result in issued patents with claims that cover our products or services in the United States or in other foreign countries. There is no assurance that all potentially relevant prior art relating to our patents and patent applications has been found, which can invalidate a patent or prevent a patent from issuing from a pending patent application. Even if patents do successfully issue, and even if such patents cover our products and services, third parties may challenge their validity, enforceability, or scope, which may result in such patents being narrowed, found unenforceable or invalidated. Furthermore, even if they are unchallenged, our patents and patent applications may not adequately protect our intellectual property, provide exclusivity for our products and services, or prevent others from designing around our claims. Any of these outcomes could impair our ability to prevent competition from third parties, which may have an adverse impact on our business.

We, independently or together with our licensors, have filed several patent applications covering various aspects of our products and services. We cannot offer any assurances about which, if any, patents will issue, the breadth of any such patent or whether any issued patents will be found invalid and unenforceable or will be threatened by third parties. Any successful opposition to these patents or any other patents owned by or licensed to us after patent issuance could deprive us of rights necessary for the successful commercialization of any products and services that we may offer. Further, if we encounter delays in regulatory approvals, the period of time during which we could market a product or service under patent protection could be reduced.

Patent policy and rule changes could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents.

Changes in either the patent laws or interpretation of the patent laws in the United States and other countries may diminish the value of our patents or narrow the scope of our patent protection. The laws of foreign countries may not protect our rights to the same extent as the laws of the United States. Publications of discoveries in the scientific literature often lag behind the actual discoveries, and patent applications in the United States and other jurisdictions are typically not published until 18 months after filing, or in some cases not at all. We therefore cannot be certain that we or our licensors were the first to make the invention claimed in our owned and licensed patents or pending applications, or that we or our licensor were the first to file for patent protection of such inventions. Assuming the other requirements for patentability are met, in the United States prior to March 15, 2013, the first to make the claimed invention is entitled to the patent, while outside the United States, the first to file a patent application is entitled to the patent. After March 15, 2013, under the Leahy-Smith America Invents Act, or the Leahy-Smith Act, enacted on September 16, 2011, the United States has moved to a first to file system. The Leahy-Smith Act also includes a number of significant changes that affect the way patent applications will be prosecuted and may also affect patent litigation. The effects of these changes are currently unclear as the United States Patent and Trademark Office, or USPTO, must still implement various regulations, the courts have yet to address any of these provisions and the applicability of the act and new regulations on specific patents discussed herein have not been determined and would need to be reviewed. In general, the Leahy-Smith Act and its implementation could increase the uncertainties and costs surrounding the prosecution of our patent applications and the enforcement or defense of our issued patents, all of which could have a material adverse effect on our business and financial condition.

If we are unable to maintain effective proprietary rights for our products or services, we may not be able to compete effectively in our markets.

In addition to the protection afforded by patents, we rely on trade secret protection and confidentiality agreements to protect proprietary know-how that is not patentable or that we elect not to patent, processes for which patents are difficult to enforce and any other elements of our products and services that involve proprietary know-how, information or technology that is not covered by patents. However, trade secrets can be difficult to protect. We seek to protect our proprietary technology and processes, in part, by entering into confidentiality agreements with our employees, consultants, scientific advisors, and contractors. We also seek to preserve the integrity and confidentiality of our data and trade secrets by maintaining physical security of our premises and physical and electronic security of our information technology systems. While we have confidence in these individuals, organizations and systems, agreements or security measures may be breached, and we may not have adequate remedies for any breach. In addition, our trade secrets may otherwise become known or be independently discovered by competitors.

Although we expect all of our employees and consultants to assign their inventions to us, and all of our employees, consultants, advisors, and any third parties who have access to our proprietary know-how, information, or technology to enter into confidentiality agreements, we cannot provide any assurances that all such agreements have been duly executed or that our trade secrets and other confidential proprietary information will not be disclosed or that competitors will not otherwise gain access to our trade secrets or independently develop substantially equivalent information and techniques. Misappropriation or unauthorized disclosure of our trade secrets could impair our competitive position and may have a material adverse effect on our business. Additionally, if the steps taken to maintain our trade secrets are deemed inadequate, we may have insufficient recourse against third parties for misappropriating the trade secret.

Third-party claims of intellectual property infringement may prevent or delay our development and commercialization efforts.

Our commercial success depends in part on our avoiding infringement of the patents and proprietary rights of third parties. There have been many lawsuits and other proceedings involving patent and other intellectual property rights in the biotechnology and pharmaceutical industries, including patent infringement lawsuits, interferences, oppositions, and reexamination proceedings before the USPTO and corresponding foreign patent offices. Numerous U.S. and foreign issued patents and pending patent applications, which are owned by third parties, exist in the fields in which we are developing products and services. As the biotechnology and pharmaceutical industries expand and more patents are issued, the risk increases that our products and services may be subject to claims of infringement of the patent rights of third parties.

Third parties may assert that we are employing their proprietary technology without authorization. There may be third-party patents or patent applications with claims to materials, formulations, methods of manufacture, or methods for treatment related to the use or manufacture of our products and services. We have conducted freedom to operate analyses with respect to only certain of our products and services, and therefore we do not know whether there are any third-party patents that would impair our ability to commercialize these products and services. We also cannot guarantee that any of our analyses are complete and thorough, nor can we be sure that we have identified each and every patent and pending application in the United States and abroad that is relevant or necessary to the commercialization of our products and services. Because patent applications can take many years to issue, there may be currently pending patent applications that may later result in issued patents that our products or services may infringe.

For example, in August 2016, we received a letter from MolecularMD Corp. offering a license to two U.S. Patents owned by the Memorial Sloan-Kettering Cancer Center, and licensed to MolecularMD Corp., that are relevant to one of the biomarkers we detect in our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target-Selector assay and our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector™ assay. One of the two patents is expected to expire in 2026. The other patent is expected to expire in 2028. Although we believe that the claims of both patents relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target-Selector Assay and our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector Assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

In addition, we are aware of a U.S. Patent owned by Amgen, Inc. that is relevant to one of the biomarkers we detect in our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target-Selector assay and our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector assay. The patent is expected to expire in 2028. Although we believe that the claims of the patent relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Non-Small Cell Lung Cancer Profile Target-Selector assay and our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

We are also aware of a U.S. Patent owned by Genentech, Inc. that is relevant to one of the biomarkers we detect in our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector assay and our Liquid Biopsy Colon Cancer Profile Target-Selector assay. The patent is expected to expire in 2025. Although we believe that the claims of the patent relevant to our assays would likely be held invalid, we cannot provide any assurances that a court or an administrative agency would agree with our assessment. If the validity of the relevant claims in question is upheld upon a validity challenge, then we may be liable for past damages and would need a license in order to continue commercializing our Liquid Biopsy Lung Cancer Resistance Profile Target-Selector assay and our Liquid Biopsy Colon Cancer Profile Target-Selector assay in the United States. However, such a license may not be available on commercially reasonable terms or at all, which could materially and adversely affect our business.

In addition, in July 2016, we received a communication from the Mayo Foundation for Medical Education and Research, or Mayo, offering a license to a U.S. Patent owned by Mayo that is relevant to an antibody that we use in our Liquid Biopsy Immuno-Oncology PD-L1 assay. The patent is expected to expire in 2021. At present, we believe that we will need a license to this patent to continue commercializing our Liquid Biopsy Immuno-Oncology PD-L1 assay. We are currently in discussions with Mayo and believe a license can be obtained on commercially reasonable terms. However, if we are unable to secure such a license, we may be liable for past damages, and our business could be materially and adversely affected.

In addition, third parties may obtain patents in the future and claim that use of our technologies infringes upon these patents. If any third-party patents were held by a court of competent jurisdiction to cover aspects of our products or services, the holders of any such patents may be able to block our ability to commercialize such products or services unless we obtained a license under the applicable patents, or until such patents expire or are finally determined to be invalid or unenforceable. Such a license may not be available on commercially reasonable terms or at all.

Parties making claims against us may obtain injunctive or other equitable relief, which could effectively block our ability to further develop and commercialize one or more of our products or services. Defense of these claims, regardless of their merit, would involve substantial litigation expense and would be a substantial diversion of employee resources from our business. In the event of a successful claim of infringement against us, we may have to pay substantial damages, including treble damages and attorneys’ fees for willful infringement, pay royalties, redesign our infringing products or obtain one or more licenses from third parties, which may be impossible or require substantial time and monetary expenditure.

We may not be successful in obtaining or maintaining necessary rights to our products or services through acquisitions and in-licenses.

We currently have rights to the intellectual property, through licenses from third parties and under patents that we own, to develop our products and services. Because our programs may require the use of proprietary rights held by third parties, the growth of our business will likely depend in part on our ability to acquire, in-license, or use these proprietary rights. We may be unable to acquire or in-license any compositions, methods of use, processes, or other third-party intellectual property rights from third parties that we identify as necessary for our products or services. The licensing and acquisition of third-party intellectual property rights is a competitive area, and a number of more established companies are also pursuing strategies to license or acquire third-party intellectual property rights that we may consider attractive. These established companies may have a competitive advantage over us due to their size, cash resources, and greater clinical development and commercialization capabilities. In addition, companies that perceive us to be a competitor may be unwilling to assign or license rights to us. We also may be unable to license or acquire third-party intellectual property rights on terms that would allow us to make an appropriate return on our investment.

We sometimes collaborate with U.S. and foreign institutions to accelerate our research or development under written agreements with these institutions. Typically, these institutions provide us with an option to negotiate a license to any of the institution’s rights in technology resulting from the collaboration. Regardless of such option, we may be unable to negotiate a license within the specified timeframe or under terms that are acceptable to us. If we are unable to do so, the institution may offer the intellectual property rights to other parties, potentially blocking our ability to pursue our program.

If we are unable to successfully obtain rights to required third-party intellectual property rights or maintain the existing intellectual property rights we have, we may have to abandon development of that program and our business and financial condition could suffer.

Although we are not currently involved in any litigation, we may be involved in lawsuits to protect or enforce our patents or the patents of our licensors, which could be expensive, time consuming, and unsuccessful.

Competitors may infringe our patents or the patents of our licensors. Although we are not currently involved in any litigation, if we or one of our licensing partners were to initiate legal proceedings against a third-party to enforce a patent covering one of our products or services, the defendant could counterclaim that the patent covering our product or service is invalid and/or unenforceable. In patent litigation in the United States, defendant counterclaims alleging invalidity and/or unenforceability are commonplace. Grounds for a validity challenge could be an alleged failure to meet any of several statutory requirements, including lack of novelty, obviousness, or non-enablement. Grounds for an unenforceability assertion could be an allegation that someone connected with prosecution of the patent withheld relevant information from the USPTO, or made a misleading statement, during prosecution. The outcome following legal assertions of invalidity and unenforceability is unpredictable.

Interference proceedings provoked by third parties or brought by us or declared by the USPTO may be necessary to determine the priority of inventions with respect to our patents or patent applications or those of our licensors. An unfavorable outcome could require us to cease using the related technology or to attempt to license rights to it from the prevailing party. Our business could be harmed if the prevailing party does not offer us a license on commercially reasonable terms. Our defense of litigation or interference proceedings may fail and, even if successful, may result in substantial costs and distract our management and other employees. In addition, the uncertainties associated with litigation could have a material adverse effect on our ability to raise sufficient capital to continue our research programs, license necessary technology from third parties, or enter into development partnerships that would help commercialize our products or services.

Furthermore, because of the substantial amount of discovery required in connection with intellectual property litigation, there is a risk that some of our confidential information could be compromised by disclosure during this type of litigation. There could also be public announcements of the results of hearings, motions, or other interim proceedings or developments. If securities analysts or investors perceive these results to be negative, it could have a material adverse effect on the price of our common stock.

We may be subject to claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties or that our employees have wrongfully used or disclosed alleged trade secrets of their former employers.

We employ certain individuals who were previously employed at universities or other biotechnology or pharmaceutical companies, including our competitors or potential competitors. Although we try to ensure that our employees, consultants, and independent contractors do not use the proprietary information or know-how of others in their work for us, and we are not currently subject to any claims that our employees, consultants, or independent contractors have wrongfully used or disclosed confidential information of third parties, we may in the future be subject to such claims. Litigation may be necessary to defend against these claims. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights or personnel, which could adversely impact our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

We may be subject to claims challenging the inventorship of our patents and other intellectual property.

Although we are not currently experiencing any claims challenging the inventorship of our patents or ownership of our intellectual property, we may in the future be subject to claims that former employees, collaborators or other third parties have an interest in our patents or other intellectual property as an inventor or co-inventor. For example, we may have inventorship disputes arise from conflicting obligations of consultants or others who are involved in developing our products or services. Litigation may be necessary to defend against these and other claims challenging inventorship. If we fail in defending any such claims, in addition to paying monetary damages, we may lose valuable intellectual property rights, such as exclusive ownership of, or right to use, valuable intellectual property. Such an outcome could have a material adverse effect on our business. Even if we are successful in defending against such claims, litigation could result in substantial costs and be a distraction to management and other employees.

Changes in U.S. patent law could diminish the value of patents in general, thereby impairing our ability to protect our products.

As is the case with other biopharmaceutical companies, our success is heavily dependent on intellectual property, particularly patents. Obtaining and enforcing patents in the biotechnology industry involves both technological and legal complexity. Therefore, obtaining and enforcing biotechnology patents is costly, time consuming, and inherently uncertain. In addition, the United States has recently enacted and is currently implementing wide-ranging patent reform legislation. Recent U.S. Supreme Court rulings have narrowed the scope of patent protection available in certain circumstances and weakened the rights of patent owners in certain situations. In addition to increasing uncertainty with regard to our ability to obtain patents in the future, this combination of events has created uncertainty with respect to the value of patents, once obtained. Depending on future actions by the U.S. Congress, the federal courts, and the USPTO, the laws and regulations governing patents could change in unpredictable ways that would weaken our ability to obtain new patents or to enforce our existing patents and patents that we might obtain in the future.

We may not be able to protect our intellectual property rights throughout the world.

Filing, prosecuting, and defending patents on products and services in all countries throughout the world would be prohibitively expensive, and our intellectual property rights in some countries outside the United States can be less extensive than those in the United States. In addition, the laws of some foreign countries do not protect intellectual property rights to the same extent as federal and state laws in the United States. Consequently, we may not be able to prevent third parties from practicing our inventions in all countries outside the United States, or from selling or importing products made using our inventions in and into the United States or other jurisdictions. Competitors may use our technologies in jurisdictions where we have not obtained patent protection to develop their own products and may also export infringing products to territories where we have patent protection, but enforcement is not as strong as that in the United States. These products may compete with our products and our patents or other intellectual property rights may not be effective or sufficient to prevent them from competing.

Many companies have encountered significant problems in protecting and defending intellectual property rights in foreign jurisdictions. The legal systems of certain countries, particularly certain developing countries, do not favor the enforcement of patents, trade secrets, and other intellectual property protection, particularly those relating to biotechnology products, which could make it difficult for us to stop the infringement of our patents or marketing of competing products in violation of our proprietary rights generally. Proceedings to enforce our patent rights in foreign jurisdictions, whether or not successful, could result in substantial costs and divert our efforts and attention from other aspects of our business, could put our patents at risk of being invalidated or interpreted narrowly and our patent applications at risk of not issuing and could provoke third parties to assert claims against us. We may not prevail in any lawsuits that we initiate, and the damages or other remedies awarded, if any, may not be commercially meaningful. Accordingly, our efforts to enforce our intellectual property rights around the world may be inadequate to obtain a significant commercial advantage from the intellectual property that we develop or license.

Our collaborators may assert ownership or commercial rights to inventions we develop from our use of the biological materials which they provide to us, or otherwise arising from the collaboration.

We collaborate with several institutions, physicians and researchers in scientific matters. We do not have written agreements with certain of such collaborators, or the written agreements we have do not cover intellectual property rights. Also, we rely on numerous third parties to provide us with blood samples and biological materials that we use to develop assays. If we cannot successfully negotiate sufficient ownership and commercial rights to any inventions that result from our use of a third-party collaborator’s materials, or if disputes arise with respect to the intellectual property developed with the use of a collaborator’s samples, or data developed in a collaborator’s study, we may be limited in our ability to capitalize on the market potential of these inventions or developments.

Risks Relating to Our Common Stock

The price of our common stock may be volatile.

Before our initial public offering, there was no public market for our common stock. Market prices for securities of early-stage life sciences companies have historically been particularly volatile. The factors that may cause the market price of our common stock to fluctuate include, but are not limited to:

•	progress, or lack of progress, in performing, developing and commercializing our current assays and our planned future assays;

•	favorable or unfavorable decisions about our assays from government regulators, insurance companies or other third-party payers;

•	our ability to recruit and retain qualified research and development personnel;

•	changes in investors’ and securities analysts’ perception of the business risks and conditions of our business;

•	changes in our relationship with key collaborators;

•	changes in the market valuation or earnings of our competitors or companies viewed as similar to us;

•	changes in key personnel;

•	depth of the trading market in our common stock;

•	changes in our capital structure, such as future issuances of securities or the incurrence of additional debt;

•	the granting or exercise of employee stock options or other equity awards;

•	realization of any of the risks described herein; and

•	general market and economic conditions.

In addition, the equity markets have experienced significant price and volume fluctuations that have affected the market prices for the securities of newly public companies for a number of reasons, including reasons that may be unrelated to our business or operating performance. These broad market fluctuations may result in a material decline in the market price of our common stock and you may not be able to sell your shares at prices you deem acceptable. In the past, following periods of volatility in the equity markets, securities class action lawsuits have been instituted against public companies. Such litigation, if instituted against us, could result in substantial cost and the diversion of management attention.

*Our failure to meet the continued listing requirements of The Nasdaq Capital Market could result in a de-listing of our common stock.

If we fail to satisfy the continued listing requirements of The Nasdaq Capital Market, such as the corporate governance requirements, the minimum closing bid price requirement, or the minimum stockholders’ equity requirement, Nasdaq may take steps to de-list our common stock. For example, in May 2016, we received a letter from Nasdaq indicating that we are not in compliance with the minimum stockholders’ equity requirement of Nasdaq Listing Rule 5550(b)(1), and in each of June 2016, November 2016, January 2018 and September 2019, we received letters from Nasdaq indicating that we are not in compliance with the minimum bid price requirement of Nasdaq Listing Rule 5550(a)(2), which requires that companies listed on The Nasdaq Capital Market maintain a minimum closing bid price of at least $1.00 per share. Although we were able to regain compliance with the Nasdaq continued listing requirements discussed in the May 2016, June 2016, November 2016 and January 2018 letter, we have not yet regained compliance with the $1.00 minimum closing bid price requirement that was the subject of the September 2019 letter from Nasdaq. We intend to monitor the closing bid price of our common stock and may, if appropriate, consider implementing available options, including a reverse stock split, to regain compliance with the minimum closing bid price requirement. There can be no assurance that we will be able to regain compliance with the $1.00 minimum closing bid price requirement or maintain compliance with the other continued listing requirements of the Nasdaq Capital Market. If we fail to regain and/or maintain compliance with Nasdaq’s continued listing

requirements, Nasdaq may take steps to de-list our common stock. Such a de-listing would likely have a negative effect on the price of our common stock and would impair your ability to sell or purchase our common stock when you wish to do so. In the event of a de-listing, we would take actions to restore our compliance with Nasdaq’s listing requirements, but we can provide no assurance that any such action taken by us would allow our common stock to become listed again, stabilize the market price or improve the liquidity of our common stock, or prevent future non-compliance with Nasdaq’s listing requirements.

If our shares become subject to the penny stock rules, it would become more difficult to trade our shares.

The SEC has adopted rules that regulate broker-dealer practices in connection with transactions in penny stocks. Penny stocks are generally equity securities with a price of less than $5.00, other than securities registered on certain national securities exchanges or authorized for quotation on certain automated quotation systems, provided that current price and volume information with respect to transactions in such securities is provided by the exchange or system. If we do not retain a listing on The Nasdaq Capital Market, and if the price of our common stock is less than $5.00, our common stock will be deemed a penny stock. The penny stock rules require a broker-dealer, before a transaction in a penny stock not otherwise exempt from those rules, to deliver a standardized risk disclosure document containing specified information. In addition, the penny stock rules require that before effecting any transaction in a penny stock not otherwise exempt from those rules, a broker-dealer must make a special written determination that the penny stock is a suitable investment for the purchaser and receive (i) the purchaser’s written acknowledgment of the receipt of a risk disclosure statement; (ii) a written agreement to transactions involving penny stocks; and (iii) a signed and dated copy of a written suitability statement. The broker-dealer must also disclose the commissions payable to the broker-dealer, current quotations for the securities and, if the broker-dealer is the sole market-maker for the security, the fact that they are the sole market-maker and their presumed control over the market. Finally, monthly statements disclosing recent price information on the limited market in penny stocks must be sent to holders of such penny stocks. These disclosure requirements may have the effect of reducing the trading activity in the secondary market for our common stock, and therefore stockholders may have difficulty selling their shares.

Our quarterly operating results may fluctuate significantly.

We expect our operating results to be subject to quarterly fluctuations. Our net loss and other operating results will be affected by numerous factors, including:

•	the rate of adoption and/or continued use of our current assays and our planned future assays by healthcare practitioners;

•	variations in the level of expenses related to our development programs;

•	addition or reduction of resources for sales and marketing;

•	addition or termination of clinical utility studies;

•	any intellectual property infringement lawsuit in which we may become involved;

•	third-party payer coverage and reimbursement determinations affecting our assays; and

•	regulatory developments affecting our assays.

If our quarterly operating results fall below the expectations of investors or securities analysts, the price of our common stock could decline substantially. Furthermore, any quarterly fluctuations in our operating results may, in turn, cause the price of our stock to fluctuate substantially.

If securities or industry analysts issue an adverse opinion regarding our stock or do not publish research or reports about our company, our stock price and trading volume could decline.

The trading market for our common stock will depend in part on the research and reports that equity research analysts publish about us, our business and our competitors. We do not control these analysts or the content and opinions or financial models included in their reports. Securities analysts may elect not to provide research coverage of our company, and such lack of research coverage may adversely affect the market price of our common stock. The price of our common stock could also decline if one or more equity research analysts downgrade our common stock or if those analysts issue other unfavorable commentary or cease publishing reports about us or our business. If one or more equity research analysts cease coverage of our company, we could lose visibility in the market, which in turn could cause our stock price to decline.

*Future sales of our common stock or other securities, or the perception that future sales may occur, may cause the market price of our common stock to decline, even if our business is doing well.

Sales of substantial amounts of our common stock or other securities, or the perception that these sales may occur, could materially and adversely affect the price of our common stock and could impair our ability to raise capital through the sale of additional equity securities. For example, in May 2018, the SEC declared effective a shelf registration statement filed by us. This shelf registration

statement allows us to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million. The specific terms of additional future offerings, if any, under this shelf registration statement would be established at the time of such offerings. Depending on a variety of factors, including market liquidity of our common stock, the sale of shares under this shelf registration statement may cause the trading price of our common stock to decline. The sale of a substantial number of shares of our common stock under this shelf registration statement, or anticipation of such sales, could cause the trading price of our common stock to decline or make it more difficult for us to sell equity or equity-related securities in the future at a time and at a price that we might otherwise desire.

We had outstanding 23,018,235 shares of common stock as of September 30, 2019, substantially all of which are not subject to resale restrictions under Rule 144 of the Securities Act. In addition, as of September 30, 2019, we had outstanding preferred stock convertible into 471,393 shares of our common stock, options to purchase 2,797,656 shares of our common stock, 360 shares of common stock were issuable upon the settlement of outstanding restricted stock units, or RSUs, and 15,197,249 shares of our common stock were issuable upon the exercise of outstanding warrants. Shares issued upon the exercise of stock options or upon the settlement of outstanding RSUs generally will be eligible for sale in the public market, except that affiliates will continue to be subject to volume limitations and other requirements of Rule 144 under the Securities Act. The issuance or sale of such shares could depress the market price of our common stock.

In the future, we also may issue our securities if we need to raise additional capital. The number of new shares of our common stock issued in connection with raising additional capital could constitute a material portion of the then-outstanding shares of our common stock.

If we are unable to favorably assess the effectiveness of our internal control over financial reporting, investors may lose confidence in our financial reporting and our stock price could be materially adversely affected.

Effective internal controls over financial reporting are necessary for us to provide reliable financial reports and, together with adequate disclosure controls and procedures, are designed to prevent fraud. Any failure to implement required new or improved controls, or difficulties encountered in their implementation could cause us to fail to meet our reporting obligations. In addition, any testing by us conducted in connection with Section 404(a) of the Sarbanes-Oxley Act, or the subsequent testing by our independent registered public accounting firm conducted in connection with Section 404(b) of the Sarbanes-Oxley Act after our public float is at least $75 million and we no longer qualify as an “emerging growth company,” may reveal deficiencies in our internal controls over financial reporting that are deemed to be material weaknesses or that may require prospective or retroactive changes to our consolidated financial statements or identify other areas for further attention or improvement. Inferior internal controls could also cause investors to lose confidence in our reported financial information, which could have a negative effect on the trading price of our common stock.

We are required to disclose changes made in our internal control procedures on a quarterly basis and our management is required to assess the effectiveness of these controls annually. However, for as long as we are an “emerging growth company” under the recently enacted JOBS Act, our independent registered public accounting firm will not be required to attest to the effectiveness of our internal control over financial reporting pursuant to Section 404. An independent assessment of the effectiveness of our internal controls could detect problems that our management’s assessment might not. Undetected material weaknesses in our internal controls could lead to financial statement restatements and require us to incur the expense of remediation.

We are an “emerging growth company,” and we cannot be certain if the reduced reporting requirements applicable to emerging growth companies will make our common stock less attractive to investors.

We are an emerging growth company, as defined in the JOBS Act. For as long as we continue to be an emerging growth company, we may take advantage of exemptions from various reporting requirements that are applicable to other public companies that are not emerging growth companies, including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act of 2002, reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements and exemptions from the requirements of holding nonbinding advisory votes on executive compensation and stockholder approval of any golden parachute payments not previously approved. We could be an emerging growth company until December 31, 2019, although circumstances could cause us to lose that status earlier, including if the market value of our common stock held by non-affiliates exceeds $700 million as of any June 30 before that time or if we have total annual gross revenue of $1.07 billion or more during any fiscal year before that time, in which cases we would no longer be an emerging growth company as of the following December 31 or, if we issue more than $1.0 billion in non-convertible debt during any three years before that time, we would cease to be an emerging growth company immediately. Even after we no longer qualify as an emerging growth company, we may still qualify as a “smaller reporting company” which would allow us to take advantage of many of the same exemptions from disclosure requirements including not being required to comply with the auditor attestation requirements of Section 404 of the Sarbanes-Oxley Act, as well as reduced disclosure obligations regarding executive compensation in our periodic reports and proxy statements. We cannot predict if investors find our common stock less attractive because we may rely on these exemptions. If some investors find our

common stock less attractive as a result, there may be a less active trading market for our common stock and our stock price may be more volatile.

Under the JOBS Act, emerging growth companies can also delay adopting new or revised accounting standards until such time as those standards apply to private companies. We have irrevocably elected not to avail ourselves of this exemption from new or revised accounting standards and, therefore, are subject to the same new or revised accounting standards as other public companies that are not emerging growth companies. As a result, changes in rules of U.S. generally accepted accounting principles or their interpretation, the adoption of new guidance or the application of existing guidance to changes in our business could significantly affect our financial position and results of operations.

*We have incurred and will continue to incur significant costs as a result of operating as a public company, and our management will be required to devote substantial time to new compliance initiatives.

As a public company, we are subject to the reporting requirements of the Securities Exchange Act of 1934, as amended, the Dodd-Frank Wall Street Reform and Consumer Protection Act, or the Dodd-Frank Act, the listing requirements of The Nasdaq Stock Market and other applicable securities rules and regulations. Compliance with these rules and regulations includes significant legal and financial compliance costs, makes some activities more difficult, time-consuming or costly, and increases demand on our systems and resources. The Sarbanes-Oxley Act requires, among other things, that we maintain effective disclosure controls and procedures and internal control over financial reporting. In order to maintain and, if required, improve our disclosure controls and procedures and internal control over financial reporting to meet this standard, significant resources and management oversight may be required. As a result, management’s attention may be diverted from other business concerns, which could harm our business and operating results. Further, there are significant corporate governance and executive compensation related provisions in the Dodd-Frank Act, enacted in 2010, that require the SEC to adopt additional rules and regulations in these areas such as “say on pay” and proxy access. Recent legislation permits smaller “emerging growth companies” to implement many of these requirements over a longer period. We intend to continue taking advantage of this new legislation but cannot guarantee that we will not be required to implement these requirements sooner than budgeted or planned and thereby incur unexpected expenses. Stockholder activism, the current political environment and the current high level of government intervention and regulatory reform may lead to substantial new regulations and disclosure obligations, which may lead to additional compliance costs and impact the manner in which we operate our business in ways we cannot currently anticipate.

In addition, changing laws, regulations and standards relating to corporate governance and public disclosure are creating uncertainty for public companies, increasing legal and financial compliance costs and making some activities more time consuming. These laws, regulations and standards are subject to varying interpretations, in many cases due to their lack of specificity, and, as a result, their application in practice may evolve over time as new guidance is provided by regulatory and governing bodies. This could result in continuing uncertainty regarding compliance matters and higher costs necessitated by ongoing revisions to disclosure and governance practices. We intend to invest resources to comply with evolving laws, regulations and standards, and this investment may result in increased general and administrative expenses and a diversion of management’s time and attention from revenue-generating activities to compliance activities. If our efforts to comply with new laws, regulations and standards differ from the activities intended by regulatory or governing bodies due to ambiguities related to practice, regulatory authorities may initiate legal proceedings against us and our business may be harmed.

Anti-takeover provisions of our certificate of incorporation, our bylaws and Delaware law could make an acquisition of us, which may be beneficial to our stockholders, more difficult and may prevent attempts by our stockholders to replace or remove the current members of our board and management.

Certain provisions of our amended certificate of incorporation and amended and restated bylaws could discourage, delay or prevent a merger, acquisition or other change of control that stockholders may consider favorable, including transactions in which you might otherwise receive a premium for your shares. Furthermore, these provisions could prevent or frustrate attempts by our stockholders to replace or remove members of our Board of Directors. (For example, Delaware law provides that if a corporation has a classified board of directors, stockholders cannot remove any director during his or her term without cause.) These provisions also could limit the price that investors might be willing to pay in the future for our common stock, thereby depressing the market price of our common stock. Stockholders who wish to participate in these transactions may not have the opportunity to do so. These provisions, among other things:

•	classify our Board of Directors into three classes of equal (or roughly equal) size, with all directors serving for a three-year term and the directors of only one class being elected at each annual meeting of stockholders, so that the terms of the classes of directors are “staggered”;

•	allow the authorized number of directors to be changed only by resolution of our Board of Directors;

•

authorize our Board of Directors to issue, without stockholder approval, preferred stock, the rights of which will be determined at the discretion of the Board of Directors and that, if issued, could operate as a “poison pill” to dilute the stock ownership of a potential hostile acquirer to prevent an acquisition that our Board of Directors does not approve;

•	establish advance notice requirements for stockholder nominations to our Board of Directors or for stockholder proposals that can be acted on at stockholder meetings; and

•	limit who may call a stockholders meeting.

In addition, we are governed by the provisions of Section 203 of the Delaware General Corporation Law, or DGCL, which may, unless certain criteria are met, prohibit large stockholders, in particular those owning 15% or more of the voting rights on our common stock, from merging or combining with us for a prescribed period of time.

Because we do not expect to pay cash dividends for the foreseeable future, you must rely on appreciation of our common stock price for any return on your investment. Even if we change that policy, we may be restricted from paying dividends on our common stock.

We do not intend to pay cash dividends on shares of our common stock for the foreseeable future. Any determination to pay dividends in the future will be at the discretion of our Board of Directors and will depend upon results of operations, financial performance, contractual restrictions, restrictions imposed by applicable law and other factors our Board of Directors deems relevant. Accordingly, you will have to rely on capital appreciation, if any, to earn a return on your investment in our common stock. Investors seeking cash dividends in the foreseeable future should not purchase our common stock.

The recently passed comprehensive U.S. federal income tax reform bill could adversely affect our business and financial condition.

On December 22, 2017, U.S. federal income tax legislation was signed into law (H.R. 1, “An Act to provide for reconciliation pursuant to titles II and V of the concurrent resolution on the budget for fiscal year 2018”, informally titled the Tax Cuts and Jobs Act, or the Tax Act). The Tax Act, among other things, contains significant changes to corporate taxation, including reduction of the corporate tax rate from a top marginal rate of 35% to a flat rate of 21%, repeal of the alternative minimum tax for corporations, limitation of the tax deduction for interest expense to 30% of adjusted earnings (except for certain small businesses), limitation of the deduction for net operating losses to 80% of current year taxable income and elimination of net operating loss carrybacks, one time taxation of offshore earnings at reduced rates regardless of whether they are repatriated, elimination of U.S. tax on foreign earnings (subject to certain important exceptions), immediate deductions for certain new investments instead of deductions for depreciation expense over time, and modifying or repealing many business deductions and credits. Notwithstanding the reduction in the corporate income tax rate, the overall impact of the Tax Act is uncertain and our business and financial condition could be adversely affected. In addition, it is uncertain if and to what extent various states will conform to the Tax Act. The impact of the Tax Act on holders of our common stock is also uncertain and could be adverse. We urge our stockholders to consult with their legal and tax advisors with respect to this legislation and the potential tax consequences of investing in or holding our common stock.

Our effective tax rate may fluctuate, and we may incur obligations in tax jurisdictions in excess of accrued amounts.

We are subject to taxation in numerous U.S. states and territories. As a result, our effective tax rate is derived from a combination of applicable tax rates in the various places that we operate. In preparing our financial statements, we estimate the amount of tax that will become payable in each of such places. Nevertheless, our effective tax rate may be different than experienced in the past due to numerous factors, including passage of the newly enacted federal income tax law, the results of examinations and audits of our tax filings, our inability to secure or sustain acceptable agreements with tax authorities, changes in accounting for income taxes and changes in tax laws. Any of these factors could cause us to experience an effective tax rate significantly different from previous periods or our current expectations and may result in tax obligations in excess of amounts accrued in our financial statements.

*Our ability to use our estimated net operating loss carryforwards and certain other tax attributes may be limited.

Our ability to utilize our estimated federal net operating loss, carryforwards and federal tax credits may be limited under Sections 382 and 383 of the Code. Under the newly enacted federal income tax law, federal net operating losses incurred in 2018 and in future years may be carried forward indefinitely, but the deductibility of such federal net operating losses is limited. It is uncertain if and to what extent various states will conform to the newly enacted federal tax law. In addition, the limitations apply if an “ownership change,” as defined by Section 382 of the Code, occurs. If we have experienced an ownership change at any time since our formation, we may already be subject to limitations on our ability to utilize our existing net operating losses and other tax attributes to offset taxable income. Future changes in our stock ownership (including in connection with future offerings, as well as other changes that may be outside of our control), may trigger an ownership change and, consequently, limitations under Sections 382 and 383 of the Code. As a result, if we earn net taxable income, our ability to use our estimated pre-change net operating loss carryforwards and other tax attributes to offset United States federal taxable income may be subject to limitations, which could potentially result in increased

future tax liability to us. As of December 31, 2018, we had estimated federal and state net operating loss carryforwards of approximately $13.6 million and $24.7 million, respectively, and estimated federal and California research and development credits of approximately $160,000 and $3,543,000, respectively, which could be limited if we have experienced or do experience any “ownership changes.” We have not completed a study to assess whether an ownership change has occurred or whether there have been multiple ownership changes since our formation, due to the complexity and cost associated with such a study, and the fact that there may be additional ownership changes in the future, however, we believe ownership changes likely occurred in each year from 2015 through 2019. As a result, we have estimated that the use of our net operating loss is limited and the amounts above represent the remaining net operating loss carryforwards and research and development credits we estimate can be used in the future, which remain fully offset by a valuation allowance to reduce the net asset to zero.

We could be subject to securities class action litigation.

In the past, securities class action litigation has often been brought against a company following a decline in the market price of its securities. This risk is especially relevant for us because early-stage life sciences companies have experienced significant stock price volatility in recent years. If we face such litigation, it could result in substantial costs and a diversion of management’s attention and resources, which could harm our business.

Item 2. Unregistered Sales of Equity Securities and Use of Proceeds

Unregistered Sales of Equity Securities

None.

Use of Proceeds

Not applicable.

Item 3. Defaults Upon Senior Securities

Not applicable.

Item 4. Mine Safety Disclosures

Not applicable.

Item 5. Other Information

Not applicable.

Item 6. Exhibits

The exhibits listed below are hereby filed with the SEC as part of this Quarterly Report on Form 10-Q.

Exhibit No.					Description of Exhibit

3.1					Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1.4 of the Registrant’s Current Report on Form 8-K, filed with the SEC on February 14, 2014).
3.2					Amended and Restated Bylaws (incorporated by reference to Exhibit 3.2.1 of the Registrant’s Registration Statement on Form S-1 (File No. 333-191323), filed with the SEC on September 23, 2013).
3.3					Certificate of Amendment of Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2016).
3.4					Amendment to Amended and Restated Bylaws (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 29, 2017).
3.5					Certificate of Amendment to Certificate of Incorporation (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on July 6, 2018).
3.6					Certificate of Designation of Preference, Rights and Limitations of Series A Convertible Preferred Stock (incorporated by reference to Exhibit 3.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 13, 2018).
4.1					Reference is made to Exhibits 3.1, 3.2, 3.3, 3.4, 3.5 and 3.6

Exhibit No.			Description of Exhibit
4.2			Specimen Common Stock certificate of Biocept, Inc. (incorporated by reference to Exhibit 4.3 of the Registrant’s Annual Report on Form 10-K, filed with the SEC on March 28, 2017).
4.3			Form of Warrant issued to the lenders under the Loan and Security Agreement, dated as of April 30, 2014, by and among Biocept, Inc., Oxford Finance LLC, as collateral agent, and the lenders party thereto from time to time, including Oxford Finance LLC (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on May 6, 2014).
4.4			Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.5 of the Registrant’s Registration Statement on Form S-1 (File No. 333-201437), filed with the SEC on February 6, 2015).
4.5			Form of Common Stock Purchase Warrant issued to the investors under the Securities Purchase Agreement, dated April 29, 2016, by and among Biocept, Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on April 29, 2016).
4.6			Form of Warrant to Purchase Common Stock (incorporated by reference to Exhibit 4.16 of the Registrant’s Post-Effective Amendment to Registration Statement on Form S-1 (File No. 333-213111), filed with the SEC on October 14, 2016).
4.7			Form of Common Stock Purchase Warrant issued to the investors under the Securities Purchase Agreement, dated March 28, 2017, by and among Biocept, Inc. and the purchasers signatory thereto (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on March 30, 2017).
4.8			Common Stock Purchase Warrant issued by the Registrant in favor of Ally Bridge LB Healthcare Master Fund Limited under the Common Stock and Warrant Purchase Agreement dated August 9, 2017 (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 10, 2017).
4.9			Common Stock Purchase Warrant issued in favor of Dawson James Securities, Inc. under the Securities Purchase Agreement dated December 5, 2017 (incorporated by reference to Exhibit 4.18 of the Registrant’s Registration Statement on Form S-1 (File No. 333-221648), filed with the SEC on January 22, 2018).
4.10			Form of Warrant to Purchase Common Stock issued to the investors under the Securities Purchase Agreement, dated January 26, 2018 (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on January 30, 2018).
4.11			Warrant Agency Agreement dated August 13, 2018 by and between the Registrant and Continental Stock Transfer & Trust Company (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on August 13, 2018).
4.12			Form of Series 1 Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.21 of the Registrant’s Registration Statement on Form S-1 (File No. 333-225147), filed with the SEC on July 11, 2018).
4.13			Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 24, 2018).
4.14			Form of Series A Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.2 of the Registrant’s Current Report on Form 8-K, filed with the SEC on September 24, 2018).
4.15	Form of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.24 of the Registrant’s Registration Statement on Form S-1 (File No. 333-228566), filed with the SEC on November 28, 2018).
4.16	Form of Pre-Funded Warrant (incorporated by reference to Exhibit 4.25 of the Registrants Registrations Statement on Form S-1 (File No. 333-228566), filed with the SEC on November 28, 2018).
4.17	Form of Series B Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on March 18, 2019).
4.18	Form of Series C Common Stock Purchase Warrant (incorporated by reference to Exhibit 4.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on May 29, 2019).
10.1		Form of Amendment to Warrant Exercise Agreement, dated July 15, 2019, by and between the Registrant and certain holders of warrants to purchase shares of the Registrant’s common stock (incorporated by reference to Exhibit 10.1 of the Registrant’s Current Report on Form 8-K, filed with the SEC on July 18, 2019).
31.1			Certification of Michael Nall, Chief Executive Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
31.2			Certification of Timothy Kennedy, Chief Financial Officer, pursuant to Section 302 of the Sarbanes-Oxley Act of 2002.
32.1*			Certification of Michael Nall, Chief Executive Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.

Exhibit No.					Description of Exhibit
32.2*					Certification of Timothy Kennedy, Chief Financial Officer, pursuant to 18 U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.
101.INS					XBRL Instance Document
101.SCH					XBRL Taxonomy Extension Schema Document
101.CAL					XBRL Taxonomy Extension Calculation Linkbase Document
101.DEF					XBRL Taxonomy Extension Definition Linkbase Document
101.LAB					XBRL Taxonomy Extension Label Linkbase Document
101.PRE					XBRL Taxonomy Extension Presentation Linkbase Document

This certification is not deemed “filed” for purposes of Section 18 of the Securities Exchange Act, or otherwise subject to the liability of that section. Such certification will not be deemed to be incorporated by reference into any filing under the Securities Act of 1933 or the Securities Exchange Act of 1934, except to the extent that the registrant specifically incorporates it by reference.

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly caused this report to be signed on its behalf by the undersigned thereunto duly authorized.

	BIOCEPT, INC. (Registrant)

Date: November 13, 2019	By:	/s/ Michael W. Nall
		Michael W. Nall
		President, Chief Executive Officer and Director
		(Principal Executive Officer)

Date: November 13, 2019	By:	/s/ Timothy C. Kennedy
		Timothy C. Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

EX-31.1 2 bioc-ex311_6.htm EX-31.1 bioc-ex311_6.htm

EXHIBIT 31.1

CERTIFICATION

I, Michael W. Nall, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

The registrant’s other certifying officer and I are responsible for establishing and maintaining disclosure controls and procedures (as defined in Exchange Act Rules 13a-15(e) and 15d-15(e)) and internal control over financial reporting (as defined in Exchange Act Rules 13a-15(f) and 15d-15(f)) for the registrant and have:

Designed such disclosure controls and procedures, or caused such disclosure controls and procedures to be designed under our supervision, to ensure that material information relating to the registrant, including its consolidated subsidiary, is made known to us by others within those entities, particularly during the period in which this report is being prepared;

Designed such internal control over financial reporting, or caused such internal control over financial reporting to be designed under our supervision, to provide reasonable assurance regarding the reliability of financial reporting and the preparation of financial statements for external purposes in accordance with generally accepted accounting principles;

Evaluated the effectiveness of the registrant’s disclosure controls and procedures and presented in this report our conclusions about the effectiveness of the disclosure controls and procedures, as of the end of the period covered by this report based on such evaluation; and

Disclosed in this report any change in the registrant’s internal control over financial reporting that occurred during the registrant’s most recent fiscal quarter (the registrant’s fourth fiscal quarter in the case of an report) that has materially affected, or is reasonably likely to materially affect, the registrant’s internal control over financial reporting; and

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

All significant deficiencies and material weaknesses in the design or operation of internal control over financial reporting which are reasonably likely to adversely affect the registrant’s ability to record, process, summarize and report financial information; and

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2019

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

EX-31.2 3 bioc-ex312_9.htm EX-31.2 bioc-ex312_9.htm

EXHIBIT 31.2

CERTIFICATION

I, Timothy Kennedy, certify that:

1.	I have reviewed this Quarterly Report on Form 10-Q of Biocept, Inc.;

2.	Based on my knowledge, this report does not contain any untrue statement of a material fact or omit to state a material fact necessary to make the statements made, in light of the circumstances under which such statements were made, not misleading with respect to the period covered by this report;

3.	Based on my knowledge, the financial statements, and other financial information included in this report, fairly present in all material respects the financial condition, results of operations and cash flows of the registrant as of, and for, the periods presented in this report;

5.	The registrant’s other certifying officer and I have disclosed, based on our most recent evaluation of internal control over financial reporting, to the registrant’s auditors and the audit committee of the registrant’s board of directors (or persons performing the equivalent functions):

Any fraud, whether or not material, that involves management or other employees who have a significant role in the registrant’s internal control over financial reporting.

Date: November 13, 2019

/s/ Timothy Kennedy

Timothy Kennedy

Chief Financial Officer, Senior Vice President of Operations

(Principal Financial and Accounting Officer)

EX-32.1 4 bioc-ex321_8.htm EX-32.1 bioc-ex321_8.htm

EXHIBIT 32.1

CERTIFICATION

I, Michael W. Nall, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended September 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: November 13, 2019

/s/ Michael W. Nall

Michael W. Nall

President and Chief Executive Officer

(Principal Executive Officer)

This certification accompanies the Report pursuant to Rule 13a-14(b) or Rule 15d-14(b) under the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350 and shall not be deemed filed by the Company for purposes of Section 18 of the Securities Exchange Act of 1934.

EX-32.2 5 bioc-ex322_7.htm EX-32.2 bioc-ex322_7.htm

EXHIBIT 32.2

CERTIFICATION

I, Timothy Kennedy, hereby certify pursuant to Rule 13a-14(b) or Rule 15d-14(b) of the Securities Exchange Act of 1934 and 18 U.S.C. Section 1350, that, to my knowledge, the Quarterly Report on Form 10-Q of Biocept, Inc. for the period ended September 30, 2019 (the “Report”) fully complies with the requirements of Section 13(a) or 15(d) of the Securities Exchange Act of 1934 and that the information contained in the Report fairly presents, in all material respects, the financial condition and results of operations of Biocept, Inc.

Date: November 13, 2019		/s/ Timothy Kennedy
		Timothy Kennedy
		Chief Financial Officer, Senior Vice President of Operations
		(Principal Financial and Accounting Officer)

EX-101.INS 6 bioc-20190930.xml XBRL INSTANCE DOCUMENT xbrli:shares iso4217:USD iso4217:USD xbrli:shares xbrli:pure utr:M bioc:Plan 0001044378 2019-01-01 2019-09-30 0001044378 2019-11-08 0001044378 2018-12-31 0001044378 2019-09-30 0001044378 2018-07-01 2018-09-30 0001044378 2019-07-01 2019-09-30 0001044378 2018-01-01 2018-09-30 0001044378 us-gaap:CommonStockMember 2017-12-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2017-12-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2017-12-31 0001044378 2017-12-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-01-01 2018-03-31 0001044378 2018-01-01 2018-03-31 0001044378 us-gaap:CommonStockMember bioc:JanuaryTwoThousandEighteenFinancingTransactionMember 2018-01-01 2018-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:JanuaryTwoThousandEighteenFinancingTransactionMember 2018-01-01 2018-03-31 0001044378 bioc:JanuaryTwoThousandEighteenFinancingTransactionMember 2018-01-01 2018-03-31 0001044378 us-gaap:CommonStockMember 2018-01-01 2018-03-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-01-01 2018-03-31 0001044378 us-gaap:CommonStockMember 2018-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-03-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-03-31 0001044378 2018-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-04-01 2018-06-30 0001044378 2018-04-01 2018-06-30 0001044378 us-gaap:CommonStockMember 2018-04-01 2018-06-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-04-01 2018-06-30 0001044378 us-gaap:CommonStockMember 2018-06-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-06-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-06-30 0001044378 2018-06-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-07-01 2018-09-30 0001044378 us-gaap:CommonStockMember 2018-07-01 2018-09-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2018-07-01 2018-09-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember bioc:AugustTwoThousandEighteenRightsOfferingMember 2018-07-01 2018-09-30 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:AugustTwoThousandEighteenRightsOfferingMember 2018-07-01 2018-09-30 0001044378 bioc:AugustTwoThousandEighteenRightsOfferingMember 2018-07-01 2018-09-30 0001044378 us-gaap:CommonStockMember bioc:SeptemberTwoThousandEighteenRegisteredDirectOfferingMember 2018-07-01 2018-09-30 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:SeptemberTwoThousandEighteenRegisteredDirectOfferingMember 2018-07-01 2018-09-30 0001044378 bioc:SeptemberTwoThousandEighteenRegisteredDirectOfferingMember 2018-07-01 2018-09-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-07-01 2018-09-30 0001044378 us-gaap:CommonStockMember 2018-09-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2018-09-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-09-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-09-30 0001044378 2018-09-30 0001044378 us-gaap:CommonStockMember 2018-12-31 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2018-12-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2018-12-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2018-12-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-01-01 2019-03-31 0001044378 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember 2019-01-01 2019-03-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember bioc:JanuaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:JanuaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 bioc:JanuaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember bioc:FebruaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:FebruaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 bioc:FebruaryTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember bioc:JanuaryTwoThousandNineteenFinancingTransactionOverallotmentMember 2019-01-01 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:JanuaryTwoThousandNineteenFinancingTransactionOverallotmentMember 2019-01-01 2019-03-31 0001044378 bioc:JanuaryTwoThousandNineteenFinancingTransactionOverallotmentMember 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember bioc:MarchTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember bioc:MarchTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 bioc:MarchTwoThousandNineteenFinancingTransactionMember 2019-01-01 2019-03-31 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2019-01-01 2019-03-31 0001044378 us-gaap:CommonStockMember 2019-03-31 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-03-31 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-03-31 0001044378 2019-03-31 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-04-01 2019-06-30 0001044378 2019-04-01 2019-06-30 0001044378 us-gaap:CommonStockMember 2019-04-01 2019-06-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2019-04-01 2019-06-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-04-01 2019-06-30 0001044378 us-gaap:CommonStockMember 2019-06-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2019-06-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-06-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-06-30 0001044378 2019-06-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-07-01 2019-09-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-07-01 2019-09-30 0001044378 us-gaap:CommonStockMember 2019-09-30 0001044378 bioc:SeriesAConvertiblePreferredStockMember 2019-09-30 0001044378 us-gaap:AdditionalPaidInCapitalMember 2019-09-30 0001044378 us-gaap:AccumulatedOtherComprehensiveIncomeMember 2019-09-30 0001044378 2017-01-01 2017-12-31 0001044378 2018-01-01 2018-12-31 0001044378 bioc:FollowOnPublicOfferingMember 2018-01-29 2018-01-30 0001044378 srt:MaximumMember bioc:FollowOnPublicOfferingMember 2018-01-30 0001044378 bioc:FollowOnPublicOfferingMember 2018-01-30 0001044378 2018-01-29 2018-01-30 0001044378 2018-08-13 2018-08-13 0001044378 us-gaap:SeriesAPreferredStockMember 2018-08-13 2018-08-13 0001044378 us-gaap:WarrantMember 2018-08-13 2018-08-13 0001044378 2018-08-13 0001044378 us-gaap:SeriesAPreferredStockMember 2018-07-01 2018-09-30 0001044378 2018-09-20 2018-09-20 0001044378 srt:MaximumMember bioc:PrefundedWarrantsMember 2018-09-20 0001044378 2018-09-20 0001044378 bioc:PrefundedWarrantsMember 2018-09-20 0001044378 bioc:PrefundedWarrantsMember 2018-09-20 2018-09-20 0001044378 us-gaap:PrivatePlacementMember 2018-09-20 0001044378 us-gaap:PrivatePlacementMember 2018-09-20 2018-09-20 0001044378 2018-09-01 2018-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001044378 us-gaap:MachineryAndEquipmentMember us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 0001044378 2019-01-18 2019-01-18 0001044378 2019-01-18 0001044378 bioc:FollowOnPublicOfferingMember 2019-02-11 2019-02-12 0001044378 srt:MaximumMember bioc:FollowOnPublicOfferingMember 2019-02-12 0001044378 bioc:FollowOnPublicOfferingMember 2019-02-12 0001044378 srt:MaximumMember us-gaap:OverAllotmentOptionMember 2019-02-12 0001044378 us-gaap:OverAllotmentOptionMember us-gaap:WarrantMember 2019-02-11 2019-02-12 0001044378 2019-02-12 0001044378 2019-03-18 2019-03-19 0001044378 2019-03-19 0001044378 2019-05-31 0001044378 srt:MaximumMember 2019-05-31 0001044378 srt:MinimumMember 2019-05-31 0001044378 2019-05-01 2019-05-31 0001044378 bioc:WarrantInducementTransactionMember 2019-05-31 0001044378 bioc:WarrantInducementTransactionMember 2019-05-01 2019-05-31 0001044378 2018-07-06 2018-07-06 0001044378 2018-07-06 0001044378 us-gaap:AccountingStandardsUpdate201409Member 2019-01-01 2019-09-30 0001044378 srt:MaximumMember us-gaap:AccountingStandardsUpdate201409Member us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:ContractedPayersMember 2018-07-01 2018-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:ContractedPayersMember 2019-07-01 2019-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:ContractedPayersMember 2018-01-01 2018-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:ContractedPayersMember 2019-01-01 2019-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:NonContractedPayersMember 2018-07-01 2018-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:NonContractedPayersMember 2019-07-01 2019-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:NonContractedPayersMember 2018-01-01 2018-09-30 0001044378 us-gaap:HealthCarePatientServiceMember bioc:NonContractedPayersMember 2019-01-01 2019-09-30 0001044378 bioc:DevelopmentServicesMember 2018-07-01 2018-09-30 0001044378 bioc:DevelopmentServicesMember 2019-07-01 2019-09-30 0001044378 bioc:DevelopmentServicesMember 2018-01-01 2018-09-30 0001044378 bioc:DevelopmentServicesMember 2019-01-01 2019-09-30 0001044378 bioc:KitsAndBloodCollectionTubesMember 2019-07-01 2019-09-30 0001044378 bioc:KitsAndBloodCollectionTubesMember 2018-01-01 2018-09-30 0001044378 bioc:KitsAndBloodCollectionTubesMember 2019-01-01 2019-09-30 0001044378 bioc:CommercialRevenuesRecognizedUponDeliveryMember us-gaap:HealthCarePatientServiceMember 2018-07-01 2018-09-30 0001044378 bioc:CommercialRevenuesRecognizedUponDeliveryMember us-gaap:HealthCarePatientServiceMember 2019-07-01 2019-09-30 0001044378 bioc:CommercialRevenuesRecognizedUponDeliveryMember us-gaap:HealthCarePatientServiceMember 2018-01-01 2018-09-30 0001044378 bioc:CommercialRevenuesRecognizedUponDeliveryMember us-gaap:HealthCarePatientServiceMember 2019-01-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:MedicareAndMedicareAdvantageMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:BlueCrossBlueShieldMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2018-07-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2019-07-01 2019-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2018-01-01 2018-09-30 0001044378 us-gaap:CustomerConcentrationRiskMember bioc:UnitedHealthcareMember us-gaap:SalesRevenueNetMember 2019-01-01 2019-09-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:BlueCrossBlueShieldMember 2018-01-01 2018-12-31 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:BlueCrossBlueShieldMember 2018-01-01 2018-09-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:MedicareAndMedicareAdvantageMember 2018-01-01 2018-12-31 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:MedicareAndMedicareAdvantageMember 2018-01-01 2018-09-30 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:UnitedHealthcareMember 2018-01-01 2018-12-31 0001044378 us-gaap:CreditConcentrationRiskMember us-gaap:AccountsReceivableMember bioc:UnitedHealthcareMember 2018-01-01 2018-09-30 0001044378 2016-02-29 0001044378 srt:MinimumMember 2016-02-01 2016-02-29 0001044378 bioc:ShelfRegistrationStatementMember 2018-05-01 2018-05-31 0001044378 bioc:ShelfRegistrationStatementMember srt:MaximumMember 2018-05-31 0001044378 bioc:ShelfRegistrationStatementMember 2018-05-31 0001044378 bioc:FollowOnPublicOfferingMember 2019-03-11 0001044378 bioc:FollowOnPublicOfferingMember 2019-03-10 2019-03-11 0001044378 bioc:WarrantExerciseInducementOfferingMember 2019-05-01 2019-05-31 0001044378 bioc:OtherWarrantExercisesMember 2019-05-01 2019-05-31 0001044378 bioc:WarrantExerciseInducementOfferingAndOtherWarrantExercisesMember srt:MinimumMember 2019-05-31 0001044378 bioc:WarrantExerciseInducementOfferingAndOtherWarrantExercisesMember srt:MaximumMember 2019-05-31 0001044378 bioc:WarrantExerciseInducementOfferingAndOtherWarrantExercisesMember us-gaap:CommonStockMember 2019-05-31 0001044378 us-gaap:SeriesAPreferredStockMember 2018-08-13 0001044378 us-gaap:WarrantMember 2019-05-01 2019-05-31 0001044378 2019-02-28 0001044378 srt:MaximumMember bioc:InvestorWarrantsMember 2019-05-28 0001044378 bioc:InvestorWarrantsMember 2019-05-27 2019-05-28 0001044378 bioc:InvestorWarrantsMember 2019-05-28 0001044378 bioc:InvestorWarrantsMember 2019-07-14 2019-07-15 0001044378 bioc:InvestorWarrantsMember 2019-07-01 2019-09-30 0001044378 bioc:InvestorWarrantsMember 2019-04-01 2019-06-30 0001044378 us-gaap:FairValueMeasurementsNonrecurringMember us-gaap:FairValueInputsLevel3Member 2019-01-01 2019-09-30 0001044378 srt:MaximumMember 2018-01-30 0001044378 2018-01-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember 2019-09-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExercisePriceMember 2019-09-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-09-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0001044378 bioc:ThirtyJanuaryTwoThousandEighteenOfferingMember us-gaap:MeasurementInputPriceVolatilityMember 2019-09-30 0001044378 srt:MaximumMember 2018-08-13 0001044378 bioc:FollowOnPublicOfferingMember 2018-08-13 0001044378 bioc:FollowOnPublicOfferingMember 2018-08-13 2018-08-13 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember 2019-09-30 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember us-gaap:MeasurementInputExercisePriceMember 2019-09-30 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-09-30 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0001044378 bioc:ThirteenAugustTwoThousandEighteenRightsOfferingMember us-gaap:MeasurementInputPriceVolatilityMember 2019-09-30 0001044378 srt:MaximumMember 2018-09-20 0001044378 bioc:FollowOnPublicOfferingMember 2018-09-20 0001044378 bioc:FollowOnPublicOfferingMember 2018-09-20 2018-09-20 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember 2019-09-30 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExercisePriceMember 2019-09-30 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExpectedDividendRateMember 2019-09-30 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember us-gaap:MeasurementInputDiscountRateMember 2019-09-30 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember us-gaap:MeasurementInputExpectedTermMember 2019-09-30 0001044378 bioc:TwentySeptemberTwoThousandEighteenOfferingMember us-gaap:MeasurementInputPriceVolatilityMember 2019-09-30 0001044378 srt:MaximumMember 2019-02-12 0001044378 2019-02-11 2019-02-12 0001044378 bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExercisePriceMember bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedDividendRateMember bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputDiscountRateMember bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedTermMember bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputPriceVolatilityMember bioc:TwelveFebruaryTwoThousandNineteenOfferingMember 2019-09-30 0001044378 srt:MaximumMember 2019-03-19 0001044378 bioc:FollowOnPublicOfferingMember 2019-03-19 0001044378 bioc:FollowOnPublicOfferingMember 2019-03-18 2019-03-19 0001044378 bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExercisePriceMember bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedDividendRateMember bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputDiscountRateMember bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedTermMember bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 us-gaap:MeasurementInputPriceVolatilityMember bioc:NineteenMarchTwoThousandNineteenOfferingMember 2019-09-30 0001044378 2019-05-30 0001044378 srt:MaximumMember 2019-05-30 0001044378 2019-05-30 2019-05-30 0001044378 bioc:WarrantInducementTransactionMember 2019-05-30 0001044378 bioc:WarrantInducementTransactionMember 2019-05-30 2019-05-30 0001044378 bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:MeasurementInputExercisePriceMember bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedDividendRateMember bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:MeasurementInputDiscountRateMember bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:MeasurementInputExpectedTermMember bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:MeasurementInputPriceVolatilityMember bioc:ThirtyMayTwoThousandNineteenWarrantInducementTransactionMember 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2019-01-01 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2018-12-31 0001044378 bioc:LoanFacilityOneMember bioc:OxfordFinanceLLCMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember us-gaap:CommonStockMember 2014-04-28 2014-04-30 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-12-31 0001044378 bioc:OxfordFinanceLLCMember bioc:LoanFacilityOneMember 2014-01-01 2014-12-31 0001044378 srt:MinimumMember us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member srt:MaximumMember 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2018-07-01 2018-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2019-07-01 2019-09-30 0001044378 us-gaap:AccountingStandardsUpdate201602Member 2018-01-01 2018-09-30 0001044378 2019-02-01 2019-02-01 0001044378 2019-01-31 2019-01-31 0001044378 2019-01-31 0001044378 2019-07-01 2019-07-31 0001044378 2019-07-31 0001044378 2019-08-01 2019-08-31 0001044378 2019-08-31 0001044378 2019-09-01 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2018-06-28 2018-06-28 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2019-06-17 2019-06-17 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:NonInducementSharesMember 2019-01-01 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember bioc:InducementSharesMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2018-12-31 0001044378 us-gaap:EmployeeStockOptionMember 2019-09-30 0001044378 srt:MinimumMember 2019-09-30 0001044378 srt:MaximumMember 2019-09-30 0001044378 srt:MinimumMember 2019-07-01 2019-09-30 0001044378 srt:MaximumMember 2019-07-01 2019-09-30 0001044378 srt:MinimumMember 2019-01-01 2019-09-30 0001044378 srt:MaximumMember 2019-01-01 2019-09-30 0001044378 bioc:TwoThousandThirteenEquityIncentivePlanMember 2019-04-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2018-12-31 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:CostOfSalesMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:ResearchAndDevelopmentExpenseMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:GeneralAndAdministrativeExpenseMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember us-gaap:SellingAndMarketingExpenseMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:CostOfSalesMember 2018-01-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:ResearchAndDevelopmentExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:GeneralAndAdministrativeExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember us-gaap:SellingAndMarketingExpenseMember 2018-01-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001044378 bioc:StockOptionsAndRestrictedStockUnitsMember 2019-09-30 0001044378 srt:MinimumMember 2018-07-01 2018-09-30 0001044378 srt:MinimumMember 2018-01-01 2018-09-30 0001044378 srt:MaximumMember 2018-07-01 2018-09-30 0001044378 srt:MaximumMember 2018-01-01 2018-09-30 0001044378 us-gaap:WarrantMember 2018-12-31 0001044378 us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 us-gaap:WarrantMember 2019-09-30 0001044378 us-gaap:WarrantMember 2018-01-01 2018-12-31 0001044378 bioc:WarrantsWithExercisePriceOneMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceTwoMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceThreeMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WeightedAverageExercisePriceFourMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceFiveMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceSixMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceSevenMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceEightMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceNineMember us-gaap:WarrantMember 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceOneMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceTwoMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceThreeMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WeightedAverageExercisePriceFourMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceFiveMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceSixMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceSevenMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceEightMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:WarrantsWithExercisePriceNineMember us-gaap:WarrantMember 2019-01-01 2019-09-30 0001044378 bioc:PreferredStockWarrantsMember 2018-07-01 2018-09-30 0001044378 bioc:CommonStockWarrantsMember 2018-07-01 2018-09-30 0001044378 bioc:CommonStockWarrantsMember 2019-07-01 2019-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2018-07-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2019-07-01 2019-09-30 0001044378 us-gaap:ConvertiblePreferredStockMember 2018-07-01 2018-09-30 0001044378 us-gaap:ConvertiblePreferredStockMember 2019-07-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2018-07-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2019-07-01 2019-09-30 0001044378 bioc:PreferredStockWarrantsMember 2018-01-01 2018-09-30 0001044378 bioc:CommonStockWarrantsMember 2018-01-01 2018-09-30 0001044378 bioc:CommonStockWarrantsMember 2019-01-01 2019-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2018-01-01 2018-09-30 0001044378 us-gaap:RestrictedStockUnitsRSUMember 2019-01-01 2019-09-30 0001044378 us-gaap:ConvertiblePreferredStockMember 2018-01-01 2018-09-30 0001044378 us-gaap:ConvertiblePreferredStockMember 2019-01-01 2019-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2018-01-01 2018-09-30 0001044378 us-gaap:EmployeeStockOptionMember 2019-01-01 2019-09-30 0001044378 bioc:AccruedOtherLiabilitiesMember 2018-12-31 0001044378 bioc:AccruedOtherLiabilitiesMember 2019-09-30 0001044378 bioc:AegeaBiotechnologiesIncMember 2019-07-01 2019-09-30 0001044378 bioc:AegeaBiotechnologiesIncMember 2018-07-01 2018-09-30 0001044378 bioc:AegeaBiotechnologiesIncMember 2019-01-01 2019-09-30 0001044378 bioc:AegeaBiotechnologiesIncMember 2018-01-01 2018-09-30 10-Q false 2019-09-30 2019 Q3 BIOC BIOCEPT INC 0001044378 --12-31 Non-accelerated Filer true true true 23018235 true false 001-36284 DE 80-0943522 5810 Nancy Ridge Drive San Diego CA 92121 858 320-8200 Common Stock, par value $.0001 per share NASDAQ false Yes Yes

3423373

6539444

1574325

2861659

587222

687186

425961

497121

6010881

10585410

2739422

1325255

2610249

8750303

14520914

2039718

1834020

1928393

1846984

132924

641536

1969285

4609647

5783213

985015

1032243

113122

5707784

6815456

463

2302

223499634

247685038

-220457578

-239981882

3042519

7705458

8750303

14520914

0.0001

5000000

4417

2133

4417

2133

0.0001

150000000

4629174

23018235

4629174

23018235

761591

1529262

2390772

3744824

2481916

2832735

7616473

8105422

1089746

1163546

3179612

3535116

1793720

1700380

5441354

5058525

1404192

1462335

4473908

4451628

6769574

7158996

20711347

21150691

-6007983

-5629734

-18320575

-17405867

63764

62028

230677

187575

23963 -6037 -1831116

-39801

-62028

-236714

-2018691

-6047784

-5691762

-18557289

-19424558

739

-6047784

-5691762

-18558028

-19424558

636370 636370 99743

-6684154

-5691762

-19194398

-19524301

2767440

23018235

2322749

17807298

2759614

23018235

2320111

17807298

-2.42

-0.25

-8.26

-1.10

-2.42

-0.25

-8.27

-1.10

1181179

118

196545523

-195249607

1296034

225263

1095153

110

13342711

13342821

6576

-6576

-6357143

2276332

6804

210106921

-201606750

8506975

173694

5834

-19

-6153101

2282166

6823

210280596

-207759851

2527568

113072

1012622 101 -4582 -101

11587

10097877

10097878

642438

2247610

2247674

636370 -636370 -6594 6594

-6047784

3937226

394

7005

223382018

-214444005

8938408

4629174

463

4417

223499634

-220457578

102459

5985

4747

4748

99743 -99743

990000

2032212

2032311

6250000

625

6602110

6602735

538867

592252

592306

5950000

595

7553198

7553793

503438 50 -2278 -50

-5916787

18867464

1887

2139

240486305

-226474108

14014084

224641

4149445

415

4845307

4845722

1326 -6 1831116 1831116

-7816012

23018235

2302

2133

247387369

-234290120

13099551

297669

-5691762

23018235

2302

2133

247685038

-239981882

580366

691191

-113419 92488 -20277

512029

624769

1831116

29425

283028

1287334

-9692

120241

-277720

-322299

413562

-198400

497119

76932

-241034

-82329

-16936994

-17577368

145253

297877

-145253

-297877

25688205 16779772

2513172

2337298

160111

378389

438290

260537

1197968

23891836

20991316

6809589

3116071

2146611

3423373

8956200

6539444

379587

187574

739

31000 488000 393000 80000

270000

583000

31000

55000

25000

67000

1095153

13.50

1.20

P5Y 9700000 1400000 11587

11587

2549140

4.53

11600000

P5Y 8400000 1400000

4582

1012622

642438

120000

3.285

3.275

0.01

2500000

3.16

P5Y 2000000 300000 636000

1930000

2201000

1400000

990000

2.25

2000000 6600000

6250000

1.20

P5Y

937500

915000

1.20

99000 7500000

5950000

1.37

1.25

P5Y6M 4100000

1.20

1.25

4800000

2100000

2300000

1. The Company, Business Activities and Basis of Presentation The Company and Business Activities The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TCTM, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations. Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-thirty reverse stock split. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss. Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of a contract is established via the order and accession, which are submitted by the patient’s physician.</td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided.</td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status.</td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur.</td> </tr> </table></div> The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations.  Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services are established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and nine months ended September 30, 2018 and 2019. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service.  Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable.   Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses.   The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses.  Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from contracted payers*</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,097</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,101</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019,857</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447,421</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from non-contracted payers</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,140</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201,869</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,080,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net commercial revenues recognized upon delivery</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698,115</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432,241</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,527,439</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and nine months ended September 30, 2018 and 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and September 30, 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div></div></div> Recent Accounting Pronouncements <p style="text-align:justify;margin-top:12pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In February 2016, the FASB issued authoritative guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2018. Effective January 1, 2019, the Company adopted the guidance and elected the optional transition method to account for the impact of the adoption with a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company also elected the practical expedient package as permitted under the transition guidance. As of January 1, 2019, the Company recorded a right-of-use asset and liability upon adoption of the guidance (See Note 7). In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity. In February 2018, the FASB issued authoritative guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from a tax bill, “H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018,” or the Tax Cuts and Jobs Act, enacted on December 22, 2017. These amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act. However, because these amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This guidance also requires certain disclosures about stranded tax effects. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 which did not have a material impact on its financial statements or disclosures because the Company does not currently maintain any stranded tax effects in accumulated other comprehensive income.   <p style="text-align:justify;margin-top:2pt;margin-bottom:0pt;text-indent:0%;color:#252525;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In June 2018, the FASB issued authoritative guidance simplifying the accounting for nonemployee stock-based compensation and largely aligning such compensation with the accounting requirements for employee stock-based awards. For public companies, this guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures. <p style="text-align:justify;margin-top:13pt;margin-bottom:0pt;text-indent:0%;color:#252525;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606).  The Company currently intends to adopt this guidance upon the effective date and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures.

4. Fair Value Measurement The estimated nonrecurring fair value measurements associated with fixed asset purchases recorded as right-of-use asset finance lease obligations totaling approximately $583,000 during the nine months ended September 30, 2019 were calculated as the present value of the lease payments based on contractual payment amounts and estimated market rates.  Upon adoption of guidance in ASC Topic 842 Leases, the estimated fair value of the right-of-use operating lease asset was recorded based on the present value of future lease payments based on contractual payment amounts and estimated market rates in effect. Other Fair Value Measurements As of the closing of the Company’s January 30, 2018 offering, the grant date fair value of the warrants issued to purchase up to 1,095,153 shares of common stock were estimated to be approximately $8.82 per share, or a total of approximately $9.7 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering currently have an exercise price of $1.20 per share, which is subject to down round adjustment, and expire five years from the date of issuance. The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> As of the closing of the Company’s August 13, 2018 rights offering, the grant date fair value of the warrants issued to purchase up to 2,549,140 shares of common stock were estimated to be approximately $3.30 per share, or a total of approximately $8.4 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering have an exercise price of $4.53 per share and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.89</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.53</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.75</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128.69</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div> As of the closing of the Company’s September 20, 2018 offering, the grant date fair value of the warrants issued to purchase up to 762,438 shares of common stock were estimated to be approximately $2.57 per share, or a total of approximately $2.0 million, was recorded as an offset to additional paid-in-capital on a relative fair value basis. The warrants sold in this offering have an exercise price of $3.16 per share and expire five years from the initial exercise date, which is the six month anniversary of the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.16</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.77</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> Also, included in the September 20, 2018 offering the Company issued 120,000 pre-funded warrants.  The pre-funded warrants had an intrinsic value of $350,000, were subsequently fully exercised and are no longer outstanding as of September 30, 2019. As of the closing of the Company’s February 12, 2019 offering, the estimated grant date fair value of approximately $0.95 per share associated with the warrants to purchase up to 7,165,000 shares of common stock issued in this offering, or a total of approximately $6.8 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.49</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> As of the closing of the Company’s March 19, 2019 offering, the estimated grant date fair value of approximately $1.01 per share associated with the warrants to purchase up to 5,950,000 shares of common stock issued in this offering, or a total of approximately $6.0 million, was recorded as an offset to additional paid-in capital on a relative fair value basis. All warrants sold in this offering have an exercise price of $1.25 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> As of the closing of the Company’s May 30, 2019 warrant inducement transaction, the estimated grant date fair value of approximately $1.18 per share associated with the warrants to purchase up to 1,547,226 shares of common stock issued in this offering, or a total of approximately $1.8 million, was recorded as a warrant inducement expense with an offset to additional paid-in capital. All warrants issued in this warrant inducement transaction have an exercise price of $1.31 per share, are exercisable immediately and expire 5.5 years from the date of issuance. The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.05</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145.9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table>  </div>

6. April 2014 Credit Facility On April 30, 2014, the Company received net cash proceeds of approximately $4,898,000 pursuant to the execution of the April 2014 Credit Facility. Upon entering into the April 2014 Credit Facility, the Company was required to pay the lender a facility fee of $50,000 in conjunction with the funding of the term loan. The April 2014 Credit Facility was secured by substantially all of the Company’s personal property other than its intellectual property. The term loan under the April 2014 Credit Facility bore interest at an annual rate of 7.95%. The Company was required to make interest-only payments on the term loan through August 1, 2015. The outstanding term loan under the April 2014 Credit Facility began amortizing at the end of the applicable interest-only period, with monthly payments of principal and interest being made by the Company to the lender in consecutive monthly installments following such interest-only period. The term loan under the April 2014 Credit Facility matured on July 1, 2018. Under the original terms of the underlying agreement, the Company was also required to make a final payment to the lender equal to 5.5% of the original principal amount of the term loan funded.  Upon maturity of the April 2014 Credit Facility on July 1, 2018, security interest in the Company’s personal property was released by the lender. A warrant to purchase up to 588 shares of the Company’s common stock at an exercise price of $424.80 per share with a term of 10 years was issued to Oxford Finance LLC on April 30, 2014. Issuance costs of approximately $102,000 associated with the term loan under the April 2014 Credit Facility were recorded as a discount to outstanding debt as of the closing date, resulting in net proceeds of approximately $4,898,000. The estimated fair value of the warrant issued of approximately $233,000 was also recorded as a discount to outstanding debt as of the closing date. The discounts and other issuance costs were amortized to interest expense utilizing the effective interest method over the underlying term of the loan.        7. Leases Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method.  The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases.  Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet.  In addition, assets under equipment leases previously classified as capital leases within Property, Plant and Equipment on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance.  Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term.  As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments.  Operating lease expense is recognized on a straight-line basis over the lease term.  Variable lease costs such as common area costs and other operating costs are expensed as incurred.  Leases with an initial term of 12 months or less are not recorded on the balance sheet.   Finance Leases The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight line basis over the lease term.  Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance.  The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $2,574,000 and $3,075,000 at December 31, 2018 and September 30, 2019, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $1,135,000 and $1,500,000 at December 31, 2018 and September 30, 2019, respectively. Total depreciation expense related to equipment under finance leases during the three months ended September 30, 2018 and 2019 was approximately $115,000 and $134,000, and during the nine months ended September 30, 2018 and 2019 was approximately $271,000 and $365,000, respectively. <p style="text-align:justify;margin-top:6pt;margin-bottom:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">On January 31, 2019, the Company executed an equipment financing commitment with a third-party lender for total amount of approximately $149,000, which was funded by the lender on February 1, 2019. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full after 36 monthly installments of $5,013 totaling approximately $180,000 through February 2022. In July 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $100,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 48 monthly installments of $2,706 totaling approximately $130,000 through May 2023. In August 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $245,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 36 monthly installments of $8,253 totaling approximately $297,000 through August 2022. In September 2019, an additional equipment financing commitment was executed with a third-party lender for total additional amount of approximately $89,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 60 monthly installments of $1,770 totaling approximately $106,000 through September 2024. Operating Lease The Company leases its primary laboratory and office facilities in San Diego, California.  This lease is classified as an operating lease in accordance with the ASC 842 guidance.  The average monthly cash payment for the operating lease is approximately $120,000 per month, and the lease term ends on July 31, 2020.  The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%. In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments. <p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and September 30, 2019 as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease right-of-use assets:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,035,210</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575,039</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,610,249</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of lease liability:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193,255</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776,030</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,969,285</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease liability:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032,243</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032,243</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule represents the components of lease expense for the three and nine months ended September 30, 2018 and 2019:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.82%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:32.98%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease cost</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%; border-top:solid 0.75pt #000000;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%; border-top:solid 0.75pt #000000;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance lease cost</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Amortization of right-of-use assets</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">134,472</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">364,401</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.38%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Interest on lease liabilities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,026</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.94%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,574</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.38%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating lease cost</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">318,005</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">954,015</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:30.38%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">514,503</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.94%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,505,990</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments, as of September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales Tax Obligation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 (remaining)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,245</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,929</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764,533</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,136</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855,136</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,927</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,974</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,318</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,260</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,274</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,799</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,448</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,241</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,231,745</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,426</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,218,065</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(423,472</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,810</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,808,273</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,426</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193,255</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   The following schedule sets forth supplemental cash flow information related to operating and finance leases as of September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from financing leases</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,026</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,574</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,813</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,067,437</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,139</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">378,389</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The aggregate weighted average remaining lease term was 3.14 years on finance leases and 0.84 years on operating leases as of September 30, 2019.  The aggregate weighted average discount rate was 20.30% on finance leases and 4.5% on operating leases as of September 30, 2019.  During the nine months ended September 30, 2019, the Company added $583,000 of right of use assets in exchange for finance lease liabilities.  In addition, upon adoption of the accounting guidance in ASC 842, $1.4 million of net machinery and equipment was reclassified to lease right-of-use assets related to assets under finance leases and $1.9 million of right-of-use facility lease was recorded under operating lease.

8. Stock-Based Compensation Equity Incentive Plans The Company maintains two equity incentive plans: The Amended and Restated 2013 Equity Incentive Plan, or the 2013 Plan, and the 2007 Equity Incentive Plan, or the 2007 Plan. The 2013 Plan includes a provision that shares available for grant under the Company’s 2007 Plan become available for issuance under the 2013 Plan and are no longer available for issuance under the 2007 Plan. At the Company’s annual meeting of stockholders held on June 28, 2018, the Company’s stockholders approved amendments to the 2013 Plan, which included an increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 146,666 shares. At the Company’s annual meeting of stockholders held on June 17, 2019, the Company’s stockholders approved additional amendments to the 2013 Plan including the increase in the number of non-inducement shares of common stock authorized for issuance under the 2013 Plan by 2,800,000 shares.  As of September 30, 2019, 124,211 shares of the Company’s common stock were authorized exclusively for the issuance of stock awards to employees who have not previously been an employee or director of the Company, except following a bona fide period of non-employment, as an inducement material to the individual’s entering into employment with the Company, as defined under applicable Nasdaq Listing Rules. As of September 30, 2019, under all plans, a total of 3,064,098 non-inducement shares were authorized for issuance, 2,711,095 shares had been issued with 2,650,970 non-inducement stock options and restricted stock units, or RSUs, underlying outstanding awards, and 353,003 non-inducement shares were available for grant. As of September 30, 2019, 118,368 inducement shares were authorized for issuance, 118,368 inducement shares had been issued under the 2013 Plan, with 117,534 inducement stock options and RSUs underlying outstanding awards and no inducement shares available for grant. Stock Options A summary of stock option activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,820</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.41</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,664,129</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,293</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,797,656</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest at September 30, 2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,701,017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.71</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2018 and September 30, 2019 were each approximately zero. The assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock and exercise prices</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $0.81 - $1.03</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;">  </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58% – 2.55%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00 – 5.96</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128% - 156%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   On April 30, 2019, the Company’s Board of Directors approved the issuance of an aggregate of 2,578,229 options to be granted to the Company’s employees, executives and Board members pursuant to the 2013 Amended Plan, subject to shareholder approval of the increase of the options available under the 2013 Amended Plan at the Company’s annual meeting on June 17, 2019.  On June 17, 2019 the Company’s shareholders approved the increase to the 2013 Amended Plan by 2.8 million shares. Restricted Stock A summary of RSU activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70.06%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.5pt;;text-indent:-6.65pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest at September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> At September 30, 2019, the intrinsic values of RSUs outstanding and RSUs unvested and expected to vest were each approximately $400. Of the 360 RSUs outstanding at September 30, 2019, all were fully vested. Stock-based Compensation Expense The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,150</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,405</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,150</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,625</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,247</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,626</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,267</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,742</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,162</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,484</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,593</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,102</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,513</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,154</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,594</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,300</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,669</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,604</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,802</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,576</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,303</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,348</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,669</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512,029</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> Stock-based compensation expense was recorded net of estimated forfeitures of 0% - 8% per annum during each of the three and nine months ended September 30, 2018 and 2019. As of September 30, 2019, total unrecognized share-based compensation expense related to unvested stock options and RSUs, adjusted for estimated forfeitures, was approximately $2,545,000 and is expected to be recognized over a weighted-average period of approximately 3.2 years.

10. Net Loss per Common Share Basic and diluted net loss per common share is determined by dividing net loss applicable to common shareholders by the weighted-average common shares outstanding during the period. Because there is a net loss attributable to common shareholders for the three and nine months ended September 30, 2018 and 2019, the outstanding RSUs, warrants, and common stock options have been excluded from the calculation of diluted loss per common share because their effect would be anti-dilutive. Based on applicable guidance, the 120,000 pre-funded warrants that were issued in the September 20, 2018 registered direct offering with an exercise price of $0.01 are considered common stock equivalents and are included in the calculation of basic and diluted loss per share. In other periods presented, the weighted-average shares used to calculate both basic and diluted loss per share are the same. The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.16%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three and nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:33.16%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.08%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Preferred warrants outstanding (number of common stock equivalents)</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common warrants outstanding</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,814,927</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,197,249</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:65.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Convertible preferred stock outstanding (number of common stock equivalents)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,560,727</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">471,393</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Common options outstanding</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">114,641</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,797,656</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:65.82%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total anti-dilutive common share equivalents</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,490,672</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:14.08%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">18,466,658</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The Company and Business Activities The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TCTM, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world. The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

Basis of Presentation The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern. On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-thirty reverse stock split. The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year. Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss.

Revenue Recognition and Accounts Receivable The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes. Contracts For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows: <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">  <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Approval of a contract is established via the order and accession, which are submitted by the patient’s physician.</td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits. </td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided.</td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Once the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status.</td> </tr> </table></div>   <div align="left"> <table border="0" cellspacing="0" cellpadding="0" style="border-collapse:collapse; width:100%;"> <tr> <td style="width:7.04%;"></td> <td style="width:3.15%;"></td> <td style="width:0.19%;"></td> <td style="width:89.63%;"></td> </tr> <tr> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:'Times New Roman';font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">• </td> <td valign="middle">  </td> <td valign="top"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur.</td> </tr> </table></div> The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract. Performance Obligations A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations.  Transaction Price The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services are established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management. <p style="text-align:justify;margin-bottom:0pt;margin-top:12pt;text-indent:0%;color:#000000;font-size:10pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and nine months ended September 30, 2018 and 2019. Allocate Transaction Price For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed. Point-in-time Recognition The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service.  Contract Balances The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable.   Practical Expedients The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less. The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses.   The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses.  Disaggregation of Revenue and Concentration of Risk The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from contracted payers*</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,097</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,101</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019,857</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447,421</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from non-contracted payers</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,140</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201,869</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,080,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table>   *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net commercial revenues recognized upon delivery</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698,115</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432,241</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,527,439</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div></div>   Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types. The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and nine months ended September 30, 2018 and 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and September 30, 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div></div>

The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from contracted payers*</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,097</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">476,101</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,019,857</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,447,421</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net revenues from non-contracted payers</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">373,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">956,140</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,201,869</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,080,018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>   *Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.     <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:100%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.4%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Net commercial revenues recognized upon delivery</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">698,115</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,432,241</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,221,726</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,527,439</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:43.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Development services revenues recognized upon delivery</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,476</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">159,606</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.6%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">125,169</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Kits and Blood Collection Tubes (BCT)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">59,040</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9,440</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">92,216</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:43.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total net revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">761,591</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,529,262</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,390,772</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.6%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,744,824</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and nine months ended September 30, 2018 and 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:30.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:35.76%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.82%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.66%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">32</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">39</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">40</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:35.76%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.66%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div> The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and September 30, 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:53.42%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31, 2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.72%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Blue Cross Blue Shield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">22</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Medicare and Medicare Advantage</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:53.42%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">United Healthcare</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.72%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:19.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10.17</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.48</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">99.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.89</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.53</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.75</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128.69</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>  The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.92</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.16</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.77</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">130.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.05</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.49</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">147.7</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.12</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.25</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.44</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:41.38%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Beginning stock price</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.29</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercise price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.31</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.05</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:69.82%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.74%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.08%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">145.9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:4.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">%</td> </tr> </table></div>

The following provides certain balance sheet details:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:60%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.78%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Fixed Assets</td> <td colspan="6" valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:38.92%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Machinery and equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,818,583</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,845,053</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Furniture and office equipment</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">157,391</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">156,987</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Computer equipment and software</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,437,408</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,552,981</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Leasehold improvements</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570,173</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">570,174</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financed equipment</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,573,955</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Construction in process</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">116,640</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">325,550</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fixed assets, gross</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">7,674,150</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5,450,745</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less accumulated depreciation and amortization</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,934,728</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,125,490</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total fixed assets, net</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,739,422</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,325,255</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-family:Times New Roman;font-size:10pt;font-style:normal;text-transform:none;font-variant: normal;">Accrued Liabilities</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:12pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued payroll</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">255,426</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">458,750</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued vacation</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">535,682</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">566,811</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued bonuses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">712,574</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">636,167</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued sales commissions</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,767</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">81,101</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:60.06%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of deferred rent</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">158,342</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.34%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Accrued other</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">203,602</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">104,155</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:60.06%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:27.35pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total accrued liabilities</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,928,393</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.34%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.78%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,846,984</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> <p style="text-align:justify;margin-bottom:6pt;margin-top:6pt;text-indent:0%;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and September 30, 2019 as follows: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Lease right-of-use assets:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,035,210</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,575,039</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,610,249</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Current portion of lease liability:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193,255</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">776,030</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,969,285</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">December 31,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;">  </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:23.94%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Long-term portion of lease liability:</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:47.3%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.78%;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032,243</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:47.3%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:13.7pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.78%; border-bottom:double 2.5pt transparent;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:22.94%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,032,243</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:justify;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments, as of September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:40.24%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Finance</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Operating</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Calibri;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Maintenance and</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-top:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Minimum</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Sales Tax Obligation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Lease</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:18.52%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Payments</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2019 (remaining)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">222,245</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">27,016</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">362,929</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2020</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">764,533</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">89,136</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">855,136</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2021</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">517,927</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">67,974</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2022</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">405,318</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,260</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2023</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">263,274</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">56,799</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Thereafter</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">58,448</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,241</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:37.04%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,231,745</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,426</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.18%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,218,065</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Less amount representing interest</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(423,472</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(24,810</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:37.04%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Present value of payments</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,808,273</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">306,426</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.18%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:17.52%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,193,255</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div> The following schedule sets forth supplemental cash flow information related to operating and finance leases as of September 30, 2019: <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;">  </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:52.32%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.52%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:21.56%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Other information</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from financing leases</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,026</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">187,574</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Operating cash flows from operating leases</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">355,813</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1,067,437</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:52.32%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Financing cash flows from finance leases</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">101,139</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.52%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:20.56%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">378,389</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:13.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">195,820</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">41.41</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.20</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,664,129</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.91</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:51.54%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.86%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cancelled/forfeited/expired</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(62,293</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">6.43</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,797,656</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.62</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:51.54%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest at September 30, 2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:12.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2,701,017</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.71</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.86%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:12.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">9.52</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2019 were as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:50%;"> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock and exercise prices</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> $0.81 - $1.03</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected dividend yield</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:0.7%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:27.7%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.00%</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;">  </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Discount rate-bond equivalent yield</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.58% – 2.55%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected life (in years)</td> <td colspan="2" valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">5.00 – 5.96</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:68.24%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expected volatility</td> <td colspan="2" valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.4%;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">128% - 156%</td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.36%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70.06%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Grant</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Date Fair Value</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Granted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:61.94%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and issued</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Forfeited</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">—</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:61.94%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:13.5pt;;text-indent:-6.65pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Vested and unvested expected to vest at September 30, 2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:double 2.5pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">360</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">415.80</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

The following table presents the effects of stock-based compensation related to equity awards to employees and nonemployees on the unaudited condensed statements of operations and comprehensive loss during the periods presented:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:90%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;">  </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the three months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">For the nine months ended</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="6" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:26.12%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">September 30,</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2018</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-top:solid 0.75pt #000000;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:11.76%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">2019</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Stock Options</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">10,150</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">29,405</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,150</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,625</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">30,247</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">37,626</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">103,267</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">102,742</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">57,162</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">168,484</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">243,593</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">361,102</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,513</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">62,154</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">63,594</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">106,300</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total expenses related to stock options</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,669</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">447,604</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">RSUs</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Cost of revenues</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(18,802</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Research and development expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">13,576</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:44.14%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">General and administrative expenses</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">54,303</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1.58%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Sales and marketing expenses</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,348</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">-</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:44.14%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Total stock-based compensation</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">113,072</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">297,669</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">512,029</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1.58%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:10.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">624,769</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:80%;"> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;">  </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Remaining</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Number of</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average Exercise</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:8pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Price Per Share</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:16.9%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Term in Years</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at December 31, 2018</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4,694,927</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8.55</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.4</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Issued</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">14,662,226</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.23</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:41.78%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Exercised</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,155,430</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.20</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:2.22%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:34.2pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Expired</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">(4,474</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">953.06</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:41.78%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:6.85pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">Outstanding at September 30, 2019</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:15.9%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,197,249</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.08</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:2.22%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:15.9%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.5</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

Further information about equity-classified common stock warrants outstanding at September 30, 2019 is as follows:   <div> <table border="0" cellspacing="0" cellpadding="0" align="center" style="border-collapse:collapse; width:70%;"> <tr> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Weighted</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:7pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="bottom" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Average</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Total Shares</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Contractual</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Exercise Price</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%; border-bottom:solid 0.75pt transparent;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Outstanding</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td colspan="2" valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:29.76%; border-bottom:solid 0.75pt #000000;"> <p style="text-align:center;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;font-weight:bold;color:#000000;font-size:8pt;font-family:Times New Roman;font-style:normal;text-transform:none;font-variant: normal;">Life (in years)</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:11pt;font-family:Calibri;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.24</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">11,601,949</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-top:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.7</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.21</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3,311,578</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.9</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">25.50</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">8,208</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.2</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">33.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">96,999</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.1</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">45.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">47,821</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">2.9</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">75.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">71,995</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">3.0</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">117.00</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">38,772</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">1.6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">140.00</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">19,339</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:3.84%;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">0.4</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">$</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">424.80</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-bottom:solid 0.75pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">588</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%; border-bottom:solid 0.75pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.76%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">4.6</td> <td valign="middle" bgcolor="#CFF0FC" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:solid 0.75pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> <tr> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:1%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;padding-Bottom:0pt;width:28.76%; border-top:solid 0.75pt #000000; border-bottom:double 2.5pt #000000;white-space:nowrap;"> <p style="text-align:right;margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;">15,197,249</td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:3.84%; border-bottom:double 2.5pt transparent;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:28.76%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-family:Times New Roman;font-size:10pt;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> <td valign="middle" bgcolor="#FFFFFF" style="padding-left:0pt;padding-Right:0.75pt;padding-Top:0.75pt;width:1%; border-bottom:double 2.5pt transparent;white-space:nowrap;"> <p style="margin-bottom:0pt;margin-top:0pt;margin-left:0pt;;text-indent:0pt;;color:#000000;font-size:1pt;font-family:Times New Roman;font-weight:normal;font-style:normal;text-transform:none;font-variant: normal;"> </td> </tr> </table></div>

0.03

150000000

The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks.

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

P1Y

325097

476101

1019857

1447421

373018

956140

1201869

2080018

63476

37981

159606

125169

59040

9440

92216

698115

1432241

2221726

3527439

0.40

0.32

0.39

0.40

0.09

0.25

0.14

0.20

0.06

0.08

0.15

0.09

0.22

0.25

0.17

0.15

0.13

-24600000

1900000 909000 3000000

1062500

62500 Quarterly

2020-05-31

154000

13300000

1300000 1.20 2023-01 2021-05-31 50000000 75000000

471393

10100000 0.01 2200000 538867

1.20

592000

2300000

2500000

1.20

1.25

4200000

1095153

1400000

P5Y 9700000 4.53

0.0001

1000 6250000

2500000

2086479

1.20

0.20 In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date.

1.31

2062966

2300000

1800000

1800000 1800000 0.75

2019-07-15

2019-07-31

583000

1095153 8.82

10.17

15.00

0.00

2.48

P5Y

99.00

2549140 3.30

4.53

P5Y

3.89

4.53

0.00

2.75

P5Y

128.69

762438 2.57

3.16

P5Y

2.92

3.16

0.00

2.77

P5Y6M

130.7

120000

350000 0.95 7165000 6800000

1.05

1.20

0.00

2.49

P5Y

147.7

1.01 5950000 6000000

1.25

P5Y6M

1.12

1.25

0.00

2.44

P5Y6M

140.0

1.18 1547226 1800000

1.31

P5Y6M

1.29

1.31

0.00

2.05

P5Y6M

145.9

2818583

2845053

157391

156987

1437408 1552981

570173

570174

2573955

116640

325550

7674150

5450745

4934728

4125490

255426

458750

535682

566811

712574

636167

62767

81101

158342

203602

104155

350000

2574000 1135000

691191

580366

240207

223194

4898000

50000

0.0795

0.055

2018-07-01

588

424.80

P10Y

102000

4898000 233000

1400000

P3Y

P7Y

3075000 1500000 115000 134000 271000 365000 149000 monthly 36 5013 180000 2022-02 100000 monthly 48 2706 130000 2023-05 245000 monthly 36 8253 297000 2022-08 89000 monthly 60 1770 106000 2024-09 monthly cash payment

120000

2020-07-31

0.045

1035210

1575039

1193255

776030

1032243

134472

364401

62026

187574

318005

954015

514503 1505990

222245

764533

517927

405318

263274

58448

2231745

423472

1808273

27016 89136 67974 57260 56799 8241 306426 306426

362929

855136

1218065

24810

1193255

62026

187574

355813

1067437

101139

P3Y2M8D

P10M2D

0.2030

0.045

583000

124211

146666

2800000

3064098

2711095

2650970

353003

118368

117534

118368

195820

2664129

62293

2797656

2701017

41.41

0.91

6.43

3.62

3.71

P9Y2M12D

P9Y6M7D

0.81

1.03

0.0000

0.0158 0.0255

P5Y

P5Y11M15D

1.28

1.56

0.0000

0.0158 0.0255

P5Y

P5Y11M15D

1.28

1.56

2578229

360

415.80

400

10150

29405

37150

54625

30247

37626

103267

102742

57162

168484

243593

361102

15513

62154

63594

106300

113072

297669

447604

624769

-18802

13576

54303

15348

113072

297669

512029

624769

2545000

P3Y2M12D

0.00 0.00 0.00 0.00 0.08 0.08 0.08 0.08

4694927

14662226 4155430 4474

15197249

8.55 1.23 1.20 953.06 3.08 P4Y4M24D P4Y6M

1.24

4.21

25.50

33.00

45.00

75.00

117.00

140.00

424.80

11601949

3311578

8208

96999

47821

71995

38772

19339

588

P4Y8M12D P3Y10M24D P3Y2M12D P2Y1M6D P2Y10M24D P3Y P1Y7M6D P4M24D P4Y7M6D 0

4814927

15197249

360

2560727

471393

114641

2797656

7490672

18466658

4814927

15197249

360

2560727

471393

114641

2797656

7490672

18466658

25000 35000 75000 82000 69000 71000 0 0 26000 19000 Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

EX-101.SCH 7 bioc-20190930.xsd XBRL TAXONOMY EXTENSION SCHEMA 00000 - Document - Template Link link:presentationLink link:calculationLink link:definitionLink 100000 - Document - Document and Entity Information link:calculationLink link:presentationLink link:definitionLink 100010 - Statement - Condensed Balance Sheets link:calculationLink link:presentationLink link:definitionLink 100020 - Statement - Condensed Balance Sheets (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100040 - Statement - Condensed Statements of Shareholders' Equity link:calculationLink link:presentationLink link:definitionLink 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) link:calculationLink link:presentationLink link:definitionLink 100060 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) link:calculationLink link:presentationLink link:definitionLink 100070 - Disclosure - The Company, Business Activities and Basis of Presentation link:calculationLink link:presentationLink link:definitionLink 100080 - Disclosure - Liquidity and Going Concern Uncertainty link:calculationLink link:presentationLink link:definitionLink 100090 - Disclosure - Sales of Equity Securities link:calculationLink link:presentationLink link:definitionLink 100100 - Disclosure - Fair Value Measurement link:calculationLink link:presentationLink link:definitionLink 100110 - Disclosure - Balance Sheet Details link:calculationLink link:presentationLink link:definitionLink 100120 - Disclosure - April 2014 Credit Facility link:calculationLink link:presentationLink link:definitionLink 100130 - Disclosure - Leases link:calculationLink link:presentationLink link:definitionLink 100140 - Disclosure - Stock-Based Compensation link:calculationLink link:presentationLink link:definitionLink 100150 - Disclosure - Common Stock Warrants Outstanding link:calculationLink link:presentationLink link:definitionLink 100160 - Disclosure - Net Loss per Common Share link:calculationLink link:presentationLink link:definitionLink 100170 - Disclosure - Commitments and Contingencies link:calculationLink link:presentationLink link:definitionLink 100180 - Disclosure - Related Party Transactions link:calculationLink link:presentationLink link:definitionLink 100190 - Disclosure - The Company, Business Activities and Basis of Presentation (Policies) link:calculationLink link:presentationLink link:definitionLink 100200 - Disclosure - The Company, Business Activities and Basis of Presentation (Tables) link:calculationLink link:presentationLink link:definitionLink 100210 - Disclosure - Fair Value Measurement (Tables) link:calculationLink link:presentationLink link:definitionLink 100220 - Disclosure - Balance Sheet Details (Tables) link:calculationLink link:presentationLink link:definitionLink 100230 - Disclosure - Leases (Tables) link:calculationLink link:presentationLink link:definitionLink 100240 - Disclosure - Stock-Based Compensation (Tables) link:calculationLink link:presentationLink link:definitionLink 100250 - Disclosure - Common Stock Warrants Outstanding (Tables) link:calculationLink link:presentationLink link:definitionLink 100260 - Disclosure - Net Loss per Common Share (Tables) link:calculationLink link:presentationLink link:definitionLink 100270 - Disclosure - The Company, Business Activities and Basis of Presentation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100280 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) link:calculationLink link:presentationLink link:definitionLink 100290 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) link:calculationLink link:presentationLink link:definitionLink 100300 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) link:calculationLink link:presentationLink link:definitionLink 100310 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100320 - Disclosure - Sales of Equity Securities - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100330 - Disclosure - Fair Value Measurement - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100340 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) link:calculationLink link:presentationLink link:definitionLink 100350 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100360 - Disclosure - Balance Sheet Details - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100370 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100380 - Disclosure - Leases - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100390 - Disclosure - Leases - Schedule of Right-Of-Use Lease Assets (Detail) link:calculationLink link:presentationLink link:definitionLink 100400 - Disclosure - Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100410 - Disclosure - Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) link:calculationLink link:presentationLink link:definitionLink 100420 - Disclosure - Leases - Schedule of Lease Expense (Detail) link:calculationLink link:presentationLink link:definitionLink 100430 - Disclosure - Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100440 - Disclosure - Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail)2 link:calculationLink link:presentationLink link:definitionLink 100450 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) link:calculationLink link:presentationLink link:definitionLink 100460 - Disclosure - Stock-Based Compensation - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100470 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100480 - Disclosure - Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) link:calculationLink link:presentationLink link:definitionLink 100490 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100500 - Disclosure - Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) link:calculationLink link:presentationLink link:definitionLink 100510 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) link:calculationLink link:presentationLink link:definitionLink 100520 - Disclosure - Common Stock Warrants Outstanding - Equity-Classified Common Stock Warrants, Outstanding (Detail) link:calculationLink link:presentationLink link:definitionLink 100530 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100540 - Disclosure - Net Loss per Common Share - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100550 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) link:calculationLink link:presentationLink link:definitionLink 100560 - Disclosure - Commitments and Contingencies - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink 100570 - Disclosure - Related Party Transactions - Additional Information (Detail) link:calculationLink link:presentationLink link:definitionLink EX-101.CAL 8 bioc-20190930_cal.xml XBRL TAXONOMY EXTENSION CALCULATION LINKBASE EX-101.DEF 9 bioc-20190930_def.xml XBRL TAXONOMY EXTENSION DEFINITION LINKBASE EX-101.LAB 10 bioc-20190930_lab.xml XBRL TAXONOMY EXTENSION LABEL LINKBASE Entity Central Index Key Finance leases maintenance and sales tax obligation payments remainder of fiscal year. Finance leases maintenance and sales tax obligation payments due In two years. Finance leases maintenance and sales tax obligation payments due in three years. Finance leases maintenance and sales tax obligation payments due in four years. Finance leases maintenance and sales tax obligation payments due in five years. Finance leases maintenance and sales tax obligation payments due thereafter. Finance leases maintenance and sales tax obligation payments interest. Finance leases maintenance and sales tax obligation payments net. Cover [Abstract] Document Type Document Type Amendment Flag Amendment Flag Document Period End Date Document Period End Date Document Fiscal Year Focus Document Fiscal Year Focus Document Fiscal Period Focus Document Fiscal Period Focus Trading Symbol Trading Symbol Entity Registrant Name Entity Registrant Name Entity Central Index Key Entity Central Index Key Current Fiscal Year End Date Current Fiscal Year End Date Entity Filer Category Entity Filer Category Entity Small Business Entity Small Business Entity Emerging Growth Company Entity Emerging Growth Company Entity Ex Transition Period Entity Ex Transition Period Entity Common Stock, Shares Outstanding Entity Common Stock Shares Outstanding Document Quarterly Report Document Quarterly Report Document Transition Report Document Transition Report Entity File Number Entity File Number Entity Incorporation, State or Country Code Entity Incorporation State Country Code Entity Tax Identification Number Entity Tax Identification Number Entity Address, Address Line One Entity Address Address Line1 Entity Address, City or Town Entity Address City Or Town Entity Address, State or Province Entity Address State Or Province Entity Address, Postal Zip Code Entity Address Postal Zip Code City Area Code City Area Code Local Phone Number Local Phone Number Title of 12(b) Security Security12b Title Security Exchange Name Security Exchange Name Entity Shell Company Entity Shell Company Entity Current Reporting Status Entity Current Reporting Status Entity Interactive Data Current Entity Interactive Data Current Operating and finance lease right-of-use assets. Supplier financings. Operating and finance lease liability current. Operating and finance lease liability noncurrent. Statement Of Financial Position [Abstract] Current assets: Assets Current [Abstract] Cash Cash Accounts receivable, net Accounts Receivable Net Current Inventories, net Inventory Net Prepaid expenses and other current assets Prepaid Expense And Other Assets Current Total current assets Assets Current Fixed assets, net Property Plant And Equipment Net Lease right-of-use assets Operating And Finance Lease Right Of Use Assets Total assets Assets Current liabilities: Liabilities Current [Abstract] Accounts payable Accounts Payable Current Accrued liabilities Accrued Liabilities Current Supplier financings Supplier Financings Current portion of equipment financings Capital Lease Obligations Current Current portion of lease liabilities Operating And Finance Lease Liability Current Total current liabilities Liabilities Current Non-current portion of equipment financings Capital Lease Obligations Noncurrent Non-current portion of lease liabilities Operating And Finance Lease Liability Noncurrent Non-current portion of deferred rent Deferred Rent Credit Noncurrent Total liabilities Liabilities Commitments and contingencies (see Note 11) Commitments And Contingencies Shareholders’ equity: Stockholders Equity [Abstract] Preferred stock, $0.0001 par value, 5,000,000 authorized; 4,417 shares issued and outstanding at December 31, 2018; and 2,133 shares issued and outstanding at September 30, 2019. Preferred Stock Value Common stock, $0.0001 par value, 150,000,000 authorized; 4,629,174 issued and outstanding at December 31, 2018; 23,018,235 issued and outstanding at September 30, 2019. Common Stock Value Additional paid-in capital Additional Paid In Capital Common Stock Accumulated deficit Retained Earnings Accumulated Deficit Total shareholders’ equity Stockholders Equity Total liabilities and shareholders’ equity Liabilities And Stockholders Equity Preferred stock, par value Preferred Stock Par Or Stated Value Per Share Preferred stock, shares authorized Preferred Stock Shares Authorized Preferred stock, shares issued Preferred Stock Shares Issued Preferred stock, shares outstanding Preferred Stock Shares Outstanding Common stock, par value Common Stock Par Or Stated Value Per Share Common stock, shares authorized Common Stock Shares Authorized Common stock, shares issued Common Stock Shares Issued Common stock, shares outstanding Common Stock Shares Outstanding Warrant inducement and other income (expenses). Deemed dividend related to warrants down round provision. Income Statement [Abstract] Net revenues Revenue From Contract With Customer Excluding Assessed Tax Costs and expenses: Costs And Expenses [Abstract] Cost of revenues Cost Of Revenue Research and development expenses Research And Development Expense General and administrative expenses General And Administrative Expense Sales and marketing expenses Selling And Marketing Expense Total costs and expenses Costs And Expenses Loss from operations Operating Income Loss Other income/ (expense): Nonoperating Income Expense [Abstract] Interest expense Interest Expense Warrant inducement and other income (expenses) Warrant Inducement And Other Income Expenses Total other income/ (expense): Nonoperating Income Expense Loss before income taxes Income Loss From Continuing Operations Before Income Taxes Extraordinary Items Noncontrolling Interest Income tax expense Income Tax Expense Benefit Net loss and comprehensive loss Net Income Loss Deemed dividend related to warrants down round provision Deemed Dividend Related To Warrants Down Round Provision Net loss attributable to common shareholders Net Income Loss Available To Common Stockholders Basic Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders: Weighted Average Number Of Shares Outstanding [Abstract] Basic Weighted Average Number Of Shares Outstanding Basic Diluted Weighted Average Number Of Diluted Shares Outstanding Net loss per common share: Earnings Per Share [Abstract] Basic Earnings Per Share Basic Diluted Earnings Per Share Diluted Shares issued upon conversion of preferred stock shares. Shares issued upon conversion of preferred stock value. Adjustment to additional paid in capital common stock reclassification. Adjustment to additional paid in capital, warrant inducement expense. Statement Of Stockholders Equity [Abstract] Statement [Table] Statement [Table] Equity Components Statement Equity Components [Axis] Equity Component Equity Component [Domain] Common Stock [Member] Common Stock [Member] Series A Convertible Preferred Stock. SeriesA Convertible Preferred Stock [Member] Series A Convertible Preferred Stock [Member] Additional Paid-in Capital [Member] Additional Paid In Capital [Member] Accumulated Deficit [Member] Accumulated Other Comprehensive Income [Member] Sale of Stock Subsidiary Sale Of Stock [Axis] Sale of Stock Sale Of Stock Name Of Transaction [Domain] August two thousand eighteen rights offering. August 2018 Rights Offering [Member] August Two Thousand Eighteen Rights Offering [Member] September two thousand eighteen registered direct offering. September 2018 Registered Direct Offering [Member] September Two Thousand Eighteen Registered Direct Offering [Member] January two thousand nineteen financing transaction. January 2019 Financing Transaction [Member] January Two Thousand Nineteen Financing Transaction [Member] February two thousand nineteen financing transaction. February 2019 Financing Transaction [Member] February Two Thousand Nineteen Financing Transaction [Member] January two thousand nineteen financing transaction overallotment. January 2019 Financing Transaction Overallotment [Member] January Two Thousand Nineteen Financing Transaction Overallotment [Member] March two thousand nineteen financing transaction. March 2019 Financing Transaction [Member] March Two Thousand Nineteen Financing Transaction [Member] January two thousand eighteen financing transaction. January 2018 financing transaction [Member] January Two Thousand Eighteen Financing Transaction [Member] Statement [Line Items] Statement [Line Items] Beginning balance Beginning balance, shares Shares Outstanding Stock-based compensation expense Adjustments To Additional Paid In Capital Sharebased Compensation Requisite Service Period Recognition Value Shares issued for restricted stock units Stock Issued During Period Value Restricted Stock Award Gross Shares issued for restricted stock units, shares Stock Issued During Period Shares Restricted Stock Award Gross Shares issued upon exercise of common stock warrants Stock Issued During Period Value Conversion Of Convertible Securities Shares issued upon exercise of common stock warrants, shares Stock Issued During Period Shares Conversion Of Convertible Securities Shares and warrants issued, net of issuance costs Stock Issued During Period Value New Issues Shares and warrants issued, net of issuance costs, shares Stock Issued During Period Shares New Issues Deemed dividends related warrants down round provision Adjustment for presentation after reverse stock split Adjustments To Additional Paid In Capital Stock Split Shares issued upon conversion of preferred stock Shares Issued Upon Conversion Of Preferred Stock Value Shares issued upon conversion of preferred stock, shares Shares Issued Upon Conversion Of Preferred Stock Shares Warrant inducement expense Adjustment To Additional Paid In Capital Warrant Inducement Expense Common stock reclassification Adjustment To Additional Paid In Capital Common Stock Reclassification Net loss Ending balance Ending balance, shares Amortization of right-of-use assets. Increase decrease in inventory reserve. Proceeds from issuance of common stock and warrants. Cash paid during period. Statement Of Cash Flows [Abstract] Cash Flows from Operating Activities Net Cash Provided By Used In Operating Activities [Abstract] Net loss Adjustments to reconcile net loss to net cash used in operating activities: Adjustments To Reconcile Net Income Loss To Cash Provided By Used In Operating Activities [Abstract] Depreciation and amortization Depreciation And Amortization Amortization of right-of-use assets Amortization Of Right Of Use Assets Inventory reserve Increase Decrease In Inventory Reserve Stock-based compensation Share Based Compensation Warrant inducement expense Adjustment Of Warrants Granted For Services Non-cash interest expense related to credit facility and other financing activities Paid In Kind Interest Increase/(decrease) in cash resulting from changes in: Increase Decrease In Operating Capital [Abstract] Accounts receivable, net Increase Decrease In Accounts Receivable Inventory Increase Decrease In Inventories Prepaid expenses and other current assets Increase Decrease In Prepaid Deferred Expense And Other Assets Accounts payable Increase Decrease In Accounts Payable Accrued liabilities Increase Decrease In Accrued Liabilities Accrued interest Increase Decrease In Interest Payable Net Deferred rent Increase Decrease In Deferred Liabilities Net cash used in operating activities Net Cash Provided By Used In Operating Activities Cash Flows from Investing Activities: Net Cash Provided By Used In Investing Activities [Abstract] Purchases of fixed assets Payments To Acquire Property Plant And Equipment Net cash used in investing activities Net Cash Provided By Used In Investing Activities Cash Flows from Financing Activities: Net Cash Provided By Used In Financing Activities [Abstract] Net proceeds from issuance of common stock and warrants Proceeds From Issuance Of Common Stock And Warrants Proceeds from exercise of common stock warrants Proceeds From Warrant Exercises Proceeds from warrant exercise inducement, net Proceeds From Issuance Of Warrants Payments on finance leases Finance Lease Principal Payments Payments on supplier and other third-party financings Repayments Of Other Debt Payments on credit facility Repayments Of Lines Of Credit Net cash provided by financing activities Net Cash Provided By Used In Financing Activities Net increase in Cash Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Period Increase Decrease Including Exchange Rate Effect Cash at Beginning of Period Cash Cash Equivalents Restricted Cash And Restricted Cash Equivalents Including Disposal Group And Discontinued Operations Cash at End of Period Supplemental Disclosures of Cash Flow Information: Supplemental Cash Flow Information [Abstract] Cash paid during the period for: Cash Paid During Period [Abstract] Interest Interest Paid Net Income taxes Income Taxes Paid Net Financial Guarantee Insurance Contracts Premium Payable. Financial guarantee insurance contracts cancelled premium remaining principal outstanding. New financial guarantee insurance contracts premium payable. Follow-on public offering. Follow-on Public Offering [Member] Follow On Public Offering [Member] Statistical Measurement Range [Axis] Statistical Measurement Range [Member] Maximum [Member] Maximum [Member] Minimum [Member] Minimum [Member] Class of Stock Statement Class Of Stock [Axis] Class of Stock Class Of Stock [Domain] Series A Preferred Stock [Member] Series A Preferred Stock [Member] Warrant [Member] Warrant [Member] Class of Warrant or Right Class Of Warrant Or Right [Axis] Class of Warrant or Right Class Of Warrant Or Right [Domain] Prefunded warrants. Pre-funded Warrants [Member] Prefunded Warrants [Member] Private Placement [Member] Private Placement [Member] Property, Plant and Equipment, Type Property Plant And Equipment By Type [Axis] Property, Plant and Equipment, Type Property Plant And Equipment Type [Domain] Property, Plant and Equipment [Member] Machinery And Equipment [Member] Adjustments for New Accounting Pronouncements Adjustments For New Accounting Pronouncements [Axis] Type of Adoption Type Of Adoption [Member] ASC Topic 842 [Member] Accounting Standards Update201602 [Member] Over-allotment Option [Member] Over Allotment Option [Member] Collaborative Arrangement and Arrangement Other than Collaborative Type Of Arrangement [Axis] Collaborative Arrangement and Arrangement Other than Collaborative EX-101.PRE 11 bioc-20190930_pre.xml XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE XML 12 R28.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Additional Information (Detail)		9 Months Ended
	Jul. 06, 2018 shares	Sep. 30, 2019 shares	Dec. 31, 2018 shares
The Company Business Activities And Basis Of Presentation [Line Items]
Stockholders equity reverse stock split ratio	0.03
Common stock, shares authorized	150,000,000	150,000,000	150,000,000
Description of reverse stock split		On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock.
ASC 606 [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Performance obligation, description of timing		The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks.
Practical expedient, description		The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.
ASC 606 [Member] \| Maximum [Member] \| Sales and Marketing Expenses [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Amortization period		1 year

XML 13 R20.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation (Policies)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

The Company and Business Activities

Basis of Presentation

Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss.

Revenue Recognition and Accounts Receivable

The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes.

Contracts


	•		Approval of a contract is established via the order and accession, which are submitted by the patient’s physician.
	•		The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.


	•		Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided.
	•		Once the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status.


	•		Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur.

Performance Obligations

Transaction Price

The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and nine months ended September 30, 2018 and 2019.

Allocate Transaction Price

Point-in-time Recognition

Contract Balances

Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses.

Disaggregation of Revenue and Concentration of Risk

The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net revenues from contracted payers*	$	325,097	$	476,101	$	1,019,857	$	1,447,421
Net revenues from non-contracted payers		373,018		956,140		1,201,869		2,080,018
Development services revenues		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

*Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net commercial revenues recognized upon delivery	$	698,115	$	1,432,241	$	2,221,726	$	3,527,439
Development services revenues recognized upon delivery		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

	For the three months ended September 30,						For the nine months ended September 30,
	2018			2019			2018			2019
Medicare and Medicare Advantage		40	%		32	%		39	%		40	%
Blue Cross Blue Shield		9	%		25	%		14	%		20	%
United Healthcare		6	%		8	%		15	%		9	%

	December 31, 2018			September 30, 2019
Blue Cross Blue Shield		22	%		25	%
Medicare and Medicare Advantage		17	%		17	%
United Healthcare		15	%		13	%

Recent Accounting Pronouncements

XML 14 R24.htm IDEA: XBRL DOCUMENT

Leases (Tables)

9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Schedule of Right-Of-Use Lease Assets

The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and September 30, 2019 as follows:

	December 31,		September 30,
	2018		2019
Lease right-of-use assets:
Operating	$	—	$	1,035,210
Finance		—		1,575,039
Total	$	—	$	2,610,249

Schedule of Current Portion of Operating and Finance Lease Liabilities

The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

	December 31,		September 30,
	2018		2019
Current portion of lease liability:
Operating	$	—		1,193,255
Finance		—		776,030
Total	$	—	$	1,969,285

Schedule of Long-Term Portion of Operating and Finance Lease Liabilities

The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

	December 31,		September 30,
	2018		2019
Long-term portion of lease liability:
Operating	$	—	$	—
Finance		—		1,032,243
Total	$	—	$	1,032,243

Schedule of Lease Expenses

The following schedule represents the components of lease expense for the three and nine months ended September 30, 2018 and 2019:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Lease cost
Finance lease cost
Amortization of right-of-use assets	$	—	$	134,472	$	—	$	364,401
Interest on lease liabilities		—		62,026		—		187,574
Operating lease cost		—		318,005		—		954,015
Total	$	—	$	514,503	$	—	$	1,505,990

Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases

	Finance					Operating
	Minimum			Maintenance and		Minimum
	Lease			Sales Tax Obligation		Lease
	Payments			Payments		Payments
2019 (remaining)	$	222,245		$	27,016	$	362,929
2020		764,533			89,136		855,136
2021		517,927			67,974		—
2022		405,318			57,260		—
2023		263,274			56,799		—
Thereafter		58,448			8,241		—
Total payments		2,231,745			306,426		1,218,065
Less amount representing interest		(423,472	)		—		(24,810	)
Present value of payments	$	1,808,273		$	306,426	$	1,193,255

Supplemental Cash Flow Information Related to Operating and Finance Leases

The following schedule sets forth supplemental cash flow information related to operating and finance leases as of September 30, 2019:

	For the three months ended		For the nine months ended
	September 30, 2019		September 30, 2019
Other information
Operating cash flows from financing leases	$	62,026	$	187,574
Operating cash flows from operating leases	$	355,813	$	1,067,437
Financing cash flows from finance leases	$	101,139	$	378,389

XML 15 report.css IDEA: XBRL DOCUMENT /* Updated 2009-11-04 */ /* v2.2.0.24 */ /* DefRef Styles */ ..report table.authRefData{ background-color: #def; border: 2px solid #2F4497; font-size: 1em; position: absolute; } ..report table.authRefData a { display: block; font-weight: bold; } ..report table.authRefData p { margin-top: 0px; } ..report table.authRefData .hide { background-color: #2F4497; padding: 1px 3px 0px 0px; text-align: right; } ..report table.authRefData .hide a:hover { background-color: #2F4497; } ..report table.authRefData .body { height: 150px; overflow: auto; width: 400px; } ..report table.authRefData table{ font-size: 1em; } /* Report Styles */ ..pl a, .pl a:visited { color: black; text-decoration: none; } /* table */ ..report { background-color: white; border: 2px solid #acf; clear: both; color: black; font: normal 8pt Helvetica, Arial, san-serif; margin-bottom: 2em; } ..report hr { border: 1px solid #acf; } /* Top labels */ ..report th { background-color: #acf; color: black; font-weight: bold; text-align: center; } ..report th.void { background-color: transparent; color: #000000; font: bold 10pt Helvetica, Arial, san-serif; text-align: left; } ..report .pl { text-align: left; vertical-align: top; white-space: normal; width: 200px; white-space: normal; /* word-wrap: break-word; */ } ..report td.pl a.a { cursor: pointer; display: block; width: 200px; overflow: hidden; } ..report td.pl div.a { width: 200px; } ..report td.pl a:hover { background-color: #ffc; } /* Header rows... */ ..report tr.rh { background-color: #acf; color: black; font-weight: bold; } /* Calendars... */ ..report .rc { background-color: #f0f0f0; } /* Even rows... */ ..report .re, .report .reu { background-color: #def; } ..report .reu td { border-bottom: 1px solid black; } /* Odd rows... */ ..report .ro, .report .rou { background-color: white; } ..report .rou td { border-bottom: 1px solid black; } ..report .rou table td, .report .reu table td { border-bottom: 0px solid black; } /* styles for footnote marker */ ..report .fn { white-space: nowrap; } /* styles for numeric types */ ..report .num, .report .nump { text-align: right; white-space: nowrap; } ..report .nump { padding-left: 2em; } ..report .nump { padding: 0px 0.4em 0px 2em; } /* styles for text types */ ..report .text { text-align: left; white-space: normal; } ..report .text .big { margin-bottom: 1em; width: 17em; } ..report .text .more { display: none; } ..report .text .note { font-style: italic; font-weight: bold; } ..report .text .small { width: 10em; } ..report sup { font-style: italic; } ..report .outerFootnotes { font-size: 1em; } XML 16 R3.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets (Parenthetical) - $ / shares	Sep. 30, 2019	Dec. 31, 2018
Statement Of Financial Position [Abstract]
Preferred stock, par value	$ 0.0001	$ 0.0001
Preferred stock, shares authorized	5,000,000	5,000,000
Preferred stock, shares issued	2,133	4,417
Preferred stock, shares outstanding	2,133	4,417
Common stock, par value	$ 0.0001	$ 0.0001
Common stock, shares authorized	150,000,000	150,000,000
Common stock, shares issued	23,018,235	4,629,174
Common stock, shares outstanding	23,018,235	4,629,174

XML 17 R7.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) (Parenthetical) - USD ($)				1 Months Ended		3 Months Ended	9 Months Ended		12 Months Ended
	Sep. 20, 2018	Aug. 13, 2018	Jan. 30, 2018	May 31, 2019	Sep. 30, 2018	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Dec. 31, 2017
Cancelled insurance premiums previously financed through third-parties, remaining principal outstanding balance							$ 31,000
Financed insurance premium through third party financing							393,000	$ 488,000
Financed insurance premium through third party financing, new policies							80,000
Fixed assets purchased under capital lease obligations							583,000	270,000
Purchases of fixed assets							67,000	$ 55,000	$ 25,000	$ 31,000
Public offering, number of common stock and warrants issued	642,438
Stock price	$ 3.285
Exercise price of unregistered warrants		$ 4.53
Class of warrant or rights, term		5 years	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 2,000,000	$ 8,400,000	$ 9,700,000
Offering fees and costs recorded within common stock issuance costs as an offset to additional paid in capital	300,000	$ 1,400,000	1,400,000
Aggregate units sold under right offering		11,587
Warrant exercisable for share of common stock		1
Gross proceeds from offering	$ 2,500,000	$ 11,600,000
Preferred stock converted to shares of common stock					1,012,622	1,012,622		1,012,622
Deemed dividend related to warrants down round provision			$ 99,000		$ 636,000	$ 636,370	99,743	$ 636,370
Operating lease, right-of-use asset							1,035,210
Operating lease liability							1,193,255
Lease right-of-use assets							1,575,039
Number of common stock warrant exercised				4,100,000
Proceeds from exercise of common stock warrants				$ 4,800,000			$ 2,513,172	$ 0
Warrant Inducement Transaction [Member]
Number of common stock warrant exercised				2,100,000
Proceeds from exercise of common stock warrants				$ 2,300,000
Pre-funded Warrants [Member]
Issuance of warrants to purchase shares of common stock	120,000
Exercise price of unregistered warrants	$ 3.275
Change in exercise price of warrants	$ 0.01
Warrant [Member]
Aggregate warrants sold under right offering		2,549,140
Proceeds from exercise of common stock warrants				$ 2,500,000
Series A Preferred Stock [Member]
Shares issued in offering		11,587
Shares converted						4,582
Maximum [Member]
Exercise price of unregistered warrants				$ 1.20
Maximum [Member] \| Pre-funded Warrants [Member]
Issuance of warrants to purchase shares of common stock	120,000
Minimum [Member]
Exercise price of unregistered warrants				$ 1.25
Follow-on Public Offering [Member]
Public offering, number of common stock and warrants issued			1,095,153
Stock price			$ 13.50
Exercise price of unregistered warrants	$ 3.16	$ 4.53	$ 1.20
Class of warrant or rights, term	5 years	5 years	5 years
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value			$ 9,700,000
Proceeds from issuance of common stock, net of issuance costs			13,300,000
Proceeds from exercise of common stock warrants			$ 0
Follow-on Public Offering [Member] \| Maximum [Member]
Issuance of warrants to purchase shares of common stock			1,095,153
Private Placement [Member]
Exercise price of unregistered warrants	$ 3.16
Class of warrant or rights, term	5 years
Warrant exercisable for share of common stock	1

XML 18 R45.htm IDEA: XBRL DOCUMENT

Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) - USD ($)	3 Months Ended	9 Months Ended
	Sep. 30, 2019	Sep. 30, 2019	Sep. 30, 2018
Other information
Operating cash flows from financing leases	$ 62,026	$ 187,574
Operating cash flows from operating leases	355,813	1,067,437
Financing cash flows from finance leases	$ 101,139	$ 378,389	$ 160,111

XML 19 R41.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail)	Sep. 30, 2019 USD ($)
Current portion of lease liability:
Operating	$ 1,193,255
Finance	776,030
Total	$ 1,969,285

XML 20 R49.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Summary of RSU Activity (Detail) - RSUs [Member]	9 Months Ended
	Sep. 30, 2019 $ / shares shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of Shares Outstanding, Beginning Balance \| shares	360
Number of Shares, Granted \| shares	0
Number of share, Vested and issued \| shares	0
Number of share, Forfeited \| shares	0
Number of Shares Outstanding, Ending Balance \| shares	360
Number of Shares, Vested and unvested expected to vest, Ending Balance \| shares	360
Weighted Average Grant Date Fair Value, Outstanding, Beginning Balance \| $ / shares	$ 415.80
Weighted Average Grant Date Fair Value, Granted \| $ / shares	0
Weighted Average Grant Date Fair Value, Vested and issued \| $ / shares	0
Weighted Average Grant Date Fair Value, Forfeited \| $ / shares	0
Weighted Average Grant Date Fair Value, Outstanding, Ending Balance \| $ / shares	415.80
Weighted Average Grant Date Fair Value, Vested and unvested expected to vest, Ending Balance \| $ / shares	$ 415.80

XML 21 R50.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 297,669	$ 113,072	$ 624,769	$ 447,604
Stock Options [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	29,405	10,150	54,625	37,150
Stock Options [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	37,626	30,247	102,742	103,267
Stock Options [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	168,484	57,162	361,102	243,593
Stock Options [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	62,154	15,513	106,300	63,594
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation	$ 297,669	$ 113,072	$ 624,769	512,029
RSUs [Member] \| Cost of revenues [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation				(18,802)
RSUs [Member] \| Research and Development Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation				13,576
RSUs [Member] \| General and Administrative Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation				54,303
RSUs [Member] \| Sales and Marketing Expenses [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock-based compensation				$ 15,348

XML 22 FilingSummary.xml IDEA: XBRL DOCUMENT 3.19.3 html 359 409 1 true 83 0 false 6 false false R1.htm 100000 - Document - Document and Entity Information Sheet http://www.biocept.com/20190930/taxonomy/role/DocumentDocumentAndEntityInformation Document and Entity Information Cover 1 false false R2.htm 100010 - Statement - Condensed Balance Sheets Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedBalanceSheets Condensed Balance Sheets Statements 2 false false R3.htm 100020 - Statement - Condensed Balance Sheets (Parenthetical) Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedBalanceSheetsParenthetical Condensed Balance Sheets (Parenthetical) Statements 3 false false R4.htm 100030 - Statement - Condensed Statements of Operations and Comprehensive Loss (Unaudited) Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedStatementsOfOperationsAndComprehensiveLossUnaudited Condensed Statements of Operations and Comprehensive Loss (Unaudited) Statements 4 false false R5.htm 100040 - Statement - Condensed Statements of Shareholders' Equity Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedStatementsOfShareholdersEquity Condensed Statements of Shareholders' Equity Statements 5 false false R6.htm 100050 - Statement - Condensed Statements of Cash Flows (Unaudited) Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnaudited Condensed Statements of Cash Flows (Unaudited) Statements 6 false false R7.htm 100060 - Statement - Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Sheet http://www.biocept.com/20190930/taxonomy/role/StatementCondensedStatementsOfCashFlowsUnauditedParenthetical Condensed Statements of Cash Flows (Unaudited) (Parenthetical) Statements 7 false false R8.htm 100070 - Disclosure - The Company, Business Activities and Basis of Presentation Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentation The Company, Business Activities and Basis of Presentation Notes 8 false false R9.htm 100080 - Disclosure - Liquidity and Going Concern Uncertainty Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertainty Liquidity and Going Concern Uncertainty Notes 9 false false R10.htm 100090 - Disclosure - Sales of Equity Securities Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureSalesOfEquitySecurities Sales of Equity Securities Notes 10 false false R11.htm 100100 - Disclosure - Fair Value Measurement Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureFairValueMeasurement Fair Value Measurement Notes 11 false false R12.htm 100110 - Disclosure - Balance Sheet Details Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureBalanceSheetDetails Balance Sheet Details Notes 12 false false R13.htm 100120 - Disclosure - April 2014 Credit Facility Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureApril2014CreditFacility April 2014 Credit Facility Notes 13 false false R14.htm 100130 - Disclosure - Leases Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeases Leases Notes 14 false false R15.htm 100140 - Disclosure - Stock-Based Compensation Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensation Stock-Based Compensation Notes 15 false false R16.htm 100150 - Disclosure - Common Stock Warrants Outstanding Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstanding Common Stock Warrants Outstanding Notes 16 false false R17.htm 100160 - Disclosure - Net Loss per Common Share Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureNetLossPerCommonShare Net Loss per Common Share Notes 17 false false R18.htm 100170 - Disclosure - Commitments and Contingencies Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingencies Commitments and Contingencies Notes 18 false false R19.htm 100180 - Disclosure - Related Party Transactions Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureRelatedPartyTransactions Related Party Transactions Notes 19 false false R20.htm 100190 - Disclosure - The Company, Business Activities and Basis of Presentation (Policies) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationPolicies The Company, Business Activities and Basis of Presentation (Policies) Policies 20 false false R21.htm 100200 - Disclosure - The Company, Business Activities and Basis of Presentation (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationTables The Company, Business Activities and Basis of Presentation (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentation 21 false false R22.htm 100210 - Disclosure - Fair Value Measurement (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementTables Fair Value Measurement (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureFairValueMeasurement 22 false false R23.htm 100220 - Disclosure - Balance Sheet Details (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureBalanceSheetDetailsTables Balance Sheet Details (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureBalanceSheetDetails 23 false false R24.htm 100230 - Disclosure - Leases (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesTables Leases (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureLeases 24 false false R25.htm 100240 - Disclosure - Stock-Based Compensation (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationTables Stock-Based Compensation (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensation 25 false false R26.htm 100250 - Disclosure - Common Stock Warrants Outstanding (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingTables Common Stock Warrants Outstanding (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstanding 26 false false R27.htm 100260 - Disclosure - Net Loss per Common Share (Tables) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureNetLossPerCommonShareTables Net Loss per Common Share (Tables) Tables http://www.biocept.com/20190930/taxonomy/role/DisclosureNetLossPerCommonShare 27 false false R28.htm 100270 - Disclosure - The Company, Business Activities and Basis of Presentation - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationAdditionalInformationDetail The Company, Business Activities and Basis of Presentation - Additional Information (Detail) Details 28 false false R29.htm 100280 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationCompositionOfNetRevenuesRecognizedDisaggregatedBySourceDetail The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) Details 29 false false R30.htm 100290 - Disclosure - The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationCompositionOfNetRevenuesRecognizedDisaggregatedByNatureDetail The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) Details 30 false false R31.htm 100300 - Disclosure - The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureTheCompanyBusinessActivitiesAndBasisOfPresentationSummaryOfThirdPartyPayersThatRepresentMoreThan10OfTotalNetRevenuesAndTotalNetAccountsReceivableAndTheirRelatedPercentageDetail The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail) Details 31 false false R32.htm 100310 - Disclosure - Liquidity and Going Concern Uncertainty- Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLiquidityAndGoingConcernUncertaintyAdditionalInformationDetail Liquidity and Going Concern Uncertainty- Additional Information (Detail) Details 32 false false R33.htm 100320 - Disclosure - Sales of Equity Securities - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureSalesOfEquitySecuritiesAdditionalInformationDetail Sales of Equity Securities - Additional Information (Detail) Details 33 false false R34.htm 100330 - Disclosure - Fair Value Measurement - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementAdditionalInformationDetail Fair Value Measurement - Additional Information (Detail) Details 34 false false R35.htm 100340 - Disclosure - Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureFairValueMeasurementAssumptionsUsedForDeterminingFairValuesOfCommonStockWarrantsDetail Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail) Details 35 false false R36.htm 100350 - Disclosure - Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureBalanceSheetDetailsScheduleOfFixedAssetsAndAccruedLiabilitiesDetail Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) Details 36 false false R37.htm 100360 - Disclosure - Balance Sheet Details - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureBalanceSheetDetailsAdditionalInformationDetail Balance Sheet Details - Additional Information (Detail) Details 37 false false R38.htm 100370 - Disclosure - April 2014 Credit Facility - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureApril2014CreditFacilityAdditionalInformationDetail April 2014 Credit Facility - Additional Information (Detail) Details 38 false false R39.htm 100380 - Disclosure - Leases - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesAdditionalInformationDetail Leases - Additional Information (Detail) Details 39 false false R40.htm 100390 - Disclosure - Leases - Schedule of Right-Of-Use Lease Assets (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesScheduleOfRightOfUseLeaseAssetsDetail Leases - Schedule of Right-Of-Use Lease Assets (Detail) Details 40 false false R41.htm 100400 - Disclosure - Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesScheduleOfCurrentPortionOfOperatingAndFinanceLeaseLiabilitiesDetail Leases - Schedule of Current Portion of Operating and Finance Lease Liabilities (Detail) Details 41 false false R42.htm 100410 - Disclosure - Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesScheduleOfLongTermPortionOfOperatingAndFinanceLeaseLiabilitiesDetail Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail) Details 42 false false R43.htm 100420 - Disclosure - Leases - Schedule of Lease Expense (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesScheduleOfLeaseExpenseDetail Leases - Schedule of Lease Expense (Detail) Details 43 false false R44.htm 100430 - Disclosure - Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesScheduleOfRemainingFutureMinimumLeasePaymentsForFinanceAndOperatingLeasesDetail Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail) Details 44 false false R45.htm 100450 - Disclosure - Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureLeasesSupplementalCashFlowInformationRelatedToOperatingAndFinanceLeasesDetail Leases - Supplemental Cash Flow Information Related to Operating and Finance Leases (Detail) Details 45 false false R46.htm 100460 - Disclosure - Stock-Based Compensation - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationAdditionalInformationDetail Stock-Based Compensation - Additional Information (Detail) Details 46 false false R47.htm 100470 - Disclosure - Stock-Based Compensation - Summary of Stock Option Activity (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfStockOptionActivityDetail Stock-Based Compensation - Summary of Stock Option Activity (Detail) Details 47 false false R48.htm 100480 - Disclosure - Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationAssumptionsUsedForDeterminingFairValueOfStockOptionsUnderBlackScholesPricingModelDetail Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail) Details 48 false false R49.htm 100490 - Disclosure - Stock-Based Compensation - Summary of RSU Activity (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationSummaryOfRSUActivityDetail Stock-Based Compensation - Summary of RSU Activity (Detail) Details 49 false false R50.htm 100500 - Disclosure - Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureStockBasedCompensationEffectsOfStockBasedCompensationRelatedToEquityAwardsToEmployeesAndNonemployeesOnCondensedStatementOfOperationsAndComprehensiveLossDetail Stock-Based Compensation - Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss (Detail) Details 50 false false R51.htm 100510 - Disclosure - Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingSummaryOfEquityClassifiedCommonStockWarrantActivityDetail Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) Details 51 false false R52.htm 100520 - Disclosure - Common Stock Warrants Outstanding - Equity-Classified Common Stock Warrants, Outstanding (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingEquityClassifiedCommonStockWarrantsOutstandingDetail Common Stock Warrants Outstanding - Equity-Classified Common Stock Warrants, Outstanding (Detail) Details 52 false false R53.htm 100530 - Disclosure - Common Stock Warrants Outstanding - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommonStockWarrantsOutstandingAdditionalInformationDetail Common Stock Warrants Outstanding - Additional Information (Detail) Details 53 false false R54.htm 100540 - Disclosure - Net Loss per Common Share - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureNetLossPerCommonShareAdditionalInformationDetail Net Loss per Common Share - Additional Information (Detail) Details 54 false false R55.htm 100550 - Disclosure - Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureNetLossPerCommonShareScheduleOfAntiDilutiveSecuritiesExcludedFromComputationsOfDilutedWeightedAverageSharesDetail Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) Details 55 false false R56.htm 100560 - Disclosure - Commitments and Contingencies - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureCommitmentsAndContingenciesAdditionalInformationDetail Commitments and Contingencies - Additional Information (Detail) Details 56 false false R57.htm 100570 - Disclosure - Related Party Transactions - Additional Information (Detail) Sheet http://www.biocept.com/20190930/taxonomy/role/DisclosureRelatedPartyTransactionsAdditionalInformationDetail Related Party Transactions - Additional Information (Detail) Details 57 false false All Reports Book All Reports bioc-20190930.xml bioc-20190930.xsd bioc-20190930_cal.xml bioc-20190930_def.xml bioc-20190930_lab.xml bioc-20190930_pre.xml http://fasb.org/srt/2019-01-31 http://xbrl.sec.gov/dei/2019-01-31 http://fasb.org/us-gaap/2019-01-31 true true XML 23 R54.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Additional Information (Detail) - Pre-funded Warrants [Member]	Sep. 20, 2018 $ / shares shares
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Issuance of warrants to purchase shares of common stock	120,000
Change in exercise price of warrants \| $ / shares	$ 0.01
Maximum [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Issuance of warrants to purchase shares of common stock	120,000

XML 24 R35.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Assumptions Used for Determining Fair Values of Common Stock Warrants (Detail)	Sep. 30, 2019 $ / shares	Mar. 19, 2019 $ / shares	Jan. 18, 2019 $ / shares	Sep. 20, 2018 $ / shares
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price		$ 1.37	$ 2.25	$ 3.285
January 30, 2018 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 10.17
January 30, 2018 Offering [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	15.00
January 30, 2018 Offering [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
January 30, 2018 Offering [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.48
January 30, 2018 Offering [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years
January 30, 2018 Offering [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	99.00
August 13, 2018 Rights Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 3.89
August 13, 2018 Rights Offering [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	4.53
August 13, 2018 Rights Offering [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
August 13, 2018 Rights Offering [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.75
August 13, 2018 Rights Offering [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years
August 13, 2018 Rights Offering [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	128.69
September 20, 2018 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 2.92
September 20, 2018 Offering [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	3.16
September 20, 2018 Offering [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
September 20, 2018 Offering [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.77
September 20, 2018 Offering [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
September 20, 2018 Offering [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	130.7
February 12, 2019 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.05
February 12, 2019 Offering [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.20
February 12, 2019 Offering [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
February 12, 2019 Offering [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.49
February 12, 2019 Offering [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years
February 12, 2019 Offering [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	147.7
March 19, 2019 Offering [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.12
March 19, 2019 Offering [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.25
March 19, 2019 Offering [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
March 19, 2019 Offering [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.44
March 19, 2019 Offering [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
March 19, 2019 Offering [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	140.0
May 30, 2019 Warrant Inducement Transaction [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Beginning stock price	$ 1.29
May 30, 2019 Warrant Inducement Transaction [Member] \| Exercise Price [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	1.31
May 30, 2019 Warrant Inducement Transaction [Member] \| Expected Dividend Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	0.00
May 30, 2019 Warrant Inducement Transaction [Member] \| Discount Rate-Bond Equivalent Yield [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	2.05
May 30, 2019 Warrant Inducement Transaction [Member] \| Expected Life [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Expected life (in years)	5 years 6 months
May 30, 2019 Warrant Inducement Transaction [Member] \| Expected Volatility [Member]
Warrant Fair Value Black Scholes Method [Line Items]
Exercise price	145.9

XML 25 R31.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage (Detail)	3 Months Ended		9 Months Ended		12 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Customer Concentration Risk [Member] \| Net Revenues [Member] \| Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage	25.00%	9.00%	20.00%	14.00%
Customer Concentration Risk [Member] \| Net Revenues [Member] \| Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage	32.00%	40.00%	40.00%	39.00%
Customer Concentration Risk [Member] \| Net Revenues [Member] \| United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage	8.00%	6.00%	9.00%	15.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| Blue Cross Blue Shield [Member]
Concentration Risk [Line Items]
Concentration risk percentage				25.00%	22.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| Medicare and Medicare Advantage [Member]
Concentration Risk [Line Items]
Concentration risk percentage				17.00%	17.00%
Credit Concentration Risk [Member] \| Net Accounts Receivable [Member] \| United Healthcare [Member]
Concentration Risk [Line Items]
Concentration risk percentage				13.00%	15.00%

XML 26 R39.htm IDEA: XBRL DOCUMENT

Leases - Additional Information (Detail)			1 Months Ended			3 Months Ended		9 Months Ended
Leases - Additional Information (Detail)	Feb. 01, 2019 USD ($)	Jan. 31, 2019 USD ($) mo	Sep. 30, 2019 USD ($) mo	Aug. 31, 2019 USD ($) mo	Jul. 31, 2019 USD ($) mo	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Sep. 30, 2019 USD ($)	Sep. 30, 2018 USD ($)	Jan. 01, 2019 USD ($)	Dec. 31, 2018 USD ($)
Leases [Line Items]
Finance lease right-of-use assets			$ 1,575,039			$ 1,575,039		$ 1,575,039
Financed equipment											$ 2,573,955
Total amount from equipment financing commitment	$ 149,000		$ 89,000	$ 245,000	$ 100,000
Finance lease transaction, frequency of payments		monthly	monthly	monthly	monthly
Finance lease transaction, number of installments payments \| mo		36	60	36	48
Finance lease transaction, monthly installments of principal and interest payments		$ 5,013	$ 1,770	$ 8,253	$ 2,706
Finance lease transaction, total amount to be repaid		$ 180,000	$ 106,000	$ 297,000	$ 130,000	106,000		106,000
Finance lease transaction, commitment period		2022-02	2024-09	2022-08	2023-05
Operating lease monthly payments						355,813		1,067,437
Operating lease, right-of-use asset			$ 1,035,210			1,035,210		1,035,210
Operating lease liability			$ 1,193,255			$ 1,193,255		$ 1,193,255
Finance lease, weighted average remaining lease term			3 years 2 months 8 days			3 years 2 months 8 days		3 years 2 months 8 days
Operating lease, weighted average remaining lease term			10 months 2 days			10 months 2 days		10 months 2 days
Finance lease, weighted average discount rate, percent			20.30%			20.30%		20.30%
Operating lease, weighted average discount rate, percent			4.50%			4.50%		4.50%
Right of use assets in exchange for finance lease liabilities								$ 583,000
ASC Topic 842 [Member]
Leases [Line Items]
Finance lease right-of-use assets										$ 1,400,000
Financed equipment			$ 3,075,000			$ 3,075,000		3,075,000			2,574,000
Accumulated depreciation related to financed equipment			$ 1,500,000			1,500,000		1,500,000			$ 1,135,000
Depreciation expense related to equipment under finance leases						$ 134,000	$ 115,000	$ 365,000	$ 271,000
Operating lease transaction, frequency of payments								monthly cash payment
Operating lease monthly payments								$ 120,000
Operating lease term								Jul. 31, 2020
Operating lease, right-of-use asset										1,930,000
Operating lease liability										$ 2,201,000
Operating lease incremental borrowing rate										4.50%
ASC Topic 842 [Member] \| Net Machinery and Equipment [Member]
Leases [Line Items]
Finance lease right-of-use assets										$ 1,400,000
Minimum [Member] \| ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life			3 years			3 years		3 years
Maximum [Member] \| ASC Topic 842 [Member]
Leases [Line Items]
Financed equipment useful life			7 years			7 years		7 years

XML 27 R12.htm IDEA: XBRL DOCUMENT

Balance Sheet Details

9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Balance Sheet Details

5. Balance Sheet Details

The following provides certain balance sheet details:

	December 31,			September 30,
	2018			2019
Fixed Assets
Machinery and equipment	$	2,818,583		$	2,845,053
Furniture and office equipment		157,391			156,987
Computer equipment and software		1,437,408			1,552,981
Leasehold improvements		570,173			570,174
Financed equipment		2,573,955			—
Construction in process		116,640			325,550
Total fixed assets, gross		7,674,150			5,450,745
Less accumulated depreciation and amortization		(4,934,728	)		(4,125,490	)
Total fixed assets, net	$	2,739,422		$	1,325,255
Accrued Liabilities
Accrued payroll		255,426			458,750
Accrued vacation		535,682			566,811
Accrued bonuses		712,574			636,167
Accrued sales commissions		62,767			81,101
Current portion of deferred rent		158,342			—
Accrued other		203,602			104,155
Total accrued liabilities	$	1,928,393		$	1,846,984

XML 28 R16.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding

9 Months Ended

Sep. 30, 2019

Other Liabilities Disclosure [Abstract]

Common Stock Warrants Outstanding

9. Common Stock Warrants Outstanding

A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2019 is as follows:

						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2018		4,694,927		$	8.55		4.4
Issued		14,662,226		$	1.23
Exercised		(4,155,430	)		1.20
Expired		(4,474	)		953.06
Outstanding at September 30, 2019		15,197,249		$	3.08		4.5

Further information about equity-classified common stock warrants outstanding at September 30, 2019 is as follows:

				Weighted
Weighted				Average
Average		Total Shares		Contractual
Exercise Price		Outstanding		Life (in years)
$	1.24		11,601,949		4.7
$	4.21		3,311,578		3.9
$	25.50		8,208		3.2
$	33.00		96,999		2.1
$	45.00		47,821		2.9
$	75.00		71,995		3.0
$	117.00		38,772		1.6
$	140.00		19,339		0.4
$	424.80		588		4.6
			15,197,249

All warrants outstanding at September 30, 2019 are exercisable. The intrinsic value of equity-classified common stock warrants outstanding at September 30, 2019 was zero.

XML 29 R51.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Summary of Equity-Classified Common Stock Warrant Activity (Detail) - Warrants [Member] - $ / shares	9 Months Ended	12 Months Ended
	Sep. 30, 2019	Dec. 31, 2018
Class Of Warrant Or Right [Line Items]
Number of Shares, Outstanding, Beginning Balance	4,694,927
Number of Shares, Issued	14,662,226
Number of Shares, Exercised	(4,155,430)
Number of Shares, Expired	(4,474)
Number of Shares, Outstanding, Ending Balance	15,197,249	4,694,927
Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance	$ 8.55
Weighted Average Exercise Price Per Share, Issued	1.23
Weighted Average Exercise Price Per Share, Exercised	1.20
Weighted Average Exercise Price Per Share, Expired	953.06
Weighted Average Exercise Price Per Share, Outstanding, Ending Balance	$ 3.08	$ 8.55
Average Remaining Contractual Term (in years)	4 years 6 months	4 years 4 months 24 days

XML 30 R55.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share - Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares (Detail) - shares	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	18,466,658	7,490,672	18,466,658	7,490,672
Convertible Preferred Stock [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	471,393	2,560,727	471,393	2,560,727
Preferred Warrants Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents		17		17
Common Warrants [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	15,197,249	4,814,927	15,197,249	4,814,927
RSUs Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	360	360	360	360
Common Options Outstanding [Member]
Antidilutive Securities Excluded from Computation of Earnings Per Share [Line Items]
Anti-dilutive common share equivalents	2,797,656	114,641	2,797,656	114,641

XML 31 R38.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility - Additional Information (Detail) - USD ($)								12 Months Ended
	May 30, 2019	Mar. 19, 2019	Feb. 12, 2019	Sep. 20, 2018	Aug. 13, 2018	Jan. 30, 2018	Apr. 30, 2014	Dec. 31, 2014	Feb. 28, 2019
Line of Credit Facility [Line Items]
Exercise price of unregistered warrants		$ 1.25	$ 1.20		$ 4.53				$ 1.20
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,800,000	$ 6,000,000	$ 6,800,000	$ 2,000,000	$ 8,400,000	$ 9,700,000
Oxford Finance LLC [Member] \| Common Stock [Member]
Line of Credit Facility [Line Items]
Warrant issued to lender							588
Exercise price of unregistered warrants							$ 424.80
Warrant term							10 years
Oxford Finance LLC [Member] \| First Term Loan [Member]
Line of Credit Facility [Line Items]
Net cash proceeds on term loan							$ 4,898,000
Line of Credit Facility fees amount payable							$ 50,000
Line of Credit Facility, interest rate during period							7.95%
Percentage of final interest payment due at maturity							5.50%
Line of credit facility, maturity date							Jul. 01, 2018
Issuance costs								$ 102,000
Net proceeds from credit facility								4,898,000
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value								$ 233,000

XML 32 R34.htm IDEA: XBRL DOCUMENT

Fair Value Measurement - Additional Information (Detail) - USD ($)							9 Months Ended
	May 30, 2019	Mar. 19, 2019	Feb. 12, 2019	Sep. 20, 2018	Aug. 13, 2018	Jan. 30, 2018	Sep. 30, 2019	Sep. 30, 2018	May 31, 2019	Feb. 28, 2019
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations							$ 583,000	$ 270,000
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value	$ 1,800,000	$ 6,000,000	$ 6,800,000	$ 2,000,000	$ 8,400,000	$ 9,700,000
Estimated grant date fair value of warrants	$ 1.18	$ 1.01	$ 0.95	$ 2.57	$ 3.30	$ 8.82
Exercise price of unregistered warrants		$ 1.25	1.20		$ 4.53					$ 1.20
Class of warrant or rights, term		5 years 6 months			5 years	5 years
Common stock warrants outstanding, intrinsic value							0
Pre-funded Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants				$ 3.275
Issuance of warrants to purchase shares of common stock				120,000
Common stock warrants outstanding, intrinsic value				$ 350,000
Follow-on Public Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock, grant date fair value						$ 9,700,000
Exercise price of unregistered warrants		$ 1.25	$ 1.20	$ 3.16	$ 4.53	$ 1.20
Class of warrant or rights, term		5 years 6 months	5 years	5 years	5 years	5 years
Warrant Inducement Transaction [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants	$ 1.31
Class of warrant or rights, term	5 years 6 months
Maximum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of unregistered warrants to purchase shares of common stock	1,547,226	5,950,000	7,165,000	762,438	2,549,140	1,095,153
Exercise price of unregistered warrants									$ 1.20
Maximum [Member] \| Pre-funded Warrants [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock				120,000
Maximum [Member] \| Follow-on Public Offering [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Issuance of warrants to purchase shares of common stock			6,250,000			1,095,153
Minimum [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Exercise price of unregistered warrants									$ 1.25
Estimated Fair Value Measurements, Nonrecurring [Member] \| Level 3 Inputs [Member]
Fair Value Assets And Liabilities Measured On Recurring And Nonrecurring Basis [Line Items]
Fixed asset purchases as right-of-use asset finance lease obligations							$ 583,000

XML 33 R30.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Nature (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 1,529,262	$ 761,591	$ 3,744,824	$ 2,390,772
Commercial Revenues [Member] \| Net Commercial Revenues Recognized Upon Delivery [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	1,432,241	698,115	3,527,439	2,221,726
Development Services Revenues [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	37,981	$ 63,476	125,169	159,606
Kits and Blood Collection Tubes [Member]
The Company Business Activities And Basis Of Presentation [Line Items]
Total net revenues	$ 59,040		$ 92,216	$ 9,440

XML 34 R13.htm IDEA: XBRL DOCUMENT

April 2014 Credit Facility

9 Months Ended

Sep. 30, 2019

Debt Disclosure [Abstract]

April 2014 Credit Facility

6. April 2014 Credit Facility

XML 35 R17.htm IDEA: XBRL DOCUMENT

Net Loss per Common Share

9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Net Loss per Common Share

10. Net Loss per Common Share

The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

	For the three and nine months ended
	September 30,
	2018		2019
Preferred warrants outstanding (number of common stock equivalents)		17		—
Common warrants outstanding		4,814,927		15,197,249
RSUs outstanding		360		360
Convertible preferred stock outstanding (number of common stock equivalents)		2,560,727		471,393
Common options outstanding		114,641		2,797,656
Total anti-dilutive common share equivalents		7,490,672		18,466,658

XML 36 R21.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation (Tables)

9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Composition of Net Revenues Recognized Disaggregated by Source and Nature

The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net revenues from contracted payers*	$	325,097	$	476,101	$	1,019,857	$	1,447,421
Net revenues from non-contracted payers		373,018		956,140		1,201,869		2,080,018
Development services revenues		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

*Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

	For the three months ended September 30,				For the nine months ended September 30,
	2018		2019		2018		2019
Net commercial revenues recognized upon delivery	$	698,115	$	1,432,241	$	2,221,726	$	3,527,439
Development services revenues recognized upon delivery		63,476		37,981		159,606		125,169
Kits and Blood Collection Tubes (BCT)		—		59,040		9,440		92,216
Total net revenues	$	761,591	$	1,529,262	$	2,390,772	$	3,744,824

Summary of Third-Party Payers That Represent More Than 10% of Total Net Revenues and Total Net Accounts Receivable and Their Related Percentage

	For the three months ended September 30,						For the nine months ended September 30,
	2018			2019			2018			2019
Medicare and Medicare Advantage		40	%		32	%		39	%		40	%
Blue Cross Blue Shield		9	%		25	%		14	%		20	%
United Healthcare		6	%		8	%		15	%		9	%

	December 31, 2018			September 30, 2019
Blue Cross Blue Shield		22	%		25	%
Medicare and Medicare Advantage		17	%		17	%
United Healthcare		15	%		13	%

XML 37 R25.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation (Tables)

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Summary of Stock Option Activity

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2018		195,820		$	41.41		9.20
Granted		2,664,129		$	0.91
Exercised		—			—
Cancelled/forfeited/expired		(62,293	)	$	6.43
Outstanding at September 30, 2019		2,797,656		$	3.62		9.52
Vested and unvested expected to vest at September 30, 2019		2,701,017		$	3.71		9.52

Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model

The assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2019 were as follows:

Stock and exercise prices	$0.81 - $1.03
Expected dividend yield		0.00%
Discount rate-bond equivalent yield	1.58% – 2.55%
Expected life (in years)	5.00 – 5.96
Expected volatility	128% - 156%

Summary of RSU Activity

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

			Weighted
	Number of		Average Grant
	Shares		Date Fair Value
Outstanding at December 31, 2018		360	$	415.80
Granted		—		—
Vested and issued		—		—
Forfeited		—		—
Outstanding at September 30, 2019		360	$	415.80
Vested and unvested expected to vest at September 30, 2019		360	$	415.80

Effects of Stock-Based Compensation Related to Equity Awards to Employees and Nonemployees on Condensed Statement of Operations and Comprehensive Loss

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2018		2019		2018			2019
Stock Options
Cost of revenues	$	10,150	$	29,405	$	37,150		$	54,625
Research and development expenses		30,247		37,626		103,267			102,742
General and administrative expenses		57,162		168,484		243,593			361,102
Sales and marketing expenses		15,513		62,154		63,594			106,300
Total expenses related to stock options		113,072		297,669		447,604			624,769
RSUs
Cost of revenues		-		-		(18,802	)		-
Research and development expenses		-		-		13,576			-
General and administrative expenses		-		-		54,303			-
Sales and marketing expenses		-		-		15,348			-
Total stock-based compensation	$	113,072	$	297,669	$	512,029		$	624,769

XML 38 R29.htm IDEA: XBRL DOCUMENT

The Company, Business Activities and Basis of Presentation - Composition of Net Revenues Recognized Disaggregated by Source (Detail) - USD ($)

3 Months Ended

9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Disaggregation Of Revenue [Line Items]

Total net revenues

$ 1,529,262

$ 761,591

$ 3,744,824

$ 2,390,772

Commercial Revenues [Member] | Contracted Payers [Member]

Disaggregation Of Revenue [Line Items]

Total net revenues

^[1]

476,101

325,097

1,447,421

1,019,857

Commercial Revenues [Member] | Non-Contracted Payers [Member]

Disaggregation Of Revenue [Line Items]

Total net revenues

956,140

373,018

2,080,018

1,201,869

Development Services Revenues [Member]

Disaggregation Of Revenue [Line Items]

Total net revenues

37,981

$ 63,476

125,169

159,606

Kits and Blood Collection Tubes [Member]

Disaggregation Of Revenue [Line Items]

Total net revenues

$ 59,040

$ 92,216

$ 9,440

[1]	Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

XML 39 R2.htm IDEA: XBRL DOCUMENT

Condensed Balance Sheets - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Current assets:
Cash	$ 6,539,444	$ 3,423,373
Accounts receivable, net	2,861,659	1,574,325
Inventories, net	687,186	587,222
Prepaid expenses and other current assets	497,121	425,961
Total current assets	10,585,410	6,010,881
Fixed assets, net	1,325,255	2,739,422
Lease right-of-use assets	2,610,249
Total assets	14,520,914	8,750,303
Current liabilities:
Accounts payable	1,834,020	2,039,718
Accrued liabilities	1,846,984	1,928,393
Supplier financings	132,924
Current portion of equipment financings		641,536
Current portion of lease liabilities	1,969,285
Total current liabilities	5,783,213	4,609,647
Non-current portion of equipment financings		985,015
Non-current portion of lease liabilities	1,032,243
Non-current portion of deferred rent		113,122
Total liabilities	6,815,456	5,707,784
Commitments and contingencies (see Note 11)
Shareholders’ equity:
Preferred stock, $0.0001 par value, 5,000,000 authorized; 4,417 shares issued and outstanding at December 31, 2018; and 2,133 shares issued and outstanding at September 30, 2019.
Common stock, $0.0001 par value, 150,000,000 authorized; 4,629,174 issued and outstanding at December 31, 2018; 23,018,235 issued and outstanding at September 30, 2019.	2,302	463
Additional paid-in capital	247,685,038	223,499,634
Accumulated deficit	(239,981,882)	(220,457,578)
Total shareholders’ equity	7,705,458	3,042,519
Total liabilities and shareholders’ equity	$ 14,520,914	$ 8,750,303

XML 40 R6.htm IDEA: XBRL DOCUMENT

Condensed Statements of Cash Flows (Unaudited) - USD ($)	3 Months Ended				9 Months Ended		12 Months Ended
	Sep. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018
Cash Flows from Operating Activities
Net loss	$ (5,691,762)	$ (5,916,787)	$ (6,047,784)	$ (6,357,143)	$ (19,424,558)	$ (18,558,028)	$ (24,600,000)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization					691,191	580,366
Amortization of right-of-use assets					(113,419)
Inventory reserve					20,277	(92,488)
Stock-based compensation					624,769	512,029
Warrant inducement expense					1,831,116
Non-cash interest expense related to credit facility and other financing activities						29,425
Increase/(decrease) in cash resulting from changes in:
Accounts receivable, net					(1,287,334)	(283,028)
Inventory					(120,241)	9,692
Prepaid expenses and other current assets					322,299	277,720
Accounts payable					(198,400)	413,562
Accrued liabilities					76,932	497,119
Accrued interest						(241,034)
Deferred rent						(82,329)
Net cash used in operating activities					(17,577,368)	(16,936,994)
Cash Flows from Investing Activities:
Purchases of fixed assets					(297,877)	(145,253)
Net cash used in investing activities					(297,877)	(145,253)
Cash Flows from Financing Activities:
Net proceeds from issuance of common stock and warrants					16,779,772	25,688,205
Proceeds from exercise of common stock warrants					2,513,172	0
Proceeds from warrant exercise inducement, net					2,337,298
Payments on finance leases	(101,139)				(378,389)	(160,111)
Payments on supplier and other third-party financings					(260,537)	(438,290)
Payments on credit facility						(1,197,968)
Net cash provided by financing activities					20,991,316	23,891,836
Net increase in Cash					3,116,071	6,809,589
Cash at Beginning of Period		$ 3,423,373		$ 2,146,611	3,423,373	2,146,611	2,146,611
Cash at End of Period	$ 6,539,444		$ 8,956,200		6,539,444	8,956,200	$ 3,423,373
Cash paid during the period for:
Interest					$ 187,574	379,587
Income taxes						$ 739

XML 41 R48.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation - Assumptions Used for Determining Fair Value of Stock Options Under Black-Scholes Pricing Model (Detail)	3 Months Ended	9 Months Ended
	Sep. 30, 2019 $ / shares	Sep. 30, 2019 $ / shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Expected dividend yield	0.00%	0.00%
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 0.81	$ 0.81
Discount rate-bond equivalent yield	1.58%	1.58%
Expected life (in years)	5 years	5 years
Expected volatility	128.00%	128.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Stock and exercise prices	$ 1.03	$ 1.03
Discount rate-bond equivalent yield	2.55%	2.55%
Expected life (in years)	5 years 11 months 15 days	5 years 11 months 15 days
Expected volatility	156.00%	156.00%

XML 42 R44.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Remaining Future Minimum Lease Payments for Finance and Operating Leases (Detail)	Sep. 30, 2019 USD ($)
Financing Lease Minimum Payment Abstract
2019 (remaining)	$ 222,245
2020	764,533
2021	517,927
2022	405,318
2023	263,274
Thereafter	58,448
Total payments	2,231,745
Less amount representing interest	(423,472)
Present value of payments	1,808,273
Financing Lease Maintenance and Sales Tax Obligation Payments Abstract
2019 (remaining)	27,016
2020	89,136
2021	67,974
2022	57,260
2023	56,799
Thereafter	8,241
Total payments	306,426
Present value of payments	306,426
Operating Lease Minimum Payment Abstract
2019 (remaining)	362,929
2020	855,136
Total payments	1,218,065
Less amount representing interest	(24,810)
Present value of payments	$ 1,193,255

XML 43 R40.htm IDEA: XBRL DOCUMENT

Leases - Schedule of Right-Of-Use Lease Assets (Detail)	Sep. 30, 2019 USD ($)
Lease right-of-use assets:
Operating	$ 1,035,210
Finance	1,575,039
Total	$ 2,610,249

XML 44 R53.htm IDEA: XBRL DOCUMENT

Common Stock Warrants Outstanding - Additional Information (Detail)	Sep. 30, 2019 USD ($)
Warrants And Rights Note Disclosure [Abstract]
Common stock warrants outstanding, intrinsic value	$ 0

XML 45 R57.htm IDEA: XBRL DOCUMENT

Related Party Transactions - Additional Information (Detail) - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2019	Sep. 30, 2018	Sep. 30, 2019	Sep. 30, 2018
Aegea Biotechnologies, Inc [Member]
Related Party Transaction [Line Items]
Reimbursement for shared patent costs	$ 0	$ 0	$ 26,000	$ 19,000

XML 46 R19.htm IDEA: XBRL DOCUMENT

Related Party Transactions

9 Months Ended

Sep. 30, 2019

Related Party Transactions

12. Related Party Transactions

XML 47 R11.htm IDEA: XBRL DOCUMENT

Fair Value Measurement

9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Fair Value Measurement

4. Fair Value Measurement

Other Fair Value Measurements

Beginning stock price	$	10.17
Exercise price	$	15.00
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.48	%
Expected life (in years)		5.00
Expected volatility		99.00	%

Beginning stock price	$	3.89
Exercise price	$	4.53
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.75	%
Expected life (in years)		5.00
Expected volatility		128.69	%

Beginning stock price	$	2.92
Exercise price	$	3.16
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.77	%
Expected life (in years)		5.50
Expected volatility		130.7	%

Beginning stock price	$	1.05
Exercise price	$	1.20
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.49	%
Expected life (in years)		5.00
Expected volatility		147.7	%

Beginning stock price	$	1.12
Exercise price	$	1.25
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.44	%
Expected life (in years)		5.50
Expected volatility		140.0	%

Beginning stock price	$	1.29
Exercise price	$	1.31
Expected dividend yield		0.00	%
Discount rate-bond equivalent yield		2.05	%
Expected life (in years)		5.50
Expected volatility		145.9	%

- Definition

The entire disclosure for the fair value of financial instruments (as defined), including financial assets and financial liabilities (collectively, as defined), and the measurements of those instruments as well as disclosures related to the fair value of non-financial assets and liabilities. Such disclosures about the financial instruments, assets, and liabilities would include: (1) the fair value of the required items together with their carrying amounts (as appropriate); (2) for items for which it is not practicable to estimate fair value, disclosure would include: (a) information pertinent to estimating fair value (including, carrying amount, effective interest rate, and maturity, and (b) the reasons why it is not practicable to estimate fair value; (3) significant concentrations of credit risk including: (a) information about the activity, region, or economic characteristics identifying a concentration, (b) the maximum amount of loss the entity is exposed to based on the gross fair value of the related item, (c) policy for requiring collateral or other security and information as to accessing such collateral or security, and (d) the nature and brief description of such collateral or security; (4) quantitative information about market risks and how such risks are managed; (5) for items measured on both a recurring and nonrecurring basis information regarding the inputs used to develop the fair value measurement; and (6) for items presented in the financial statement for which fair value measurement is elected: (a) information necessary to understand the reasons for the election, (b) discussion of the effect of fair value changes on earnings, (c) a description of [similar groups] items for which the election is made and the relation thereof to the balance sheet, the aggregate carrying value of items included in the balance sheet that are not eligible for the election; (7) all other required (as defined) and desired information.

+ References + Details

XML 48 R15.htm IDEA: XBRL DOCUMENT

Stock-Based Compensation

9 Months Ended

Sep. 30, 2019

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Stock-Based Compensation

8. Stock-Based Compensation

Equity Incentive Plans

Stock Options

A summary of stock option activity for the nine months ended September 30, 2019 is as follows:

						Weighted
						Average
				Weighted		Remaining
	Number of			Average Exercise		Contractual
	Shares			Price Per Share		Term in Years
Outstanding at December 31, 2018		195,820		$	41.41		9.20
Granted		2,664,129		$	0.91
Exercised		—			—
Cancelled/forfeited/expired		(62,293	)	$	6.43
Outstanding at September 30, 2019		2,797,656		$	3.62		9.52
Vested and unvested expected to vest at September 30, 2019		2,701,017		$	3.71		9.52

The intrinsic values of options outstanding, options exercisable, and options vested and unvested expected to vest at December 31, 2018 and September 30, 2019 were each approximately zero.

The assumptions used in the Black-Scholes pricing model for stock options granted during the three and nine months ended September 30, 2019 were as follows:

Stock and exercise prices	$0.81 - $1.03
Expected dividend yield		0.00%
Discount rate-bond equivalent yield	1.58% – 2.55%
Expected life (in years)	5.00 – 5.96
Expected volatility	128% - 156%

Restricted Stock

A summary of RSU activity for the nine months ended September 30, 2019 is as follows:

			Weighted
	Number of		Average Grant
	Shares		Date Fair Value
Outstanding at December 31, 2018		360	$	415.80
Granted		—		—
Vested and issued		—		—
Forfeited		—		—
Outstanding at September 30, 2019		360	$	415.80
Vested and unvested expected to vest at September 30, 2019		360	$	415.80

Stock-based Compensation Expense

	For the three months ended				For the nine months ended
	September 30,				September 30,
	2018		2019		2018			2019
Stock Options
Cost of revenues	$	10,150	$	29,405	$	37,150		$	54,625
Research and development expenses		30,247		37,626		103,267			102,742
General and administrative expenses		57,162		168,484		243,593			361,102
Sales and marketing expenses		15,513		62,154		63,594			106,300
Total expenses related to stock options		113,072		297,669		447,604			624,769
RSUs
Cost of revenues		-		-		(18,802	)		-
Research and development expenses		-		-		13,576			-
General and administrative expenses		-		-		54,303			-
Sales and marketing expenses		-		-		15,348			-
Total stock-based compensation	$	113,072	$	297,669	$	512,029		$	624,769

ZIP 49 0001564590-19-043276-xbrl.zip IDEA: XBRL DOCUMENT begin 644 0001564590-19-043276-xbrl.zip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

#C7>Y$#ST\%,I8.E)NI/1QHI<6C>1T@Z%C%AT]B%M&--6/ISLY7C"]+8K)W3T<\GOA M(X6&?B9H!/8Z=H #SN=!NH:P'%0,%T(/BN_=!B6-GH?,&M-8AHK1)-G6'+(+-IMS98AX A]E#=\*ITM2=\HEW/," MZE$_+X*050N3I \2'RSAIH,-Q;-C@DEI!SB@MP;A@^&JJQ72,,P8A]D2>BJ* M36MM<2?*-\/]K=\R0/6Z:_ 3K0[Y/7N-G4%BZ?0,T0![8D*:L*J;:_N.%CR* M5H!8Y9R;7E698DK?U3#,LZNA_$:&H"M9HP/.DD 1MS ''Y!ST5]-[R>3;@O'Q%3R:_>Q^AD8(U'UY,Q#UG^XSG; MWDR=L\L<4 W4!NQ/W^SVR)^3$,KT^C =.-E@+%=9FSL_C?A8'7*>1[]5D)MD M:NBX]BFRM>&<9)-__R-X;AZY0HV!.'AQU&V=XM0&HA7WD'ZWA6V9-C"-5VX:HMPZ\2FJU%-,LC6-E;.^M3> FG+7!:0\S38]XE=F%P MSJ>*)R$(/1CI0:51/2C+UXMTJB6:.B])5V)LV; B%%HOKS]7.PW0>3M!N?5; M5(3.ZPDA,8W6#GD3.J]Y&C00L)X_=2UT5T^DITW^6EY/0>BXIFEU1,?U6U2$ MSNL)(=ODKPF=5V\&;Y^$MY\^#3_==K42VZ99P%_YIH1@%^?.]LS_75+.:B<2 M)WJ(_(.*\6PRUR:B_JZU%!OR!NU$HG$&SD& ^C:F>Z1,!L/%K+6T/&.BHDUD M.=F/KY\R9TU?"$(( R4,U"4:J/%L.I"'1-@F M"NV7K@Y.%Q5;.MI%MM;TP608,&&?:!%J-AHTWUXFA*A[0B0"J)800HA(6RDC M[$Q$K<5D.I#'P]:22@A16RDC[$Q+""%$I*V4$7:&R[R&$R'(IQI&5DZ($3"SK2$$$)$VDH986=B.Z-,!G+IG@$A M1!VKY%S& 1&-D>VOAL>.:'QOVC:>&!B=;/KH/P$L?WA_^_A#BZNF>09R"GEL M)_6&>2>J"L,7410/L%2:)FE[IZVVCEYMD,!J#@\1U!'635!/6+>:*#I9#(:- M[SD2AJU3PB<,6YNI(PQ;/ZDG#%NQW;2#L;!KG:!4:V1/V+4V4T?8M7Y23]BU M8G9-&2ARV78/8=C:)GQ-[K)*J\WIMO]D$DFYOCR+]VA[JBE9W&B]%A>],V>, MIM'UHDUCUX?'5D?8OIO,V50>3!9-M^(?LYE'->U%2F5KFL*.!X,7;!I;0QUA M$H5)%";QA&[.P419#)2IT@XM*XQB-]2N,(IMIHXPBL(H"J-8GM+*8+08#F8S M812[0*W6J%UA%-M,'6$4A5$41O&$,2:#V7@\F"OC=FC9;AA%1I&0(&FT:[;B M^-93 7DEL)) PN]WV? H+)6^Y M=44&DHJC&HW-D^^XA$YP5#>V;^&./[AN:7PG^C6'G;KQE$X-W7B.!1FY(9"O MG]X,WT@:,4V4()#%Z',@F_1S(/4:O)@XD8P' @IR8:I;E[P+__A1"G7TD)\\ M<+CLS5;;GV/C.N&. :J!W(#]Z9LF>X*4Z?5A.G#&EO%<%=:61_>3;>I'%?H\ MC](Y@4B?;$?RU@3^YQ B;>"ZM2L1@%27'LC6(YLGXDBCX:"UK5QGW(/?&J(5 M#'0:4&OG'?3"U-BN[W,+RW]R#*':+ERU688E-%M':"9&B_0U!.35H=*H.I3E MO-W?%Z;/S1#*K_F-$]5L2NJWJ B=UQ-"@LYK^E0ZH?-:I?.$OR9T5S>D MITW^6NNVY;6&2AW1D+(-OEK0N>=.Y$G3GNLR@G\2CS0=IL-<31# M-:-]Q_"'9J\L>+,N^5O;DG1B&L_$>6UM]U6.UBO1+]+$RI81I@.:49BHEA!"F"AAHOIKHD:#B3*#2$H<=MDR MPK2](UT4LCZ09V+:6[KIU27.LZ'1*E8]Y:Q>;?MH$Q5;TR238<^$N:)5J=%@ M/&MZ(KR0H>[)D BG6D(((2)MI8PP,W%4-!LLYF4+2T*&+E>&A)EI"2&$B+25 M,L+,Q"T,D\5@.A3A3,O(T@$A$G:F)800(M)6R@@[$]L993*0ITWO7A)"U+&] M2NT>.M08V?YJX'132Y?>F[:M2[>V:1+-,VQ+>O2? )8_O+]]_*'%Y51Q@'!W MFU'$ <+%*?J?[?NMHY>;9# :B91">H(ZR:H)ZQ;312=+ ;#\; = MFE(8MFX(GS!L;::.,&S]I)XP;(4HNAB,A5WK!*5:(WO"KK69.L*N]9-ZPJX5 MLVO*0)&;W@PL#%L?ME^EU>8N^"C>1]M333!9--V*WZD#>5MM,QL^1^:"36-KJ"-,HC")PB2>T,TYF"B+@3)5 MVJ%EA5'LAMH51K'-U!%&41A%813+4UH9C!;#P6PFC&(7J-4:M2N,8INI(XRB M,(K"*)XPQF0P&X\'()'/U^ETN/@GK:BV4E\\UG)L>M;>$AAHZ*._MC&\ MM>00=TLTX%P['OL(_"MM'0.6!G!*IK$!1M;QBA6Q5\#':P,N@H_ X=I:\M9$ MNK4W6]5ZA;OL9T/'1T@NX,U8&AH )3W;IK\A^'[<=AC.F1S0#8CP'(0 +X5' M&8Y^!?+CP:/45^)0F+D71'NA9C_&SY%<'\!07>D+K$T#X >28;D^($DC>$H; MW&B$;[/A8HID&#L=\4EU\F.4:KD>AVN!Z(X1HJ@FHT@U8BN," MLMA=+GSS#%_ XN [57-LUY604K8/#P:>LC<(S>N6 #]9<,$:K>V"U@]0&EO MK6+%>PL6M7(H!M77H@6X]LGH"LH^% PC.&Z85X\": !$N"URUMT[1?W'?'*%ZK>N-U M+-6^@3W[ZSVD:0="+ZT<(#>Z>-'M@[&E[+\PL\5OF3[7#Z MY+@::6VL<\:9%ZTA6L'$0@-Z3;Z>*V>G\A)^6^NVR+1>$2J-*D)Y=#W-(%N(SHM3EA@GMB6_*=1>TS2@ M_ML)ZJW?LB*T7E\HB4FQ=DBI-[#4PG:/6&FV;VMS"WA7:+1!]N-&?5=J54%+$Q,GB M+:_ -TDZ)6'53B1?W]M0&Y_EUHI*59LH\OO6$N2\]7>AXH1UZB'IA'4JLDFB M[)9!89V$=>HG 3J@XH1UZBSIA'4J8IW*9@B%=1+6J9\$Z("*$]:ILZ03UDED M]CI,D13KU.2X:E&D>F_Z1+JENYCIGP]K@YBZV,+1+BJUIL4ERT )^X.K;;I] M0LA/1<%1WS9V"@4F1*-[E!&FA6O.F[263!!R#83*Z'I\VDK\"%=0)H]V2B:U* MXA1F,;"5(^2>PFFXU4),;^U.]U(@7-^X+CM 5'1QOPM@[.A>(KYW M\! ::FH7_$:P;U6Z89MS@%6D>\>VX&^-; CNUHGQE7<35;3,?43L++Q-C/'9 MDCZ1)\=7G5?L=)T.<.^3].GFX;UDN*X/\9;J>VO;,3S5,YZ)M/(-'3<]#220 M(VTM:6O56@',+GDFCFI*JKLE&N /]T#!@]08P0"-9!+5)>Y ,BS-]%%"Z44. M^9=O.!3Q;/.6:IK!I=*+X:TEW7?@[;;E2BN'J!YQV'XN[X68 -(&%K=VI2=\ MD&:O+$"7+MD6?72X1B.OA:(+:%5ZA+A"S:9B%/V#:+:^EC]):_ MJ!;%--N!L6#(#G:T2:IN;S' ]7@@$1ABPNW!#W )( +>3BELX =I0X!"\+,= MHINN!J\VX,F:%Q%#9W>6[^!H7M^;!0DQ#?3), MPWN5_"VN+5QD@+*(#G]X($3Z:L-29S]';(T+ !V3?35GAH 9*SAK19< G<;@JH\W1@_1VH(H<"7&Y;K.3[E[V";)P,0!-XCFY#G8T HHC@FRM-V:(#ETI08G*CL2%RD2 M'N)0)W#/Y>"$!^Y($I-SXN$[+/HTU4NJ$8I<_A6Z#11'M;!6 2NJM$%=C7@, M]1! #40YA%\)H-,!,M-V?: G0*:I**F\-$>/UWP'MSD 0M;@-TCX6_S,F,9N MR'< /=7ON$\W9 740<\@]]>]EF7>ML]S2[.*.XTIDE#83-"6QC)DNZ5C;Q"O MS':@I86'.E1:';(FH*;A26#?[0U!B^003Z7L ^R&C.922KBX!M3+GOH]DE4@ MNV\R'4'?07\$Y6P.)!K^_>=<488__OGZVS5PZ WH*> H> ,X;L^&SO@;W#H; MN "4.H7UWG=<7[7H98^&9P+"/W^F?/W?H6:XA>L9-\'-KFWZC+.9(GCO@VY@ MUO03DYK_0:FAN(Q DG^4 LEZ!'AO_4!?_<5^&BD!Q2%"MF, M"BX:).!7G?$L,0T0.#2J^,P\F#KZ[FOIS_8+.F8#7IZ2K[,M\S78Z8YH"A1L MDN8!KD*JH\'4ADJ?S[0EK[:HAQ*!HQ$'63:A MC=0GV_<.TJ(E=B%4R;4;!>;UA^[?V?3\!BA"J8*_'Y0)_"V75CJJ\ L-4)A< M+^1V17),([LAIRQ:Y'059G@_S4?NO[%MT@QT^8"BYJP\C#VW/%,\95P M@?U*4/7:VF]73Q"&ZI21@(O4R.DT 5,$)0_1B7>[/D;#_&4TRMIY!Q?J,DMX M\&WJB^I@&/4)8RK_"5P^^F35,C!X]JI5.'$L?E3M@'[FGLK"'Z1+R%A),=@= MU=('?Y0I#5QSE 0KGAP:=5#"OMK/@<=21,K ?W X(:.,A0XW(/R)>"^$6, < MI@EFU6%WWC@.VGN&^C\\VEM@^?EP_@,E^C=P82P_L/#@L'GXK" U= MX!J7N M1'=-A],?:"I$UX%N+A 1_!\7 WQ@Y2#U0*+1/G#AVGZ)I2N10=$2(*HP+3-'<3NY"(;PHX51FA$@#V-C1CRSSK3-WQ M H%'?7KCCV]]]VJEJMMW=\X*F.??U&0 7NEN(/KAO>H:[MWRGLMNO/==3*JX M'XBK.08%_,;2XR3V/=RL 2,^@I2_-\&>_/R__D.2_AB^ZL%_ D#A2M7\8/M/ MW@UZM7^RX4:,@HAC1?=)AO[3FT__ $*-A\H;ZE7#3]_(\J5:^L4 \ZRCLD#.H:B1 MQ(OUI!9 "B4E'* M8-JVC %+J>[/OQA(FNJNV50ST)J_FUY/)(#)#+TAWGM?JYB123CC.H%0TJ"1 MW>^4\?!Z&-Z\IR2XY:,_NNO8)EW<4*RH,D80J ]!:&AP>+P:7@0J-ZH9L&L/ MK9=?D<%2!&P0' @VUB7L90P,K.EZRN/C^*H6X:*DQ I^)R^NQS%2#JC%&R\3 M3(KXUDZR\&"3O[=**8I/H9%7\!L5WL@A-F6,/%N!$KR M9"ZX">!13?.5 GB@KA6BR@41I56!I>%L!A10#;6^&8\ ]"%8M,(GHHT'(QH6 M1I"](T2K&^HP4&P.AE-E,$'$L0H+V$P=>=,&7\'1UN#<1^D%PX(?/1O P]0S M^ Y;]94.UH/?P,$U-OY&^A> [Q%JT#=LB""^)7B%MW9L?[66OJBX0@58@M5+ M A+*DS$E(00;+ $'NAZU/W4GU$/<)/W!#6L(OY226(6.CO@:IR#@/&0$%*PW>'&5:&=K2 M6:''Z?B_KPTSF>@"?Y-W<>EOJ&F(@SP2.(7(*FRH:)S1W%7\S,%]I>-&UP:X MZE@5LY<0EW'4C_W?@'Y@D9,\#*2AMHXW=%&8;J,C2M28X:ZE/QO@^#M8RD65 M>TP';$'OXWN!Z6W0@M1X,G^"BEN4R@6(-4+ R8^8"<68.N-X ^ E+O@M"37( M-&DR.' G^8XX=.F=+S1R8_(3JV'VN*,/X%^--G,05#5I%!1<%P2'J,-=XCQ# M7)DL?1_!@N\>10']RG=97ILG-Q@'I@-HX$K54;P8^C18 EP?D!JS3-NHS(FJ M++@=+@28':I3=^KT6(Q']1'IN2,0AT52IG0H SV1(%X^D'P?2&N#&GZXWU6Q M!(,@@:#^1L*^"M>V+!+V76@.H3FP0]<&-3L::B]]9LK@LO=6MX0:,!&G,,R1@E5\2B_2HOMO,;53_!E7R"[CA^!JBY(F98 3X'AP&F MV#\,'0.*];CL""%[H&H^$1!1[(>17#"#A-4_\#D#ICF9\AWL6R6+L-P&6Z5' MJ,-#E3F\%Y_N43JBF$>KH.TC5'E02%U0LNI.=26F:G4M$*V+@>[BS&/@&70]BAW6T$6.U SF"0(N5@-OYPI^ M#S)+-ECT4'; MUQ,!O)D)+EKU6'RB$D(7I%1PAU4=_Z6TI?W6W,_$_D/OGEB M7F0($F@'IAUQB9,ARC$XH(9W+6&: :2(L+KKSBIIDB5\"'K>41R!7G8"F;$S M%F$\7;^[V Q U5/B'X#4*PPS%;]@S!]"!'_U/PNK7NOT"*P3'2^>Y*"V)2C5ZX*[%;X'8.43Q((G\B >8/QX1 L-& M]F2FAO FAHL=]HE0$UH5/F9;A.XR6CN47I9!/C45WQ$U]-D*(KM0_3Q\O 7S M@9EU[*:(\IPJ]C::: 17!A9&0Y>111> 0DS8/+WR&BSD0\I6A)9.@R!29B8O M]8FT.<3==>EIQ$4C%J8JHJAA5Y\,]MTW]*_ @P+'DP47"2W&1-Y@W23TOZQ5 MD]-D!C:#@?K8UTU,[?UN,MP3]@$O@F%,CIT77M S0-M4;/""4=!=NHQ *R]- M&YUG5S(QBT*3Z+^;3?;><#"-4R.['IN\VI -#;H(Y='_S][;-C=N'&O#WU-U M_L/4QJZRJR : -_7=JIDK3>W\]C9O5?KD[H_I2!@*"(& 1HOTBJ__NF>P2M% M4B1%"0VR3YTD*XD$9N::[JO?IF<=A:)+',BT*LQ,:N#5M!4F)\J=OGX_]L2J M>EMYX$KD1Q>,K?"@90PG8T5?N%G#!-Y3L/+ZCU9\>0TO@7]=BH_EMKY6O G/ M ?<[S9UA&-M@;!G]Z9/\;1O#P=2P!F9-ZRH*DV">E=24ZV#MCL%6Q="_&O2 _&L$5546Y>9A28'YXA;KN,;2,7M6%4O4.2WP:3)7/:XT=NL. MS%JTJJ27)\&DCB]@CX(#' -!Y;JA>):1_U1\'L=5H^S<9E"YH;J]H*SD?&F/ M%FX@QQ\@@E6(SUYKR#:D4 F7C.LF'JS5:& ;@_ZDMF?F/]C&H^0MTTN1^ M)BD,%<.6FX6DH"CU=Q7MTS*-9FKY\&J']WOV9%@S-(HTP+KA[?2TL7[:X^_G MK%K>/),4!?3YFU<>5P16\IGD9 *&DMDSK=K75J16%8V@)E %)X]'L99V<,6V M27-I5Y?8ZUMGFA)N]^Q=!;RR^\HG5G*]@\GZ"J+?,"-[XI?*U[),OV>-ZBQ3V]:*P,KT?>)_N5"I M.3R+HPHWT!= )5"$X_)- '8KF+9W,J^E4/M7"03F" Y0ZH4*[]39K5JD E7[ MXXS@#@I^.EW5M[MLMSUU,"B.=2IX!XU4WV#K5=(ZT_X9NNDIQ7-&>ZOTQ2U[ MP]FJW<-@H][H*%&PD6$/GS(0]HV"[?;,)Z-@1:A'!\$:=/+( =EC=-/^6*5[ M][3 0#V[&%9WFZ6H>%&>KP+B%2DJ20!=>X&>O8X%Y451MSC(2EQ4?OD>G'2) ME>>_H])N1/9D/4QC[$+S:]=A:@WK:-02N@W?4$VGX&-8,[2X:NNQ::I^K"9; MSK493B(6O.RMJWKX@.$:3"A8C3./=71J8<@U4R[@11M@V)\8D]%XW^VUHD@? MJ8J:%%?KE2.LJJ7UZQ['2'45]@X:93BU<9>\:+Z86$@E1WWZ;&T\KI=O58FD M/,V*)D-Q^*NT&3RPN-39G$H7#XUI4V\J'1G*VPCD+M72NFH)6+W^N +[A+-( M5?AV&U!;,+)[_1*C%6DK'BS^E9OU/Q<*Y9<03!ZM$#^4'@:JT"!00(=UA06O MJ+:!SN^ILJV5$!/:/!MH&B]":'@"6#H6WY6$U+>\8E;766X7YU:F9 M"EQ@TKC43$V"TXS0-6HZ&D6SIZRC*MK')XH:=J0GS>PW HUJ=IM6%]YBV&- MND%1E"3D=3-@5;.OMOB,5Z@,'""I5Y M%MVH%(ERLLL1E4&L6JFL*EUK%M04K+'5OL#"B_2AG@?"4GI5>J/FLMV.JN=E M&WJB"J+C4"O[% ,T=U%PIZWX"%W%9NU(*MUY" ; [8, +P2/$")8C5,A4=@3 ME6 H+);Y:62T#4%#Q1BTR&MJM/5?5D YL)8SK(M6YFM91%KE/(O2FD:*N1&# M![7MW,%(U-]DC%6D_DSH!BHU150=-MC]!( ^.7#C1^[;:RQL^3#[6>%S7<+S MKCSEL/;80/]T*M$(*GUTA4BW2ZRH_+9)Y5)I/G], (&M0+Y]TH29/< MV,:R[R2)7&U,EV9,^>BJN8VR[.#WV-0F;3BE2\?W+M >RKE$EXCG;410;=3. MIE:==1JVW5K'=%NT]QE%+ZN!87^QD)ZO]\B6R&]9'%Z+%&\T6BMH)'YP[Z#3$ M*QQ1)1&G/)4R&; +3J%,!J>Q;YG,F97$5"NP=VT,V5J7(]6MK K!J]6M[)U# MHE/ (GZNLK[;("J\B5I9DB&WBF9_VF]1&@4U59POC#H"X,=)NIJI?<1S M4GS2*U3&6/ A^L7-9GO8S$O&]5<:NG)*)0O7!(1V"57CV8F"T+&TPFP45]3Z M28#R]WSPW8K39GB:#V.;J;(0] .J+^9OW[C<\#0G7^L$I[AIZZ[)%#WZ5JU* MMF%$U8MW55,M?+&: YZ5-_ <>AK[-UGN^\,W\8^)_JG&/[JUTDK3IZ26>Q#_ M1R&S70? "/4.4^T$ AVNS#=Q-2KQ3:3/3R87_NPBWXS2 PU^H5&[T-.XP=/O MWQ;5"8FC"6V!'%,]"SSY#,\>*8M+E#&XIC$WC,9)97"U2/P@*= M1T]YG//>.'UE$(/7?Q?I1B]JS^=9LDW[-%#'S1T-/:!5]1^+05Y5,.,B6Z(= M(E60Z [^'J9*T&(=OM _&KGH; >HT #K\,$SG/FJZ2.!U4L+*Q9W6!8O@RPQ M5F2O@B@/8^AP1R'/JY';^R@+O/+-_A."I-)_LPQ1+G>+^ 86"WDJ]HK&/;H: M"L:'+;(TC9925+=7<$I2>4'?ZK!=75-H>Z\X!5EN:+4O0(OX\%]@O^4'"K ] M1+7JCW=*[9 ?'LZ+P"BZ+:+X,#TI%UKL2N=34?:37,L5B]HVJA*+7*=X;G6* M3U<%<:'B[H6*7(+X B6(!S:0[V*=V,XUB$V5S96'KU)YV+V0WFN4'JY4O9QH M$6)#:3X[CG_,X#S71W)])-='TJR/["9K$#KDOAJU6U'4^QYU/P/P3K.XM2N> MVJXNV8J>?:Y+UJS_W&Y?*/=LG0 MY60@ELG(&(RG*SJLW R/:>MXE=Z[:3*]_-;K+_]SNO _9\+MJF[8 &N=?QEJ M!:NR>(_JKR_!C->=MHRB ^':ORGKO"@^:.0*2S=)?LG3V,URS^J)^+<\B_4X MB[[VK>N__*C=K8-?T=WH&\42ZF]5G=6-#%437$RDW(?PH+F_K"AK M7?HNZ@71OBJNWS0K3+TTIK1AI!O0*JFNUJ_OA"V_Z-]@#+QKV9A@II? M_?=Y#Z>*R]#9U"DM\'GPTKU(C(?%JM=2TJM+45]%W B/9J939&A"-I9!9:'_ MD8$6+IK ZWA78Y#*X7L4NVR0HTYJ*PH,*SK431\3Y:%?:-)4G=Z*B.KT6JG;'R]5K>9"EXF!T?&)9]G'5+]!%]AK#9J5CNF9$CP^\ M (R3TCA058OX@/Q:%.R4NRQJZ\MRQ@WO6C=FO4\FC8++//RI"BX+Z[?VW?S/ MA<':Z+;KENWT51%=U:*_WDJUU""[] 5?:P5/.1@-%?*GZ1=[%?[HI:XR=:/&_FB''-><3J\%4J!1(J/0?WB#H M::/!C[VB!;MBIS4*X(7:NVT2KZH*?)NT;93Y'[[;\T!/\_Z0]Z#$_Q=U>/7) MZJJ1^MF?P8N=_=E4M-+2V9]!3^"B"+4JXC?IX)HH7CK9*AUD\^K@!'PXQ@VD MY*=&\HMJ*9)'IUAF_A?=6%]6Y0#-DQ5K+FO6 5*I[P4OJJET21=:;\K27HF M3_HJ@%>3[ETX/K>NG,#-;R]QDJ(0!ZMEFE:,'DW97EM?WQ8I0T[=D)2IXR / MB^J,7Y[4+5=0-XO6-UNNU6Z_K]Y+7=TO%8K+ZRN1WY8UL,6O^?7J:0.CQ[97 M8WES4PA62$]&+W?CK$LYK;7KD'<"/^Y2*!)3IS<.NZ^1F*+XH$HIU^N*Y&1U MQ655BMO,@ZZ+4*^>)EPYU+#QB-8ZQ^5QVGC=&;YF5:KR+\N]J*VA%8TRZ4WL M>L0:"]DK[W7EP[638\;!1\=0]/,3!W>-B:OZZ)U.ZM4NRWZ9,WO[IOZ?\#V5 M25CBD"4Z6_,;VA/BRHF#"._P1-6,ZK#R/A>1)X/\XW^7T4*F,#GQ4PR#AHT) MWR_2, #",LHU7G4EAE>HL2H1AT?CRU@1#K&*CM1?_*U'I=^;US]4QV04$]=^)X7R#?BYE:%/7Y\\]>K]^_- M]U?E>_*17 1REJIU*'ZACHF\-7OC8>V7GW&QFK_ZJ5I1/;+1%.2R/K+=,OW1F4K/.MY; M!>>[.O_L2$7OU?\Q%1T%I)\;9N2!4O3BB# '$<2$.:C&0<.>:5)%BCGHZ!S$ M[M!1.0@OY5,EG/HDMWCP9>!1->G.F(QV$2?VC,C 91Y.2NP8O1PL7[,_1!8; MS(JK>@E,8,'$\GMX8?4QY?4<7F(GB3 OL;?TFG#9O<&$*E#,2^PC$<2F])$" M?R;%-WZH4[3?4C7OF(S82>H&7,^(W+&3U+W('7M++\%*=Q'6\@1^^D#5KF-" M8N^H&W!-IYQ+HHC+CN[1=ZJ4[TB5SCN4$JI_U4L)C_5&RG7&N@N[*)JOKV^A M_LQJXZH7^C.JC?N]OKESM?&DND>DU6KC+37&S<;7KU0W_%/@N']<7+OS"*_H M447"JT7 7-K+I;T42()+>[M!YES:VP64^KW)E"I09VP)+* MWBZ@A X/5:"8@KBPES)(7-A[2N+$?A$9N+BPER0L7-A+%QLN[.VB1''JNE-P MP4X=4@6*>8E])(+8<&%O9\2(G:1.P<6%O21AX>11EUB)"WL)H\3>4:?@LNQ) M;W1H/0/[1ZW[1P=5]N*/1Z_L/:^FPE5[;_M%V@J/1[8QZ$^>4^9K]X;CG=/Z4V6^:^\8JO4?SJ]D%VNO9.U.;*E!G;%=SJ*<#3,1UPL0!XCKA+J"$'A-5H)B"N$Z8,DA<)WQ*XL1^$1FX MN$Z8)"Q<)TP7&ZX3[J)$<2:\4W#!3CWTQBYVECK#2^PC<9WP.8H1.TF=@FO8 M&[*31 \63AYUB96X3I@P2NP==0HNJP_+116I,V:DO3'+0GQ04>'9J^FL\E]8%+KFLV+N M>%C'ZH@IPDD>NK)]S[Z;Q9#KRFIMNP1D.UN394=>=;<+4H^HG2 M;3#*#B[=%KN6;E\&P3-*MZV>W>@XC8N7?TP5&/N+A?1\/9_6VC=7&'(Q-A=C MMTWL7(S=#0.,B[&[@)+5,P]M L/Q-(ZGG343<3$V<8"X&+L+**$/1!4HIB N MQJ8,$A=CGY(XL5]$!BXNQB8)"Q=CT\6&B[&[*%%<;M IN.S>@)N2T8.%B['I M8L/%V)T1(W:2.@47-VTF"0LGC[K$2ER,31@E]HXZ!9 MHWG+5;K=8&:NTNT"2E;/XI;)]&#A0$L'F(BK=(D#Q%6Z74 )72"J0#$%<94N M99"X2O>4Q(G](C)P<94N25BX2IX,!5:"8E]A'(H@- M5^EV1HS82>H47-PRF20LG#SJ$BMQE2YAE-@[ZA1KAPE>[!5;H/ M98OAHG)3P$PR5RXPJJ;>ZKBIJG ]M'+7FAQ>N6L9P\'8L.W1<2MWK:T-=M>M MA 0^#6%8:M [UO:N%.^N#'7[=8F5N-R6,$KL'74*+FLP[/&=(?1PV;O<=H_5F"P/[MM9+^K]X;LLN;AU MG.7;]XX?_R_6,F) *XB2+);)9WC!3T'D_O&W__F+$#\4'[W.ELM 56(ZP4]. M@ 61UW,ITW7?%+[WXYOW_P8P!N;PC7!AC/"G3W+VXYLK_*UE#@;]\>3?6%D+ M/UCZ'].^^>9O>^Z-=:N1XWD3!=[>Y<;/LA!%OBY"+8QX)U/'#Q*Q4LUY+*B? MG,MQ]_7G1K7J,HXP"9<(5\8PRU# MRC1[YNCY5N9ZK=L)Z-)VN!J-DI>L\=PU!YI ?7,*1" M9_+"2O&==.7B1L;Z8(4U,K_O6P95J\5JUV31XF*M('(%ZW$3^V=J\??Z@S.4 M&M9M74#I6BY3I=SPE!A5"7I-G48&&>I1P89QEANGQ![0G]0GWE;.C$L M\2OST$X0L46W%;UB5<].,X([/VE9(9;:;U?Q8BW9,E;:UGN&-CQMF6+M>"I( M8K"3A,2Q=FS!AGSY>J?CQ/PV9I9W06B/J. S('KO?Y&>N$P2F2:[*<71-J7X MXLCT)[WI$7+^]'-@]&N;6@[UD4:&9KW,<;2:/>[UZ1?,_.:X^;:&BGKFPMEE+EM3*R),9STR:)UIN)#)OZP?_J)D6 988IA MBJDH9C TS"%3##%@SCV(TPUWYWT6AWZ:80-4<'>BV0Q[>3[7Z^$0 E5CX>61 M86ZJG1,8CHW^]-"N4RQ%9RM%[/Q008)EA"PRS#1UIAD9T\F8+%8L19SR(8L2 M7D"1I3*N_![E#"71++UW8K(==UFHR"+#U%2C)F/0'QL#L^VJ5):CSLD1NT%4 MD& 9(8L,68XX&407I5^ED\AY%'C"7V"7"=5R9'MY+P<5 M2,H2A^;(P#4 M^R$VT>,C/V01XEA&X;TR'9.\183FBB@Q[/E208!DABPQSS0ILQM+P5IWQX:P]8O?61N MX_36J?ARGZ/4"<1,=>UT5-=.0]S&T<'>W&O$2PJQPU5GNNM<:/)(\)TZUXV- MT7A@6 >S'47,;2]1V5>,-6%,XBBE/_O^H79(-<'*+D$.7Y$.$W V/: M'QAC^]"^%ARE?$VXOB6!$B?>.J<7F=6ZC!ZSVMZL9MG@XTTY]]8%N+:P&M4[ MEKTHNPFDL'OGZ>NMR\.%DO)9LR<#8]L /FM^I'Z!R"LB>^J\:1OC_M08V';+ MD&^BS8U:]RP%DTQ28HM7^&(\R? P+3(M,BV^3C]&K.2T6S\#SK1X"BG$EZ[D M[,"UZY>N&V?@.O[J.S=^X*>^[,)Q/%QLYK_.ADT9OH[!QR4P1)'A@DTJ2%!G M)PV/7<"S#4NN7TW#DN M]2-F+$4TD6$NJIV1[@^-T>304D"6HK.5(O9ZJ"#!,D(6&6::&M.,1L;$.O2V M8Y:BCGD]G.IY":_G)@JSY. Z.@X=4*4B#L"]:AM#"R_\.O3R29:BLY4B=GJH M(,$R0A899IH*KE%_9%BC,5FL6(HXU4,6I<+I29P WNQ&BX6?)'X44CY&Q.)$ M$QDFI1HIV<;X8$YB(3I;(6+OAPH2+"-DD6&BJ>":6(9EF"\W.5 MQ=C=0RRQFWH4BF@F/#F3\$M/X!\XI$ ++P[,=0HN:S@Q^H.V6^"Q%'5.BM@) MHH($RPA99)AI5N#ZZ\2V;+IXL2213 /Q/51/YH:B="YCPA$&OI"CZZ$\OI!C MYPX*9M\8F6V?)>+;.#HE?GS9%&EXF-M.$SWFMCWCA2;>>W]H;W#F-FKBQU=. MD81.7SGEY,Y=\.S.X7R[!F6T^7:-\^%/8VI/C/ZTWS+D?+M&IU(,?.D4:7B8 M%ID6F1:?18N3PK XI6?\OR[K1O\/UF2^K.' M^A*IWN^/%[&Q2%^WO(7?93%L)I'.I0C]4(H%?'*>" G#\\2U7*9R<2-CT3<- M89O6%#\82W&/_Q5&PO.3990X02*F 3ACM6/]WF']< M7,;2]9UB %]9AM4?JH^JX<,? YB./_/APVDDE$*[B&8765*,-)\M?!]'?Q4M MED[X4!80C+]/Q(T3J*DD MZ''8 ].PS?'J.$H9_>&[++FX=9SEV^MLN0PDHNL$/^F5O,:%?.-O__,7(7ZX\2/W[15L.C]][[@8C'BH/EQ^5OC>CV_>_QN@'IBC M-[!90I2A3W+VXYLK_*UE#@;]\>3?. 'XP=+_F/;--W_;4V&N$_WZ;6_KY'VK M:GC&,;*>N%S&?H"P#(1>(U$LDJB6?U>%MW[2HPV3WF..Q]5W'\)\VOG6'!AU M844IE[ !/;PI7;A.,A?+.'*E]!+4":E[0ND^6!RI-+$?YL_8_)7FD%&B8JEU*[Y_Z3SDVA.6 M/ 85."M G8&@HF;+M33H4]CJ_\E"5XU4*4S\XBP+T< HA@[C6H@@^+QU M6&HD"4PN$XS+F6<1"&H:EAA^#<\3=6&P.>= M4/B@56%=9!" ?LAJ'])#*DLI%%,(48>51.94,4(T+E&24W<[%978+4B,LM?6&^@51 MEN(RJ27?=R;R%L>^P$,&_\7OPV34]@.]FJ\U;-G =]&261TL;+?(,S3L2GTW M9C"#-?9#UU]B0!<>5Z[7C<07+1Q/(L;UC9COVWS?Z=V5*#FXD^4;_! F&P3Z M+;,H"*)[?%Z2N?.U SP(81!0M0D!AW]D\"B]WA,0M?+;$?"WC_L-'YT4JZ6> M'CRHI;P%7L-A/I8VL'>BQWL!!$T],%_#E>6 3^/+(C'L#;\N7E<.HK;6BR@+ MTT>RIX1RF^VDIHQS?U+AK*Z*H646_U*"[&\V81X+JI8,90)YQ9[0L^X=BT:4 M)4V*1RYAVG&3,#" T\KV:;QL","0)&D:(%H+02T$;L^ M/ ? <[6N'MB#WL3$5=>/+.U:W!GP =A?: MF[_^>H6P-YFO)WY)D+7@[V@?KV,XR[2UL9PD$1J \/"2)O:4R<*(1@<5'0.8 M W@/KMKM,."Z%O3D38J?R!B!U5\4;M0FO3\)B[:?=):7L-;"FIA MC8.2#30%*/T_FVE#NOK@0J;S")Y_ER-5TW3%5E)RBSR/HHH[OY#6FJ2A'-;J MHJV1N?N_4!?@HS9^O6;R[V:XUXS\7R4X7_(#R(F#F^,R]/*]KWW$M;;^^%QL M_7&O<)5/UJ[_N=SR_W# E(L+>ILVZ5N%&$"&?K\6?[^\_(@1 !0^%(,XPSXU MNP09LJ00M$7DZ8! +-,X*MS77-C6DG7=I)1HSFJ!UI:0>N;2J=2N6B5?6?%EM 3U=#X9-8T\W@$J"P8?@ _A^>#E M1"D,'>,6":B9N53:1PWMRU(9-^#DRR]^HA8(904'!)HJ1MM%_<*!=RCJ3]8\ M<=U3B@_C>!Y]P0]]=!?@#Z!=TUS]8:1!CZGQB*?C2(]"B._$=)9.Z9?<$2>KT>4QXBRPBC,HU5Z2H"MO/.C+ '" MJ46;@#Y<9^EC("O_7 [NQ]P$,\3' ,D+Q_QS^HECO!C2/"B\EE9UP&RJVNU%F93X76)\$IU92=RP7L ,K>"H' MIB Z_7ODN+5#NDPV+M(J]%X$*X_;-9= W![^ MTKL'-B99R@#5<:&6#2QWFT M"GW.6'LZRL5$(R)+5F?GAZCI=)C-N7/\0+EMN4]7+C2:#JBF/(F3TI-?NS;- M%5D[^P\K4RS,"3^I0X## :*('05?@'%'&+>_^R+_+VILG(O^G!9KY?(YI1T, M.L7)_U(90A4$^5_BE7[:R4K"JI"[SR3:_6BU="#46IZL]5!GY5S%NJ!8%;DY(+M.&H%% M4:EKK;Z5RW K%SDMEZH[-RK0ST#J6M7>1EVW[ZRDX3&-G H*"7C=2M,TJ[B:(_ M]>3D?:40=N0(5"KL#9SB+H\6* M.]G'68RUZYZ'N%2BZA:LR*12X=6H\BVD]+$>H=*?>>*IOA&5@[KBNS:R7E^! M(SO6F2W@EG?2S7,U5BU7\SCSMY*?$66MY_H,6K$U89I/+.V:\5:I-S5>RQB: MYG'&ZZU+9>T^5J_*EAZ0]UJ=I56?8U\!E-O%>R5EM[_%'ELUY$=#_98-N;9] MLMNC79+;E*HU/H2E;]A?ZQSJK(WV$*J-H+> MD$6"S]M9)?G?NQ=+!T,@^:! M7I47U;)1AG)7@1],-0KW]V7H(NQ&Y7C?>6@B[ M>M,CV[3M1W&KYN93>T THU OM_'; MW>J_Y"%^O<=WV,Y.4NW^Y^UMK:D/W7$58^^_Z[;LN,%D\XZSC;$YVKSC^LT= M]YNC-EO_)95FZWLG3U.^_NZQ!T."NV>;OIH8]G"SOK*GX\;N*1/&] M]3@>1(:Y@*>"MH>]L\'_!<]5['O[1]-G7A, WN-AY0.!I5]L!'QD3',76 MUV56>=5$(3^/7OK8?;(U,V-J7#U*^T[-6 ;Z3$E9\:#-?MM\,C-3Y0JV)P@> MY024X$YSFT&7-QJ@ A\[74:>%'Z4K2HCPH_BN65L.T]-;(DOPZ<'O>'7!^H! MJT]?0!I)E6::Y\Z7]TGE_"08-8"UDCIT!>JXB)S#KE+.$VI?-\@PHJ\1U3OI M?BY#_66N%_ZK M(P'Y(8L?WYAOA"N# (]1P(C+G_,#&NKG_.B'J\H[RX,>^2D-6/S 62;R;?&/ M[X4^R3$UZSTJUQ]PUQ"_Z@&BP;C77]L\<]_X_VYG1SIQ2@\6'_ '/.PWK?8U M[?>FZQN;UK#1N_!HT-2+63:=\YF\<&5+(=]5%1$(.MD#> )NS14.SN]B5X3E?/M;#[MV7GEJ3:!N^LGFBO)^J,+^F-* M0AK8MNI&WWPJ\2=*L=%?-Q4\OCU0M%ZSP_#&3D-MBB,E=.EW'+;M!L$QHIU' MM&4V9+".'?1D<)CI&$UF.D:4F>ZU7;_NEAZ,>A/Z??7+JL>=1*R%RA 6L1*K MW=K_MH!13FSE]YLS\T M;,NDBA9+5&>R:40JE3KA9^7=;@@',E[DRL(,3$RH$R,K7B,0VSIUC^TTI)IL0,RV?ZMUVO=R'VN\GPND%:_-R:/ MI6HU2#BMT,X-D"CN"\2]U4[#3.*^ZJQ_J"C/\B$3=G& MZL!)$,+1J-;,J:O'P="5.UVXP=H)P-RYBE=&M/.(\AG)#H'%Y_<)@\-,=TIH M,M.=&J+,=)V)L[^^#]B)@__<8*T[(D;]P 57=M(Z*\$R=0I%]NR@$0:'):E# M8#%--<[-6].^80^'5-%BT>I,?HU(#5,G'"[NM'9NDDDJZ,@-98[MOW%+&9H0 M4I!*[K36-<28&,\%4";&/2$=CT>&V3^T,S>38@8.N]X7AC3-MGU@B_NLD42,&944HW*?M1. VC*FHZEA3]I.E.#5%FNLY$VE_?"^S$ M"7QN>=8=$:-^]H&++&D=6V"9.H5Z=W;0=@6')8G9B=F)V>G$T"*<6B-2OM0) M3XM[G9V;9)**-G)+EV-3([=UH0DA!:GD7F==0XR)\5P 96+<^]BXV;<->] G MH529%LFXD=SMC+N=<6^6,XZI2REZF$6^J$4"WCE/!$2YKFFJYEN=K:VO=FS=N3VM=VX M#\ZSKYH>0]_L]3N25B#?;6W4ZC'_OMV;V'S,?WVY1$-+;59.5,C]Q%J)O'AX M@6XKD0T;NIOZ9?K$*I^]?GG"]J&B7KJ0\B*#[7'R76S'=<>.:[==DS77.51/5U0YK#-889VN[O)A[ M>*Z:98N-C318\5Y2F@R#YX4G,R#'0*+ MFQ42!H?UXBFAR31W4G RS74(K-V20(P>3?18<9X2FLR#)P4G\V!7VC9QUF]S MF]_\S.TSLG_<9YN6I+4,UB$=[!DM%BT&BV.670:'):E#8#%)=0DM!JM#8#%) M$0:'):E#8#%)=0DM!JM#8*FT&(-#$QR6I Z!Q235);08+#ZIMA&T3MQ.>;F( MXM3_KY/Z48@M8U5'Z(MH=I$E4CA)(M-D)^E[?"*;,\;4NINW@1%?P'RT>SY8 MH&C16=NEB!P8I L.2])^U-12_2!3$\[6Z@^,P=@F"Q0+4X/H1=E-((7=>P6FM/J],7DP/T>I$^PDB8];)KQ& MFO_)6QNW IQ&)J]2>-,.TB=)L,_OAG)<7?R89#?J81958L5R6X*QKTFF M)X<8TVGG$6<292L^#2MDS/0T(*='I MFH0HTRG3Z3G+*-/I>="I!7[IT)A.32;39P&H02HPV@9GNZG4[U('UK/\E.?? M/7_1+!M^;BS2UVMW[NNMRN>Y%+,H"*)[/ R9N'/I9;"+\'XY^'VG)I?.P@-DD(LK2)'5"W+(B@QG&8N:'3NA* ;\4 M4?/096(()Q'W,@CP?]THCF6RC/27JQ9AK!-:_I65)M4;;GZ]E,;,Y?^']^8;X0+@T/YAC>5/^>:0_V< MZR178O/64@/EZ@-$-'"6B7Q;_.-[H57,U*QWNEA?6?#2:JX_[IG/J\$[@A+K MA$4)ZP^K )",WK39+6!@]NP="[2VDY#>K,?@H#HF-U'@;22ER2[J]QE(OM>Z MD(8KMVM7AU,"@)@[;?>LHYVZ.4%QV5?QV:TJ/FO2&]JL^+9WVR A=D52EDY4@2%JT=!(QL$-+#A+W@O9*Y MJ]G>R7&I(,F*L&T$6!&>/GBL",DCR8JP;02H7[Q))A_;VBDU/+0HOBD//'Y[H*R\ M9COXC24HKR9?E #@8@IC"CME"NN/;&-J3\F"R1QV MU#CBR9WK:#&.:._68/'$Z] H84(_#9F3$W,/SG8\&AC#_FY7:+ 4L10MGZQ0 M9R181A@99II5N"93P^H?&JAC(3I;(6*BH8($RPA99)AH:D0S'#+3T(.%R_*H M(V2;ML5!:%J8=" [Q]Q3P36TQL;4'I/%BJ6(*#+LY5!!@F6$+#+,-!5<(R": M\8 L5"Q$1)%AHJ&"!,L(6628:%;@VN-F<)8D4I+$%6HMA]1L#D33PH33.9V" M:V .C;XU(8L52Q%19-C3H8($RPA99)AI:LF;L6&/^$ !,53H"Q$3#14D6$;( M(L-$<\R0&DM2QT)J7*5VQ)#:HIW9LL>P!X>V'F%F.TOA8V8C#0\SVVFBQ\S6U5(_ MYC>N_SL%A#Y'J1.(Y?.N6>8[BR@+&(F\&E]>M%LMH6'W+6/,M\A2 X:^H'&1 M!Q4DF*VZ"QVSU3Y7[9DC8V#S=;'$8*$O9LQ55)!@KNHN=,Q5>^!I&;8U,U;$@.&"QD["]JM,$N$LHBQ,12R7L4Q@F+!TP@]3"3^E9),NG#+CE-GY\-XW M [MO#,9M]\WD?-DN8'U+ B4N ^F<5F1.ZS)ZS&ELQO M>_IL]L"86&WWSF5N>Z;+UF9EX[:HI1=E-X$4=N_\J.ZCCE,B )D4T>PD*A^W MP7O6U/@5651W3-T=#]E3ITS+F)@3PQZWW.(T]!S5J#FJT85 K MHO-Z2'V>2S&+@B"ZQS+0Q)U++X-MG,@T@=_'Z5PDV7(92(RW.H%PG60N9O!I MX8?X>"?UHU#$,G!2Z8DT$M%2QHXJ*75"3\S\T E=*0+I)# 3)\'H[;54?Z M%H+1 U%:#WW#&8M[[>-U'@;53NDUU4QC-0>A_%(@4=DF03UZ]X)(,,3'OZ.2UH,EL9Q*]L^:R:/E2]=,%VM;(_/[PD>C4M?&VK U MVZYNR+'68ZUW*@+&6H\@*)WM0OJB(3M*&9D/X$C%]3@PV60I?CWK(%XD$ZT#JVF;C9V@>C68RG\],4C/3UQ]HZGZ,SP: MU%'?_'K#R :]X=?/'].[+,:OKNTEL>89AOKD5;18.N&# -&$3WTUG/0-D M\ MJU*$^(\,5ME)5/LM/Q3RBSMWPEMLT14WYR("W[GQ S_U9;)V@+^$^!H?SV49 M(EM&^&.T5.VZX#4X&L=5RX;3N,U\3ST;WGEY?24F ]L07UF]@8"-&.3?"64J M%HX[A^G&#VHIY9^9O\3.8&K58^D&,'1_YNM68'J<:F87T>RB-K-:O[#\-QFL M6[P.+1C$M#Z(QN-FCHM+\)"_*A\$%F-[^1-70.Y5LO_#=S=^Y+[%&W&E+!.. MEZ&GO6_YJQK#9Y"FGX+(_>-O__,7(7[(DHM;QUF^?0=;+HB2+)8?9@BJ#!-U M NZ3GMA5E*3)]=R)Y4_P$.]C?EU%^3#A>S^^>?]OP'Y@3MX(%_8._.F3G/WX MY@I_:YF# ;#(OW'GP ^6_L>T;[[YVYXJ>IVRJ9_NW%?[/$/53'KB.H7)7Z@U M$?5E$Q4L>\QO4R^]EN;W,P@#;,5?0CPA[=])\3& ;VZ:V;[40;)Q8*'/D"12 M^$\BTOM(:058"+]C/J)_ M@U_5OS+'3WX+/H*_Z:F7EP_!L069ARI&+./HSD]P$Z9S)Q4)2BW\_L[Q ]5Y M$#7O+2Q*FFN4FAXO;S0[Q2[3C:OMA&'F!&(AI5+N0 P)ZI8YR+P$DV,N P\Y_A\94+,] M41P\,38^K?%=9XE; OI#PQOMY M).9@]<+JI*"WY)T?90D\Y49*U"'E)U']>3Y80FD4KPS3P-?#W&H]7QUQ ["! M[>6!II:Q'WD% /IY"("!QK&"KX1D :H;9#8H,(8_^7>^!QNML12J6PB^!ABB MF(NV&/UTWAP9O,*38 *6QAMLKL!WE1;\IY-XSI_B5S]16_A3%N">/UW-MW$3 MYBL3!)I58=4 .S,"Y\';V(T,,SI9(/XK.[$NLS \XVQ9<&WA\7'YXZGMQ9^ M!CZN$+.-T= TIF/ST3O4MM4>AC;=X1EI[+O(\/J/6>BGB2+G3]>_)_E<@@>E MD[(4C(%0:0:]]371]X?H(O6W3N@Q58,VW"S%0 3]T43LNSR;O[>Z3FNTCZ$7 MSP+M.NP/Q-9EP[79OC3J8V K/![*VK4XR+C>&*IHR;I6KH/XD*_34?V%]J1< M)-D"!OA0J?W<0W=<,&;1L)UMZE>Y9F_#_D,=JC5[LMI3^WD^XZZ-T8EV[FZC M8,'J#0=GW;F[Q6;#)&+<]'K1M8F(W9LR*-1 842H(=*;K&_+?9X(G'AZ])%! M3;G98LNP[,$?I]VMM -8L0B1A&43M["\;.C3W(8!T$<]=W8@_2LOZB!KE[%* MZ])AD9>,O3P+C;/S9]C#I(8(!V((@L*(4$.$ S%MNRML.C$L,?NL%%7>-O"* M13T[M:@ZBK9]ZPGJ'A3EM06..=") ?8]^5XJ.,A=)]-&2/55_[ MJN_L)(%5VHD ^5G&BRIXYX?5O_\?WI9 0\9VMRU8%9Z[_]N)*Q4_U)NHIN*= M=//>F9;N#4XXS%3@B&N_5H7NHF;/\KHL,I;+$T7@KXAPC5M/\NXM:SHT)K;) M+-H!K,B(YY%B*@S/*TG307KR[,6M[:3A8M])[\L_;@316]\QK=[ M&0=[UUX8[%#A;+\9V88][;<,)Y=T[X+5MS10XE-,-'4B"U$7RN5VI2D^>K2* MW*@W8)[J E#4-"(3%FEX6)HZ!=<+,!>YZ/8:+"!- =I#NH\\0R$3]WULXWQ=&R,AJ.6$=]$ MJ!O5, LH ;C6^7\O1IP,#TL3B8#E2S93.@Y0I\Y:_=[(I@$>BUBG-"(3%FEX M6)HZ!1E=/$?:23P M5T<-:KYVM\"UX2P.:E+/&>T1U'QAA$^=9&UC;%J&:8V)9@F9:4D**/N(78"' MI:FK59CL&CX1U!RWWK&(GV]=H>^WJI\GDOAAVGLAXGO MXE;-X(W13$3+U(]"^&=5"VF4OY2ZQ2&NCZ%"C<4?[G:,/CZZNEE]Y7%,4MS+ M6 KIN'/A+)=Q],5?.*D,'L1_91SU*AQW1:7$X#%*ZU!I3:<@*DZ29(M\7;,$ MUL\/10J__REPW#\NKMUY%,"HEK'O8IWJ(O)D(.#9L B1^T>)R*V^"D9X68P? MPP>D\UA*M>"A'TKX9IC. 5.8^F8(G 2>'031??)6;%KV)]4%J276+9^LD?G] MRGSJ@JY40*Y4?WQCOA'8=0#5)JQE^7.ND-7/N:IW88HR+A5[KI5!&0;.,I%O MBW]\+_)$AEGO'T3FRJ31I&1UF %L!H+'? ME"CI%7E5E.Q);SU(IVYXB:_,WL02%^(KJV?N=H2S!7CZO?[HG/OKK*A82B=@ M6/']7-AF0'H^#-$3#[X,R':NAK^S*!'%QA[O#LZI,Y/9,\VOJ0+URH2T!Q*= M*#UBTGCG)VZ4A:F(P1>'6:'9_&?FP]+#<'<@$+:;V\7/Z@TG7XNRY;'U/08( MA[OI*S:@J;$^&] D#.C GTGQC1^*!^G$R?:6:KLIP)>WV,Y5 0[!/&OHOV%O MNML1X!908O5W=/7'IN#1U=]=%#BI'_CI YM^A/&R;+#\+H0U'+&Y1S-!O8>Z MVR5!?5!.3B^ W=(*K/C^STNX;Y]B"_GV#Z&X7,9^4.97#963O8H6H! T$C>R3 ?#3YM>*Q?+('J0,C$P&^9FJ7\'BX+),3V@AC/-9. $.5$TD=&/I M)++XN1BR<^?X@5#VU\>&U&J\ 4\]FT,N+F 7SNB8!-%\!,]:.2C?4,AY64Y/OV!D:X M]YY_Q@;_)),T]I51H-*J!TUJ1$UL+V$O+V" #[A'/UW_+AP7Y +,'55R@2#O M5$OA)_5*BJ,64K2KM(D44HS-GCDZI);BY2,B5F_Z8BX! 3=M]QK6%GSHEB^X MT:N_:E%>P7K^S)P4*]>[2[1C"ST*#5=O9J;9_9NB?5QYL M-&,E1P@>,BW?]C?03EMN6+EU *3+.QD[M[+2;G_'X#]526(%1]"*:YALY*ZZ M8M-N=^VWR]6U9ZK66-R+$W LNO[;AG:+C3%A36>"<"Y#NL#WGO^+'X M7VSU0$+VV/(C6-O:BN77B0[+*[?#/6IE!,/S2M)TD(X\>W$CTF+Y^6S'G2Q7H1W MJDZ8]+H %?7$P4N7?_0'/9L\2'_7AVT(9]R>5* L7#2AVXW^F-9*./'4EDT7 MSW,^X4]:TEZY IN18!GI'C)['.9ALFD?+A8DDBDW]IEN&_>78G^#@[VGUTBG ML1311(;IZ(ATQ()TMH+$O@\5)%A&R"+#9,-DTQ%H".>+6BDW[(1#]#Z*9]+O M1AJ)RP8[&KOCJL#NQ?>X4*)3$LC5@1V AZ6I6W ]25YQ4\G8O1F56O_?(^[L8]49#:NC5BAFS\$[_ M((LK\])(X*^.ZAJ^]IFQM4X!NX;4HZ=[N(8OC/"I4^WAKN%+1UF99TF*)KN& M'8"'I>EE7,-7R ZR:_ARKN%9"EFKMP7OX1D^^[;@C1>-MG7KQ8V3P/KAI;DR3!R\ MS%?@3?%A(L5!LR1W'>QG0%S?XHHPZ\M-E[%,8'")V@YR-H--I+9=4EL2M[XD ML0RSD-[;PZ R MMT+UU/6T&S6;&D$+%\I.39*WR0X&/>N\;Y,M6XV/6FTU;H]ZUCE> /0^JMV: M!?JC_D,L:S_J&[&KG]75V&3#7]R)G.(MJ%9O..%;4%GE455YH1^RQNL0DMU( MJN8V'KFS(EVY=8N$EN1+:-8%">HQ$2JQ1E:#K1E^=2N/IKIC:Y#UW(GH.7*' MKY(59.=%E$#E M."M(6@J2]1KKMOCE$E:*O7_XSD?B MS4A8U;J-'S,2LQ*S$K,2B<& M';-2I^%C5F)68E9B5CHQZ)B5.@T?LQ+)NGA.6UU%28H=7V)Y)\-,)BVG@EF" MB/7#>XJ1N/<=SM8R#6O8=N\[EAVJ567L$[7=?)5E@WFE@RC94V-@#LE"=::R MP[S"O,*RP;S2793Z8_97Z*'"O,*\PK+!O-)=E(8#8V2SOT(,%3X\1!VA3S*1 M3HS71(2>\.2=#*(E-N-7-TJ$R<%I&4YLTC#5VJL88%Y2_HYIV(,Q6:A8B+AF MK9O^#LL&#=E@@FD]H#:R1V2A8B%B@F&"8=GH%C),,/4*L[YAC]B%(08+,PPS M#,M&9Y%AAJDSC&V,!S99K%B*CIJ\X2,TQT+H[S*4L1.HW(WC+?S03U)L^G8G MGYN^X8PH56KBLH)7+2L8&];H4&9B(:(A1%RNUC8"+!M498,)IF7?9S0Q!I,! M6:Q8BIAAF&%8-KJ%##-,[23GH&\,IWVR6+$4,<,PP[!L= L99IA:"=K(,BR3 MHV3$8*%^^(;VU>"MP7;M!/!&3.G N/^0*:Q:%P[C['+%&8LA3?2:+3Z?C^"I M$YXU-(;6H1[5<=4GQ;OK*$%%IDQNW?V>9,BN>[X74UIWA(HIC3ZD(]NPAH>F MH9C2"$L?4QI3&E/:":#'E+8GI6'>BRFM"U QI3&E,:6='WI,:?N>E!H9??/0 M]JG,:=3$CX]/M8G0YRAU@C*W)F(9.*GT1!K!?"/W#Q$M4S\**1^AXEO9.ET^ M?^,.:HCPL,<11Q/>SHV1J,I63"9HYBCF*.8 MHTX,.N:H/? <#("C3#YK3 P6YBCF*.:HTX6..6JO.L2!,68_BAHLU,^2<3(+ MYX9_;2@*3[H1-@2,PK<9C#L.?'B&^OBGZ]]U8@N_4Z))L4: )8XJ,ON<@69T M6&XH(O-RI83L3;%L=%LVF%,8'98;YA3F%):-+B/#G$(9'4:&.84YA66C6\@P MIU!&AY$Y:I:&CQP="Z&K*$E%-!.QO)-AQMR M==.K8=F@(1O,+@6,DPP[+R0!82/SU!'Z.\RE+$3J%2-XRW\T$]2[&]V)Y^;K>$$*%52X@*" M+I 2RP\-^>'BM+818-F@*AO,+_<0&4FO'2B6&5SP"V:R> -V(" M!\;]ATQAU;IPTF8;@'P!6Q>*#HZ'(%/=:VC.)X2NKC59\-JLA*L[4N1XKGL. M%[-9=X2*V8P^I,QF74")V8S9C-GL_-!C-MOS5-+0Z \F3&D=@(HIC2F-*>W\ MT&-*8P?M/ 6OS<-1V])M7I3=!%+8O?-+MWV.4B> N47N'QP8C)D,F0R9#)D,GPA MJ(>6;9@VDV$7L&(R9#)D,F0R9#)\(:A']L 8LV>XO[9=4;9KD6LWS?A=ZL#B ME9_R_+NMV_L_69+ZLX?M&]RRX>?&(GV]=I.^WJI<;\C?%2?GQ+V3B%BZN*\\ M$X\[Q M ^EFADA5+C(+<:"W(:RE)Y(Y;/5M$XMEH*:01O#%.Y@2?@E70T1+_* ^2OCI M^O?$$(Z'\.KYKI^]H1;*62[CZ(OZ:_ @OK*-X6!HP,Y7C_(3]6XW?^F-%+7A M1G>X9$*#*[T+!WYV;B6NI!]Y.._FL_L]6SQ()TYZHMK./WR7)1>WCK-\^\Y/ MW"!*8&0?9E>UV7_2D[Z*DC2YQA7Z"1?HH_. ]Y(EGV'K_!3 $OSM?_XBQ \W M?N2^A6\#0FJ;_,N)85NER8F!.W\#:A[@C M/\G9CV^N\+>6.1CTQY-_(W+P@Z7_,>V;;_ZVI_I9)TBY=-Q$@;>W9#U#C&!W MZH42:J5$L52BME853GO,T[\*+95R2?,[00(R!LTSDV^(?WPO-XA.SWC2$ M3B-@JS=^L78F["23;L1 W3]N Y%A;\J@4 .%$2&&B-VS;>Z!Q3+!B#!UT :% M$2&&"%.'0@"&"EL2(+#?M)HY&*'2VA[@UX[N,2+\CR(YFP";O'!8YU)'X'")L%!,$A1$AA@@;Q6P4MVZ _2O/4;-5 M3 @4^B6%&W77:4L+J[0.@/1)+AP_;-1HT!(>UFGLZ7?6TV?=UJ84_3/#LBH% MU5^MD?E]-&,E1P@>-MRZ#0PK-PH)FE*[_?Q%QJZ?<,J&$DJLX[H-#.NX-D&Z M@K_$CIMF3D!5?%BK$71/&[XHS>[,[+/NI/)VZ?A[=FI1'5\[]&*_X\H8)TI; M77YMO#U#PYVVH+#&.Q$@/\:^*\5'&0NE^TC('JL^ JKO["2!5=J) /E9QHLJ M>.>'U;__'S8W("%C';F_@:0J)'!-^NOZOZ/>9+@K8JV=>*\UI1!.*MY)-V^] M8.F>*P>*W6M>7[1K[RJ^W^AHELO+PSNL\^0K('SJW+%LTH=N- M^IC2<+;6P!B-;,.V1V3A;+<*@@5M_\)^1H)EA'2<\94XB"E&44S/[I/%Z4P% MA[Y*8W*A@@3+"%EDF&6ZA!;+$HSZ1I80A9XCI=L[0-"4S4@G!*.Y^_; MKJ"!-,&/6A;HCT!.JFGR?^52[0 M1DG^3Y:D_NQANRP_L0+FZZ_ ^RQ.YS(6?HB?=E(_"H5S$V6ID']F?OIPX09. MDO@S7^)-5HL%_#E)(__$$XT$=%3<53A)$)Q"P*@N@^>7NLM30W+&7] M1JG5Q=VX[]50ZCM:[?5<>_SXQGPC7!G@/5XN3+/\.=<\ZN=,7C>XP RP1Y1)@[**+"8.2A<6VU.EM;;'ST[P-N)_J3&0/OWX M:GJ+#"C/*_-CB6*)(B)1'>*A%A'9: F\B*!LPF1,,R? 9C-A86'WDE%A.2&) M"+N7; RW;PQ?WLG8N954+2_V+MF[[!9X+%#T,&$/L]O L$IK%:7/4>H$5?7; M]=R)94)5DEC!D82%%1PK.+(H7<%?8L=-,U!S1.6'U5K'':%=.HR>G> 5MV=5 MQL7'V'?;=IY8XMHW).I6PS/ZKYVV^'32NF!%N+W[$ G!XW01 ;UW=E+ ^NQ4 MD/S5G]6,NF_\L/KA03IQ0J,U>4>Z&9+4AB1O'MZE%]Y9ME%HN^_/4]5"1T+M MU%LI6#W[T*LW^%ZI%\*$3(<2*I5&C 3ST^E!QT2U%U%9QLBTC&GK35:9KCHG M:4Q75)!@NNHL=$Q7^[6H&U,%DGGJN#&HDZK4H 38H2$F6@?23E_3V195H,Y5 M#!,L(56289^H\,S8F M!Y_-92$Z6R%BHJ&"!,L(5628:!JA&V[*1@P2KKKI&&!<==,%E,;/"-VPZ%"U M%C@9>C9(L(Q0189YILXSEC&=#JE"Q4)$%1DF&BI(L(Q018:)IGZ,H,?N##%( MN.JF8X!QU4T74+*L,9?=D$.%?J:'36HJ2+",4$6&B:9N4D^,\9C;$!!#A;X0 M,=%008)EA"HR3#1UCZ8WHHH32Q"7W70","Z[Z0)*UL#DNAMRJ-!/];!)304) MEA&JR##1U(EF:O3[W.V&&"KTA8B)A@H2+"-4D6&BJ<%E]@94<6()HEEW4Z(C M;J+8DW&Q\$D4^)[0'Q)JMDLGAA4^3Q3;+L9IZ+KC(G7J.G%@#WJ3MBMT6,HZ ME2FJF]^[(L;PD$@0;8.K6$86+I+H[4!O^R%XZM0VG+1]^Q7S6J=$CWFM _"P M-'4*+G;*#G'*6B\R8ED[A& M/6B[K(KYL5,B2IH?&1Z6I@["Q?Y_,AJ702#NG1@^GB8BRM(D=4+)%&M?6SB[@=A? MK9%9_Q=BAQ\N]Y "\H?O;OS(?7NEQG6-P_I7/JH/U:#>^8D;1$D6R\^PK#\% M\*F__<]?A/@A2RYN'6?Y]F$[_WXYOV_0=P&EOD&IA\B M,)_D[,1(&W]S9^ MCG]B]N!IJ?@U2A*QA,VB,10* '$L41U1$]6?'!0QV)?"\X,L!9D*81&"8A$* M 5.+X"?"DZF,%WX(G[MY@*_<^4K*RN\XRV7@NRC%(HT:WYX#GC).\&LIB+>> MA?0NG#L9.[>R\=FF"'M9C/^#WX(A^9'7$S])U\D2B;_3XW)J0TA!<=QDZ;9! MP,JHYZ7S6$HU>Y W*>!SZ3P1$K#Q'JN-B?H@2I2AOEP?XZ?KWQ.CU$"&^F1# M.47+U(_"1,QAON)&RA TGAMD^*)9'"W4 UTG<+/ P0^BNBL 60_&3;4$?BSD M;";=5-Q'60#(X)12_T(]P+^3O9/>OK!"L"BUC7>;^9X3NE*C9-FF 9I1+&-Y M,MG+A2[#M42)R5$FPR>\^0+U:#Q MN8FS..)>L\B9-6B6S*(@B.X1]F64PJA$P@>1"%I(I$N:*O4ET](>K18@H;2 M*J$FZIN0J:N:0G>M =?!+2T?-JB!MT>EZ5V-@;IIK76R=F-^?(,&C P"=%1@ M7N7/N0ND?LZ=*Q?G%Y>N5.X'@?L1.,M$OBW^\;W0OM+8K)_!(]-;8S3L3>R7 M.AW8"6<9EAK0AM4?O6GUE&:_9XW6 E'347K/'2,*_\BJW>0W3U[8Q'T?Q94# M XJB_L,:.ZCZLS*(J*9J7O.<&ADHNU'FDVL\3908XJ!A,"RTB38_Z6=^"*ETIR/L9S).*YG/EV(\\GMU%O,F0DF*;. M&#JFJ7WQ_.O$MFRZ@#)?D8S]LY^65]"N<](.-/Y.JIB $E3/=J]>'AG-6TQ+ M.-N!,;$&QM0^U(EB.:(A1VV<;&:'Q(I 2),U5M(H3'PH[@ M]G ,@2H5O5:XCJD(9]L?[78M!$L050GBK!$5)%A&&!EF&6:93D#"N1[J"%U% MX9V,4Q\/>"_+^KR\]\7K%.=QG($J?W' [C7ALHWAR#3&G!RB!@PGASJ*!,L( M(\-?!->IS)3CYH?O#31G8<+QMS&Z#&W'3-L.)Z.C=%PMWM>F=WH"R#5 MSF=G?&_3YRAU@F9;YF9;]UH>C&J0F*\^/.DCN2'=U%P MIR_:"N0M?'$91ZZ4J!82H:Y9BJ632KSM[M'?]2V5Q1/]!-Z="E +Z0->H86_ M6_M(YQZ]?!@9?F+;\_7E9/IJS*5T4WTUE[I4RH$)I!)6(1".=R=QJOG];U$H M? !^YH<. *Y6(O1\S"8;(I9)%J3JNJEH*>/B\JE8!/Z?F0^?>N@=:WO0N[H+ M]L=[>1-G3OR ][F-FOLA@9G!^CJP(!>@YM*7^65AN91J60LI MP[WCP/_?WL: 8 K@+*(L3-7M;Y9ACFQC:)KY%7'B3H8>;JM(++/8G3L G"OC MU(%GP%Z$IT4P/&"4!>S7I?.@;LN"ORW\T%]D"_$G#!]P#Q[RER@LO\I? 7LI MRF[GXC<'9VB;/7&Y[NI3F(VX<0*OM M4 PPPKE4HI.K*;RE%SM$W>;OQ\MY5_:E/53;$E_S55_]6^DSU(LPHN#!R"6L M^:UQ[5L3.]_8^?+4+A7=\^K/^GM[-6.H_!?(W3OIYM^W:M]?*XW-(8^FU9#' MUKJ) CI)YLYW7'P_=#-U$N,F2W.&\CU]Y65]ISBN&^/]E_K:R,!W;OQ WV*X M91L5:B292YF*;Q+8M?^,0 ,.O^V)]UF:Q;+44VJ/*J";T^V;(V-@CYZQF_0> M@I^J;:5FYV4R5UA/[K>U5T3#CIK[L,SW?A"@K9#+EX=W+):+6LUY_&V-/"O; M=C^CM6GP?I)X!:?W$4V*SZA''%H;OR[TBWYP.IV/BA-Z:/+$$9HH6D%HJYU M]0YG<'7Q[XHA5N,!>Z3^C;18OOXX]&7HH6N U./]Q0VZ3OF\HOR&7P_FBI?= M L!)FI2&X,;UJU\"7"G#/12:UH0W?N2^_:>#3/)A]J$T23Y&@>\^K%5^_>Z?_@3^@> M6=/I6"V1]IJ5YP=;'SR\>!GI388^VCO8K_?Z0F[QCRQ0CF/_D=N/%W\[Z).! M!7V+@AA(O#P;-&>(0;M;O!S:N0U!<'PW49:T]OS!ZO D"&&T+&WL!=X?#J/] MK\1;G:-E[,L4'5;7C_4%X"CQV0*D$N])5DKLZO-5?MG\H\^\^^>E^HB;JG^! MX>0\@.RF8-G]5]E 0GEV3@S&81!%'E[?O41WMPP)"!# 9?+0F'*# 909E"O= M)1B#RHG6[]'KEFJ%A YO'-WY'OX.X2S7&*W1N72"=.[B-_)/Q6@Q@ESC_=HS M6%E06/[,=]62@OF$MY$':>FAJ+7$D [XQP%^'F:6W212.>'*CX]1?_FE3H-% MO94JH +6KK-\0 LP!\E'SSN.0)$!I2!]Q>H;H%Y]<,YQV7S\I=)_ZT8(W_-Q M6<%J70#;.:&?+)*>N(X6,E52 #NZC"*H: ]H.N[\,=474FO M(5!\J>,WRB!7^.8?4+/WT2A-LAD,P<\!^0X^ HX>AA!JRX]*N]JBL$SIP[() M2@@4 Q#"ML.)N\#E:C@>3!!7)-F\&S3R!C(_/@[=B5!O+4/'K=2MY<6MZ?51 MP72T\2 7*("AC+*D,:A(>R&PH#&0AHQ]+4T8P"B@;0S%\Q.)X8E[\%FUS,6% MPU!?5ZTH$1% W%F"P2^ @4')W?;$I5?@A#RII%/[#@# !S>-D%Y!(8R-C?81 M#&RN-0"&!4/8U7-_J7>7LS#$#4S4TP[%SS!M\%K$YZO-090))A]R"QL^E&3+ M-9\9?OT] "8OYEJY6C8H9G4L'R#,]3NH;ZTQ?U-D ,\I(RM%F,4H@-%671:" M-@!?3OF$>EL44_,3Y=RI"<+60RNA\!A1^.-E+-,B=XP?E M;JU6#O$&\T)_;AXE2Q^C'@ H>PVPP\66 RCE)8Q^\XRA.MAF[=7VLU27>.B]=KT2SSC\R ML,K0]"H<2=A'T;U6/WIU8&)Y+BF*T\?KH[6Q5EBP5L Q\) ,H]JA"@/$XM/O M'W(#+I:WVCF.D?;4"^ZC./!..*!;9V$=K<(]4NFK&M*%AKSZ]9?+"XRW@J9& MY[UFQA;?^K7ZUB\+% +MWES"?WOJ7P"3-9U,OM6YE=-(GNL'Y:UU=<4CQP0;32XRZ MJ_1(BJF8 N.J>:0069:RM'S> O^NM!BJ^-K'< M[$/[0ZZX4[B&(,S*D%-<6_>C=G.'FD&DGQR8Z(?9I>MB( Z61']ZBPLU>$T7 M:J->:QC90'KF'RY]>!CX&/YBM5 ,<'^#3"5Y;H8KB@3%@T.K^E0)8M_O[S\ MJ+5G;A'>*,"4AJ^+H8K:NBKI.+K M,,,@\[16[+;"Y%):/5Q955/V-SXD(< M1D9NU&TB4M7-"JA>.;$JJ'I'.?8QC(_=AZ8#NOY4L >]M!G ]$USOW 6>4J*\ M5P--7*%:?Z$5K+:\/M.@P@,R+G[*-ZJ6]T3N)VP-,=62IWS+&RG1XDGCR,F# MF[B]4R>OFZC+WM/K8(#MA5JIM!F<#,RW?2'O9OTQ-9ZO3T.AP!I];]>Y^ M.E*MI5RK[P-NZG2@?"?AK.6#Z/,5SFZ$L4I0ENY4?KTI$]8 M>C_/]]AEN0;/"0G8Y3U:H)9Y\7]K.VT;XRD6ZUWWQ+5TLUCKW#PM,<>LHZ[1 M4O$E16K7/U\9&+Y)XTP'Q-6V^[]EL<@-YLF7K<(3 MU]< QY,S%BIT=!=0>K5K6MG,E:W^H+@714D53E5+!$Y"!M_,PVWK7JWYM9DM M=JH<>97K*9/E<]C$:IE!BZIT1TE1Q?C73S'-XZJH"C'A[44R:;(RC#27U_HT M<35F491J??)HT@B'H\)(@80G/SG5K8,L5,H#>/1YOF;S2AB:*)ZQK]0WHRP6 MEV&8P4CT9JKOI?\/?_@-PPNUK-M49\&KA0,5OUA@\ /]*W@<)MP4ZZ#363/Q MT+$H!I;,HRQ /P]=4;598*_])PNU3YO/J2Y@/9'7\45+\-^TY5)E&37!U$K? M*NNJ"EJJJ**RW<%Y]5%\M#VUKO9-Y;1PJ7.8ORJ'@\W#G%C,#30F?\91)=R>+3;SY>?A7 M=&UCO=-Z&YV8CJGRJSRX ;X$QB'5:A6ZI6D*U/QO;;;J2((VLHK,1?Z 91EZ M^=>33RKQB_'1+:[[\,5*/ZCYZ?E:B=IB*8U3+)>HUNNDG??2Z 37+;HW1P;U0=F"Z*S[,WL%'^X82J#MA:X\LI MSQMVU'^5': WV1H3[_+Z2HQ,< :+C:C6%>N[,&*;Z ]=P;:* (]$5[D47]%V M>FYD%&7>H5+6:>W]Y>M5#LO/YU:=^F:,.CY:%V:'I!F.OC\;3S)8[ M7K3,TZYZOR6Z!'U6+([ DH7;/$GI:=VM?+JB9 4]ZJ (:RPDO-73O]*C*H:'_2A+E"^)9E/E3N53PEKQ6.#7_;2 M%$W%;*%"N'=E87YE*HALB,"^_N9.9?ZN^!>;RT9 &QD,=4A1/ M54$A3Y?PR%HD"E=* R ==[[.%A:8JE3E[GKT93%&HNHQ5&Q*EZ@'#V6Q$VC4 MLFQ!Q0-P(V+M01GJJENF>H?F!/UZ5>1*J6.BTG>?21)[-V'7>_]D2>\]FLKI M6J93\A[(E8,^\1\8(_5 +MTTT.Y!R62&?E2N+XLBQIQU>IBST_23.\JJZE#7 M'.KG":$LJ#ZW4#//H'H,LQH82A8J\=*CWMLR,Y0]4OA.P(8H+DH JS8;I MJ^@.S T54K[EM39/ROB=SBO=%]Y7_GI5^H"J)Y4^ MU5.L+;R:0<$S*P2I%U4ERXLRM#*5KW3>+,)\>/+V6#MU3=DPI2.NE6Y==<0\ M_T[D!UOQ_&=U?%0=F\P/HO[XQGRC*MIUKM\-QL#Y<_0GQSWS,'75U.:\QW,W2H;V)%1G1OWP-2=E\C&R5 M;[8,M"9T$]L>/3Y&]N@5&U3#.A@?&Q)/GU;G74B^#<&ERM8Y@8[C%;R'9D'% MA[!*OJ-#E*H(-$])R3SJFI=Z@;V<9#<+/ZUY#%N=ZMYF8%C/L9YC/7>ZN["% M'H3- PSYZ9VJ#H YE4:K2AX*[R.O2<\C M..J>, P2ZLQ)?0SE*:1FQ40]S!5CXDREZ)Q$EL5 V]VL&QG*F9\VBNKV[UMR M="]EUXW,S@(["P35%Y,HDVC[N_#U2?2C3C:)5,8+G63#0IB\M&'CN23YQ=>% M[(]IR;QVYL]C'^AEA\L*FQ5VB_ON]57TAW"'U*_;]#(\&?AWJG1[K?Y6)WZ* MW&2>9%46M*I]JWR?LAD&JO"\^5>A#[&XL99%P:/*ZL#P:BH8M:[J"H>J,S\8 MF9\Y+%I/E*48F ;-TS&%GU5J:>Q+%GM*IP.9:)^K'!LF8S.5LB]U_2HSY9_9 ME$-E%XI=*-:%S,',P?3W71LW6M9KS%:;MZVK5_23LC -LRWX4-3+ND4*'I+0 MC2FQIC901P_T.3M5&8U'JM2#L3*W?&+9Z"XG;)B + KB?.7<@ MRHRE6%>,U M2HCT21D8H3I3B,47D>MF\8[>RDLP(+VB[$T=0?*3SLI4J<5N:Y6IV(6A+*PK MK!(\IU KK4'H5RI8M1VV]O'U0E95L>CG%2?W>,0>;:^\@ESW.GRR%K96+:2: MA=1'7Q9K>CHPGEN/Y;')/)J^IBMCPT)\A9-7;56D?:RMP(=J!8XU87+U:?\_ M>^_:W+B19 U_GPC_APK-^ E[ V(#('CK6X2DMF:]:[O[;D.T"+_A2IM?+\=E/\<^K0S1IMSS)N60DZ<;<-)IEDLJ*3;/ILMDJ_VSY M*S=@N4E2W]T-@\1Y"[+$P\>)K'_ARZKAV>2;N"#Y%@JGQ;_&ZS+U_*(T>)92 MG278%<6 W>FB6Y[ *TMM:/,-<0L)NZ+9:=:ETF .T K?M6V9Y^6CN;JYN5(Y M0_8I$KVXM@Y.U$/NTT=79>^_S)WH*G]1E*&PNF4QK/=A04+C%GS=H= M#_;,XV4;MXM)]&D6?_$#13DR/K+]8:[/7N3FA:L6ZJ]-JQ!/-R\L/LFL%G^Q MWOUTDF>63"RWGTPW3PZ][S*M/6^/5AK33C\1SR/@'ZTNK78OZVPN'2[G&W&* M&H!AE*?X9L^??\>>[HB*9CNBM&F"TK]YKCZRN,XX&UP5&VP6-D=FA:OR[77Y M $B:OC!\%&6;,I+Y_HCRR'N^UT66*.'Z?7SFWN)Z.L3G[N^")O6NFB.,%!;B80_CG) M"SH6=4FR$D73P1K[;.=5Q8I5FFSSR9,[R>K3LOR!C!T$6K+,4QB5>EF^/I+/ MX8V$X,NR0++LHNU\S=VUW%^<;;.8;ZZ:KL\LKO'(0?%TFT->L:]H9V'*["R# M^4?3FV0)Y,6,GQ.>3[=.:>4M5OFN*OF F0B(WBSUZF$Z,,C6LGAQCD#,Y?9S MF>]=[/PJRI!X8W''0/38N+4H"B],RY9S5*:XYV9;4)2YPYD!O,C7\H:B6.XX M^Q)Q3!CHKY7EGE4?BS?\FM9//* MQ;.N5ZZ_IRT."9*B-$X:3#,ABP<0I)_MW,NJKTUK\,_J)A815M:"\W*%S,)_ MV%\E^XLJ*4)'Q$U:>?&T0EJ*K=#RZ:0M\R-4@J5N,,IU0SKE^0"JK3,W*] U M9V)>)UEV\PG/O4NX&(MQ-]]CL<":? OW+*K+C2PZD?QZ]HS3+E-HQKS'RF'A MM :^%,%L$D&,"Z>%GO.]\?GNK*SUI8=;%IH.GS>N(-QT]UEY[N+?J7N? 7WW M6-I'OWHO^"$&8BM/JJIV7D)0?^PE3X\5\53Y#5J)CN>)%EO>7%&>\1--G MR6=&9,&I)Q-U6?/F=YKMM,UJ4PY%2)K-VRT(LN!Y=KA2R>]_6*+^PIN)WB1C MEAEGLM(1LUO)!\JS'LJN=IA])^9)XO-"N<00I"C\,)7# KWIG==8-DNCB/@S MX(OR .)=/I*)\\H TYVK\BMCV^6+VUR+8L%Q%G ON(*E_4BX(L])YBQBV6; MC:>P^(\EES^M@[)\R*O-[C_5B^E&T6)4G^U0E2:.LMJ\2]!9SK4G6.0UEXNR MBN4;9JFC&<5*]KG)=5#&S=X6IBKQT4N6A2O3\7]I\^!<>%88<&ZAA?)WJVPE M\WVV--7BU^8&T4ISFO+QLG[LAM^";]D^VOGFY-D$P;S:] KW(H.\^3;GZ:;D MN6.;^[N2L\LEKD3/IT\0SPI8E7_TV=D*VN'GQ5E9G',W"P>G7IJ4GV&51B^OXCUKI%+@85N;+5D]&/OF"UVRZ(IL&L^-1Z;2 M>%:UK:B;\&1Z=J,C'.?%'A?J*I9GV?XY'6/.FI-G+I3CM#S^>&E539:3V&(] M:WI427%8ACU[RM)#ECG1 '9\FBW-_3)=FJOO&GC9U\[BB3S&6!&VS H63JM@ M#Y]$'?.3&^6$M/CYK!ID5O%SOD\[D"5[\UK^RY::LO'4;'+1>73\J=L7]\O+ M<*%!QYT@HP-.<:;E=-'+F94/C8NB8[/#0[ECI_/J3E%25&^;Q>3Q,QN6 M]\+/')H<9PJ/D/]F;V?)BCE1^[-#@.?8;*8UCVM M#[18MV ZQ5>4M,QOE>^Y\<9Y3='I$2+R<)SL"/+Y,L2\ E_6-=)@6@DS&T[% MO'2_I:>CYJN%B] 7$Q_YA)LK#[:6LZ=YI;0E/:"V@O#!BZ='AAX9ZMN<9A& M3G&K; 4H7SDO5:\ZF&-:OZM!WV17P^X;&8JL9"?LPZFMWJ=TH>WTE*+'UW.S9DWRVJW.E:Y M99L?.TP]F7K#+'-A:H&VL'[W[&F._"F!,+NMY3B4N)%WN8.EN9>K$:]:A^QO MXM\.,#?YTB' VVQM."5LQH]OQ,@MX>?28T@;?(OLR3'I1 &T+?=O5.#6C%;W M6$YMY8J]\<3J\KBWN\B#:VNX:WMA7 7/1@BS38CU\M;.XSF\A4%;,6B=6CX. M93I]?F%Q5*HM3VV 'YSY0;-2/V@8K<%ZU!:2.IOD*V5L6;$CA-?;=#QW= SD MX&T/YU9OJL#GU01(.8U&@V_P>=5C4$' >OJI:_BNFK"'TGAMTY$"?%S56*WP M38"D-%Z#SSON#-YS"*^NK_7K*U578BG5 OZCG)10[.)\LCWS/W;D MV=%!*E%/&G^I8SP9YRB!^@^RB.EE0=L3M)+ 1;)!=2O3W38[FC[HD<7RA!,5 ME >QQ_?&1..GT!("!0$*@F"I35ZVJ&;I#%$@)%%1D(%!$@(% 0J/H*E*') MS1']#F(H8L HX!DA442 @$1!HNHL49;5TRP3410Q8(ZU=*7V)D)*"#U?NEI: M711;.FC!1B8/Y@4!@SYEBU"]ME9]>AE(I!Z)$$ 1 0(4H8H,=&:&UJ#3U0Q+ M)PL52$05&>@,$2! $:K(0&=*\VVF;FC];M7)XZ"1>C2"TA ! A2AB@R49KY# M2=/[.N;.Z "G4$?JP[G@1+)32 DN!%!*HT@RM;ENS>EVR2(%#5)%!\$,$ M"%"$*C*0F5+:@#;H(Z>-&"H*< @R0P0(4(0J,I"9^6I.9Z!U=80SQ&!1@$30 M&2) @")4D8'.S'7&[&C&SCD#()%B*SG-.""B,MC^VTOR(QHO_3"4)P;.3C:] M3>]$6WZZO+K]F?"JZ28%.<%'FNCIFU94A?#-$)4'6)I50TJWVBHYO"@P\#"' MAP =J!O0@[H="='.0-,KWW,$85.*?! VRNA V.J)'H1MN]VTF@5=4P(I,MR# MKE%&![I63_2@:]OIFJF9QJ[I'A V:N2K]7ZPQN@[71DNCZL5C#P=LW26SUS6TSJ#J5/Q5FKG2TS:2E622PE8' M@PV61C+H0!(AB9#$/;(YM8XYT,RN2NYXA.EFW@F[VY[,_V,.=SW)8,$%V?O"VYF[PO6.^*'>33C>$%0P0O?GL3\]?3%&S;UT7JY M\L#R9>_\:>MS;)P2PS%A:@&WL'[WK,J<(+/;6HY#26SS/G<(M2V;^R[TW94. MO;^)T]D#I.LP8LF(B_\BSME87#>*&15('/JPF0PN=5?2H=?!XIGX?Q&GR7&NRA M-%XCMRV/#$J*^+AZ4P4^KR9 4AJOP>>=>B(/IST>:A#X!T^$MQN/>>1XMC_; M=RQ>..%]('[99>DD#)C+?>^!1X]DLZ\V2+U"OAPIQ#;+ET,NG'S:[J"O&4:' M+):H@4\5&9RU0@0("!0$JKX"96A6V]1,J^I:%Y H]3PC)(H($) H2%1])4K( MDVEH/1,G5A(#1@'/"(DB @0D"A)57XEJ:QVS)R(I''9)#!CJ&>E8R/K '[@? M3K)-KS&/'CPG6\4ZSG)6K;9]4$*13)+,"WH&N%?6T07_7A25PJ+D<@LP0 0(4H8H,9&:>PM 9:%T=X0PQ6!0@ M$72&"!"@"%5DH#-SG3$[FM&M>O<22*387B7:18S#9B M$5[TQI&\I]Y[?**L$QS)>S"D>UU#ZPRJ3L57ZD!>TII9\3DR#99&,NA $B&) MD,0]LCFUCCG0S*Y)P\M"%-5PNQ!%RNA %"&*$,7=D3:U]D#7>CV(H@IHD7&[ M$$7*Z$ 4(8H0Q3W*F&@]R]+ZID7#RZHABI0/1RVO.+Y*;&&\V56N]_#T]/S[ML2N;O=\/&^:+OWQB:*["0!YH&-EREU_,PB%S(NYZ M"8N\^"O[YB4C%O%XPAW1B\-Y"4C1E]DD\L2CB78RWQN+3NW**^YY>"_Z],@3 M%XFWHK<[(Y:,.+L*QQ,[>!3?"A\\5]Z"Q<)NWM!S1*/80^BG8RY_7VY!G-:< MU++-B.(^L@7R4G$K+W+/!9<2<2O[D4=9FTL_,-L7U7LSOP^+4]$,.V:_BV=S M1.,UY@5Q*HSD<'EBF_BB-_VU4-PL6O([+7:[XE<)8J%L?)OQ>*3!_&!>#CQF>U$81PSB528BAN+/A6.96L> M)UPTH+[=<,&TDS 65EV"=#*RY>KW1/1(:?!Q*'JA^"Q@AOYCU@V>+9$+F%G6 MZ[BPJ,N*;W)7DYWA&_=]^:\ W(O$5WQ;=N+2UYD]#E/Q0[;LK>(6DBGV/5_^ M4QISTTBH0]89DU'$>=:= B_@HJ5!,HH9%]9VV0V?)'Q\)V!MZQJ3YPUG%\I# M.$63Q".)GQN&OA]^BU^O0ORH[JWL8S-/7&C;NS/]C#G":%*]Q)/.WA>ZF+TO M%#<_)76FKX4X"DWR[4G,7T]?O&&Y@/;U=-C6[K1Z1RM'HD0D MY$P/[^U6>GAO6V\9_08>L7P=1B5_LMJ-D(U[3EC_@@QH6TXR5.#7C%;?/&&5 MI=R1/0T\KL3SWT4>G%O3G=L+0R3X-D*8'29Y^'@N;V'<1FZ[#'E':%;J"(UV MJ_L";%-S-LY9RCB1REPGW%[5&&3CMSW<6[VY J]7%R3EI!@-QL'K58_!JJBU MWAR -ZL+DI3&<.2VR))!"5Y/(13@]<@C26D,!Z]WW(F]"BIU''6-EE+*VS1W M)\-4]);7RNFXD5JHH(?(C64!. MN_X.%P=UJB%T4*=M-DSLNGT0Z@1UJB< "K@XJ).RT$&=ME&G76<(H4Y0IWH" MH("+@SHI"QW4"3-["B.R1IVJ+%V-1:I+/^7L*MO%G+V\&7G<=[&%@Q9*9%)< M7A(HZ(]\VJK3)\"? P5'==O8"0<&:JB'#*2EE)S7(0M30PD$;8$' S5410;: M,H?+J+HX(P@$;:$%@ (>K*'44 9:$MY4Q%9F!I*H ,OR6#?T*& ^3/(BO/^ M)[?]9"3W#&$QDQ9 RJ0+0'KDTU9]RC7X@U0U6@ HX, :2@T%D(&TS.':M3H, M^ -IJ2< "CBPAE)# 60@+:7%F%T7^D$@:$L] 5# @S64&@H@ VW9/S\9_*EV M+69^SN+*_HKSY+)#WFS'D2?!Q>)JAWL/TFS%V83/SHY;L_4KR'\ %*2':1"JVF@LG M,J-@:PG(9PZGXE0+5&]5)WNI(%>KA_-)X"EK#^3S01@)^L%5[DD^DC4$BB%F M_:-7Y6H(H H.Z3'):N@&965#$9SU&=>[%A!%QC6Q!:3CCQBSX7_] 5# PT&< ME(4.XH0R!NHBHMIVH,9$5^H>(]1('BF0"I$)%70HR[+KD46IH?PAFV6'((D* M$DVEA@+(0%H@+6014:T(=6-"G$-5/,#D %7E.='L&Y0G4QY,KA%#!"L_<&"@ MAJK(0%KFTM(FBU)#^;/UUJ'L7;'KH_SZ[:L[+W1>?^8//$CY9^Z$]V)8[H7! M1>!>%%M=/L]VNGP*?<]YO!5-O?1#Y^O['_[&V-LT/K^W[GU(5_#=@UOXM2.WJ4.;E=3>[28M<7-Y?,B^-41(9VFHS"R$OLQ'O@[#[U M7+D]2V."\6N)$]-[!H#?.Y'?-88U[@ M^*GT)=E%$?\K]:+,\/DV,]OWBTO9-R\9,3>-;,F&F-U'W$YXE.\\2[YQ7S1I M+!YN%+,[>:.,./\G6AT&V:VGF\GB$>=)B\FM;M,G$,_'^' H6BN?2[;.#H)4 M/D+@B@:*7_'&RI;--H08 MG7Q#2(O],ON5_[*#S-+Y7I%!;NQB[QVSW7 B0_&DW$C9&.Z+KQ=_$)<(0XA? MSQ#.? 0;IX;0EPA.W4& MA)<;,']L>8?9MV637,\5W4AN"(Q%QQ"7B:NBJ8UR.\\>RX_#A4>81*)-GK0@ M_S[AKB=_333SJ]SD9\?R)F,OD1>G@C'Y=FJ9%KO(>ME:D\H.$;FR$[-L M2' >#L_36/Y,+#<1B@?Q/?O.\[WDD:43^6S3ARQ,-L/AIQO.V1^A>-3>SZT= MO(,JFT&%/[A([T7;I35[FWJ#G+8"3F'2.+-KQ(=>(!H[XN[],S<@C#$2OQJ( M2\2WO8)S\W>1%W\52C06B&3.6/XULVKA+F;RF/VEV))JEW'+^_/,#9^A;)RZP- M8,&[F2,HMGOJ$TGU+[10W?,*DG.<\D;\1 M9'>SDT4WDAFW_!-N*!"7;F%D"ZO8;"Q]M;3CU ^)5@M0EMF7B=:YHF5^&*<" M3]$RQY9,+;-Y=GLGC>2&#&&0D1@W,/FW^3WG&,?3?B=:G_EWN:-XVA6D#WH0 MO&_5FLME;>]OS&9;[HG.C"3)Y@MOZ0VGW6X8A6-IUUP[I-**FT896R,^XL)- MBSL)?0_'7"I2Q!,[ZSZBN\F.%F=(Q/(9I%].[.\SK@K84S_W$=EO9'\4SMG7 M6!:H_KUOFOJ;_VQ];HD>>B'\E.A1XA?$P.W!<_/^+4?.HA<(IYZU]5,:Q:D= M9)?=>HDO#/[KKUF__I^I9[@2U^>]27PY#OTT[]FY([A,A6_(U?0Z9\W_2M9D MMIPUR7C#"F;=BO9>I86_^J_P+I9-U!@/[$S[Q$UG?L T,Y+U,N)*01+]UFUAJY6^WV'^&W^3 3"OS:?'GPL!_+/;D2S,5#G81\\)64U1+ M+2G^LN+)Y9\R$?0@P#,]]0 M#""EWPZFSR2Z[X(WL MNS!-EF)!1!>F+OGHHI"/^J?#OY/Y^;% )$-%_GTI)^3?-O)**QW^5J4>.JV! M02N2RQV2T=6?5IG8,';=)G0U._+_J@]=_RL-^';2%HLNZHLGG\:>3T:F\B?% M!>$CEZXW=+Z>WXDPU,TZDNA%]FS0Z0M+<O(;I5 W M5\*EOV9_LR,91EW+F"J]$T.^[,YVX,G@.3FLPYG'XBO=CO#/I;OFX8_$9=JQ M%FGPM*A,'<:CN=.0SSR;NMM^,!,0@4@Y@@E$-QWYM.HHG_%T\D[#,=T!J]-_'\!JX< M%PIB;8U!:P,G45I_FKTJ.XZY_LOGEU,+&;"AW)>_8.EL[F8^A)3VSAJ>N8RI M$Q#=VW.\23ZR?M%W?!.!Q_'\QMM7N\[7+\[V?_!B^_X^XO>9Y'P<%C#=RF6" MI5/\O7VF^-4/B67ORB:6BMG$6118E#\K44"6&8MR<\;EF64WC:9^+1E%/.]D M@L>SB6B>C4V?E;O(2Y'EQ';GL(E+[\20-DRC8K97A'ZBYXA 8+% V<'F')=H MSA-,R!4M&U1:M&SELJ?5;G6L8V5P$ @FMJBZTZVVZDZWM1R'>E?4N2Y&T+D; M6NU]D#9 "+0M5NS'AB]2OQ^'>1!]?6<-?VPK@*GHT09HET[567B]JC&0@S<4DX7/JS>0E,K' MPN=5C4$% >OIIZ[ANVK"'DKC-92^5MS'U9LJ\'DU 9+2> T^[[@S>!54U3GJ M2BRE),\_RDD)LXSG*$\PST]J^X\=>7:*TD>HK[P,U'^014Q'6>6-46R;'4T? MH/ 8,5@4*-QWTND+ &!@D U4:"L7ET?K?JY''02#T:06F( &*4$4&2C/?H:3I M?1US9_2 P:8DZ@A]X _<#R?9L3HQCQX\)ZN8FB_U8*&4%E@*I)! E69H==N: MU>N210HE'X9N=G GS\_RO$WO1%M^NKRZ_9GPJNDF!3G!1YKHZ9M65(7PS1"5!UB: M54-*M]HJ.;PH,/ PAX< ':@;T(.Z'0G1SD#3*]]S!&%3BGP0-LKH0-CJB1Z$ M;;O=M)H%75,"*3+<@ZY11@>Z5D_TH&O;Z9JIF<:NZ1X0-FKDJW*7U;JU.3=, M[WS.S%;S%.\V3&R?!:72>H07O5^L,;H.UT9+H^K%8P\';-TEL]5Z#SM8:,$@/S[MDBO;==!?.;&=_^/7P/%3 M5_S,[]SU'-'ALLU\LS<7[H/XCGW/-6;+LHW>^"Z-8IY5<[3'81K(W7_BNJ'W MG;NMDG6.;:?U:)3QSWI&P;5W9_H9<[CO2S8)7L[>%SS-WA<>P!$_S*,9WPNR M"H[X]B3FKZA[ZYT[OU-G,X>(%V'$4M&7/P7<<[&XKI1S+AHJL;:ND4WK.N%^?#*@;1GT5.#63EOT)7=C3\=!5^+Q[R(/KJWAKBWP G@V M13!#F9&ZAH-E=VA6Z@X-8]-,\,:Y3+/Z,S3@_*K?1'&8#4KUI@I\7DV %#ZO MZA/JX/-(^3R,U^"[U& /I?$:N2UZ9%!2Q,?5FRKP>34!DM)X#3[OU!-Y./GQ M4(/ /W@BO-UXS"/'L_W9'F3QP@GO _'++DLG8<9(5%$@(!$0:+J*U%"GDQ#ZYDXO9(8, IX1D@4$2 @49"H^DI46^N8/1%) MX>!+8L!0STC'0M8'_L#]<))M>HUY]. YV2K6<9:S:K7M@Q**9))D7M SR%6V M*M76K%[5U>'!(?4XA'"*"!"@"%5D(#/SJ*BG#?J[+BR!0\WE$&2&"!"@"%5D M(#/S%(;.0.OJ"&>(P:( B: S1( 1:@B YV9ZXS9T8QNU;N70"+%]BK1+CI4 M&6S_[] URNA U^J)'G1M.UTS-=.H>C,PA*T.VZ_6 MKVS"Q?1;P9+81B_"B-X[G/?7>XQ-EG>!XWH,AW>L:6F=0=2J^4H?S MDM;,BL^1:; TDD$'D@A)A"3NDZUNM!%%5 BXS;A2A21@>B"%&$*.Y1QD3K69;6-RT:7E8-4:1\.&IY MQ?%58@OCS:YRO0?Y^NVK-#Z_M^W)ZP]>;-_?1_S>EGO3/@X_YPMBM_);MZ)E MEW[H?'W_P]\8>SO]RHTSXF[J\_CC\"H,Y!E^T?3+7OSU\E'^[[7M)&$TNP'S MW'=GUU^$]2RC?\8<\7CB3Y_Y\-W9E?S4T"VKW>M_D:?GB3=&_F+0UL_>K^3B MO],X\8:/Z]EHF.+] IX_+F74Z0"\'7%V%8XG=O#X_^Q)&+^)63+R(O=<=.KD MD4WL1Q[)CVRY.#F)>"P+1X[#B,O/ F;H/[)PR))G*YC,"YBX)YOPR M=5GR3 MNQJS8_:-^[[\-QEQ+Q)?\6WQE_+7F3T.4_%#XAI;WD*B:M_SY3^E,3>-!'GE M[<1_$>?91L? "[AH:9",8L:%M5UVPR<)']_QB+5UC*1Q,\- M0]\/O\6OY]UY2_JN1WB0^SC9Y0O7\^Y,%[U4&$TZ%_&DL_>%V\K> M%PXQ/\1RYOX*WR5$) _[$E5M=UI]8Y6+4*) M@:HS/5NU6^G9JFV]9?0;> +N=1B5_,EJ-T)V6'K"\@1D0-LR!JS KQFMOGG" M(CBY(WLZ+KP2SW\7>7!N37=N+PR1X-L(87:8W,[CN;R%<1NYW0SD':%9J2,T MVJWN"[!-S=DX9RGC1"I347![56.0C=_V<&_UY@J\7EV0E)-B-!@'KU<]!JNB MUGIS -ZL+DA2&L.1V\%(!B5X/850@-*X1!HXBOP54)G+JC:GO#5/6.P\K);)%:J*"'R M(UE 3KO^#A<'=:HA=%"G;?+9=]W=!76".M43 5<'-1)6>B@3MNHTZXSA% G MJ%,] 5# Q4&=E(4.ZH29/8416:-.5586QB+5I9]R=A6%<2I<+*YVN/<@3:AE-=F>GR.WY%)V9_MV MX/#UA\HM_XV$?1!O\W-1C-+1<<].E&ON07+=2@^2R]O0:;>L_KA[-*X"EK#^3S01@)^L%5[DD^ MDO4$BB%F_2-9Y>H)H"(.Z3'):N@&965#09SUV=>[%A-%]C6QQ:3CCQBSX7_] M 5# PT&*=1('BF0%I$)%70HR[CKD46IH?PA MFW&'((D*$DVEA@+(0%H@+6014:T@=6-"G$-5/\#D %7E.='L&Y0G4QY,KA%# M!"L_<&"@AJK(0%KFTM(FBU)#^;/7-J*WK]+X_-ZV)Z]OG!%W4Y_''X=782!3 M/R,[\<+@X_"S%W^]?)3_>VT[21C=BN9=^J'S]?T/?V/L[?0&U[87_8_MI_PB MCGD27P3N;YY]Y_E>XO'X=V[':<3=C\%G[J11)! 4%_P1!M'T[:4=>['\?O:K MM]P9!=Y?*8]O9;-G/\D\]]W9]1=A=_TO M,K-3O#'R%X.V?O9>[C :BC;*/IKF.WG$)]_L2!@ZB<6+F/$X\<;9OJ T%DUB M-OM=_@"[LB,_9+$W3OVL==DM\E?CT.5^3CF2>0Y[#(*OP4"*O%]>97& MO, )HTDH32KO&R2>XTVR7QJFB3 ,&WJ!'NJ]NY81JO=?WG[3@6S&MW!0;9$=UO]#GG27W+1WD#VB3B1M)B( M7D=V)5",,:V&.N=_D,6DW=+[&-04@QJ]17>RUFJU-][#7C- ML+XL6;6/+B%((JQ+B)9.NGVL955=Y BZI/X>LB;ITBQ&\KTA9S]Y 7OD=A3_ M3'5X!S%"D*0&7'O,W"%(4F_F#M'2,53I(92Y-;Z7/%(=UT&0$!VI ==@@+4D MBK@J0W2(("4(:(V60D,98)SHA M+B(#%](82<*"-$:ZV""-445&8:%.*;A$3R5;J@NZA!B)(#9(8U2&1@B2E((+ M:8PD8<'BD4JJA#1&PB@A.E(*+L/LM[I5'] ,2:HNCU&^52N/\>C/A6S))@\S MD"VIAH-$MJ0**)FMP:Y'9"/@1<#;:"5"MB1Q@) MJ0)*[9;1I0H4) C9DI1! M0K9DG>B$N(@,7,B6) D+LB7I8H-L2149A?5 I> 2/7774UH0+"FC2XB1D"W9 M1!HA2%(*KDZK@R")'BQ8/%))E9 M21@E1$=*P66TA;FH(M5@1=HK6?)0:8P; MG2:-Y$7$HDA>;+SN(WE1!92,EK[KUG'$GX@_&ZU$2%XD#A"2%U5 R6B9.&6 M'BQ(7E1"@I"\6!\Z(2XB Q>2%TG"@N1%NM@@>5%%1F%Y3BFXS):%4B;T8$'R M(EULD+RH#(T0)"D%%TH]DH0%BT1%IA0_48:85J MN!*D%:J DM$R=]UCC<@0D6&CE0AIA<0!0EJA"BB)4;5!%2A($-(**8.$M,(Z MT0EQ$1FXD%9($A:D%=+%!FF%*C(*"V=*P67N?H8)@B5E= DQ$M(*FT@C!$E* MP86T0I*P8/%()55"6B%AE! =*067875:*!E/#Y>]T@JWL$Q_LG.MPK>OTOC\ MWK8GKZ]M+_H?F<%X$<<\B2\"]S?/OI,>VN/Q[]R.TXB['X//W$FC2" M+O@C M#*+IVTL[]F+Y?5MF*]YR9Q1X?Z4\OI7/=BL:=^F'SM?W/_R-L;=QE+R^<4;< M37W^<7@5RE;'W+VT?3MP^,V(\V3Q:\QSWYU=?Q&(6J;,:Q0/)_[TF0_?G5W) M3PW=LMJ]_A=3-P;BC9&_&+3UL_<'->.+W>FP_>=V(1=T$H5RL2MF#H\26\1S M=[F]6"P-QEPN/O3CUVP.[I;D4JS<95??)2GU^*,YO:5W]Q_-+?=N2@P+A*D% MVL+ZYEF50!B]5J^_%(C2>"#O=Y'7T)%UJVTUD#7P;2J@=,,G2>;< M6%N'3Z.$#/79MX7!63$XG5H^#GW/9?F%+'OBB1T)$Y]8AS:""".ZM>A-K=HX MSR@BWG[%#G'F_3:E%[QDQ5CE8[T]O&&].07O6!C(M/NMP0'6UNFO-='/(:IX MJH\T,C3S4@[CUJTT_,>5WVQEY 8\>F5UD\$_&HJ&88Z(%$]F]S48W&WTC M(24;;FM]HZ]U^FVR:#64/F3F'[9??@(2X @D!A(SEQBKH^D=2 PQ8)H^B:-& MN'.=1H&7I!'/PIUP./0S&I0))+F)HC U>GIVM&;]?T!+"HL2Q" M]$,%"7"$+#)0FJ=*8Y'%"BS"(A!9E*Z]0!;1PY8?L@AA+DXIN$RMTVMK@P[9 M\SK (ZK((/*A@@0X0A89:,T3N/[>-PV3+EY@$LF5GTKJ :H1$EV%09Q$J2,+ MN3,OD(7''1Y37@_:I.856$@3O>[&55FN@]'5NE;5!U#1K69&"2LR]#M0 MN4? VT#>M"V8T':-CM:I_+#%:%M6-ZJ2RQW&R:VSX99U4X[J]JIL?LHW#F: M.\5\R91VTNJ0.^6F)@\$7]VUKJ=U>Y9F[*QVF+EL+-&P3D8%":B5NM!!K;;) M,=2LCJ[U+&1U$ ,&ZVS*QF:_\3AFMN.DX]2W$Q&@N7P2<N:N=2TP2WE*N'XF@1(6WI3SBU UE=&# MJFVM:H8I8KP!UMY4@&N-JE$]8]D-TSN?,[/5S%AOV3I#2=!#R01<@B9/$T M]1AE)J=9^1YPR&(=EA"/G-8AV3CH%% GP$=5G4@C@WUR52O7-,": MV(]1Z/MDIZHPQ*.*#.IRE9;%.AW-,KMDL0*+B"*#0(D*$N (662@-'.XK$Y? MZV$/-358FKZDI%;0\V [U+>8@44TD8$6E?9(MSM:M[]K*B!8U%@6(>JA@@0X M0A89*$U):;I=K6_L>MHQ6*18U(.EGF-$/7=AD,8[Y]%AZH"J%&$"[J1E# UY MX->NAT^"18UE$8(>*DB (V21@=+,X>JVNYK1[9'%"BS"4@]9E*9!3VS[XI>= M<#SVXM@+ \K;B$ GFLA E$JB9&J]G34))&HLB1#]4$$"'"&+#(1F#E??T P= M*S[$4,&*CPK!SU4:R>H>;"*KJ8 R.GVM M;55= @\L4HY%"(*H( &.D$4&2O,$KK_W3<.DBQ>81'(9".=0O;@V%"8C'A&> M8<"!'*I/Y>% CHTK*.AMK:M7O9<(IW$H13\<-D4:'FA;/=&#MFTY7ZC+<^]W MK0T.;:-&/QPY11*Z_,@INPCN_+TKA^-T#WS@C[J8^_SB\"N73QMR]M'T[>Z[L^LOPG"6:9PQ1SR9^--G/GQW M=B4_-73+:O?Z7TS=&(@W1OYBT-;/WJ^DX;_3./&&CT^(V%V$5KY=0/)'4JR[ M'7$V#'T__"9HP.+"I$P:4'P>)2.6B"N<<#P1]PG$A^&09>[G/!R>IS%GOK1X M<2:R^$?^_0-W^/B.1ZQM:$S8L<_LP&4W?)(4'^O9QP-Y>?[;\>MY-\K,7720 MG/42R(*,[\YT 1[W?4DWT>+9^X+(V?O"13BBO3R:.82"S<+XOCV)^>OIBS&^3%V!D]=71EH:1VY1\V1=(H]WJD<%FAFDHA-24N]?4^E(6IX:+AD0K#U)^M9!:KUD2?I]13( 9%I88X]35**.KA MSJ;0NH:NF1:9#8**ZJGJM=>V+Z)6*K[V&Q=_YW%Q-.LL5_(B<(OUO.PFO\VK M5J\NQV967(YM&>-.A^:&!=B>'X$;3FV>55<;YE8ORK&5JH5O69/M-9MW*E1B M([83%@5%4&0)]=BHE,$@GOE*TVAP%:C'1CS1D0Q8"B]/(9E#^6$4ZBJA+EL] MAE&HRP;_0<=_D)EVQ1A+@9TDA&>C*AM.73V?#%V<]GQ$@;8:P*QJ&*)1.F7GVT\> 2A0.0($V=2A&?<,&,D-I[;4 MI^J0I(\ C3 X8))"8$&F%O;=&X.V9G8Z5-$"M9197R.2PZ1$P(5*;4UC)JE) M1Q2D.73\AI(T-"&DP$I4:E,-,0AC4P"%,&X)::_7U?3VKI6](8H*,)+H1AC4 M:4.=MN82E_JR'ZK*U'#M4/6Z,J1EMNH-6ZC31A(Q*"HI146=MAI ;6B#[D S M^U4O)L#2*MZ%X M&XJWK1P_-+0B$XJWU;3JR%Y9L32-!E>!XFW$)M\!]T_ >*MU$"A/KF$L*S494-IWY;-AV*\FWU UJY-%H@JCRBV'BI M$%BH#D 8'"A=G="$TM4-42B=,C/MIX\"E:@F@/)MZE",^CX.)(S2VH(!3M4A M=Q\!VJ;@@$E0)Z@3U*EF:!%>6B.2OJ1$I(6Z;4UC)JG91I2G.;0THD0-30@I ML!)UVU1##,+8%$ AC%MO@=?;IF9:;1).%;)()HQ$Y394;D.=F0;/J:+.3 TG M9E6O-$-:9JO>K87*;201@Z*24E14;JL!U/N&K=#3,DB3#381TJ_=VC]4_E .GQ;2*P=JET#[0 K4 %N8L508'3%((+(B42F@!+(7 @D@1!@=, M4@@LB)1*: $LA<#*EL4 #DUPP"2%P()(J806P,).M96@*7&(YL4XC!+O_^S$ M"P-9,C8K7'T>#L_3F#,[CGD2;\2^YSNRL6),K0A[%1CAG.B#'4<"0M&2LZI3 M$3$Q2!<<,&D[::HH?Q#2))_6:%N:U3/) @4R*>3Y($L[U[ "DZC)$B*FJOF$ MB$DEM(A+$U:IZ((#)B%B4@:B=E=$3+I!%BB0"7NIU%Z7^E468>5QPL*@V%+E MST^2Q'HP>?P46+R'FNT8:(%9E:-%FUF8 R0,#IBD$%C0J *KKJGI9I&0GPGS[UP4\97G<95BBI*IR.376D1"MI3SN'$=UKTJF'055BR7)K)F-/*::U0PQRJCSBD--FR&G'L+2.WH:4J@D?I+3F MB$%*E4<<4MH,*45D6@\(* M[P>N88KW"V#^N)1AIT/O=L39,/3]$O92,6"*NB/C8]@)Y MQ3 5!N5L+-Z-TW&QRW-B/X[%T\0L3),XL0-)+9:*)XS8,$>(B0]9N+@Y--:8 M';-OW/?EOTX813R>A/F7YS\8V[ZP06)_SVXA/TUX?LOP3A@^/\AOUH!D9"=, MT)/Q[Q,>Q-R5M_8")Q4W=[,[N"EGW[QDY 6,V\Z(R1_E3N(]D3Q(W"X?9AXE% +U?D6)X!<6QWW.ZU]/UR!0_@;)48 M^0K["RL(2+IG558UL/26N6$BV7JQS#OK(;2RC,E=Z+LKQ;._B?O= \E"K6B$ MG)M6GZ@3 ,3"?K-E'&QW4 WILJWC,RMU?$:_U3'A^-97!2%!NX.GR]8)JL,D MQE8P*U.,%(\#S^KYDBOQQ'>11W <2,H=KIPG:YPO_#V/!"OVA.MFL>'TZ,&R M.%0$F^ 4:P7C[Z5I/3MPJ;(0SI$D++ES;!QIX/MJ 2,&A/0P012\U:+STU7G MA: 847#S?%JV" ^/1@@1C.+4!@8.K5*4;K(LE%O[._LXRSJA2B3X-Y*PP+_! MOY%%"0,V:HA0#T$)Y>&B:FFE579>>Q%0N)5CH'_^P>X8YH(*&T8 . M&E8+&,V>IAM=LEA"PH@B PE3!BI(&"2LSA+6[IK:P!R0!1,:=M!YQ-KMZZAP M'M'=:(.)&HLB2 T5) 1\@B Z$I"4VG Z6A!PO2\J@C9.JF@4EH6I@H ML#H'[9G#U3%ZVL#LD<4*+"**#*(<*DB (V21@=+,X>H*H>E99*$"B8@B Z&A M@@0X0A89",T3N+8XP1Q,(L4D9*A5/*5F8B*:%B98SE$*+DOO:&VC3Q8KL(@H M,HATJ" !CI!%!DI36KSI:687&PJ(H4*?1! :*DB (V21@= <<4MMUNQHFHJGJ#Y9T3DJA;ELSD3Q #1;Z+$*D0P4)<(0L,E":TI1:5^L- M4-F&&"KT202AH8($.$(6&0@-LM14@89PEAKMPPDK@^UVQ"-N#Q,>$9ZCWN0( M&I".)GJ]C0\1@L1EL51?LZRJ\^ V8E[948)]UE V55/]H&_(_ZL#0K=A8OMLLM\QRSBS MB#+!2*RKX?"BS7()-;-M:#V<(DL-&/I$0Y('%22@5NI"![7:YJ@]O:M9)HZ+ M)08+?9I!JZ@@ :U2%SIHU19X&III]#6]B\B*&#!(:%02MM]X'#-['*9!PB(^ MB7@LFBE,Q[P@X>)=0G;1!4MF6#)KCN[]9)EMS>I573<3ZV6;@/4S"920!J*< M5X2FJ8P>- UI(* @]*WI\$#?ZHD>]&W+F,VTM+Y1=>U<:-N>(5N5F8WK9BW= M,+WS.3-;S9.Z3_D\I00@Y2P)YDJ?VTABDEE<7Q,0-E@ER< #680L0A:5S]"$*"KE=2&*I.&!*$(4 M(8I[Q8K&H*V9G:I30962Q1R1*2#KL*LV/?158@OCS:YRO0?Y^NVK.R]T7M\X M(^ZF/O\XO/8".W#X1>!^G/#(EIF+OW$[YK]Y]IWG>\GC[W:21N+?6WF[6]'D M2S]TOK[_X6^,O3A[9_9<>C:S_\]FL@'TG<+0P^<]].N'L;SNXO M?JOXU>R7XL4[,\]]=W;]1=A;C-?.F",,(O[TF0_?G5W)3PW=LMJ]_A=3-P;B MC9&_&+3UL_,3_G87>X1\N] !?EQ*P=,A?COB;!CZPIPRG30N M(&,Q3V+Q>92,6%PR/7.$[=E07,V\N?59E)N?)2$+IP P.W#9,(> ^1D&S([E M+/ -GR1\?,M[;,O,6_2AW#A*X@K/OSG0!%O=]R4KQ&[/W!=^S M]X4G<;A,C9WYC8+T@FN^/8GYZ^F+-RQW# .]O$5F^0)"#NE)5_,Z9JMM'FOS MCA)#/&%J@;:POGE6Z4&)1JO370I$R07D?>X0"EZV]UWHNRM%HK^)R]@#I>LP M8HGP$*D"3V9F ^L3CZ">#J&NQ//? M11[<6=/=6> %\&9D43K,+K7C.;F%L1FYU$:XODU2 'KP>O5Q>"P>L1!$79:J9'G;*CM++S401247D>F.RB M'LKNJ+K*;NH+L@7XU((/97:H(G/BZ5@@ 76J'W10)Z7A@SH=-K12)1NBV^IW MR(,TRV2:Y]S$;!B%XR*I1OXE3ZO!TA4MY'9-;CW^'& N5\A+E4_;-35]Y[T: MX [504/=\EB !#@"?5$0):/?TSH]BRI6325/TY>5%(]]YML+]HI],+5 3)M. M-54';9)/V^YTM+Y1=?46D$>Y&5,$/U20:"I'(# JH&1H>K>G6>T>5;2:2A\L M_2@0_ES/%GB6+_UP+/R0Q T391;;T#P0P6)IG($ J," M2NU>7VOW(3!U+FUUV')4>:&K-#Z_M^U)J6[6SQ-G=;Q+Q ME8\3^3*^ M0T(SZ.WMKA(1LS4 *-1 2+4$&GUEY>Y:B8"-0\WR@8F7[R@8EBVT(]Z5_]0 M "M0B"0LJ[0%?%E1]ZB* 4!;^KG&@?2OK T;EK6L^4B9#"CJ)E\<<^YE+S0: M%\\@PJ2&""9B"(("1*@A@HF8JL,5#+E(PH*)&'6P H5(PH*)&$S$$ 7IXH%' M]CTG.RR#1\,\#.9A2/-&P? &\S !30AB0CF80B=RM+00?%6JY.(\^F,BA'G MTP4&+JU*D#[SL>T%PB)DR0.?ADA?U4@?OJU*%OV1+AZ.%P[AY C!@X&;VL# MN5%8H)EYMU^^\\CQXLV6;.#C2%$)/HXH,/!Q58)T)?X2V4Z2VCY9^L"KT0M/ M%V)1FB>^(V;=R.7AW/=EY[[+\CI55]'$0BD%\V>#MST\7+V) H]7$R _19[# MV2<>L >7%_UKJ]Q3(!+JPF0MSP:SR?OO&#^^G^Y'9$9W6TZMH K;'K\ MJ\01!1_3)$[L0!J,V0G[P)VB=J:1U<[L$YYFFN(H;;_4A6[B9AM9?IK,R.6% M)/ 3(ES2UEK6LC8&':UOZE!1!; B0\\#S:D GA.Q:2<_V7BZ57T8P\$4;WLD MZZYZEM&R#!KP0O.4A.6+ D%E'0FBS*5I_[YN&215N'K(1=]U7_'O M$R]2(ND->WS56W$P-ZV%@8!*/NU/75,S!^V*X41*]R98_4P#)>QBHND302(5 MTN4VE2EL/7J*7+=E0:=4 (J:1X1@D88';%(*KB,H%Q #P6C#1;7.H!NF=SYG M9NO0,J9BG<$;/DF*0H-Z5FAPU_U\% L-+B"-24C:ZS0[59[8 ^&ZAWZFUAOT MM&ZG6S'BJP1UI1L&00G M2S^.YIP AZPB<2$Y3&+*1T&J+JK5KO5-6F !XHI MY1$A6*3A 9N4@@O*M36$@U8'RJ4"4"IG1C9[[O)_>)QPE]F!R]+@(7_#OT^X M(U\D(9,?'712\]35 I=.9V%2D_J:T1:3FD=&N.XB:VH]W=!THT=TE1!*2Y*@ MB!%5@ =L4C4+$Z'A"Y.:O:HK&8)B*GI$"!9I>, FI>""]N>O+YQ1MQ-??YQ>#,25KVT8^Y>A>,) M#V([\<+@)@F=KQ\G\F5\X23>@Y<\WLI;WHIF7_KBC^]_^!MC;]?=[Y/].!:V MO/AF1V[Y?O]C^VGV(Q=QG([SSQ;OS3SWW=GU%V%UR^R?,4>81?SI,Q^^.[N2 MGQJZ9;5[_2]RYD^\,?(7@[9^]GXE??^=QHDW?"SW L.<+"/T0C_XL6*"WHXX ML^=V8JDP+/,"EHC/+WW;^7HN3!_ZHE63R'-DTNG>FB4W+?ESY(V'+VOO!NV?O";SKB M$7DT\Y*%BQ.>Q;KD8#YGSA[K]EGF $JCT]3#S4QDC>%$) M->,5C]>*I'@"T14$-.;9#*7<(B=%R>RWEH-4]U$,^X?>ZAOLG/W#:.F;[8>L M )YVJ]UMTO4?J0)U8D': @DE\G@@&A^\V G3(&&1+;K072B'S7^EGC"]:.X& H)Q M<[7X&:U._T>6WO)+\F<=)Y$G7D/W*GX&7Q-F/ M+E]6+B_]#O99^EW;([J3Y6N03RAW.L0OF#"V:. C"X?L\\V?S"ZLDRWDRK7: MC59HO;B\/GO0Y=G<-"8-,E2U/-O36WIWEQ7:X\=91FMPM($&@<'?YFEF%8S, M*SZ#(K?^4YVZ$O:XB[R&(M*I^L@6@ *:D$?$;)GF":-3J@@L"T:K*)'7E4YK M?3":#U@.$8V6S7T7^NY*P/J;C/GV .E?61MPY#0I4*@7@*UF(+P7&G!MC7-M M?Z0R/I]'L.$03HX0/&2J,FT_0*LW;^#<% #IXH%']CV?>[=_RATF5)D$!T=P M%+'JS=1X/%J M N0'.^'LVO8B)O,(. GN8>1',&.NDI&?$D50GQS@]($[19*'D25Y]'?DU*E+ MG6YRN@\.D2=72N>%%?43(ESW#,QV5Z\8:QR%J!0U#Q1) )X3L6DG']EXNA&I M@KJ_VJ'8W%-H+6'5/D1/!:BH+QP<._VC;;5,\B#],Z_H1GC%[44'"G+1A&XS M^8.LS>"4^X=-NG@V>=\P:::=. ,;2( CZB&SQ68>B$WU<(%())?<$#/=+QPQ MZ,5QNG/T=(KE-+"()C*0HP/*$8C46"(A]J&"!#A"%AF(#<1&$6@(KQ=5DFZH M1$!T'49#[JFQC(2T047G[I 5J-[\'A(EE&(@L@,5@ =L4@NN%\4+27X0L!K@ M17C5:EWD=K2CTE7<*/:\'##A29)M,ZL7D$;(I\"4Y0D1KKNDTMTI1O*,=E!S M32QX-,D$/&!3[3>"'0:HNNL5Z7U>(%E=UNV.)F5&N_4L^COOMKH=:NB5DAG3 MX"%_PZ<'<24ADQ\=-#0\]9ZQI4$!0D/JLZ=;A(9'1KCN4KM[:'CL65;H+$EJ M(C14 !ZPZ3BAX0E6!Q$:'B\T;"3)*CV#=(O(<)/(_5Q^)D[X7T@C.Q^XI$7BNOB))[]3.DXTK;>G.-(;T>\ M.$54+B[FAVM.(AZ+QL79::1\.!119BQ/*XTE7.=WTL;"/G,CLXC[=A&(\K]2 M>9:I+?&,LP\*F.(L>)6MF7T@OBE_(0WLU)5YJ=+HPBKR]G$B;CC.&B%^.)SP M*/NE_";RMR,^$E=Z#YSY81PS-XVR]HO;33)PX^E3/0^/IPZ2:BSJ%6,\8H2R%R&@Z3E(.'7 MX->49Q:E@1_B9Z7\WXN$@X.$@U2>>I0&?G"0IYY@/'K%DJ.F&U)*OY?/)O^Z MX#5<[H1Y(NWK5+0[\CUQCWR"7Z;VLH^3+,DV0T]^>08KQ=HS.'.0>/&+U=#I MFPDDX*,)'RJ?[Q85'!\93)14SPVX-46A@RHI#1]4":H$58(JU0PZJ)+2\$&5 MH$I0):A2S:"#*BD-'U2)9%X\EJUD31Y9\27B#SQ(>5SQ4C 81*P>VTN*A-IK M\FD-73,Z5==> W>H9I4A)JJZ^">X 5U1$"5SH%EZARQ4#>4.= 6Z FY 5]1% MJ=U#O$(/%>@*= 7<@*ZHBU+'TKHFXA5BJ&#S$'6$/O.8VY$SRJKMN_R!^^%$ M%N//CIP+XIV79;"P26.H5EW& '0IBW=TS;1Z9*$"B9"SIF:\ V[0X 8$IO() MM:[9)0L52 2!@<" &VHA X$I9YBU-;.+$(88+% 8* RXH2PR4)BRPIA:SS+) M8@46'73Q!EMH#H70/WG (]O/UFYL=^P%7IS(HF\/?-_E&ZR(4I4FI!6<-*V@ MIQG=794))*)!(J2K58T N$&5&Q"8BF.?;E^S^A99K, B* P4!MQ0"QDH3&DG MI]76.H,V6:S (B@,% ;<4 L9*$PI!:UK:(:.63)BL%#??$/[:/#*8+NQ??&+ M"I*D %20-D@9):QYZD+1M=TIUM;:^:_E4:!HU^F'[5)4(W8:)[<_6UEC$ M?3OA+DM"\;RA\Y6%D\0+ \I;J' JF]+I(P>"K_:J9[0UO8?\$F*P((-1^?@, M&J4(>:!1Q/$T!SVMVQV0!1,:!8V"1D&C:@8=-&H+/"U+:)2.O<;$8(%&0:.@ M4?6%#AJU51ZBI?401U&#A?I>,BQFR6>3?UUP%"YW0ED0, Q>IZ+=D>^)>V27 M?[[Y,U_8DM^9H4DQ1P",HXK,-GN@@0YX0Q&9XZ42(IH"-]3F!C0%Z( WT!1H M"KBA,C+0%,KH !EH"C0%W% +&6@*972 S$%7:;#EZ% (785QPL(AB_@##U(< MST0-'V72"9 M()_VG"Q*X ]RV=2,:L -&MR MD!;P!]H"[0%W*@#,M"6.5P_ M&7VMCQ,SJ,'R,X0%P@)**(8,A 5!"UE L'&&.D*?>^#[KM9@ 92J*"&!0 51 G]H\ ?):54C &Y0Y0:T!=H"_D!;H"W@1AV0@;;, MX>I86EMODX4*)(+ 0&# #;60@< @>"$+"/6=-0M+,]/3GPKC+QP E3WQQ(Z$ ME1L VXWMBU^4"SBBW5]Y(JRFPDZ;=0#B #85D@X.AR"D[A2>\P72E;TFB%=E M)EPYD"*G<^H%7% S=4@%-:,/*=1,!92@9E SJ%GST(.:;;DKJ:.UK3XD30&H M(&F0-$A:\]"#I"% :R;QJMPK%TKUPD&((67600P;(X;FH*=UNP.(H0)800PAAA!# MB"'$\$A0=PQ3TTV(H0I800PAAA!#B"'$\$A0=TU+ZR$RW-[;/G&V2Y&K=IGQ M56(+X\VNL;9\3=U.*Z^(DOA5/ ]>\G@KVSG[-O/<=V?77X2YK;9QQAQA M#_&GSWSX[NQ*?FKHEM7N];^8NC$0;XS\Q:"MG[W? OVN>+L ]H]+R78Z="]8 MG(Y% Q]9.&3\KU38Y=SQ[3CVAEZ^-"G,EZ]6LF^Y 9E=&)")'V#)B+/ "S@3 MUR6CF''Q8"Z[X9.$C^]XQ-JZQJ2IF!RQV:_4O3% MW,%(] O>OSO3!>+<]R6SA8^8O2]\1O:^\$:.^&$>S7Q/X3@$7WU[$O/7TQ=O M6.Y<^GJYE@&=^J1&JW>T*@L8NY/>'TY]V%X%(IW6 *!0 P6($$/$;)DF2O. M$T $TD$;%"!"#!%(1X: :*KHD@("\ZS2"CJ;\(AG!PA>#!P4QL8.#<*"S0S[_;+=QXY7HPE M&THHP<>I#0Q\7)4@78F_1+:3I+9/E3[P:@3#TX58E&;16,2L&[F\30J1-LXM M9KN_=CUO[+ ;/!V][>+AZ$P4>KR9 ?HH\A[-//&*9[R/!/;@^ JZO M<4R 2ZL)D+<\&L\G[[Q@_OI_N1V1&=VI4%:>I"LD<'KS:>/?;JO?V12QRG:\ M?TR3.+$#:3!F)^P#=XK2"T96>J'JLXG633-M6U('QZX<;.1R?'@[99T\ <)U M+YID:=V!I0W,7L6(*Z6C(.B!9E4 SXG8M).G;#S==BT>>& 8]]>\[9&LN^[U M6YT.#70A>2KY5$@>:7@@>37#$]IWA)BO9=$ %]*G=/;0L3>WM*V621ZD7^,X M);W1]47G"6[1A&XSZ8.DR:_ETGY$Z1 MGPCVT$0&*C1#ZR=+,SH=S6KK9-%J*(]^I@H( ATJ2#25&@H@ XDI3Z=!7(AA M0I]!4!DJ2( C9)&!RJB$%GA$,KFMDJW!BLRQ3;Q(B90W;/!5;W6ALVDA# A< M,5-G]79-YVYD$0SEINZ(54*K&2ID7")(I")<+\H5MA\]A7#0:;?TJO.TP38% MV0;M(@T/V*067- NY2$$XY3.V5LWR>B&Z9W/F=DZM*ZI6'_PAD^2H@"AGA4@ M'!">S]^V7,$"TIB?I+U["K7>Y"OW[ZZ\T+G]8TSXF[J\X_#JW \ M#H.;)'2^_LN.1&.2^,))O ;R5-[@5C;STQ5_?__ WQMZF\?F];4]*-\B^ M.@I]@5O\RU^I^-X?8<*G]_H89>#'L]LPSWUW=OU%F--JFV?,$<\K_O29#]^= M7F(1,I%P#^<2FY3H?H M=1HE(QXQ+Y!7VXD7!LR^"].$\\*5_#N3!>= MA/OR4"Y'/.;L?>%&LO>%@\K/NIJYH\*7" K[]B3FKZ,WJ9P"R2.AJD7$[+=Z7:!"#!7PA!HB[5;?.N%>/" 3I!'!-I!$17PA!HB MT Y*IP^;@\QKK9\,J^'1PO_*VD!Z*^/)_!894/;+V0.CP"@BC%)(ARI$9.5( MX"A$685)C^8$/X;-A,F"\!*H@"V?>DV3&P_@^KO1E=_?(L^I.G@"XZH?2)1'#7L44ZLW M?90<7< 1KB\E1()X6"XBX/<:QP+XL[H@^9LW+ WJ?O*"^9M';D>@ M:I6I00FP7:>8:&U(J[^G,PVJ0#65.606'S$D)X\$.$(5&I&U"'ZF@! MBZ&-00(7)"HL22"T%!! ARAB@R$9F'J!D79B$&"K!O% M $/6C0HH]?:8N@%UJ(X6L!C:&"3 $:K(0&?*.F-H@T&'*E0@$55D(#14D !' MJ"(#H2EO(V@AG"$&";)N% ,,639 2NU2'S:!6*;IC>^9R9+:!(:19_G<<$9(0A M \.4@FOI"'\E8B>#)X=@BL ZL&J*SB835]+"2^<\UL&)F2W2\#Y1O!- 7/< MPNAHQJ"GF5;5:5701Z4H2EH? 0_8I"!4@TP1AE$.&,K37J\26QAO=I7K M/WS@C[J8^_SB\24+GZRCTA>7C7_Y*O>3QCS#A_[(CT;0D M_AAE\,6WHK67OKCR_0]_8^SM\]MGZ:> _\ACMIY"4>CW_Y[OBIR]WK M*!Q?A>-)FMB)%P8?A[_842#Z0?R)1SOL_LQSWYU=?Q$&M]KM,^8(BX@_ M?>;#=V=7\E-#MZQVK__%U(V!>&/D+P9M_>S]RO'FO],X\8:/ZT>+W2! M'Y>R\'28WXXX&X:^'WX3EF(3@8JPL>W[CVQJ:!;/+,U&MGA_QWG >&%T-A16 M9XFXBS,W?7NZ>B^]&]KVXG\1"7)(F<6('DJFB!5%VCPF/O-"- MV41<(!K"78W9L?S+(_L6IKXK?IN)1_#.IXU[/>^I6S)S/0HK^9#]2M'3<_EWQ#/-7M?>*3L?>'K'/E\T /?GL3\]?3%&Y:[ MKIY>3HDGL]6UVVGUS6,EZRNA7<+4 FUA_>Y9I9LFVBVCNQ2(DH_*^]PA@N*R MO>^$7U\I8_U-7-H>*%V'40;4WXVN_D8XBO*;B$MOX3(A IR-Q2U&\?S/7#R- M2W7FY)1IXV2@5&/5K?!XY/)(-H<(;G*C9+O&N=(;/DGX^(Y'K*UK5.(UN$&X MP3JZ0;-2-VAT6GI_^Y49^$GYK*9N[)J #/=8MRE% DZ\TD.,W&0"UG M4$D0%DZ3X';L:N87*:V4?8KXD$>1G"\O5D46)LA_"M(L,@N'@(>\4CQSQO1*[=75=L35_I,K([2A,[:3/*0G95E9_7(XH@R)+N-/8Z_ M^W=_<>NV^AT@ 9EJ,'20J6WQ_'O?-$RZ@$*O2,[](TZ[RJ.O94':CH._6B43 M4()J[_#J^,CDN@59DD]K:7W#T@;FKD$4>$2#1U5L-$,0!8X &6C-D?91@DBD MB(25JBH1^GSSYR'"'LPA4)6B4TW708KDT[:[FU5I!H.H,@BK1E20 $> #%0& M*J,$)%CKH8[051@\\"CQY ;OR2P_+T^\.U%R'N89J.H7)NQ."9>I=;JZUL/B M$#5@L#BD*!+@")"!UBQ-1.@96GO0)HL56$1R98CVOOBJ$^;"25$83(F%(QRG MIOJT'XY3VS@7PK"TKF54C"<.IE%J9>I9\8-C"UTS0C!H&]"#MAURVK WZ&G= MSF;'KD'=Z!.0:N6S!A^C4^S!KK6[9D50Z[4P0Y@Z*JX\6CR6<>X$?H(]D$?:6-N]#6KVQ6A)YE2 ML2H(9/U./CK4D45/CD1:>IY2]NG-Q/>2/',Q%K?\+&]LE \\LM8?>-37>WIW M]N*,N=SQA)WBK/IJ&GCYM_[\\OTN\KU)&O&S]WI+;Y>>? MZ8'+[>YN=]K4QX#]5^H_LJ[&Y%-IV2%)LL/8P>/_DR5\>F_B/-FT: *S)Y,H M?,@.3@K<\N5LZ/GYQ\P>\\ 5_PG>ATOO>"6S7H>>8R=<)K5>S*X7;Y[\[=? M":-)&&7]5]Z/#X?<29C-!./.!??.DY$7)8\LRLU2I,;&F6'$]Y?]?#FWMIQ0 MVUK7R9Z9?1$G^><@Y8)7TA_8@<,_W@G7FS7[ X^=R)OD#!3>1OYN";/>&LR* MVU^X\O@O::+X.HR$J[IPG# 5U _N/T5A(%XZ//OKQ7_9V3"7[3@\ENP2%G>X>*JL M([C<%PXH>I27VYGJN,R.8UOB$J?^K"=D$B&??S)ZC#U'>$KQ$9-G@@D(O9@E MCQ,!O3P>S!>_(KXB+DB^A4S\]->XA,^6YEZ.560[B?RU7[Y/N.N)1GSF8]N3 M_O&E^Y;AZU.$;TI*-Q32%H0"I*P)&0:9:LE'%\\QB3R'SXY'R[D5YR#&8N"0 M$5'P4&2G9QF)]FS2T,R3SQ$9IP%+\*X,*Z\9WZ$F^_S_(>= M1T>,#D2ON..2R>R1VY'L"A+V)3CO#E4._9T7.J\OQJ'P+?^77?$I.PFNC.-@ M#8YQE'RV@WN>X2/>_&Y_]\;IN,#@^"@7%TMG.!8N2/Q9WNBWT,F>I7R_&^[[ MXF87@?N['7WE\L;29D',5W>83\;_OGVUPD)+F9,/*W+<_^4EHROQW*)A43[L MD#\?QP)'[M[:WTLFMO3U)O[=_G<83>^56TFV:OI+W/UD/XH_% \BOB#,ZJ9. M\C&ZX=&#Z,AE0_PGMWW1,J&MG\3C"&L5U\S-($7L?VYCD(-:U"!ET<'4HH/-+6KUNJ(WTK&H2#3E<,'.@8=5U$6E%/W<&ERLN[ SI671JIM[723F =:'< M*@M)NWX0/^N'D_'<,/%^GK';%L,B.G9Y(33:S2Z[.+=V;]"GH\*=%^*97?O+ M#OZI,^CJ=#I,YX6P9-<.L\/ S>P8A/QVYX7H8J5A_MM+8A'37_IAZ%[-9E%N MT[M]&=49Z(1&"YT70H7][+,+LP86)?.\,.S?M_MLSZ^!:1J$_,X+(_@]ACC% M5?ET\L?A;;;RQZ./PW\*DSXWN%S?X9'CV7[Q1/%G[H3W@5S@^7,B)RCS^?(] MAPE"#8T.'?._,-:G;/Y=?*=AM4W3(C0>>2$JH&S_77RS*9Q/SR3D?G:)'XC8 M?Q?GW^Z8/:M]R-&5^)8\FS1?>OSLQ5\_B:<0']CWO)QCT'DA(+F22RH\FMA1 M\OB'/9[;Y7?N>HZPL5P>F;YT'^SL!Q8M_:PEEX^7/'!&8SOZNK#>8OO2N-ES M_\&3%V]R^SA9P'UJFV>7;J(,:S(FK(5D@]56W/:;-7PA7?DPE[>T:MRIC\YW\^5$'C;U=8]6#R6B18BNGP+CW(#?6;&_Y2$1KR49] MW3#;QJ8Z>LPY@MZN,:JB=J?FZ ;,L<$8-/(XN>2VW%'W:^#R.X%DP!=;O"ZT6S9. M7--0<7'>S&W:LGWK/Z1 _Z_<%E9ZFG5!TY:9*_I@ZV=YVK+2LWU, M1CSZ(PR>?/LJC>2F]]\\^\[SLZW9I:?IKPM'ML2FK9>QV;@UB]W^SR#BCMRB MZ?XI>E\@Z"B(8ON?TL@9V7%I?]VE[D%I MKV#^_+F3>&:(I[O(%W)]N=\[:Q0V>4OWT4IKU0IF"; M7*:.I1^>:)^BT.'EX@?"WWX<3O]R%<;)@G]<-Z:9SJFD M=['G>G;T*&=7/@ZSN\X&-]>A[X??/@:?4M%>Y^-PF&T^7QA2F(/BQ>8RV&Z7 M?>T.S[C8%\HW^)<=12+B^.6[S-Z)%]5B@SH!Q[+&ZGY3ZC+KGF-%G_BGG&=X M>NW'4GF&TN-OL,^^DLZPJB^\]&PEDQ17Q<5EY*M%&WUA#L8Y9?O$R]:OJ=_L&Z =0PC29EHG\OMS'L]0LD*PJ_Z MP\_\WHN+N&6V^W_=8:$O#,V7/U_9/V9=[=H/[>G0\3=/#(JNPVCZ MC;(QUHW"*GG<7F?A<5]^FB7UCJ18.:][ M5;;,N@'>U#+31[WR[3@N6V9Z@?AQ'E]\FA[.F5U0MDO?:,]>;%P/RNH9[<'3 MBE8[/_.+PRTYPQ,O#$+^__:NK;EM'4G_%=?9VK>)0H#WJ=U4.7$\ZZTX3B7. MFSB@6171_:#2Z&XWNJB)(\37> M( !6MUE9Y*WHDR]F(:PA!&A[)GH#TX 2IIK H9K.2OW>Y.6##N$H;CY%(,>5AJ6HEV*+.IZ:%*00DB): UML-;BL-4H8UFO.#'C M9PB'7D HX@2A7FG:K\/]^KS-OJ,9S)_1TD.+LOQ\@Y;D.;(22K?UIFI#1;"L MW6X-+1L ;N7CVD'@^8<=6IBUEKK&+^@L%>VV*9-ENDG:I5Z5SXHV/Q.\6[T@ MT&YY0DT.Z_$%M78AP>"P0^DZL^4_7:6KW;Z(5A\N;AVQ:5LK%-U1NV]\O,DX M[JY%,UBY4"C#N>T1QG+N4CCO=]\/YR@2>PT@ 6$[2[,&V]4/]N<=)A2IZ8/)_2':;.+5^]?VVTC8:8:S$6#;/LZ^ MC.F'NGYCHPHAH?PIT]+2)DV?!K;4R4@H._;7^5.4;' $!;F.:#*?" ^:A'W" MD#&]!K 5NL"U&W87A:6F6!*5)6^S\]4A&!\EJZOT0_28;*,-X40.VB831I!I M[J#3$ITQ[+*\P.(VSA](3$R'E=]]<7_0?+:2P,9975X&9^+\Z#CN^?X;_HR/ MEBZC)/\SVNQBDJ\)X\.4N0Y]TE<3X8V<6"(DT@S-W&:$)CL^UG)07, X>.\$ M,_C<<6=Q6.!R) Z6*O\2Y3=YJ)+F")F#B+*R[*Y^J!SNJ1_D+^/#X[O\_C?6G[,]P=)%FAY5WW%$@JZQPW M%4CCY[/GPRNJ!W#CG>-[GY/M^JS8+=>-OU>- I)R!2(.]EU&RFRH^)^[:(._ M]]W_K!M^I*6;B?]U5#?[M7J&#V#RS2MF&7X1SW@-0-DP!1GW25KV-DE+4G&I__V827%V MESS%;W GA*)\N$A>WB!3:[M&WY1[&Z:ZQ!3):X*X/DP2?LNB-CU9,JA6-4&. M@+>VU3JLUL@\/06!H5'[&QP=!N=>Z?P[G =#SU.WPW%:/'!T+%P&"MD# +K- M4[?+UNCLQ)HLN4#I_[@((?*HRM?"G-Y;_!C!.)O@9T04*1^13D>@< M0&'MRK*@C-N>M1KB0^J.NCU;ZC;F4=#86HT[IX;&FP::SUF*C?R;_$N4;ZM_ MG"__N4,>$?[99?(2KW"IRFU1_C6/5Z3A:W-8=8>-]?WKX>/_)'$>YN4H?=]NB_-YN^KW$"Z_CJ$!*MW%9IO=MQ(,%XC+'9V_MR)AX\4\W ML!LVA 28Q#Y(9FIUSP1N,_*"4*-O)CDA\HG!(X_SI*DG$/A8;-' V[ZCC]Z= MWV;&$2P"6''%11$['EBT^_S=*=^B!V^?L=IWM"N0A M?\2J)H[3OE@O]8KP<)"_<36^G1]6_[UF_CQ=55F#QVL=Q&HKES$)!$>XM_WS M]BWI]O<--U8DS5TYIH09"-P%J1I$X%(#-(=5+ XT[F.)=IH$Q[<0/6@]S 5O M:V*X."@3T.XS'GB95R.1'":] M*&REAOTSVT1;?'?^=2Y"&88C%[\R^XO5WI5E?XE^*;8_":MZ5&6UVVXL@U&9U4]MZ3F)U:T"6V!":2\6X,4AM^#FE[:T7 M]8E-<&I#T"E,<+UHP_*H_%5KN'#]Z>QR:M]01;:H%"SV@FS_ M:,0NI_8(58?%$115=CFU>R>?VGI&&N+U6_RX+6G5&0F'BQ!J,\FI?3J-F^3J M026V@>8",6X74EMR3F6-:P5\8D.ZF]J$ M'7]XZ@CU5;I%$UHDR_9=56H[2^78T/K9$LF;(KR,<%>HK23[[JKQ5H8*77%W M19G'R6K02/FJ1X)M;,@ MKQ[?/,67\<^\=;3Y.4ECM:DY"\O5YI!0>_U-X) HQI3<&AL7_HR;Q]3N?M/Y M(_KPGM@=H7;V,^^.Z,,9+IQ1P58);X3:P<^\-R*'[01G =0N?).X(J/%QU3^G M-*/24F-4CCW6H+9J4Q+*EY9T187E^(\UJ%W3E&%!B$H=AAI_L$'M/<9%>JUJ MK_'%&+U>!-!WK$'M#F;:BU .:=.)T)Y^0<-98QA8UHG0"??$/@2UZ9IA'T(G MS,B%< R[$-0.<(9="%EH)SG.H/:8,^]#*!!+B@N!UK]Q%X+:XJXJJ"6W_P83 MNA#4IG4<+D2+9_HQB^OX$'K3NQ#L5G>(K5[^N"M=3.="4%O@<:W=ZNW'*AVW MZ)]%M,2WEBESSROOB@H1\3L2X[OF"2!RA$:=.S&^T=W^OM5UU!?-X65.TKV M^BXR\'3 ,WQ]6"/$#7>#7$3&[5^>5GO3W"8V __$[@=/$S^SMXO-P X;!YY& MW!&>OH%F;QN/AWH2]X3:HW"BZPYJQ9;BKK@+)2=QU]%RC6C,7]%/<='?1_Q< MV525!)I5!05 F[-'$@Q @!R$(^G#!,@0RC3"N2OOP,!Q+5>"T,M=CMZ($$?/ M728O^%/1H9/5\(\?4.#Z=DALW(/#2U!)LW'%T 2N%P8^-Y5U;A@2US@_@(V> M_9;=;9^1O=OZ%O")534\OCB='K4MG&#A+4RGPT]GB?UEDN+H M0_EL58:K0R+KXI2 *L4KWZT3$(?&;G>[2(MMOBOWG:OT2Y[=HX77)9(1EA)9 M3<#S'#(-=I@ *4J9![?<,VY#UW5E*$5?/<9HY_^RB=0F86*P^I[O M +=94)="A"S!S.JM_.L)[::^X\H1?+Y<[AYV90?1B_@Q1\.5/931YTV,/Z"? MGS]D^3;YU[[;]="K2=88>YO 7#BA[?B0J%FDBES](# ;'G#/KP-PL1C+ CY M+EXA\SO"#6@^[/*\Q1)C7Q72KZX#O09'/6.+TL?82D4@=P/?M:3H^S-:EJAW MZ6,V;1+8ZFW7"V"'OM;8HO0QDZ[X59+G!0!(T?<^2W=%W_12FRL)JGBTHD@+ MI'=H0>K4[9:>[0'/EZ$.N\X%/H!)BJ)_BM5MDQ[T>XCLIT"26'5;)!)&JRN. M/,1>5)VROJ)O/J#_3[8]A*K;\ !RX!UB80\.WZ2R;*-9@=W$(ODN(Q*]#(),W,?6BH6#%_&R\& M-2WJH]?2I[K-JLK%/ 8,3UL4HL_E999_CI\1G#@JC2M9YUF*/NXC5\=G MON$P6I2OBN^/N/\+0@0)U+BBSO4-.''6Q7Q-GHXH>M$1\V:=XU$WW9OM//() M>69QW#$YHV8S*(^G+\IL ' =OL!H7';WAB.EC>) ],.$!=J+P2 C$.20_,1 MQ=KV:Z("D?+I2/][8XAB;N]#G0/BYFZ_^9.4\K0$*7]T&2W+ Y?#:7 M-R]W6;ZJ%\RG#\?5YU@.#*H/W%Y6$ ;64.NB7OX)'=5'YV4<%^=E5S6D]YO= M0CRN;B'SQHN\T<'%?BO.V_.3JQ2G/!7E.3+9@H($CJ>[R!R ]AEMFB]?'E,]S_*\;/1:W*0M M0M-#:C4)%4\#0).;0>4*"6!VL&.E\1B=(^_QM#"9.8S0ME4DY)/N?+F0;^Z^ M%W$9Z"#QXG '#(2W>"\K.%8SKD5ALIW<@0,:Y./8J<(=+=-M'BVWC8V09NEW M+IKN6[$]OF0]@\R>83!GSP<(]J!&(7#%X>#-\Q)[1%BD$F^V*_E#T3U MU(4Y>?J+S 80X%I6/R#L,&?G)V34JM.,V./I-:(Y_"L1F0-@0&!ZF)6#A<,8 MUBTNXE%48 \<%RB#A<,\UBTMXA%OZ /-L'"8PC,\I)-GLLVZ2;$HL M8[?-K[$PT3FB4,5FZ7J/&EB]9008&A_;YK.$ILV-G]E7DZIZ(YKK80*N]6^N'6A!^,:"=!Y8XZM09=1.$,W-V^#M3) MZ%=E3C"E*F/>+Q*7+.A;#.UL1)4QMW_^I6+/3Y4QS8#FVD&JS'YC]5U4,:W* MF(9 4!,>< NO14R=CAE89N\"\N&0%T)V!548M,B^X M5$)_;JJ,74V^N7;V5AECTS2ARJA%Y?>^L;"3'$SM7U(+Q'>9FHTF8U^CXLRE MWFLRC[%&]&HR=C*[>*S.]QDL&=%DZJY> 7S7>%Z:C%KONV?M($WFO+%"99KL MYC'&>4;IO=3*I];2GB*J6.N6LV54K,\>]P178$FPVKI9TGA!SR*D%N&>;9"U MW?*HG\UAF6F4R?&H-;DG$0FT9"R<#?D'HU+79GV UGR*+(I'HMK9=" 8%DYJ:P)>H0:W-+7H>ZKN6'4ID432Y MJF^+O7;OJU$K: M2"T)<-V$(VC81P]C2R%5WO<[W/R%"1H/5SEBZ[Y*HT M,VP('9M![Y$*;M$E;]X3I%,+)S4J= MS]\]9647!A:?"0_M7UX_]2U"I"C6<*<,!'[C"CPWR4TMA/-!24KY0__\HH%/ MG ;5("9 A$#FUB<.9>@BT>4@L&G7G#<=_C:=_/%[_AM[P$';7]N^ZJ%#@ESF MMB^Y[@V:[?L$B/!P3J/2=U'+9XJ*O]^"'U!'C YXEQ< M9CM2JJAE2<68<"S7!H$8$Y@:"1Z2I\9$,+=-_I7AV7!H[Z%1(\;#^1W:Q?H8 M45>IQ0T<1V N&A2),4/2K[ 0)[2!SZVC+FB9]H>GOZ>KRD&-5Q]?ELB!W4?K M2 [4^9\.M =-8"9)'-R05"MT1 ,K@#Y+G0[$,(MKM%-LX_(/N E+F)S&[T< MHXB\>QVKL*>(("%KI.^,:'?4<8 MDD0J8/EVC;S2".^A),?JS)( .F DPT<2%?!+?^&W0#P5?.O=976.[5]F!(-FF1IT^"SSX_TV<5?!59@ZY;;JB21,EQ M1+*B,'X/D9GG,0YSV$8V]5=L8]MG56T5JJX4D$<]4I1QG:N0Y"L,^7,>J+!# MM-5DW:1]%+/*O&J*+W=I&LN'AC _3]29Q0CKA-]G%8J5"D*[;@!LOO-W?D)U MQ/7Q>;?MBU%*3D.[Y$^#8 WA?<0B&#J3[= R3/;?8WQ*%*_.GQ"[]_%^OR/3 M!P#)!]=NC"^:P^O@HI\V]H T:1 CEVM_Q05-KN'%T,R+TDOAEU,41@^Q[]1Z MOMNNLSSY5[PBH>%('\0D?8X>XF._KF.;KK)U5QRG/5Q0BAK0&]-")&Q$LH!R M]A6C>[Y:)?@GT8:&,T=>XCB[#4O=/V!)+WY#T8'#[P MSY#C>61Q6(T03C)7'/F3YN:ZKM%T2T*=6>IYP+GCW].9R08ZQ15:358J:H@FY><0/DJTJ M]Q) 3@I'L9&Y+Q#HN5;HJU!=0X#I45A/4;+!]9F1Y5M6LR.GA:..W]RGQ7:1 M!V"K5UMMV SN)AS5 K7,BJHI 2"PO5]@)^&H16Y\'J2V$0!\UW9.?A?A*7?^ M>RR,V>P@/-759STE*ET1O3L'SP(1[5I'E];0#> )V#O5Z_^V+]M;::56<5&? M6G=]A('N>0X@#\@U<*$6)B25=W'9LKOHV?.H!=7E8?(@#%78:,,\&%QDHMD5 M# \O]#U71?3*S"K#>CA>X5YF+X_Q$GV\S?"?J(")9FPP ,,BZ*L#C) A:,BO"W&ER"8A9#6Y 64705S0-?Q(6LM0A%@U?&H M&-P>;9$T6MK&\"5G5<:=NTKM X25HDRU:S()^K M_CY^Y^WK8TQ6O/GX\+C)7N.X;*VU'U"J :^>$$:3WPE@Y:G?+PRK0.K51+". M6$75OH=C<\UA&FN=XTS,J+AJ87@*8'F:8)D46%/ :C7MSN_O\_@^VL;#BH+C M&.M4]*\T'O.;%FK_AQ/3WU-/RZ$YWWE1[!X:2[3CTE&[4]#[SHT)!04J'#XF MGU/@2?/9Z(WKY/$$"R4I']/BN5\J%\E3LHK35;..I"_0K8/_AH.BU$M>=E3D MU/>-1=Y6>)\AK?//7?(4;=!/?B3QACS.HG8'X5CL,A@#-QB;C"_!] RPIOEY M'(I !FMX:!YO'NO1MB1M&;4C$-06*Z*"_.Z+^T.!+RF.4-'C/^VDP@41SI%,AC_KG82M<40AS:0P?JWL9.H78Y$ M!?D7MI.H_9)$A?#WL9.HW9I&Z,E_VTDEND).#K]F_.7L)/[\?&I+*W47ZAV1 M!$[7#Z"2E&DS>?R7RE]N"BQ?B_ MHO?E"9:?,LK_'4%9?/WVG7+\0K\CYZDP9T6!,(5_,S&2A%_VY(L)OV0:O)%9 M:,*APMYE#GDX_QF\2T?M:C;15$P#BJE5426S]L\&3Y>V7VYA=!"9?H/@Z@\G M.1%"EZ@GW"!,+#V8V.5L\ M[?;46%B\UVG<16!V,3'QFL80$YI&V1S1$1O24&;,Y"8;YWQ.8[X(S:ILBJJ) M69TI?(;-0WS726A*9;-C?XV%*H+:O/=-;9$)R8RN^>Z;T]I@0I.J,=XQ:E)G M#J&B\Q3U@!.1=*\ F!4+,5JL%I(QJ5O4_O2&IV> MJ4%IKI[SS29;1IB[7HHZ_69]:H=*BWO$HN%#X>QV,G&*K1A-YRL1,,.A@[9=-<,=K*1 M XUR!R3DSO8GD#OU5SI'RQUOW+E1/=[QH'&Y4W]ODQ\[M/G$4;Y<(S5_$3_% MF^P1/UD1.58#VA9T?--HJK^MJ1Q-.9UH^Q[9A<<,FNJO:&J031DM"2P;>L:% M4_W-2PW"*:,X@05]!QJ&D]J=6S>;' 8(5U=1_D_8ES.5Y'V!+B1IVDHI_2!>*"44YP>!*YQO3FE M2\0GE3(JTT,:TSB44_I#?%(I9V]ZMF4ZRA%J*5@CJ>& ;?G&=PLME6-D0X2^ MYX5F 0@L+35:Y+2)X_B>95B=($KU2(",#O @0L"X!.A)T)PD4OP&!(%IBS.P M]*13SB6L9+N^X2!=8.E)>9R-I^DZMF78F \L/?F'<[!"@6L[@6DXM27^G8[U MA"C5ER%P.A:4OAMP$L;O+>.*]3HJ.?1S^ETN(XLYB%<-^EWP7545<3AC?>WQ]5T=9#?!==1=4'D M]*N6VE1SPU5EL<1_XWK$5:B:8E=>9?3K;X'KR#J*,OK5.*ZU[?QA$Q7%S=W? M(SS$]B;_BB^Q]%X5"2"'GW2(/NTO8V FLA3?Q2#]S6HPV3(SCAA#AM4XPG6-P:RDE;-?-@=.X>?"OR9ZB:'B'85:Q@%*,-8?)+8GU[7,V*=;. H)Y M8']R2)]T?\ MV+1X.];<\'8X_"])O#\G$]O<#G0:=>MTP=T?!W XW+F9.S,M9>&AGX@'AV6@ MT^<'FO)-6A8; *X?F$!.HU=GS--H!M^A902X\2[:''R&9I#4"T,CRW6\OS6Y M^=_<./R &4%0 IP^O\F4)=\TWT$8NB9PT^@!&3/*FSM$X).78/0AI\^=,6=> M-\V2T+:-*#E]CHDQ0[D!G!L([ZL]!P;=1SE.#G"OP(+ UM7GA"@SE3LG*,'^ M/H523#3#K,\C4696=ZZM &OPT&ZV.&MT7]09X4,7A$X)Z/'>CA&CO04U_ &N MO1-#6M\)ECH3OPOS">H.?;Z4,I>@HSE."V&-3ID*70U MVF;=Z2D,?1Z=.K^D8SQKEN;LX2%+RV3V0SS_^,*AOA&!2W/QQ"ZDU]F<(I2T M*AFDVV25;':X>LNW>+G+DVT2%Q]?EIO=*EY=YMD#1G^W+>^ZW-Q]C'(,2E%G M\YT_9#NRVW3@\5S8'S?F^]?^%QPD[4L>W\5Y7EWWKP'AN0YH40( 9.EH%:!I MG@>>LEV:YZ%'*D=.@A. YO6B4Y@)GOIA4\[$\"U.VG+HW.$XA:G@J42F<2JJ M(4:4.*+,2*.![RE,!D\1LQE,AM3R.+G)$+D,59E2)5[-0H4I,IZVR<]-W-R" M1THV=#W+/S6M+W)I:@2@4M+I^,!N5'(_ 3QY2JGIUQ:2=7UI&REP/ >"ZDU@7T0]]SO=.:#(8W*264OA-:7J-I[29&SB>Y[G!:2$Q M ]^/[8,/E3CY=7QP?^Z>G]0DG*(/[D_L^''XX'RMST_?!_=/Q.V36ANGYO;Y M/$6O9S 94LOCY";#D,LH)=FGZ(/[(H4X1OG@$M)Y@CZX?P)^GYQ=>7H^N,]3 M4'QR'UQB79RB#QXP7$\IH3Q%'SP0JQ<^ Q^\/#Z_3-(H7<:?XJB(B[+1SFWT M4C;B2! OY7[^,,.66-- M!<1A0[^/-OCEW]9QW&S$@VDY7R[S7;RZV:[C_%,2_4PVI6ZA%/<;AL@+!R 2 M9U$/6!SV\3BP!.3)!SK ^AHG#S]W>5&:^)?97O^OOB";'UG\6;$E4]P"#O/V M:[S!75*^1/GV]3:/TB):EC+]_I7\Y@A0?!]'[Y-L&R_7:;;)[A$Z5^ER;!^? M&BAO/J94)<&T/ON'JT8<%QK*!>*L1W7A *8[%) MTG_\]2[+MBDBY1/ZQ]E+^:<\V\3__<=ZNWW\Z]NWS\_/"VR8+K+\_BW:_>RW M^.NW^,$_JN>WKX_H>010G")#](_RY?7K-]FR\539<"G+ZY^N<\S)?Y10.[A< MQO[/F^AGO*EF /WY_S8_-W^[?!FWW_/Y%K_)L@X#\+!8 MCX!^\[!!KTKO$9/IF^_?_GB'9@L;W<79=;Q*E@C7+FAGTD<%/]<3;.R28 M;PB^]B,@SZ&-=352UL3NK?S4@OZI!;2I-<0RT,0R[&<9SH!EJ(EENY]E>P8L MVVR66\L0:T3T]_]Z6_KE?\7_???_4$L#!!0 ( J+;4]^'Q<.1AL '!& M 0 1 8FEO8RTR,#$Y,#DS,"YXZF,P_[X7^R/8=C/?^]O.__LM/_S8: M66>3\ROKV GP SK#ON-1/V3HU=WE#];?3VXOK#MG@9:V=4:=<(E(8(VL11"L MCO;W'Q\?7[LS3'SJA0$TY;]VZ'+?&HUBPJ<,V?R%=68'R!+_'5F'XX-/HX.# MT<&;Z?C-T?C#T>&'U^_&;]]_'(__LQ_.]P_%$! MO+&=W^TYLL[/%$#[O?/NP\#!^/W8^O/]PKW)* M5VN&YXO >N7\(%@$>0E!GH?6U@03FSC8]JR[6-(?K7/BO+:./<^ZY6B^=8M\ MQ!Z0^SJB^N2[1[[4'%B#^$<$Z(7+SWN*\I[NF?>:LOF^&[#]8+U"^P T BC$ ML+,7X=UCZF2P^ .T"H2R.:?C3V_&,;!&"UGJ/DZ)"V ?.:_G]&$?7G#J!Z/Q MP>C-00(>K%@%/+SA"!^S",3&CE^.(5YQE ]9%$P>D!^4X\AW'.E-CC$6C+A\ M:5LSV[\7HB>OA+:R:)RXFVN+XQR.Q^_VY4NEA5+:)52AB\UM>U4$CUZ4H+@( METL,+RKXQN66!M;?@)[\ 'P6Q? .#4G UN5-1"]+3.%A\GM-*_SUO>TGK3P5 MX!_?".B#3Y\^[8NW"4,A8S F57$4O2W7;86=XS$91BZ,I1[B V$&0'D=V&R.@BM[B?R5[2#MO@LC M1IGN0-,'^W^_O)##\!Z,+98E1A>\7%$66'*0N:".&&IKK,7_&L6.,>*/1@>' M(/-K(+9GD5)^J[QJ?T,V8L_IQ$;J=IW9B#LW;_]=5FWY=)XO_&*4] MKI:'NH[:E1VUAR5_C=*>H,=063_MR%$\T/$?;?G(#Y+=_$*=A:_D-,G]XQ/W MSX/W6OY9/I%ORLZFO+3CHV"99(P4O]K:IC#"=N1"F?JCWZ,T#-#BI"1XZ&89 MC[%]FSF,>@BF'R?X\K3R;&('5'3I5D;BX!E:(Y02F\#?F_ HB!(TA^C;[<28 M2J '1H)-F.@^]*:!IOS9=M@M!JH=&8EC:OYCE ;76DSDXW%M8P@JA8!U'WF! M+T+CYNY<&>WVQ@,WL=^2$XFT'7Y$'-F6GV+PV=5-XJ64^#5*%U5ZCI)?B'74 MBKI6D9J)GK312]F"IT]^6CM.C+,UCEJ[3NFR1>'()H0&@@WQ+'ZZ6F$RH]$C M>,B#XB,NVA2(61B6$E.TA)DD0!=BV<5??;L];UR-R.$VB]MN,9CP%'/EHADF M6$@PYO]9(W4S*6[*XFW]M)_'R!,+?>1>DY_%[Q5#/A 1RE&P(Y Z3,?VG-#K M@)AR5HT7/8V-D;-1K*=;-+/$DO@HFO[K%\[[*T97B 48/$59=PL""X9FG_>X M-4>Q&7\#"5^#W6*00@-9XPFCYY02,1E3"'# 29RF0,)B_H^6[27-<$_^O.=# M+_+0-C<1]E]&J6#]MDK-.DRY3L\2F$:5OI#@GGW?5G! 05ZUS!?\M:GBPL#2 M5MS\6%0N]8T"U5KX9'37'LL#^XD2NEQ+%N-!-_[WF+A?"#"V/H>9A"T%4WMB MZK@%\-^TP.L&^X.2T3[Y:1/7DN0LA5Z[\;_S*-Y]XMA\_-_4BG? MMA_/*7$ M102:/K$]OBMWMT H\!4#-D$VV>Z VRXA8O%3DHB.%1&R)*7!:IM:[<9F\&Z! M @S:T3=A%JW)GH>Z]K1>90C_,-BW@WV3)_[U[!HF'R&6#X/H*5V"I L P@_H M@OK^-V*'+A9;+#6&[T*OR2/>5'M$VIQ%9U;:H!BX,TU:O$WK5=+JX"Z;NLO= M KK?@GHN8OZ7/T*8([4]HP2UR0G>ZCJ!2OL_[!7U_\N230P&W]#@I[:_F'CT ML<-04(+:9/!WN@;GM"U!?.C>6[6V_O3?ADZ3'[S?S ^&**']"BQ)KYHN$)]$ M;;(^"7U,D.^+!"S,EZ@PIY_8/@8+J\M%=66V"9DFK_@@5FQ)"WR';H&LJ)4? MK;@=*VU(A 2B*>XL:F.#2[1PB0L,DRETK348[BO%9 [=T4&,?./_']B89,* M=GA-1O]8,'I"55A7T+4BPI9">;!P"PO?V1Z"[BB#ICODA$STGU*K5L$V6?)3 MP9*"$N^9DI:5$AN,U\)X$QNS7VPO1)?(YG_SV;'4[6PU_&*80^@WIXR!%// MQ':PARMFO2K8)KL=%NPF*/&<[[>6I&7%Q ;CM0E?8)"JF,NB5TVF>5,,0@3B M8(8V,49 G=\A&$=B7Q!6<]6+APK0)C.]+488G-!(4+)44H/A6A@.%+>D1*CR M5YLQFR_QPX G7/-[.Z4&;$!I,N2[@B$E06E/*R9I*30'B[:PZ!4*^-;X#6*1 MH?C^::DARR&;[/>^8#^@(W?C5X@EQN2T!KNU[(DX$+M?XGB%!.#YB#A52[4Z M^"8;%G=;%&K168M";[!C"SO>(IY7QC=%@_44AC+?=L015JD1*X&;+%C<.HE( M68*6I1(;S+?5+=(;ZN'*7KH!N287*.ZY=-\RM5[%S0X;ZMOUEJE][_7F*Q&Q M!D\Y+&[S;.(ILM'!3S;=QJOQA!KP)EL7=XC*M_0&._:TMU=CQFKH)BL6]XM* M]_D&(W;?,ZJQ6P:@R515^T>#;?K;2*JQ52U"D^WT-Y4&:_:_NU1C52W$)NMV MV&D:S-S;EE.-=>O@FXS:8OMI,.;S+&F.75?P;GO*G0H9H?2TSJEKH1F<+7MNAH'I[Y@_WH&'?\6/2 2(O\6.71.\)_(!>KV?,YD M]8"3]1T-F8-Z=<;->&ARU^+&WD;NJC#+W_*Q,N;72AFV,AQ;]VM+\CRXM:%N M?64'T-#+NG6&AR:W[G6SLKM;2YX'MWX>M[X+ETN;K:]GTP5F\I#CQEXCYD\7 M-OA7I)9+RFG;Y& ,@#2P/<7Y@&[\Z-@1A:BX/R+\P ,[_G*!,(L/41",6-#R MO-]^\<)"-'2L-[WN[<+Z5TK+WPAY1_(X24IL<9&M1&:+"\V?$>M@_.\"A8N9 M[8V\L?1Q++^5*D!"NJ6<[K8Q^X8DF[RXN&NMF0D^!.3/D"K> MUEDZD&ERD.*&>'6"^;!*Z]4IR@ZCVGI$6QI-[E#<=*\XY1I<8>NNX/OA"%0[5LJ-Q=FQP+DLA2$% M4]YG+-U\'ORPGV-87JC8#3UT/9O@)^2"<9!(C(.(DX7(O<#V/<^NA^FAQNGZ MH-OD8<53B?*CW9$5-\V=1S1NR=9%1!2U;RD,#+[4DR^UG=U:DFCRD.(11Y6' M#'/;UJ\!M?6%#F2:_*%X@E%]>6APBGY7TB*5H_5BN1&KR>0E-Z-E4LE@WO[- MFT[QXJLJUS.(YL0;.=TV&EH/O\GDQ1WRQ.1J("":&%W/1M"(A(BC@L$#>O" M4_%M@>"&,GD0$I6@(G,(^>07>22*7CS9'_4&[WE;W 8N]9Z( 2OB0"FR!>L5 M'E9&7$2>-027/;O7!27S*2P0M^1?&Y!O=+7'0Y)+%#>VZ M$4O_9#WOMH# N;4$NZ.(7RMBV!(<#PZ]A9'O]N[;YB->D4B36Y74'=4:Z:"E M88#;@C]\FGXLFCRP>.]1Y MI'K^Q9D=Q=RJ]ZYB?JT9,&RI''.TB&K?U05&&[K'%WH-'E&\9BBNH;Q7]HM?MI_\MTC>[7"(+=X%CTA MA$I.Y$/^#,GS8F%#[BF_98ZD+_FE:12G28@KM%/[Z?K>PW-!)\Y=D"D.+F+\ MVI,/ROH'LMF>1>PE^KS7)T7Y[7'^97-\!/,-F)*MSP.TY-+O67YX[P)7_#;(6I.Q6$,.%1=0"<8L_CU04^[P4L!$HV$&+@2Y_W9K8G M/L,N<._EQ9K/>XZX1A%__;Q'39Z%Z)Q,'RD7U]](@SE*?Q'-+1A"?>E.H?77 MT-Z$AJPGY2FD_B*Z@^"V+]VEI/X*NILN$$/V+$";S1@Y2M^]YLX!"H*+8".E MI41,T9>+[K>B+EBM;J0I@6^*DG2^'R+WVXJ7[R0/B'$Y1/G"&0*'=\6A MDX1,ALG6>*I6?(G]+#KI1WJ1)=A>^ C-&(_0Z2K'[C]#7^RK3FFZ679C8_>< MG-HKS.\QI >?M\B)CJV=F">AHTVI?&\J*PRKT4#:0E_5)'9*67?0$O*/9:<) M,%#/]IE+M+Q/UWRZT%(%A!(2+H]M6X1SL.GTD4X7-/1MXGX1 M1U:(B-C9OYZ!'#P!.B-P2R03Y;Y#JT"P5R8%FF.?+RYA3F7("9:$C9&L1K]Z H]=O>ZCLC& MZ$?+\2A$A(_7Y":\][!3OAJKAS$Q7]6,IV.#LUB,8..)$W>4^I+[[-1!D?8G"P MP$2)2>- 54 = SQ@PTJE9@'_&Z M'2@5,QY@:X=?;1K1A JS*8@G9JB7UTKCNO@*@5TS8X3VDKH,=9?&CE)KYWI" M;'2WUD6JD7KM*?K)(;4Q5OG'M)1/&J*GX,0# R?15@N,3%09Q,]?OB-DOYY0 M(ZP&H*DR7B#?1ZBR?&!!5'UX4R5NN*I?8^7VB*;J0'Z"5JT)WSE)]+WD(R;\V]2C.A,R5D>;EBJN MT%C?9(W57_J%EF*@$9>,:O*J%JBFZB%?6BF1(W> V0QGX"%F^T^_7P 49SM9 M8V]$XKM0R50]9NN,WD$5;G"T@/?,">^%0I\G>46>S986- M-6(YH:K>FBC)E;A542-,#8")\O!9G6\/VEZT+/6C=>F?\@K)&?+P V+KO,7: M89DH^8D7HE-&?9__N%M@Y+E9(6L 3)3G$KG8X67,J@%I MHH3\3 RY_XUL+UAPIK-25;TU49+TI L%\97V$V2+2(&XZ!X$X>%&\6"L ;SG M\XZM7O_4%.HL1/(0^9H@M4I/9_1=TM$WXE"2G(N'S%G LC.M+S9AZ(\0$6<- M4:A@"3O1]?^T4W0F\.SQO$;<)^[[P@R;,WBT;Z;L_B2Y"?H(WY%?_%]H,Y#7 M6T?&A, ^U/:)*N1=.DN]P+""=WD]>YCB; +SFJB)<0,4_,*J5Q/8P/6M\GG+ M&ADR:]I6*$:O8^\6R)O).W>27%*K/W=EKQ'.Q @A=W:?IDZ69\)J@YLHJQBD M^P,HS7W)=H!W.+LU5\>9R) FG MGLGMNHFRMW(NH0%O8@:8+O=?GE:8E>Q1=L=7?6+.EP*7E 2+E]=(]?Q4I8,V M&)G]6X!Z>7F3A5L\A F[%99UN;>[%)W+Y/^)1^T@_I0OAN!Z0ED^XU4'E*9T-V;ZE2<&U.:+="/8ZH_24 M/ZK4/)I2\77$1P9-,OE=1UY;X#BN+1!]0S%[;:#W-&/P"N1_0.,;-A M19TC*0#0 &CB[G)3*;0=J'.F$5^D/I;)Z4INB<"L\.7)$?-_:KND.W9#[M.7 M^YI4E'BR>/]S2M6-\4C*;*7)#0@8&$-\@4:7?' MWGDM>H$FL+D#<\*N^MGO M2Q0LJ%LX'FB%8N A03/_F0,";7"C#P>F"\R"=77%J?)=]+98)H:80@;@M5.- MQX[(1NKA$?Y4$UIPDKAVZ&9*'O,:U7-O7+1VV*9*+D< MOR[M,LOI5VO9E(J)FJF_8'E.^/SE8R=3%Z0=CBG;M#H[C.++E8CQ:PXB19I_ M2(3.@D>(T,39FJ*!)L =$EN]NN/*:X89::O?[ZB0\M+.$RU!LC)^A%4/9 M<<@D?DL$#-W)T7Y6E$+E.NFIHFL#%K?+V#F*A 7I3$5=Q]JH,P M<+E^_32C++E]=W&:2P^I>&OB5'1!;1*[V37))3%7O#11CHICI15FZ^QQM09@ MYI3:F%M&5RA03R!/*&/TD7]YZ9ID1XN2"K#=<(T98UK.-'*BP**QW*9I(]@N MR2RO_18S2/./#=P&4FXL9]G>A>T$K<(P9B-I^@E,13<:L9R$2 M&0Q)7?UC/L'(!.\&W>@0V*650(68Z76'],N9PBU@.J[Z%G@K=%.S#=6@Y )Q M&T_I),S6M4AE*DO$TL$RIBMIS.G9&BFM9I=.J";.+SE!E!+ 96\RT;H1.:6E M'W[-5_5H #(P9HNNJ=WPL@P\Z2=?XZCPX05M> .%C6L[E7._+EA3%]Q 4:L* M"O&JI86.5PJS2P-LIF029S]ORAH XW7]6/OI=*VPM^]N"N>-W3%+/>,[E0, M=)_HD\5)E;&\R-7O#11&)/6<\/,2?E2$(/P1+*>+A9-U"A+?)WZTF1NO/V6E MK7/"-YGQ Q*73S/9ROT3-W)UJQRUQCD8)=SG#^O;X)BXA2PNYLB>Q%=9MS^ZAO8K$JDS[C'_T.,<)9]QB@LEA;:GKCE> MJ'$S#R$V54;R#:UK-J%LAH!=^"F.7]!S&Z8?7KXS.R69EK @#9=24;SB-]^' MNX75]0DE+A_7'R#>(<$_>!FJC>W1J4T#3X4[*R">**&M4,2,(NR:+FP2N>HO MR.>^2%QY/>R\< 7WV1O.A'^&W,QZ!C5\$]>[D,O/"QUQN9._DB'>,UJCGHU> M;=/CI<#G]-#<^%W]O2T3.\PR"Y82 M@N7%*GS:K#N^B=JH,&:T]FUA_E(,$R7.S=&9ZDRUKIW<1.Q.P,1PKH,XA3ZQ M&8WO1BNB!VRDDXC"=Z*1DGIYFU(Q,'RN8%MCW_ "SU##L*I-Q\6@ MFINK]9^>[43/3'W%YN>UP;.EL/(W,G0@38SH*_F>/E)-"17(W9)PP9"N%3.P M1DJ9[6D9YB3D 32%54!-ES!:8*R\Q6 ]CHE0EM0N*7W"J #!1GDS2 M9)SY)SY(' =HR?+Y M2I)\MI\T )G85VX17MZ'S!>/)U2NWMT;&VP9\.SJ9)&G 6A,'] R*)HC^P33 M #D+0CTZ!T.=$R=GT'J@ES3H3_M<+-]9P&KZY_\'4$L#!!0 ( J+;4\" M\K)M* \ &_O 5 8FEO8RTR,#$Y,#DS,%]C86PN>&UL[5U;<^(X%G[? MJOT/7N9EIG8)D'0GG51GIDA(IE*;[J1(NF?V:?__ZWC_]HMZW![=UGJ^\$< X&D#@>(B$&/SY]^LGZ_6IX;]U#_]O( M)L :(">< C^PVM8D"&87G<[KZ^N1.X8^05X8T,;(D8.F':O=7I.^QL!F7U@# M.P 6_^?".N[VSMN]7KMW\MP]N>B>71R?';WOOC\].W__SV[WHMM-$/BZ0F$E M_KFPWA]UZ;_'W0^)!Q]MYYO] JR[0>)!^]1Y?_:A"T;V>>^=?>R.>J?O/IQ^ MZ'5/N\[9Z=DHR2F:+3%\F036C\Y/G$6*U_>!YX&E=0M]VW>@[5E/:Z3_LNY\ MY\CJ>YXU9*\1:P@(P'/@'D54/2JW"V\M/-HE/N&_7K82TEN,L'>$\$OGN-L] MZ:R?;D6/+W:>?SWA3_?.S\\[_-NW1PE,>Y"2[75^_W3_Y$S U&[3K@HH$M8 M@1>$?WB/'-Y' GQ9F4^PW]KKQ]KLHW;ON'W2.UH0MT6E85DK>6#D@2$86YSW MBV Y Y&;O@%G Q^#ZU0Y[L+/Y;B>%'V%Z@;U /IHN5X2? DJ5S8EKY+O )\"]LCTF MX*<) $IPC2D-/X0I+$IJR0&Q_:+ M&6N_[[L/P03@/B&T_>L08\K=/Z=M(;S\ M#*0 ;+ZG@].^XZ#0#\@0. #.[9$':-,*HL^GHP/)M4TF,AROGL_G;'=JLT_^ M>)@!3.>E_T*'V,J&@'M %22W& _C+W3L\3$GPHXD01V2?,2(\A,L'ZDV""A' M-W^&<,84A>1HSJ>C972K:I(:=(;XD-E^H](Q? _M$?1@L)20FB1!/=I@!@/; MXQP\C#SXPNVHRE HHJ0D_:=P-O,@P)$'ZK^(ZXJT5S59"AP"=]V=$"C-JVPB M.JW=H[UD)JJ$G=NFH(/[ 1@#VIP[9#X;_1L&GY'OR&/(I[,?;2+'J3S-&G6* M6B<($-.!J=QTKFL>#T%@0Q^X-S;VF0:DLS*X\TBKGSHR%RC:93Y#\%R/DFI:D$J&F9-7VTO!%*39.==/?YOI"#5 MF$Y]70??O+T)\ER "?.U@Z4,VVEOZQH?,&!A :&*_AKY3.4#ZMD *6<6AL& M8+I^?XS15(;'B V4T2D(TXYWAXI[U^6(0;\_ M5- BOF(LAM-#%8-((!"+X7C[TK.7H&+V!+EX^^LPT0HS9 M0/=.K,>+LCFQ" QT]@2Z73Q+%TO"0']O*YF*MK])06F@.Y>-,C_U'H,VT*?; M!2U90A&C-]"E2Z]HV%!PK*SE#>.Q@0Y;(<;\8J,8NX$N6R'VS1*Q&*N!/EHA M5J%ZOE@$BH[:Q\ZV!.[I[_LL)GW[A#R,([U%?1"^UCJ=83"A#\$YN$>$?/'M MD$8D<:&G9,EIB9::5)BJ D-'P@UXWLKB?++Q-\"L3S16I1)O.51T)(1^!3Z5 MJ$?;[[M3Z$,2,/G.@0*40E)ZB@,(H&IH0KD8@#GP$'=\%- 4$-*3'"74>1G2 MUGW9S/G&B[IX97,R$I!D]G;[73TCA8OGEEHEEN7"MA/\!H/)=4@"- 7X9N%X M(=M=PRP._<]]MA=RXT>!O%+YU6\VQM31O_/=T.%Z(#@P/FVTSRRK#?>KK>L8*:X].I$A: M5]0@C>6JP3))Z..?R6NM-: ?4CG&3L\5&",,WI@$Y&9!-0MU@FG,BY=WU$WB M^0NF;Q#W*]9S0%X&>V)#2<,- -5#[@#.(?4(W2'@2;EG%"DJ,D"O_I#&A.XC M1G/(MA8*ZSH%REJT" C4YM[6B]IY[<]MZ+&8_!DE\L=1[O7*)M!11B-"NOZP M5E4:*+,/C:Y *B$.U?FI5*/4;J3 TI> ]JB=C2YM$A1=BG%7JFQJS)#1X3:@ M O?.Z#(IS0+,\>Z-+K,J#GU03G"F5%K5F#DHA%TNNC:Z]BHOA$0E%TF,KLH2 M%,SNDIA2%59CYD?F\B#*7+4TNOA*!&_!"K/1%5@B^ OS!49788E(("_Y4[H< MJ][,)JM$N/70:Z5)S&RB3>OZUP5]ZD)$M2T2+K% MRMJ5C$I8I4_=$:%7#[+="M5RR-+HU88L679<&M8FL7HP104KZYF16KA2#JA8 M"W7-PE5I4NE!ND&HWM$9EYA5,T"3]+3L9>?[N?X-?57]F?P+U%^ G@.73D!IDH12W[]"D1&[ I$-5D+MA#" MD_0N<*^6U.I2I_)M]R$_IUPZOI6A6B-*Y@21H&J4J51K1!GOP*H292I57><) ML_^9$9_;'N#!&PDP=&C,P+[HLVJ4Y >))Q\!ALC==8>C9-;-PIG8_@L8V@&X M&8^!(WETH%[.&K"27D]?(+71:72Y5F-%G:KNC#Z-JK&B3K6?IA>&R;H?2,F7 M,OJ$+#4IB3G'1I>'52>8M C([)*O4J(IB'0-KP@K)9J,A0REFK #%,G6VI12 M15C3Q9(7-R*U=4BS:\@4(D^!714F5I>5DT1N\L#HJC,UN0@EAXRN12LA%Y&D MGE*IVH&HE:QDK-%'B943B6BVW>@SQLJ)**VTPNC#R,J)0ZQB1NG@L@-1,P5E M4DJGFAVL:,3*Y)1.23M8F>W44!I]D-H>I+-3.&OTZ6O5:Z/=FNG29[,=DH!2 MZ^5C"35TCT=\=7CR=N !.RG?(^SZ:3?TP,/X%BZ N]*K+*# MB'T8T/G&3P)>L)_DQ9Q#1 >&3[8S@3[ R^3JK32(/"J:KEN-[T^)5QSISQY( M67JLI"BWNC8U%2:F-R_=UT64:D5CW,7AJS"QBAN/BRC5)J"1]Z^VP_6G.O,[%/2.(AN7 MNL%\AX)&[C5=P5[+D?"%"'=O[]GI"J/K+U4DL#.5C"Z+5)' MB8TNEA1<1*D MFC.CZQ&E!)'CGQA=>R@EA")OT^A20Z'P0N02I"@D,OHJ3UEA5!<7FUV!*!AQ M([%5%*,/HI,713(R,XP&%T]*#\@ MMZK,+483] MR"(HMGV@Z)YEU9*8RMMMHDU1!Z79XNS>FJUF@J[=UGYM:XK+G7#*Z<6RM;:B>\BQ,LE+3)CIP M!(@T5$%O(!1;GLHX).-@;):(2'*N[#,HMZ4\:J2AR8Z =4 K"NP7+,X"$%_3.?] M?X!->16[#4*1L&XKG<;2/F V$"$*<>4(.B1'1QF!\194C9"1K MQ[?2G-2ZLHW1A&IPQEIE4#.HUXYZ$%8Z8"O89DT^44%1$QD9*%YE_FPO'D8> M?%G5B<;-/4^H;V@SA2X<.U31E%:,[*C*.9\G:KO.E=O2C9*JV_J.A:#$ RT@15Q""*#30)^SYA M-QBQ9(PB3[MIB*5C%@7BC<,L%\-(DVX,WM(Q39E6&B,%R1A'G&;]NR2D\:-J M^M;(7(0VH25U@9'I"NV26MD)H[?0ZY+5RHTP>I.]-E'!C8/B3=R*KT-46U&( MD1OVJPEKT_94E@W0C=SRWP!Q;JWM*!T!\%V,NPN!1IX?T!1!)A:.C3Q]H#%R MC-,,1AY;T PY)G-21A]Y()RB+*ID%K7%)IZ(4+F04L-4U?,1#E(R6V&IB;MR$4M8W)@ZVEO6XMF+6 MTG55-9:'??%=VBWL;B9VDY4#".E/V6^E,643_EX*IQX+"!YV7[(!?7CB^PGW M"2INY7L1364[J66F4":)VE/'5>@_Q09JQ_X];:Z>568 NHK'^RLM>%>3#,QV8\,UMGD_)CO'%B6XX?>W(^ M;=$D9/$L17A!TF.=7Q^ E A2X@,-@@!(\R2UY9'$1G>ST6CT\R___KH,]EX0 MB7P<_O+NX*?]=WLH=+'GAT^_O$NB]T[D^OZ[?_^W__M__O+_WK_?.SN_N-X[ M=F/_!9WYD1O@*"'HG^^N_F7O?TYN+_47\IT6\]\_NOZ0H4GK#$ 4!6NV=^Z$3NKX3[-UM*/W7O8O0 M_6GO. CV;MECT=XMBA!Y0=Y/:Z@!Y=O/P89Y])6$4?K/7]X5N/?Z2(*?,'GZ M<+B___'#YM?OUC]GWWIQ_D#QQY\_9%_F/]T!_>-C^MN#;]^^?4B_S7\:^54_ MI$ //OS/U>6=NT!+YSU]JS$EFN$2^3]'Z8>7V$U?IP )>[6_8/]ZO_G9>_;1 M^X/#]Q\/?GJ-O'>4<7M[&>L/:-?WD7^\CE@6*6?+0B: MUV*SX1%;Y#,#_T].$+S;6P-^N+W8Y:P?QA\\?_EA_9L/Z0,?>L:*+HA")N;O M/31WDB"&X5CQN$:,\=+Q0VF$UT_WCF^ZSOLE6CXB D2V_&C?F"XH".(FC^A] MSB48OI4 BEB+HOSH8_<]4X3[WS[NI[C=(_HKJL@O4V6RC1&CC3V#GN/T&-@\ M^B%%J_QL%3["\&+G%8=XN9W"X>@!0X\>HY\ M_S/QXU4;D;<4Z.^R0,O<+%))MZ8?^DQY,@Z4?HY>8T17\39 &%F]4PP^H"".-I^D_'N_?[#6X?^T_OCW:Q33,Q(O MT26.HC*' G:08++Y,' >49":)E4/?FC$=?<-LD]^/_;^GD0QH_\>'WM>RGDG MN'%\[R(\=9[]V E.\7*)P[L8NW_<(C=PHLB?^]D!)X*MDF7ZHNVO#B%.2-GH M)6XJ!=]?GYE8J"2L?@TIJE(AC2ZB*$'>PS,.J22O;=C9_(8^B AA4DW9F/U2 MF!0XX)[Q_\T)$O$W 8;;C+V:OC=$/SB1Q"%( %9Q_M*.9;)T%E"Z$7P!A$? M>YEL7:,?Z5<@)2T*T2!UZ7Y02=PV0.-OKJ@+LK]C_S% =\BE/XU]A6]48"73 M;UH',T07,BX9MRB*B>_&ZZ/A^(=#O%\)T!"37<&T)/1)?-L"UIR^["4Q%XM' M#5!FEZ46YRVBYG_DQU18R8OOHHPF:I?BI^QV(FR;Z,-%BS2E(CU+8N;T8HY2 MD*3L/JQM!S1<0P7$>^MI*5OJ/YTP<^7^ DHASXSARB"(5KMVGX=$]M MG\AQV3N]6OM1!,TI.>!2=%PYQ%T4%KKV0Z2("AG0BMY%TU(S>G(Y08#3W=OY MQ8!7DJ+P'#T2P,) JB2A:WA7O;Z>3G3#:G MUU6Z-I":+DO(>5B2)WJH5:V6QGHDR0!"U7*&. &:S=.SX-I9TC\+4G&V=LX# MSA0!:&.DZO=#370ECY'O^71C%W Z?O5A=FT]$"VVJ^LFRR1UB\SB!2+,(B1H MP2(5+RAS^XIO*PF@>NSS2C-8@JYF0)+ZFM KZG'AXEKV(H)ULQ@X'7PON-KA MO*YX6 ?.F>W-!!:'U#B"JZ<: ,/%79LVW43(MK"(P!JU&9!66NZ=QP!T?]]^ M4BNVE]0HO:!_RK&[\'09:QYL/29N"3*]B&V@K@/F@CD@V3-S@I?-B*P7P_4, MQH1>N7]Y=["_?[#_T_[^N[UGXF-"Y>:7=U3PDXABA)\SI4_!I>D!/[LXC-%K M_#U( ?WR+D)/[ _^?8 CY/WR+B:[#A.US*A,+VAD3EDBJQA3O6TXGSZU\ZE/ MDBOR:QH);E0G6$#Y<76@X4Z;=?RP$\95C.B\FY8=J8Z84;75S3G#7V'PT2K)&+07"F MV&\=23!%,L*4<^6C:9UJ@:A41A,YAT:I=65"R)PEHU2]??TZ$IY)YNEM&'%@W+W8,R-:LS4Y M)X[&S0G1Y-V<(<;O\%I$ \21T1PG8AG^.>$?1[XW=NHVA'P22A9"< 4-7?]V+6G->?'LKO&BL7-ZP MX^/!T,^'S:^VRLYS @^%U?]?/FS11]?[0U>K@U,G6IP'^$?T$#H)?9_(NZ&; M.(P7**8O+4]AZ=#W0' %2YL@M&&O(>^)&A"*XR4*4P+S*#G6VL:1&[R.2ZB^[K MV7SSS2F.8O'6 5*P=63091Y.=(F<"*5,GC'O\.;: $T]BX'$*UTNG#")W01;A3'#?'9KMPLOOZ5 M^";OMHB>O/::Q*IZBQXB>U+@]=&=75 *"*WQ1=X!G,I&8#IH:CU29 V!&F!: MWE/3,<_]B*=.$"#O9/7=<1?EWX+>8_?%Y&H"GYX(>J**;LM^6>^/FX0P_M/; MU%IY9[D>PEI(%KSQ3A,&N\>(OJD'>NF([G"@_B6U0Y:B8//X.4+1<>BEAB6+ MY=$KJ?=7/U[X86&/E\S/8_I[^C0U&FJO]<+4]HR%%&<>0I)G595WR*_L;]9G M]MSQ":S%%@RH.DLFND=DV,K">\GI9\L;YR5:!UF%^AR M'53Z(\,J&D[9OYCV6:]XBUB<@)F:=(.[_K,3 -L]];6R% =VXE3RO6)$0&GI MFL#0>,K<]=3G55W-]3U&?S G+02OL: %H\O2^( M'&^2SF?/L'TF $13[Q6TCT.\Z.'9H[<;^ONC_4.IOBLB #7*EH.+F0441N:FC%<(FX(#NF?[EH+ 7' M+O^%'A84CVPSPS=3'03)3 (T3U@2RL9; 32D:Y\WYON!2WTCF''0H6O75J( MW:L-0'30L%X7OC&W'AQN-[*I%QF8EJP;C&Q702$P&O=ONJZT BH]/42LM7?C M*Z(@+?V[0"1HB$AB.V'I SLN.@P#_F(7ET!BTI7HCD#%V@YYZ04]=2QLP MOIRZE@ZZ:ZE [S?C+04,-SX;0 -/F=9-C2>9-5T]%"%E)U_3&CR K[C1A(]EZ!#XW9E)S^\1@XP,18S@+330S%=(-<0G&! M/W79T)P1I@T!(;70"Q^*[9_MMPX:\^++PXA$BA XZ:;/A;X,HX;JDKR7J>G) M6PHU84TQ$&_9.PQKJ+DHJBCG\*(NS@O3,B^D]/IB19$1]EM"LG6!&%#/R?EA MVA^@I)EI#U6Y(^M_+5.:S5E@VF&FA 621?8Y%SX/O0GTYE=271,X&X:N,7)W MFW"G#-X)WG0@4V$?\*;F)SG! W <"+[LKOUJ.$O&(O_%[D2<.M.WXUY?>'LS MJ9P1 [@@"VSUIIYAG%33EP,EI,*:N''BAZ[A=+3JX]P:NO*3;>.8<^#;T*\# M_%? 04#?1F'\R/99Y6P8^F5(TB2J:J3+F6(ZNJ"**0(=E?-!,/MC404"K;%S MH@_&<@N6ZGK.V3#T=Z^@]7W.#./)KJ9'Q!U^&OK9F,>0FN=0<(+'[UT]?R@>>[8_1F-N=D\4GV DK[YX' MO)WY$:N)30BZ7R"6S^V$JY,DHB1&T;$;TY.)&>3T?G_B1'Z4#FV,* _2B7S\ M[GX1SC%9IA^>H=CQQ4:_];QV)@T&AL+U19?48(HEI@;G/U(PV6V[S)ZFR1,5 MC^HH>K]%+RA,J W(XL=N%BWQ?,H@'CY%).4-4["/@?^T9E+D$C_=/2(DJEQ- M)U=:D)G-[_VE8'=I:=#:!L L<$ 59I15FS T282*TX+%:10"IV? 5&X/K(-B M2;R@9\ _Q&8<"H$Q\WZN<5S@)K_"WC)! O78A\/6TV0LH#"?J-Z^#.YM6BL!RW30T[J_@Z3:*8VH[D^ZL;)*RE M 8.D'#?M11O#UW43D!HU$190D9Q8 MTQ[BUDAE)UJ'$8\7.Q*QN*UA321>!=%M9B(/4ML;[($1*V"M-'35 M#_U6%8'>RP*>HA4#D-?.$.(C/990 MR#K8A6LF+':PWR7+I4-65,(6/O'8$*]5%F2Y7SCQ+7K.?GJ%&6PG/-BG/\2Q M$Q16CA;YB2=FMRZ6W+J!#MNYQ*5RN*'D,""O+WOSIO3BIM 'Q$@$EA>-)D*!3@J.( M_7&W\%'@ 5%K@-!;-SSTG!!WX43H^(F@U$MTRC8$(L],][&,!9@7& !P?#3U MF1^_O2+$UUW]K)8NLT[ [/#T:*0GHD1KV6H >GH;;ZG3$Q2Z"VH>_ $/7+;# M&AM%NJ*PNWBL_@)%'.P4EN(E1Q^&%$>B'G)P;8+M8$?/7L]BU+=&C1/F$[O9$+NW>,@47Y M^F##L*)[PI=0W.H%L":$IU #U/MK> S.[AW?ZJW"$FXU3KS5VUPY[47*[=W; M=L-]<:$N6C2D7L-0^[8Y9L5MECM= ML+D9%V'I9]U(D%M1BN)J 66&1U0:9;]N]Q^M<[3N<8;*;#Y'1' 4L=KUM,0B MFB;=WR$W(6G2W*D3!*RP_;OC+LJ_!84LNB\F)0''F]+\S5H;<T>U POT5/?K2^+.03;.AIX9-2%W]AV I/#; MD+D66@:Z)+]TNZ8K2^L$^05ZI4.PCM;8;Y6Z29UBB,QM2,/6\?[> @)*[-\YJG:4E]MXZ MK- '1?^=."1&)%BM5SE>,K>V*FKJH%LEAR=.P+8(M3 1@'PERTB]T5F\0.0: MAQ-$]8''ISPP7*1^WSQOQ&$G5236",T0&ND:H' MHH.&];IP<=YZ4 >NV53HM,EV2#<07&)J .B)*&V:02C0F3UF(BZ)43.D^IRHOH92&,8+W 03"EL&Z">PGN]"T(37]/;QB96(;](Z]A MEY9QO+.];*Q?KZGNVM4BN$*'#:$NNTY7X\K3PIIJZPX4E<]F:WIH][K3! PH MS@CAYJXF2ZC;[4D,,X+M*2%O+S@"7!&PT+UF2*7C$L2W7SAYN9GMPUZ5J(%Z MST#.B,]?!Z$&6ATEN-F;P^OM[*VJ%?!E84&7&R=W$-,35,EYM1]5HM;2"EEO M="_C5E(TXL'(!K0Q4YC5_>@EG7$%_BC!B$6=<>;FLC>T?*O]AOSXD$ M2W%;5)<3/#8;KBVZGE/^=:R4-R1&;(@_&, H<(B<"V>WY SX-"X&-"8@<:+' MI=TZYXMQQMBO"X2-FXJLOYS.S_;2*>=B+V=DYG0>F;Z/]D6G2,9LS@7C5EQ? M7-A*?.8$F[Z:J288EJR>\^'K_AOFPV[) >>+Z5A1+WP!E))P3HQ507:J#6!PK["8DS67< MG'Y[/I>%9URJ.DSVV M^[QPY[ZCO+-+]%OD'!GMZ2#8.S/GA.G$#C.<$.B=RCDTMK.U4X-=SI;) M!JWMJ,R9-$KS0UDW[IQ/7\>FA=*G%'9ISSDU3O][4TO^#>D?]T=)NM3HA)PG M'\<6>*CRG%:-P,@Y<"1\K=$VX"6=L#>;9WDI_,10-]1%?@$+!KE((&^H04T4 ML]A-ZKM?^/DIGZOJ@@>SS%YX%QO(2G)-D/+A2*6HS.:4\>C%\?NKFYX]L)$U M7:!W:?_%4]K65H8PLO4 =#1P.'=\\IL3).C8^WL295I=:D90"R"Y039.M-B\ M- [L#$4N\5-E*LQD 4BJVEYSX8.*0!T4XV,STB_7AWV^B2#"(0/]+0R5&GV3 M[[^E>AOM,@^N49>3U9EGU-[@NJX]7<8'PC,;A,#H/G(M'NH@UVQ2X!BT9OZ#:L&O&T5R8+H+C.I1) ?V%H7)#NZPMYY+.%,9KG+EC<[T+ 706>N_#)]G[T746[9=3"IV%8C:I'+5C< MSD/,R2\P:N'3R&Q"@4 1GY9CM9TH'C<#3U?X;*\]"8EZBD]7^&RON2EGG+6% MR?FXF+%2+C)=80"W?8B$UOMPEWA%+[Z#+Z9-K;NDP>?+.W@170S@,TECSX-A;KMDLO28O; M4L$-&FC[2./1Z]XD -H/<7_L-HYD"\3]T=@[DA7P?,K#"!1%3_T?#T:@1O(? MBC2TX)2/0&V(=B?A1(]%)P!F-I@.QO=[[^O8U=3BB1[@_2\X\V< 80#('I!L M8&IS_W&UUG--U[4A=+>%R4-+TL'2D[S6%YT M?>?0G-;#$;S?+BU=.2-&8.(U78@6=*F&8B[7LB_?5[G\\)&(%V%,;8C(=V$MF&! IQ8R"EK(3"VI#+6DJGD? MWZ/87S+_PVYH3J*YN2 TN:8X!>_9;GSQ'A>'+J\W=7:;$,:^PPKC;"NG9K]< MX]"E9O^,W#@D7O_CV/TS\:/TA#CW7Y%W'$4HCM)/*=Z@W2(%7DT[_4*J'[#T M6P34U"QH:A8DTRQH:ED@SN2I9<'42&5JI**CD8KBD3 7X3.]J5VB%Q1\A+>C M:@2CE8["E3G*/_P/'Q&'VIHKN$(# GX[M/Y^J)G:D]4N*JF@0=6Z*$1C[Y(: MW83Y"V#V!!BD*?K."?HS0:&K2$)WP(V3+@/[K0J9#INM'IS>X6?9W37T+GWG MT0]2I]P:-6\6WFYV"?U!<=.<.)$/;Q>E<-&A\&@WFJ&)3X6%C32SZH=YE3'/ MSL+T1EIFJ=_S5:^C2;/9V&H+S9TDB%LX)J#]JWC1?'YQ;IA.0!*JM>^/&VG.;,-*X]]!^H[F_QKV'DY4LV-+M:!#;I(>6;D?V[P^U+=V.[#W>.R@$ MD:RFO"'" %H.]^XBEE<>1O)1:%UY-&'%11MPM72P9]H;^L.!W%IZ2J*NX7 M/HE75\[J_@>^7^ DHCRXIJHT1BA46"_4=1DIVC8+7+' 5<7"DC4D4+!R[^4' M"E[0.7HDB4.JN":)/!BN+/9AO+JC*C>%4ECF.]MMG= ' I;?%138].514TD^_JS'_Q/6KKJ:&N":H9*@N>!!7D58 S0=<]11Z> MI-\$90Q4Z*HPJ,( 6E90#Z.#U?F?3KAEA'2U#H!@IWK?8=;[-O/^ M<>#UAN^O2ZH[QI:&J#6F2,?1EC+S60DK2ISGETYQR M\.DXG#*!KGNBWKH96LY_JZW70O5@4_K5$#ZLC'V!"TH#U96W0VO2]#607W_W M'])8^6Y?U@\9,R[I#J?_B2*$CETW62;I/+P,OC!:0("=\5T7 MZ?Q*<"0>;*@'H","=>.L-K/*L]*B&X*?$3V4;ZA,QE3+?*>?/J^]^,)R (&J MADF?,:1$X ";B+0=%!%Y9@Y':CFOV,G@$.\Z.'9HV)]R!HA',(S'P0! MZJ"-W<%G\V,O.ZK@I%0_K^6MY*.=HG-,KM$/SE4J."'],S-G(VB<%PA82_QZ M,]$.3QW!:)Q-+;:#GM@]L4YY!B MNHU'!P:?=M;$;T5<,$*J0<1^L:>EDC*J 38I=U/;ZTT0H[[EBF%/:Q[EA#;? M]3CA]D]=%)/O\MT[I^^C?5Z@8XI+0'_UZ90@SX_/'3>-G*GS!,DO8($W2 +Y M44X=JZM&0W%Q7/@))@3_H&=X- NW&!9ZO/V"(/YRP'7<7<[0'!&*PEK#G>(H MCBBV,.=<#0AU$QR_OS[[9)7-\!9FN@"D:9ZC =H'.6]4#3_803N;E[=\*I&9 MUJ5J#/3FA,57?P9A^Q^#BYTJ@&@U=NZA0/8[]T"2&[G8B?<[+%9""@2 M;7I:BQ27U(/$4-3*YX>*N:[:SRWC'SK"M>)I*:F=O=*;W\9^O[P\!8IMW>.F M3OE+=FLF<$EHAS4VBG3)>14>4&FOAV&* G!PL@&(,&LL#\#!R8+31&UG.K/INTS30*P$^?D'#!]Q/7 67S!O8_C_"$Z#CW M8_^S_1FX,$TAD/K""^)-7W%Z$(C:E"1.M?VW'=@KETLQX_RPWT"&\4-N>!=@ M5*"VM-8TZUAA/;,P/ N25MMQU1 W2;7G;/X090-P9H]TX1!Y%^'W5W?!YOJ> M8U+*$%]/QUE!8BH=%M$1.YH](V9MA4_IXG]%:=L9[_B%?OJ$BFVJUD8IA'0X M;!T4%YFMEEXH9./O]Q8QY;SYDMV_06F*<-B&WV]'>J&0M<1^TZJ5\ILH"ALH M_-L*2[_$2NG<6A#Z\=]2__)4[ "2RP@JP10=3E7[J'Y^;JKRY!G)(:C@(.\Q M=4[0GPD*W=5LGMW%?'>]E"R+Q6!W[D)26(>YH/VT&GCV&/A/J3UVA<-X02\7 M?T..>.J8-'R5U&2^U+,$/;!8$.C-=%A!)44IKX+5+?,.!I"M M( %4)=X;C]9%&-$U@M3)J0C[1M J:5"POR4@2U9Y%"(K:2+$/3Y/0J^X/M^ MPNA#P7;F?K%$E36-#2/QZHA6.%.W*2A^^KM-91PI;1MJ=[!QGV%,Z.:!556U M ]-]/^E@'3:"T3+?R'$7?HC(JM@*06)Z5A,8H[V^*MHZ=VGV501GE*Z3U4Z7 M_BYT%<%-7Z14O45G<>D"N@C"->, FH96>Z;#J)7BBV6U:&.JY@S M\LJ.6@G".\)I8]5&149H]1[$%1I@")4(=9H.5^I::\H,.E!4/MFLR:OOM),D M30Y.O.D$-2LZ/IK.PS?8\='TW"HETB]TT>-Y-8.0>T(2E/KF@WTZ\C(E&PC^DW MTXI;(PVP+F2+))EP'@S7".N6.,0Y,'"M)Y4$EE/_9;C4MZ7KY31^';AZ MJ\JDY,0-=P,+)J[FI'X;[AG=FFG,B1SNH22>%\ZI';[Z@6;Y;V@_W+>W1%]. MG$'4&^\?U.N;KZS?X;0/UWT@7ZO%J;>W'X,H]1V*]'(VB'?@T59AFO:2.6%N M+]9^!E%#,N6YLHI3:?@65*#"<9?)OT@'<>^NPJ]N)RO^D[6I>_S#(5Y>PTP% M,EFF A0QUY9+=R45QCGR8TJ$:(67/ERT=#FG8H-7"-TA\N*S.M M8*RFWO:R6R]K'L:\?21)K\&S>('(/3V39MD^S&G./(,0GFI$2BIW31J_-18/ M&VD(O8VVNL>_T8]F21RQ>#YSHCT]$?1$-==%&!,_C'P7-L#**([:)/>QG*!*OD(V+ ? ''*DQ;%;I#4A8S<.\?23[-CI^C>K@IO]E)[36HP +&5C6=,+QHYM7;*;<]Y\-)U;+K:KJ^X*N[15[.F/I@MA MA/8TA+PBVT:*?MCQ??-+<,.R.:H\? M[M^=R1EE>J.(]<@RP:=A#7/LU?%>G !='YD9TIQ'M9?2/F-VO"F.::M+-U=[ M# D/H=.0Y4QMRE+@[+6W%M%2]E:GSPRA>9*E#*W/W^),G92 ZGQ"SMM) RA/ M=\V9:]Q1892Y/25D<^Z:OAL-570[U!1PYH_@#J'HRM52"I.S[+/AAB=F74(U M??'-+WAK1].6@2EF]]B]A3/7WC-]H,RM MZ3G$>SV^M7-37QW:")DW0H6R,Z>L-!;?%N%4+%;Z@G.)B:]. %]Y&\^"H2*DPT@974!0]-[ M/_-??(_J4BOV=!F9 ?(T#5,@IO1-,K.$Q=2J3!2WJ569S:W*IA*WJ<0-=L.= M2MS>8HG;--#;O -I&NAMR4#OX04(!"Q:7E3S5IW6&BY?O#K@K:6P&O ><&;; M.U;6TF"Z@$^+:W=P_';DSU7[Q2&#AI M!V]M[*,!=:T.XM9T@3QW=9/04<[FV)K$E6:[GU%IS>6Z?W>R!A*L=BVTTL^C MMY&2UV4;QGI#*N+B5BY:&M1. :,^[!V24A0I?5,6(CWL=Y2G" WD]4#PM56# M51^8XLWF[%V; EM7P@V2&FVS@-F\-CF*8X MS=5Z"SWBQ]0A?DJOF-(KIO2**;U"3WI%6RL_N],L;.E09W'NAJ7M$FQ.#K$T M>"=?:[E_,(*">,N8O7W5RWE]:%IC#BO!0MY]84]#[/%)=X6_C;/[K:5=V.%7 MYFERDS(W&3T955MBR]X#.,C(DY3L[ZL_3*4$CLWS5S)9^&8S5?(W\>6MM5*T M/L6+MV@6/D0,)U=^G\\IB=&Z/\+.U[S6?/E&$IA^G/&72"%LS[\X(N<10I3.6TC1AK$T>M892. M\$Z0.O"15ZTXV!ZGF(/B/H(0M00[4!"P)FBA=^60/Q ;?K->'Q[%;(>E@Z)? M44@%)Z!8''NLBPM5UPZ;W"!-EB! 30%G1$_/!<7E#+V@ #^SO2)-F1 X'72Q MSEI4F3@!9*9TP\,Z<+X(J0)%N<*Z9#C2W0N/?+< ,D@+-*#="&9*R(#1TC#3 M1YR.!B!6A-*GI)(IJ61**IF22J:DDBFI9$HJF9)*8$DE(F,/QY!0HCD'YV": MLMUVF>%I'::CKD(Z2^1^UT[Z[M1J^_O>B-W2<:,W84A3NL'T"OF AC3"&\P! M0?\>YX']!S"8!^VN6T[^" Y4J5N$J-M>HJ>2MB >17B)P_3X_ZM#TK2*PBB4 MO!](%KY);%H;*,WNC16CGF*1+=]\U\@NH? >["'1]!540M<1]2^BLL0%N$7%8.BA:+P^/ MU&T]J"7"F%D?U(;%(;6 X>&U&@!:XBF;N\T6#A$T7M8"R-@N ?$FJ 8HV+W M0B5+R:7AR)0@>5CLA;R1,)* 9&/AK3BP.)&8AL*MVG1(@9_F$P77GG9#BM8H M4@258WZ'4"4J3C_4XN0N1OO[8P.Y(']QX/5]]I>SJA&-ROO@D,H<@6SH>KWG ME57V'Q#]LV;CT!E2E5/_7*E2*%_MCV;J8,S:59NSY9O]06TU>E;8,Y\/LSX8 M6D"K/;Y2_'4/L:PN"%@?QI(BKKL?=-> %I!D-B1$R FA>,')BZJ,HM)\J%UU M!AJN++G Y$&>/,AJ/ X(5!$!<&IY>@]?4P9 M2TO %./Y RO#DH-2B^-,G=JM"0Y]0.-)M11 M+VCQ<_H'&F:"OOWBU8P3_T947N'R;$VUK#;:B^X-GK#R1I1>R0G%J1^9TA/Q M%'+B#6L\PUF(AZ;[G9O)0CRT7]UUSD(<0%V[HDMN>\B+,V5,B5<2J9E'IO=[ MSWDA7:+P-(NO\!)8-=.QY?H;/13C'9)F5Q\OD?\B" MMR"[ XRZLMR-TP6KQ+$6]1/MWP-X46,^5RS&1ZS^1UR$[I;?!2=.D& O).5 M#">4+27!CXC$!5[0?VWS@7[T^Q45ZV6R%(_#5#S4&V[.JP1NY8?ZPNV6R3$, ML](CO>(E&L'9>D JNG=#OTR8_MO(+#"D5_O\%,=[6W$\WCCL.(Q]SP\2UO"' MZ\;OKVZ04#DYI^85NTO688J<#1 M)%'F;]9-6CX:SD0Y2CF4_G9G<&H*5&YBFS'\;'74]DJ[_;?*XR5.T@N'KBOE M9D$]\[!"^E)BG]I3S-!$A*Q[MLM,QVH!I=%GE*XK[?(J/:VU0JR(@'1UV"Z0 M:8K4D*9ZU<6W=HN>@5[I!@C27G*^S3NXRNN!F/,ZRLT!:XL/"YG@UL29^B"]X4HTI'(["-V"=]0AU=O)D"\RTM%T MM,VB [[!N\3993IQ'5:H4NMLVPUFE3R"0PKT-?A#,AQZKP* 4H-!EYI.R6H9NBU@0*),D0,;+>NZ'3NBB2^1$ M*+JBTD_I8!_0==/AH??.Z^PQ$_2==8S!J.S1'R>FOP"4EYCV>5.$ZJ6Q )Q M:M;I3MUFG73:98X 7S7*1SG*T"0.78>G["$DR&6*S7L(71QN]L!-0MP%Q9:C M=4:/7X@[# A8ZJU50N9[_)R@/Q.ZNU>S>=8FWG?7 B/\YCJLT =%_YTX)$8D M6&V&D@H'N;M MTH.3YR [9>[!4( \I4L(_5&CUV7),B;Q0M$+GWGT0]2XP,8 M;FN!HN,-%3ER63TP6. %-$$9 Q6ZXFI5&$"#8O4PWF(5G&(XT"9.'V%_!&8H M$MQ01&%1U$U-$87%,1S) MD@.+0S.R92&&'8T*]U6[E61CO5)3@+O59FRANB(N;3S*)!0[4$.X11$F 7^Z MP$4'BUTNAU#S)6=;=/(&\."*_8,7Q=C2Q4?$VX"])6XT^?^&-)BSIVV3N79S M1GP>"R.Z./7YW,GQ3(X G3($X D%_Y M3\@Y\7&,W$6( _Q$=\M%Z$+#'\U0]!29\5<*#QA4/3U$K'6%-^HVT,FJ^ TT MX &!JK>H1PRS#K4[H 4,OF$I%W<[+"..;F$2*TME0&_LC7C#NVT8+*<);/2H M-[GY)'1G#6<&6XBBF@7#B$(('/I8S* :0H1"1LN*FKH2GOVZN]?Z<_:?1WH' M_+?_!5!+ P04 " *BVU/1VW6_KJ+ "ME @ %0 &)I;V,M,C Q.3 Y M,S!?;&%B+GAM;.R]>W/D1I(G^/^9W7>(T]R===N14I74K6YIIFGNX3]WCP@/#X]_ M^V_OVP2\PBR/4?J7KSY^_>$K -,017'Z_)>O]OEID(=Q_!7(BR"-@@2E\"]? M'6#^U7_[]__]?_NW_^/T%%Q<7=^"55C$K_ BSL,$Y?L,_N[AT^_!_SJ[OP$W MWKZ.-G&:HV1?8.[YUR':?@-.3P7I M\PP&Y!_ 15! 0/_G1_#MAX\_G'[\>/KQN\V#P??A M'__TYP_P*?CAXQ^";Z.GC]__X<_?__GCA^\_A'_Z_D]/=4G1[I#%SR\%^%WX M>RHB'F^:PB2!!W 5IT$:QD$"'L1(3\!U&GX-5DD"[LG7OLQ$FO^,??CS[_]AW]],8()EIB1>,KCI_EZ298VO$3E^(')\_)[(\2]=U(K##OM#'F]W M"=;*-\:BWL+"KK1M@K8%OH-9C*++U+*2N\FZ$?ZA"#++6N\C;'L CSB^0;NB M'Y.T+C0J@L2RT$]4O:*#P:5RX&EL/PZV?T^DT$8S8F_$-[)/A/_WF9%G%Q M.,=+D"Q(KC&3]_^ AR;WA$QF*!-_I$/ZRU<#7_ZF*2;Y/)E1\4]D]033T\\/ MLL3^,WEJF4<&<[3/Z'0KK=&B FS]C\'[^BF)G^ERYBXXD,5J?H^7.#'F MG:TW5WAU&R1_AT$F8S366:J;FF41[!AHQ+;X"< MB B*X!V@4DBPXU*"3(@)T 9LJ*#@@"7]>EX+=V5MR!&DTWG3Q1Y>IX]OB/#. MW7I1B]64WM-@[9_71'N\STU!\8:HL^2+]99N:S+RD@[HIO8.3!=.YA\U9M-[ M2,G<3Q^)L8\0$;\(+SFV*@M^T@)P8D^YPA8RE:/4>$WN)R5O;]UD@X7X$KSD MV*+,G:2%WM0^$K].-IG4>$WO(X*WOSZ")?PB?.3(HBSX2!.]27WD\05F,-@4 MT/&NOL5J8@^I6/OI($4IWY*]H\.63)VC#=QTOG&-/X5-HW#K%A67*3U"5%%H12%MWQ);TSK@81.Y;'X/MW2AG\+&C_?_,?9W5K&?4JP@'0 MHKKJ$0]2%N?F=_1@KM.P?X)9UHP1\O/CW*EDU*<(7Q2:*.G2AC&N,)^(\+I* M@F=9:VQ]24][#2+V[;$D#PC]^0VR6]&H5Q?>*#51TZ?-"%F6EI&B4M50V?JR MF8LWB#D,GHP/P(QH(>W\9CL,!1K5DG=J;X=8:8W;-.SJ6/\*_T4JXSOX=3,M MM\@Y-&_&"1!6@/+RQ\#[($$2NO)0_6TS5]"\?4-G/F9@Z@T"-K1=(^C>W'F( M\=+@NZ#I-/DCC7D)0X_9RR%@P_ ?LX!3G=_UZ28NDG+62UUQ080 M/O-;[" *:$Q#OFD\T5?VO&7WKS![0H:%]_..(-$5W4J:>I]EC46KXO:\__N: MR>L>>O;C"N?46$K[LU$?Q07)Z,M'#!(3]=N;/J_B!&;GF-DSRA3O(K6^:A+* M&Z2\?[IIPR]%2_G:+L+4L6HW$/" M1-&=))V9M^ &&#O ^?EBY\,0(4F]>0I'8H:$14=X?\3;KCRF92HTS:7H!1W? M-]+Y$3UW]O\.*EX\Q^>-\??#@F34Y2,$B8'V+78%0-LM2A\*%/[R\!+@<:SW M!>UXA/U/S?2'*1GU"QB@[*YY &4**-<3P/B"&F-?7$,*0*2F3K_!2GIQ4H+) MYL'<_]P'&;:AY' /=RB3KC?L_;K9:5"+G,,CN9(38*SF=XHQ1)"$JCS4?OLD M3E[Q5FLLRQE*S\Z/OV]8*MBBY[(.LYJ"B" IZC?5ID>$$6*1Y/CY R4?D@:6=VWN"*%_.$+T 9X+P!8>Z+ \CA MB!25ZCEF23]<'"TYJ.RYTV/P?AWAN2?>Q*S-J\Y4T$O$!(X>HLZ M31EC4"%I[7D+2V**B#W'6$41'D'._W,3I_"CFE-T$C#1? =!9\[ F9R('TB7 M;PC6J3?3QQ \2$IK7D*1=*'0 .'CA,9_CG]<9X_H+=4R_?K7+6B[(N?>[ DO MLG(BW#PS^0Y0N@R^K2T/ >@V=JKZ]9CJK=LZ77ZML[L,O<9IJ+B3Z*-A0>DM MFNY-O]PU"):>V7\?4%U.T*D\7T'I=@<&QUH&#NL^<8?R(DC^WWBGOK?NIF!! M]0V*[KV!L0.8GU>[YT& NCRA0VU^@M'M!=(P6"E6)@/,8*!B]'[]]>HR+1#J"'G]/3YEM.@XN-1*R MY$6"C]_^[NGW0#"2FXR *:$Q#OFD\T5.VQ2L;+S!)M$KZ?VT;!N_-)THJ-DBP6[[.(>JX,AE^F+H)!O!#),PZCNLY.FN_)0&#BBT.,P(1D5>;SSEHV;-9EH&3'LTE<]J2>5/OV SHJ]6G:'.ZQ[\$5 8?6C(K(XRT%*W5 M4?QAO]LE,G&WSJ]-T M98$5CQF-,"V%6(0==F M;8IM?8_WH?]1ZO%P\I?VSH3_^3]I@0(!A;P[2P-Q MD-PA=HU%Y6$"-7KJ%JM"WVX*4# $ZPTH60+!TYN'#K0 13J*G<(LV2*0QV8= M.^PAH&]XG03=-1QC2_T?_;"I8320E)*\U#SW<<:AS _)N+03JS\/\A<5(V>? MU]B8WV+H.[((XN MWWZ'2Z@@ MBC14NP#TDB9PG"' ' %E"9HK^JF75;K.9X;IF(29?KKV9X>K^!U&W,@] M6AA)@814E.8S(&7 9XP Y43C?&WE9R% XQI%WWG_T@;%L:J.=PA,XAUJ M-DK*F"34/Y-9>V24#N=H]V^"L M8XB*OH[[J;H[]4@JGIX3HL-D](XQ\L,;1A#I2#]WZT7S[R-BA$$W M42=.0%C5IP5O_& $'22M,&^12)H@=$P-YCL35U6RC1N3QR6R_@J>M&2^DI#9 M42W"+B9;#+)?6S\E\3.MVM.)0F.43,[@ARB[6Z;2ZT,H)9?(89E^D+6NZ8H? MI !$:NKT&ZRRE(*RXLF&&C-[@6O:\NT1(VS6S([.DOZ-3R)E5#*>:4%FMA*S MNP1SMO;J/>/Q;@4FM_2RO^9RO-A26F1-.>^KW6%0(&9]0K%]:Z$>>S'MT_ + M6 1TWU)05*SWR(VN!BJ&$TR8,]CE'.L"1R#*+0UD '42-2_@!F*^T3UF?8[_ M&Q=Z 7.8CK['#=&=S!PC+@28_\:_$FY(18\^8\1]23 "A!-@K.9SG=J21W-% M;6D]YVH-[?/:>631;'&U[&J9//7R&&VW<4'6>CF>B,Y12N8DB)=\:M8[2,9@ M8=5/UD$BHF)&*V;#.COPNQQ"'%0*"#Y^_+T?=B^#'5)0IL]^\7]5$QN%?=1=7 <05Y_Y;S^[W_Y\[9 "LFKSE]0Q%%+C0U@?.8K>;C+^-J,2O77(-E+M3(=_+I1/7^;G)/; M%WPYFK-7K/_/#U]_^/#A(]@%&7@E/$_ 'T_P7\C_!\&^>$%9_ \8_2OXP\D? M/OX)Y.PUY3C/R2DEO;I1/:P,@@)-N4PPSJ//Q"N[(7'WS5;*=1I MN5G&X?UYO_-]_..''O?[_ML?3C[^Z0]JOO?M=R?XOR???O?')7I=KUV@,CU!T4094\ ;GL=AJG M(&1L_? (!?R0NB;]QRHY@HGP ];V+GN81'$*8PN@RPEIU*K,-QO M]TE0P.@";N(P5MI\R5#3!VRP^$AK0K>_8'1\>T:3X_"[63*C4\J^M1"?)5F>32=[EC2K8@:U.>P,5XDKQ*_OGH:KW8];I8MR;]QJG' MI1@SL)) :#(WNJ;975,7$E3LPL*H3NSO9(*?MWGJZYV29-AU74*Z]/^J*8(D\W1(!DK,+G?%C5= MR=,]D0Q>W:YD>S?D')LNUYE['W0T:/5-4"\)BU"XVOYTNHA/>Y\Q?(90$QW>@B?HTCF$;WD);-/"+..+] ;^D] MVJ?1789>XYRH7]8"-2AKVJ(R)R=6R:0 $1<#9$P.4"#PQB4!$18%9$06L!/" M^&"?^E: S#"8XJ5 YBOEZX4Z=\IZ29@\)=-)TO*K,C065@]4^O84Y1@T2%)? M4YC1/7R%Z1Y>X0&02Y*$^=_BXN5\CU=K6YA=OH?)GJP$2)MH_+_18_"N8F): MY$VJ-)79.>@" 0L<)JD@GEQ\-P$96=#N @'EL8;S!T0 ("0 1 0@9 "E$$!( M ; 8D^\X=.:#?AHF.YENFBYVF3F_D"\6R9[<*QZ%!LFJRU<8DCH" M]'$2\:+8?$_*8EG6&^Z^JDY0^Z*9RDM";LR=-!?R:Z;I5CL:U(I7*JZ9,GFG MA=.>_/92#K'27[ K76 !$D2;['&G4EM^#1(RF9<'"-LW=L&.AO>H8EB&>C^L M7PXWI*1&KS%*6O"0V%_C)>:!B=WG)YC"+$BP,*MH&ZDY5DD3)N)+36XSN=,#3!+6^/)3D/T"22,E M#4\:HF)P"ZV7JH,&1D'"KSIM!2_/'$<"*22O.W]1X9["V5!/*1G-Y"3M#9;) MOMOF1L]9@_2CW;8?+M"+P\ FV_;FVO&F>F+++CL0LUSU#F/<0&$A"2QXJGMMYU>B:G^\0#A.;^BU*47.8XDEWC6RJ M!#%]-$:)VU_^K&N%"-^4E0B_]R3)*@\=4M:B]S!Q%ZIS$U[$^RA3O9,YPM95#RYS8E29T M9Q/Y5!/XY+.V6.2+THLXW6.IUN5^Z QN4 ;9YQZ#=YA?ON/U!FG>UA<- M5EIU0O9G0U*XR^(+U34Y7D\&$XZ1KWDX4T*"2O-)X4BE;*ILK MNXF=^DY,9ZC4O1*SO.&WG\^CXQ;L >=/+LR"/0^T@)T/:DE..LW(9*(LBBY_V!>%/;#SDMWEK[5X]C)H* MP/?%55FM+PSD[M@,2O;$G^O7@D6'6"K"Q+[\-Q@_O^ 8LWK%^XIG>+LG3Z.L M-T=WHG7.Y]1IZP.MRLM!NIE+_]6H"XXR:>L(][&R[YN.8KI MN'\.*W1A^(W[*.<_?^=0\9R0:.:HLW#NIZ&/6Q]--[?SRR5M??'JR:IU%"$D MJS5?T>#N4KYL5;;XG&])V1ZP\M*QAX ]"+[\I> P!@-6;V5IYU#?_?8^QSJM M/5 ^-9D8>TG"GOHYR2]\?36&Q8#1-Q3DJ=[[#7\4!;DV;_5&HI]W*#U'*5YZ MD3.']::K0;R,D6L2UFSRILK(28^WA\9;\'LL!EX8"3E(CXE=\YT"GCOTH<6; MM@4@(P"TFA+*LY)^>5V/KG-;M?A:MZFITJ[_R[+4H_?5];6O9:>KZ+_V>4&4 M_HC&'Y.^AV$2Y'F\B4.&D:S9FK+1M&(SMDZ,NA*)'*@$S7?/0?7N>;E=I9:= MM43SP<@MF0ZRB)4K%SBZ3Z%P?\"X$+L?M1<% MHQ_&:(JVH67'TO7F^-5:G:2B)$&3]ZHE&%A^PEHTJ"6G-,>/[7K7MU8-5*2E MVTF-\Y$4*6A9(?^F!7.CE!PTHZFZ'U,.OIE04_5=ME)3C%]J/G+?40V[M6+F M1GBA@U?]^-=\]1XKE6:/$+*@_"["]DV>1\V*C6=)]M9'>!EO\XV,6I'D0DHE4/?/;^CQ!>WS((TNZ14EF-Z3_^;K#=ZOQ>FS8L9% MD:INK8H*%S?5*50"4+PA4' 9 .1"@(Q*@1V,B>%#'D8/;:2O[^4@VUBF,UBQ MM_P9,(Y L+28E)EAD$EC?)@U$+R!8*XQ8-FD[JZ@E+I&#)_CG+3UBR[B#(:% M9M@Q8:&=/]1EZ2@AS,7IBTFE2""B,GD5GBR8"+*$RT+-H9EB%K; ED%/>/O M(J;-/?ZD/?2>&&>B"[EP]S^"=(_W034]W,8I)-ROXC1(0\RKMIY3#'1ZQ#5M M6H>9D^#&!6F&MI3+ C9"&%!4TO@0U8PL 1F#L#C4ZS%,0$[\"Y2,FSLA:\%K MOB$GS=$V@I:007OXW*SU=$AKVKHZ*R=Q MD(JQM"6>@04@0_4O#.UZ*&-03[*LFVNX27VD?BSH1.+.2>I,AKBUN7BE%=,*%O>KF2;GK !9=]W%;6O)/[XF^RJ4E;[=OL"/Y M#F8QBK#@6<'MY@P^QRGI"PB> BQ7./4+IT8=R:WV''?4E5I"Y2>\DY\GWBK3 M3]QZQW"W/<%G;_A==1/*>]L)42&?@AQ&I.(=XAF4?.@>8O_/XP(^P.PU#N$= MM:=[&*+GE%*1[E(XG2PFEWW!ANXJE:)#.HR@U)HP*4&3&Q0DQM0P2=?JF,/8ATU+_:D/(C)146Y MAWF1Q6'!K]"NWH(L^BE3?!15DX')PE.#H8/0U.C2ND$9R$KFO'OE'N/NR[K# MR R0%>TO$O*D-A$!)@)@,@@/IU* 2@Q^Y8$* J@D?K@\,UB7/C_*P;H%C'"< MS^L]VW686<2X^TOAL$STQP, MPG_(P"-5/6>VK7&%@\PQ)\L8KD'!"PQA0=%4)!<(DL@LVBQD%PR5..1B9+W% M3"61'V&#&?<4<4.:DZ.I9"&18T&+"YLA1 FC95N(]*)C.5&$1KU;^$;_Q=HB MHT;0S:Q1,G#F^N285W@VCP,G]%%R[/[D5W*(@>- OH05PS&^DBN#EIH7@:7L M3(_9LG_VQ!.9W=ETQ2.*CJ*O3\ZXH$E8QRL[%;X,6*4G3QG'E"T?NH!P2ZX% MO\813*-[2'ML/2+^BDE^@=[2>[1/H[L,O<:YM5>6&L\^4A% Q&7(0<:DJ PZ MPE* C(@!=D(.'\]JZ5-TNR16>EU%E;+CLZV2DXM>E^6+0B0#NKN M"QCH40 ?B=]"&94XX')"93A_"K3C<8ONYSV_C.&JPM]X@*(MDI6*YUM8L,Z^ M-TX.Q3%YD R>86947\ M#VITZPUMH;?>?,[A*L]A(?^J_!@9W7:*@V3==,:LL23+$=H,\Q1M3O=X8Q50 MOCY<,)/$#2DH4NLY81Q@,ACD\ *R_UZGUWA5DV(S.=SC_6GV*O]JL PI33L: M)^W$E@1;$'&^Y-W?6' F-42$M0_FI C4M2IEEG=92B$,,JOL(C7/ %+CM[* M.7R51B+))FU@:D0U34V%B1.C$P( F^5O6Z?*M=3WCY8H!;B2%OI6E9Y'N0O M9!E7SV6KO @M0433ZH:(.K$RPI ]91ZQ'#M;KOA@25(H(6G%3?SF.!'H*D%O MN>%3XQUTK+PP?D37W,=&[9T< D4P.CO@ M%2#>(:^Q[V*W3I]781&_TN(1'>/3H:YODNK<'&0U*@.EDVW)'%3<_;!7 ^21 MN879$U)(XK@_#R:7Y=(P3F!C MM(_(8:QRP]_2@:,E>5R>0.>@0"2/R^2DI3+$BLA?R<\A\9D]\1.\X46EGP2E MC#_Z$1:=FF'?Z;55>+]$D^L^"2]%!"1F\2?KB)3D'^T':2=A[P+NL-/$= ^% MMZ3UK)Q*]!HDHV\1 V1=E"U5S&@R(JBQ\R,ZR*"%%-3G,3))!RB8$5A)@^)+ M.K\Q7XWG\IY\A_8F%+X3,H4.537[:SX @;2 M!*=,]@M^9/JIAG4_-BQWK:#.VKTVE%)*/10,VQ(=49RNBXP?D\L(,NV^4#WZ M\A.%>LT3.#MJFS+;7G.]$8< /Y'_"Z,KE/'&+4KW(60IVEB<#W'PIT!K^@V; M%):=6[!QC2X#M^."([P2$$P!YPHP6]&<:.HD#ZN_^@]L2];,L5TK1='U; M'YAC:@X*HE!Z2C,?,6\DE$@@-<&45R 38"WLG%QH%L?1-]DKUK=!IYE MCP> 1.,J]@\T[CFB(H\P (+#Q#YRO$@M,Q:\4% GO:E"51\>>2[V?4WP_N9W MHK;F]R372-T/T]XG-.=#3V7"%SP24G*>>I)UU, LEE48HCV>=.]A"./7X"E1ZATJ1\\FC,?T76SI!1=R3L#9T$NUOCKA (J# M[M>G3:\1DW"Y$K^*Z>R>)O(IBHUG1@C91*I&V&F>S%+5FFT)GL-^>I^4PXVP93AZ,+G.%^QF\MK>[9P MCR7!.V^9PX3Y?%+)& :=51Z"A0$OX=["#(08XK8>/2BCDHR>P4R\'KT+#O86 MHR4Q%^L:3MS!$:!8Q.P8!U]=M \RJ95G0WO>PR.UYKP;@VLZ5\KV>":(@R>2 MKS->=W;1LXQ8B[X3GR(\0%(Q\=BM^N ;\ZQ.-2X!JA'_HM#=R$ WV9Z.95ZY MR]]"PU1G%SV[>XHV?7?>[?5B-[+IZ];A$G :W@+RDQ_.E-0JSNY@ M8L%J;1+K)&@3N@X&+BH0^3J>[.!\=; A[ 8]K%>%B\!IR,=*W.:;Q.2OI:@X MF@K5*:[46'(Y5 2)."&7N1O@ARMJ0*QU4VJZ&U+SWHSRPT-)BC9W=M5QD+IU MB >XN;_J6#*O0>S)\;H!].,>/*KTY<$LX]%=<,]W H\7UZ(W9_CK/LX@%AF' MG.)PA[5GHPL- M8)&^:A< 8KM@[5 UAF6,@> ,*&MZ%E$R]W;.=3/73A-\)U@5QV6T7 AB MK3EUNKETWCG4#P^]$I7'3E;%@]2M0SS S?VJN&2^F%6Q#/3C'CRJ].7!+./1 M77#;Z@ R4S.Y=H/7G7HWN24.6RRPQ&BOZ!Y7C):^L57KUDL667\;':V;K4]- M-5R$2_YPG-*J:IB.P0'!;&+/N8<[SGB]H77$%_!):>/=0T ?BDZ"KCTDW^]V20RS M6GE]\1)GT>DN(/G-\GJT)\XSC!J24J9?"#6=I.) )A56WTZ8S.@<-W$*\7_. MZ15Z70=I$;$#08.H:T=IM1#PSQVZ<>IQB0[5^8?)D&M0/C1'0#EYF])UD\J= M)K?G\-!E)Q)[3P>/6W!HP*R5MITN73MOFG9B+R6RD?]/CF9?@P32J]QYD<4A M#O'D'U;D]>#Z'VJ?9*\2'%=?ALF>/ EU^)RLX%JAS932Z9O6M-* MZB;BQ**@-4ZIO?H17&:R3C0OMK\M2TQJ)Y;T_]1$ I6P[-_( 4?[;_7/\P?5 MN\JS^3" & <@ P%L)$L*NN5(+N)\A_(@^2E#^QW^!OX=NU01IWL8\4)7E"HM MKJ:5:R8S5Y33YIN)#T60%?43^J 9_ Y3E-BF&C#S?<+B+VZ1FHK\FJ!_%LR M2*M1MPJN8@B CH%^L3X*4 W#RBLDR]-[^_%4$08N26IQ/ "XZ<5,\IOT!"U( MQ"-0U^D&95O6UUWGO2]9D@9]@N58.&C?7&-,K3M!^3YCE))H94J MS$A3UPN!-.E LQ,^JX53- ?A]#W$HS+ ^F.(Q0OD#R("/+X1P_1C//69BC9& M9:S$4G_&;HOB%G<<*;<&:'W5Y.IK@Y2+?J9^7?3O5CH:T8AG"DZ:NF5V/X6]2<].8E;S,5A(DO]MR+ !K7C7_:3AJ*IO35C;OG MD6.>+\C#ZQ0OO$C!Q#E>KI,Y(+_+X#;>;Q7ZBVF3UGP069V5DV>2 M2S% *0&:IXE0;(6DYW"]\:U#6=1XN;$P?!DHA2A%$G$:ZQ\V?F,#,* M9 Z'WOR!D@2]K=.[_5,2A^O-!I+][R>X?8*9_%0P2$0WJ@\0=1.@*<-3E((= M90D0Y^F#=4GAA*15YRTF]1U5!0CC!P1#\#-C:2%EYGY$27TP8*TS&)G]>9X5 MM;TY_JV]+\=_^L][H^E#FY;7U WF08!%R\=8L?-BSC$L\4G&) T^7#[ MARF*;H5(@G>FT: MY73Q\5/P'F_W6S7#;'U)3X4-(O:-DY.7G#BGL,IN5:->;7BCUD15H_:L$^]E MU:VS^25--=:).+!.1MXGZ^Q4->K5AC=J350UZJ;H \^%=/8[3X(\7V]8^PK) M=:<$$8,J@#ZB#L['"0=2MT%Y^'$D- X,DM:5MR"(X@O!!3 DUAP)*ZM<];+< MVE O$,E+JOA"U[<-*@J/J/TVK'\ S2N'?_TG=1579DW8S%YS(?D";C57<8; ME5-AY-(%H>^67XW6I'@UKQ2L6)JG9=+FFX%.OL/GY^*517^0-$C"?< M8Z(.USD"#)0!RLX/4Q_'Z'CETZ[VL>7??0W#Z4$(PA@B2T92/VF_V"E<5J :?#2,H1J _ 4;_0^#4HX%T2L!:8 MZMN4/@HFO2:[*+JP(\H'E(P\V\*,8(/D-.8G#HD^!*[ZYG8_,2#5-WQ M2)$SZL8Z1MY)&UW*](0_R!+4'V0Y 82Q+WXCCR724.H"<$N:D'4]H4/Z2!&F M\VR<>C5!1%+?0$F17&F@#!!\_W&H0"R2C(Q_UGM14OJY4/MM\5?K? [D$&V11_GD7!07$G__^ MP[?J'B!)T"!^R3!P,"\]G(-'M(M#\.<_?.O9JD\-1*2ERT4 )B:::E(I68(Z MS[F\;8UW%JLD07027&O.,0-$]$'J)6K?DPBKTT#P FO9^#>E1XT#A:1UYRTH M284'6*GCX7(!1DZYGNE"4'6?U$/ >"G0).B@'@(EF#$BS3]?(:BQH_F&^N]K M_B)0D(+&E_SPG&$ CY=M77KU$JSVPJV&R"Q;E9H ^2J-;E$:5']YQ#_EY.D. ME"I466B3-E@GK>F:;9Q%O[FJT19OKT7[;+W&:)\GXI4P_+'B)4/[YY?: M,Y4QS$_&NM2!IR AW_]B=/+N^AO8H20.1Y\E]%P=W!+(29AU M:W#SRB9>) 7YRSJ[PYCP7U;AK_LXC\D\>16_PVB5YQ OZ*11G9T+-\!<0$#9@!VF]!*0]QI)P7<&PF 7DYS:3O<9I M8 [( @X+A%ZX/&-);MD0"8#XO28#8);!I "E&),_'DG:?)&EAP/!Y68W(?I];9-S;O]\%EE0)&N4I<" M7B*V/2S6UKD"P19@OMA)"X YTR<&3+-!#R\!IK]Z#>*$S.-7*&LV')7.!8T3 MTDPOC!%VD@=B3$$@N-(B, ^[[TK#AY2TJ=6QN?.*:/X(LZVT$0V1T#2??I). M#*>\4/Q672C.*,L3@*/SU@>CD0 *26I/RU ^IQE\CG/R"E!Y7_$ZS_$%,10#/U.!(?0G88"G *Q'# M!X/3 AQIZUS+*$4 O(*0G .=HYR\JAFBC%RJC8N7.#U'VRU*:5L>PI_MRO&G M5OCS^-MX:?6(5E%$%\U!0B;GZY1/YM)6[%@*3;-W*I43/RE[F&\@F<;3"(1$ M')!QJ<$;%1O_E<@-:2\\\&Y(MDML?2@P*!H)2?/2Y(OLZ&X(./36._ M:#J+\'JYV-QH-9:%)R#=DT,:L@AHF!>QPE;(-L\:3C-%/TJM M3X/@;EB?T\UVE^\P"^.<#;3\Q]*YE4Z^-!E8CEQC#%WWK*]]&/VV17Y(F!2@T<$*KG9&_'7 M^.MCFI5+8:^>G[&O8&<0.[_/:5SD#RB)[O89D0EKC<9+Y<-=#G@@".,G%2HI)K%&@='%GE"]P[11Q$Y*;N$;_2=+"=9FPH(?QG!/ MCE.7@$X8Q;IMN Q<4YKQA*,>L.7VGD?'H'TX>KL,PI?F9QT>OG4QF^QXY9BY MNPN0D.6KRAI%FA;X(H[=!NQ%_^"M#YK%VX;IX1N1Z^A+T[=7#B&,\BML-F(3 MO=[4<@$J 4."F%&+WF'B+B;\GS*4DXNOC#4@SB4Y^TW84UD20*2L2^_!XAXH MN '"KLH%8;^K)XFFGJI1BFTIQ_M"_M@G6SRR/Q>*M^,DB!F$TS'B#H['V4(Z M%"S\\"5YR)"R]KR'1\QF);?J$5F.5L5Q%ED;2N5P_?R$MEZ[3D1H$Z:2S&1.;%YTDF4Y[%0J$5"J2LX)'53=E MIJ>L4O A%6W%; 8O52DAM5@3:=2E2%B!H]J42<<\NC7GBKA.I:J/S%5R >$6 M1A?Q:QS!-+J'28#GVD[=,(;V5>8WNAO[F;94* B$L!,B8&F?++ M$!!A24!&1"';7B;+U+V2=Y#T5TR?;TCK"Y[Y_9Q#V@Y!96$W0LB@/>\083O( M[1!I!?%:UIL(CJP?R F+TZ=H<[K'IDN;#/BQ/I,##RGITFN@DC9 E%5Y3 P M-];(8U8ONHF#ISB)BX.^_]1(V *D)#F%SX!$%]A' M$O*W$ ^M4?@IO?76HJW]=K@R+T>ONM>/A,K"WO;]XQ22:HE6X:\/FVL3>T"F M6"P-^]9CJQ+ GW0C;^/1^9ETH'34!K 4Y&_-LFPG><16X9#8S4LUI=.A:C,- MU,=EVM3@R7&Q:ID=BGR(57JX#V;^AC6_'(SKD>FVNP7&$:2.\GMN!ZI0:R/^ MZ7)\P(X?UKOCC8I73SEMX:NRT1BB8N-%MC955\^P"3[@9\')DX>^)&#J?"^O M6W'#]S L972RYR"-_T'C^3E*L0KQ19[6" MY%XA%9U$];KP?KC0- :))L7WBS8^D9.K20H:HG)K6S>MK;+-FKST:F9GH"=" M RKUU"^C/>R?R L911PD%VC_5*R>T+[X"6'QSHDU9ZE6N%.A:M X19J+_4!T M$_^ZCZ.X.-"(0YD"SA5\)O\I@CCU)6^N 3+25_-R .7.76,+*%] &;=0U7+2 MOG[600)Q?+O$-E0>;2ARM/,LP'8.#PP&Z=D\.RR8\-63\ M2[=(X854]#?%Q-$EA=8>8H2073MS&.IJUO8)!H0;6=/X:V*#>P$)W7D-S$@$ MF"\X]Z9"5J3"M4HLK#?EVW3B%V[DDDLJL,WQ;3TL-_M$LH\2,[84[H/+Q 6IK.4&EV3U(@\'_MS M&.<(*$MP 8L@3CPI?-,"%IDH=DD@EAFNBC%H@6DZ__65GF0PBHNK(*2EJR:9 M+0E*NN4'8Y3=E)50KF##V8*HY.M#'DL>-Z2FQ2FB_ 5\JCF3SK*HCX*^TW=3 MM.K>A$4CR>#9(F0$%B2G++^=O-$1;)?%"< V^@? G5VPMU!)-,UP1/504WSC M3%;/9'$#\QS"\N(#7D+6J\C55F:*!#6M2I:!DQF$,3\!J+PI0@XA-[P@GE[= M\>),1!E6I*7=*686QEAG1FE_4W\F:5*RZN>,M'<31X_6T;!.%N'2C6("RL!\ M;IAV!*7I$*:@NK5&]@FM,HRB^4TS)[VLOC"4L:W04' M[8R:*2>#):819[M+T6J!P&XXE,( +@UO.%_) X1 WH4?2[:#["(UR49*5LZS MNIQ:&31C5A/X33=K1V^@G5)N#=]9F#N,&(6./PPAL' #T(JON^E4YN4GU=5PKR@&J!/$M^:>-/#+3^R2708H7 MF(EF"HV"(*WS4PEJ!H>CH]3MGGP2=J#&S^=LH@*.2%VCRXHWC4YE]>O$54>N M2@H+R<=Y1IE(#M"30KO+($NQ-/D=S.AE'$!G'"$FKS5L\N-\(+@"SX:O'&;V#V$)5:/WH6":6@\(RL2 M-FE+J\#(>@3DG/D[?S7>/L_9>J C(YU/L::4$DLK_JM2=FS.CM)1Q M5%MT&Q0TO\\/J#$GVG?AH)Z]EJ"DF3T:I>PD.\VXDEN8J.3K0Q9:'C&DIC^_ MT>GI<\-:VARWNC'/YDTT+N[YW-K6&U#Q8RU0#G.N!7FKF58CF8-&C%"EJ!^\ MY3BXN ;B;6,E11B1GC*7 5E21PO[6[OET,'([7JFV7OX"M,]O(D[C9GNF M'/\5QJ_D^5?=N5>7O&;(UV/G9);FHH"LDH5."0&7AOP#%\>'R=O0#I % !:( M>7.3PP"_;P$N1 &5+.9K@#D'G?2/=]4]7@_6"[?PK1;$,Y3B'T-VJ]5XY:!. M6W]"4N7EPLY#S*TQ.S7$\&-AH8TW,M7UTK 5ZWSXUH^IC06(M0K7X/DY@\_\ MECJ/0H\DS.C6L^I-S?GP;T\' M\$"YTIF+;?W\\&!,7?7)D>R71#S,64Z:V_2\ 5&>]K,BS9A3(M, MJ"7.?SD[D/][%838)?5:-^B0-[C\K\[.08'Y?KL-L@-QY,>7.(M.61[V+CC@ M#^$_!<2Y=VQW#SZA#)*_I>#CA_^+?@61_@&-"$#FBM:I_>D;U_&KL_=HC03O])T"OD^'=\C#%_2^%?L OHKAHD$LM"0RZ6 M#J[?Y_E^NV,)YL_DEL0&&]X%Q!_9QJ00#E3MOV@VL[.NU(_0-*W-=C5Z<"L-9YC,M-,1[WP7H@-UN3>#Y>4?JHN.N\Z7PH/*NFMK]ORK*@%6?Q; M.\#B/Y4S$9V((IABMZMW.%(/DAI$U0U)F8F#%1EG3P+15?R.@>>&P5-^V1XV M#&3>N*0/-=+6]F)@;2V*^)J(\6YUW3+PT;Z6\N5XJTU[9D[J#JA#5;<3 MM0H7-[WE:U[8>..5O8/,7GKUX7A%#V:DK^CE0-H75:D I^O-*7D:EKT6NY)X MN=?3478$F<;;M_4!.@@SK-M'?HZ7(=A[^EJ-U.8KSH"8PV7X?MGG(0 M,J&&VCZ5+[9[\BJ&+7-!-N%9LFGT!3DN%;A#FATH"1F4-H,W8:+!,LU2E)^2PP7)K;#+(* MT:+MHR]B$K%.B5QSQLR9==,*FD0:0%4R0=BTV)>1],713\/WDC#LU'A,TK%! M4W0NWTG?H+GS1++PM#LY]NG,4RA*_R&:)TR<)G:X&V*/+-VS$20.GTB=!?ZO M<;)'FY-QMD"3L_.DD%@VD&FA6E T%Q$'L.7"^;"6L&=/F$?]ONMSPLEXW:R%GD5Y"]7"7J[3C$DVWK;OT?4WT)7,[+:YJOK0W;ET M$:5]5%:BK*='--SY>_8-8C4;5HUQKC1[;AN)N6%=Z/5H+M( MPI?UJ[<@B^JZ+ NS:K6(=J.*"6>[]J0OR:REG^V(A+^01C##MA6$OYSB@2)2 MUWR7Q2'YWB<4P<3?6&7!#D?BEBG*7Y;-C<0S+AZ@\K6LK*K9K!NKE]&MV1(_ M+[ OX#4?'<[G-"YR.CSWBR9EUN[F2T51G"ZG[A\^+VP5I6M#"DLJ+8"^,'M1 M66Q5 O(P147D@@ X0/,'N-23%OE]I7"8TX_ JEN*-Z![,8L4<] M#..4=2%L6*!EH>S'KLO-!H9%7BZ\.AZZJ>=?+G_=$]NCIIC3/_ !LMKX6Y3" M\@_LP79>:EV^,UX[T2=S+&LNN]UE\ 5_,'Z%M$&Y;Z'3E8%W!E$G-O/%&G-' M8!5R BYH?Z2MA&67K,N;\TQ>_KB/FY/CCG<;])=M^K2-3_ZD>3D_#PX[7_8) MN#!>G#P8H']\XJNH^>$^NCWVR@+^>1+D>;R)850R4FC++$E(TQ+'"#LQ.SX/ MAB77TMY\,#-IT)"2#KT&B,\#')B*6_4HC6S';*_#7\^^DPW[M#;LK@O4DEM3 MKQ70,=]WOT'DXT:)BOB"D@BCR""[104LGVW*Z*TATXV0,A,K6VTUIF[K?N2\ M(3^1?XAKAFR-IJETYV5TT%FL673E6FIRB$TLD:3V9%G&[NS-^C!VI;A56L11 MG.QQ#,/[K9 47\4POWP/DWT$HRML-&0CLR_X3LO*\V8NN-LP(EO2N TZ1,K3 M"RXFJ.0$0E! 7!W41*59%_H-LDR!Q/I@=+IZA5GPS#>MWF5"K-ME9[RRB_B7 M9X,=$:XN8*?U7;6LCV9*++U"U[-Y?'R!O&&^Z)5?MKRX,F,2&0AWS.K+A+G:G"RF:D:3C^0/38Y,?R\BX("XL__X<,/G^#V"68R M,5"1H/YR3XJ!@P*YAW/P_8?OP<^,@27+$&=IP1^ M3OSL.L7S(RP/V&_XB>;J/99:14N1T0=J@*Q]3V+,:L4&@IT?+B6#%%)0G<>H M)". @)\)+T]Z(6G$40L@X,(_Q/A^G$:]QEZNKS&IMQMV'<)D],PR1A M]]T^!=DOD,R"O*F%^C)NG)9!PFZ$MH,4<)#P36C)L>SWX=F*3AI$I*I0WP$3 M^5+&C.Z4CM"2!&L1^4%+NVE?WW8)7%QCM)7 M_$^DNIW(^E$I'BO3-G!W15X.XG7])!BRD^ ,$J:05P[F1!! "Y0]B=NZX"-3 MQ2\-Z*0#X_II/ZO_H * 2@+ 1)C=I>^9&59*,O/B#G(V\3PB;]]7+V >9C&[ MFTZ:@!^[J:\.V@_EH$_VZ'0!L UX'N=8=[Z)78V_C'4',]HL ^.Y?DIB]KI: MS<;6F\=XBU>$*FZG3%H?2T56]MVQQAF@DO4)B)IN6E#V?GBF+O+(4.T+0YE[ MKWAEL YTQ1W4PS%>&S^.X.S4E4D==QP&"=F\13%>HI>]WL8TI^/=)MS,34&? MNX,8((0!4$C3" !^N;T%*^F(!*9X+-\BVO&B-(I2H%KOQ?%H8EIGMMJ2;M'_ MH'39S3WITIJNKVK62QR34DS>_3TH-%A>N",E2,0V@'52>AL<9'^@+:Q+/D$$S'LU^OXH8K M)]T_$*]B6L-TW#P5[B ]TOM,N%3=FP^ONW<9VK@2?08H,<;&VON?=QF*]F&Q MSG@?!-F*H/[OZCW[V$7+Q9#!.SRYX(TA%TB]$F>,DOX\.TS9OF>0^]TP"^,@$?.L;\4WDJ@A-1WZC1#W M'L8*$%Z ,ZLF#M6:Z9X4T 5&/4&[;3607-X?QBAH)BAZ*3K)"]6X@9RS\R$Q M-(X,DM.7GR@TSZLK",I90C$>>3"D9& TMOSU/V(Z9Y\EB+2%2Q(8TDM3^R=E MOY6@I&DYHY2=^#'ARBXU$KX@+!F#@G#VP:7EP4-JJO0;J+JKERA1IJ#B"BA; MB\X^T>"2VKA6)N.RMM7[%/P7RL[W>8'PTBY725YT?5-O>W%,R<':E9.??RLW MH'$TK ^_M,MMF9(')?WIDA2WP1:N-XW1J24I!@CH:;J7X)=LSN,P("GM>*ER M;N.$"\DN-VU=/371LTP[1RD]XJ&O.V"0%==F?5_7G.>[R3E9A56LP([R\F'= M-8(&DE"3AYIOYG%*M3-&%A=2+L>0Z(LOYXBW*#7TQ0$*FD;12]&)1V)NIZ&/ M7CD.#9)3F)\PU-V38.#211T/)2E' 2QXJM.2AAN51FCRM*R?G-^XN[@X<(1^ M(WLQ<>8:AV,4Q^L<;@8;DGF'V'B]@S18:A5 M0_R_T6/P;F>HKS![0M6]6D1>8DUA0>\ED0SOQ)&#U=^O-X]9D.8;F*TW/R$4 M*5=[*)'3MT8)\@[N/E.FY%**8$M^)HP!ROPX0M=!$VFH=0'()0W0UC70UAPT MRQ4GMEU.O8^,)$%GX+E* GTYCM??:T9!M8O 3\W]K"681.&&.">M7F'ZO"-7 M5Y(8S[L'Y<23&EGMM(@*&T>)JK+R1:Q#\ _E0U9[+ 6(N!@^[)8U 4<&&E\0 MN(W--BQ 5UU3[9DR(@803L0!&9)TEQ'!6P*.JIB4$R-F-62?:W[BD= M. U.(2W%>8Q)OZDY6(D-G*9:I)W!-'S9!MDO%E9J+5I6EP8-VI/,1"5'3YQ)%KOAU5N''GW' M:7 =5_+S9#%7RF-A17=$RR923=K_]*@![ 8]JDN/ON,TX%&5.\WTD@'IU\\S MR[>PT'B^H)N 08_6+H)NCA,\O1L]C F24I67^N=^P-Z($ 51!(@)KU&=DU>K M8+8+LN) ;@NH7*3J_J[>?8@N6BYFA8H+(&SFOX8R" :4XYORDYZ]#S=[:I[ MN,-"OP0Y7#UGD+Z/TQZNVFTK!8)Z:$@S^$WX@SI^2$N-B\!*G**67$')%G3X MF*6JF[-D#\\SE.?DAX>7&":18H'- 7-BD[*9@@3$!)VX(G\F%.&/A3( MC&.#Y#3F)P[UX$1!H+P _9%QLUC'XG@LB>$PY)SU$XSB,,@@>2-+_!B]!MB4 MGQ5Z/DF3TC2;<=)._%CPHKT8MN4O@K,/#JV 'U)4IN=8U7V] 53Y2\G6HM-/ M-;JD-;"5[L#DPL#G-"Y@Q'II$1:*KM_W=4T3ZB;GQ,49*_!2\O+!J4?00!)J M\E#S=8?E:J\86711EV-(],5WD\'/<$PH;)PQ#Q,RR D/$7:P):7L%G"Z+ 4< M4M*CUR EYO@X\:!5&)*=,*E!A_$K*3Y4=YY^&OJ0]-%TD[L7W$#%SC.'&<4) MR>K.5TRXA^A!,T@78D+\<*=!G M 3WC&1Y]"EDPK2]'2?^)*C M[^:=-<&;]OB(.??3)\8>_Z'B[T-"0A5:I*/BX0MO9D9WL8>DC4N1@F@/P1N5"" \"1_P9Q9DN+WFH6C(W;!H&?;G%(\M MHD^A!X4O#N^" _D7A:2M-@?M[*(F1T>I MWYHTH#PB#TMYP$8(1/J+[+A(I#D@^5I.@F') MF1415;S!CC#W(>*I 8G45:IE7@_A"XSV"5QOACA)-ZQ1IZEI:@H\G!BJ C705OA1@ZRGU$M7U!E0AA5:%U5"E$LBU,?)RQ(F#P4I& MFQ>8;.[AO6*%6?31JD89*A[J;I)#H@FI-^XZJ'@J,/ 4$&(B2K-E_A MJ#L[.Q]HNX'-1Y2<#R%Q2+%E-])K M#QF?2Z88PF@6XL/0,V]2"3.<8W:>%C M'4:%JL>%C3)I#Y!@!%@0P20 6!?S= MBA(FKDPZWG:D*#V5*4M:W% ;6Q+RONL1NIPSN)$9I9."CL\I>9?VMK82$P\]BET2\%(14-0A1A";ZN%"[P!.9D;< ( M3Q#^":-9K)PBO+!9OP&WSCQ?:7M1T.K,Y82[Z0G$789""*.6U>^KA!C:AFWEB%B9.#!"$ (*8.GFESQ*/3 H J*7PX.=#"&VFK M7*OFEE/-.5E262D:YMCG79>J@-=XU@NBH+7($[H7UJ.OK2!-D_$[K,,$L(:;%!6FI$/!J0 )%+4ZD(FCN/[;;*SALN+;DX7-(-7WA36+SX$Z^[* ML&:D]GL$1Q5=99'MG1WAIPJ#C7M@/.KM:K&P(P0N9W!B;\_&0_D!,4C*$6"6 M)70V3VNN\WQ/2CG6&_(.1'X+B_5&_ T[*TQS\N1G@BTG>D3W\?-+D:M/PK;X M64A6&?"?X/@GYI*0)-:>R$>K4/$OY3] +B.>1ZB0H$ @HV+Z-?-;-K&NLR-C M* U>PB691<(+1A=[&K'I9$;WZ%B0-_I/EBHV=RB/B_@5/C:6$H01M0IL J3^ MV$;(DQK=.4I?L238>-<;]G,1/R7P 8;XH_;J5#'=)U1+^$(\O@R/E3N[ &C_;S%;CABG/2&C"],+YWY<"$!J4VB!DEJ72$:<0>6:\FJ*SYDG[V+#Z3%Y^* LRB;D7F4=CHX[Z M2A.OM/8U4=@O &%A0""D 8B)XT-L-+$&9(K$TI!O5%B(0M%V-<73H6D!=.W] MRHV@M &R"MV3:]KD^_3\UD( MF73[?7:@D[]TNUHI,@;)F'ZR;GN7LES$V0&PM9!4J]*IKDK(0(84=.@Q/(DY M,G)A^#I]A7@6%&U25-LG]7U=,^!VDW,2906K ZBBZ"#_(38H[-XZ.$[KX/(("F% M>8E".TFB"H!^-OZ<[M8HOT9._ASEA9.S&9)@#\E3(\V#B3Q@;?OS\F#(U@[0 M^1Y#G+B5AT_-[41];]O8&Y-N;F7RF&5,%C/FYAZW9$?K#H0"QL]'U)VOF=6\ MI8K%+ED:S7F0)# Z.[03G$Z0OJX=II5 %JBZ%\U2&6W@)Y[.5M%_[7.69GE$ MJZB\5QS$T75Z'NSB(DAJ1[B- * RZYGQ,7B9WH"OB_>?\P)$<0;#(CD ;+,H MC.FY(>G\)7GN/M5T:L4RD$TDEFP%/"36!"%)OTH40&0A)QA<&C[)\_Q@&4NH M1.Y"YLA!D(,7T2\=GG61S@6DA5-!UH,*&%X1'U9N5V#!*4 MM.M%1R@[J@1M6B&]&Q"Q0.)7YP5Y#)&:1I=5D%D>E=*B[:[=85X_/+=0"#)C M &V<@>"!DDTB&"K+; 71DZ,HNFQ]B 1/-2C2#:VE#[Q<9'+PWVN?MG7[PJ>* MS..\T*RUJI,$\69;"ID(OIBA)>U1,2-F_ !E:+,Q04>BBT96M[F]_N"MG]IS M;J5.QU[ZJH3M>B:U?R M]&$;(P?80)NMM@JU-L3T+7MN@U7Z[@+F8193$Y5/YXQ3TLWE>*;"A], M910<)*4S?Z>!CB?0^N8 )PV\;(\G:0VEWJ7KSN)0)@JQC9--F?BZF)$EM4&5 M)U3UNT<7,H-RLG4K3ZRJH\1*$2J[M!%"^FOV0<+V+>^J/"%KF)U,GG2JW9<< M9DA)A5[CD]2@8;F=BE?=CZQ%;4?+@:XW.(_7 KZ/HCGMU!_)O!P;@.0Y7#EW M-4H&R]WP%4()>G'O]\6)^: MF04R!V1Y)M X =#!/X5O%BMH9M1$36@45*5 MLS(C[!1_>XG#EW9%56T'H+)V,^5D7.:NR7FB;6$T^ K-E"L_2R9Q?'G!"(!E MPR\V9ST](_*"OD+$6OA0B;I:1M2DFFT#E^>PR%=I5'L<]1,,\GT&HW5Z3ZK6 M^7OJMXB\P<1^/0OR6/VVK$6F-C8>AD(XVD3RG0H5CKXW7A,/"/G .@6EA/13 M=1D!%=*OV[OV#:YSIVH%TR_&N#IVP%/8E=N(=7;@TC;>D%R]QWJ)IR%R%@RA MG[R#)K(5I^I-2\_<7P*]+L<>4^,"D#IVQK,#Z(0,_$RXSN9@76JX0-L@ECJX M52)G ;9^\K]-!Y- K\O!QM2X *2.':S'NQA3'_PKKT^O\LTWE$G:1:^#A8,[ M67D1;VE=9C>@^4ES;2+72&).=QP">\0E>S6^$& '73-7!=+U^K+\\;_',,.@ MOQQNX"NV'?TEYB!%*VN7 0Y.-ZHE.UI0?+OZJV?^)X=F]Y)S5*?+0*YSX=D) M(67LS^HS/U:-G77H &'+ ;6/T6_:)Y4@'IL9AS6\*#A'9LE.A.=>S%ZGNWV1 MT\#QG<$"MHN,!>R.R=IW/!8TOP.,EZ_KT &8W+L/1P1QFKV=:5! M2OA&I\6;9<;S)L5OW+64LYT=O_&M)9T;"[1\_')CJP6>A];FZ!A&VM D-8=Y MD*YWZ^PNR K^RRK\=1_GM#W05?P.(ZY4\EY' MI5$G*TE-TWBEJ#LQU"H=W=D7R[>J5S50D;IZEQE]&KVHE4*/:I_,A2@D:>F" M/C)7TT59M/:(0/F"2J, ]L'26R@3NG;W,=.H7R]JC$E[>)0E+TJL%J(Z=-U=O*!(:1NK3M/L"JD,#Z?7>VM&1T4 7 :PI4+X,*OH M0(QTU6QR57R BW35JAH]9\9GL1SP2S:\H]I0=?4N <*NNX#U@[T&?HR[7!VP M=R--+ ]2+GX\OL19*G#V(.L@[? "$/?#N5PV/"GX#7M2KR 5@U>M7RL!- MY&$[&!8PNHA?XPBFT7U06'&T?JHV,>SCXL+M&"\@F(&_QS")O/>_470'W7!8 MO\M!^+_4 M[,5.8HIK:]%_G,:G-,+1%\^B:]Z_HB0H2 'IP=RY>@C:PZV3@4,7JUAY[FC# M4 [XVH!&%P%;K\>Q#9T2@ I'?!"FJ_WS/B\ZSAB:#TGIG/2I4SQ>($9<*Z)JO(R$V@HD* 7$BQA!(%7>21 MD>(7A7+S-4^![;53):IJE&ALG<:>$9DMD6$#8T40<&:A\ M0>@V:G\HHA]_EW;)13A1N6#GHIZ KN!Z]E/.(?\V#D/B95F6X M/ANC6F)=MBXKQ[=!WXI(O&I<>_NHJ"3S(6!9LAED$:0%VT+=1S3P= ]- = "=3RN3W);7N/-U8:HXRSY"3F48K#H#HI6YZ M F-G/*\P>T(EB&?P.4Y3,EFS3AX[PFCBLU1QZWF51CQOO"_R GL47<,TC[]4 MCE35Z.H?T:GP<8%A67@Y MZ4AZI:F"(3G2X)OV9,8866+'U0#*!9"L&8( M/FPHM?!&VBI?#+:-1]_'@#UI(VOA!?C)1YPT!LM:+U4O"M:LN&3.-@P6(@Y> M \",E(3OB#OAZ/: -@56-/PI0[E\+Q\)2OKV-TS954"A7 $4;&F[]9PS!L^$ MLR=!1!)"I*90K0X]5ZQ9YPWIU."\ZNY=SO1^^) $2DE>;OX D;2R:CD(Y3?VNPSY+XV*? M02P*#K+D)_F%C 01@P[X?40=S"Z"%74.M-F0.QN>^<@X4$A:=]Z"DK3Q( XB M^(SYAV?[K-;F?FB3M9@Q):WA5+&+ "48SA+(Z!+^!271]7:7H5?VV)1R)!NB MHN\U_51=O./$>8&XQLR/&":!$9+7FK]X)&THZGQLA3&W^_WFYHMRDEXVSB]] MTA <,"[BN9HYHM,Y2O'^9T^+6*Y3O%UZQL-2#T^#9/3]88"LB[FP8@;B%&#/ M".&80TP5H61P0@J*\QB3I ..ZQ0(3K.X26_B0ME3QB@Y2*[8]!=4! GWET?R M,]A4#TGE)RS1ZH?'2$(FDP&SXC=3P".3]9K#?59AN-_N$_)0Q@7<93",:;H> M_YQ \@.6<+5%61'_@_Z]5U4JCF:/IS[FMF0PM(X?F'6D\)E(4J['<2P-*@%! M5).0[@*#FFA^^+1U.T*NL%J\S30C2DTH4)<*E&+1*%,7# Q%(2M5M$.G"=-, M=RF)NZ@609C67_STYNX)8D:4E:@ M]P@EO> SF^^4S@NU$.0!%DU?@T?.J)@#$N+HCMOV04'_&^)5Y[2!\BQ>W2J MR4_EMQQ!\!!>,(_I_S4(Z72M;_I'%(RUWZ+HSO1?.2.O;+\/D6/;[]23G]IO MV;[@,:_MGZ%TGYM$_38!8]TW";HS_"?&QRN[[T'CV.R[E.2EYEM&SUG,:_-X MUL&C1-MMG.=&8;^/D(VYMX.P.U_("3_Z[#!CZ)=7C.#5N2#J59_7V!POCXBO ME+QFH@Z,QOD_;D?0.(EUL0,2Y@V%, MIO28<:B0M/:\A85[B> ""!O ^,SD(>OB!6:]N005-QFCI _*,&5W'*&FR5JL?6ODQ&2F@)U.@T=*C_TC)%&J4+.T1[J6:S'\]QJ:E,K9-_$UAKD=I=_)%!]L<"X=#A MML36_8B3!H"LY!8PMN"XK&'D.,!1BJ'2O5I6H?X]DQUK1 M2%+37/=+47>RZ">J4Q0W3,;C=-4#7[OTN$J'6&Y$6%KRDRJRFG("E $,J"IS+S!YE9T8) M(G8-[-'>/-BXS=EG8I2?Q_;UV)[N))7G+2IC/C\&R'2A^#U6N_+<2\-R",8T M75QW3B.8@=M@Z\EN9Q22L4!;JLE7]8_.?IB3#X[ 3.,";8-8:;\_3LLN,G7: MCF80= 33"6!L_76:3OA&G.=8E;Y#->),/+S]S%@:OP:S?M^@+!*)P9MSQ5=> M^KZNN0WL)N=D"\A8B30KP,Q\V/B-P($D].2AZNO1A^O]JM*[Q2<\7 XBZ98? M_S^9$;CI(6&TS+.[P)MB:=>*A7[,5'(+._M+.L>+.2\6<N M%F@+,//^15B_BGQ4>Y^Q6UI=W: @%437*51<7/5\6_?F^AWG,M9[JW.")!]", M$P85(OTO6D"A3>99LU7W $W5BRH*E)KV$:R[E)(>2J0#2$,,JO,$ W MB#U(1*3)A494/$F"F%'1X3!Q^QY%6I^'0?["FMQAWGA^! 4)VPF.@G[XDCR M2%F7WH/%_4IP X0=(/SXY$HX5@YG87J=KIQ&)K)WU-(L:HPC89%P!8PMN!L; MWF1KC.L40P/SXCXHX,6>O/9]![,81:9+CGZZ=J>V/CX3GEW$7 2081E 1(4@ M13U8"C^"JA;N(^N58;TO">,1MQ7, >$.&'MP)X&N#[5G=?NM:+/K(6F05*8K M:M&B/01! ;9!@0ON_BC+7TPU;TT32X'I&S MZV\M\NY"::N:]J2T.Q!AQOX&SSXX1V)FIUX7 -U(A*QX LK4^'G$),CQRIJ_ MQ+C.Z+NOE,E!?FTB2TGW><0QRFZ>1R1/P)SD!RD!&.),[%I@U7W7XD/.4 M!Q&IJ52K\AQO?>M[N#.49>@-3^3Y.FV=9:61> %4VLKTB&L:G@XS)[9(L@EE M(H$ #YY*64ABH7U3@C07%B_)^F"@1B:!C-$P.)'J\I/;/4E:KS[AU,,OB[NV1#$<2*=(O L M+0:QSMC#Z6R:/HQN79PV5.*E*^OL5_0DIV0 ML/!C73L&24?;I$X]>:I^[@YERR11-$6YD%= S1U[OJFXG=5OSL.MF7?) TVJ M,3:SXI4,8)T>[4A(3P4AB,WN./5[MY?L5K/T*G&4CH5>.!UT)VB!$W5<]O9A MA2>+7%>_FUY-:FT_*,G\1N4XO_M[NH4@33IN*F\H#Q]P[],V&M*& :[2]P"/ MOV.$I\7[9)YC>71_KUL+OFCSZ 7,7.Z*Y"S")M;E%.N[S@>L716AD25"\UGQ MJJF2Q8(T%X&TRUQN9(N<9I,Z<2.P,)[Z9$SWK^O-YQS2AD_.WA3EZQF:43U% MF],]_F6L@9JCYX-)IZ*Z"D@!R'ISCE)Z[UWM &FKC(VT(9;S2Y3B%G?:E* MJER#2BB/+5G!2D;,6A8;FS9.WSHJ".WU4Q(_!Z5[K=+H[S"0O[&K3=^N?8_Q MF]BZPU(<@$IY6+BF2<(#%LECVY:VCA'+ED-%LZEK[6X4K?IY1%WFKRIL'#6$K1_>L\(IVH4=B]',&]1,V >;U40>&:A^02C7\\O\Z1XV MTU*8J_Q0-=U6L'Q$@[%NYP$H"NQFQ"?,O_<<(M6GH MI)5]X2OFQ0ZZ,S%8XP]* 4BF5X@@KN8X&[;SM(4DV)U)B]P][,['/XH[DX" M7I-!X.YNX Y3 )*0BP1 W#BZN6]-++:;%^W6Z1&1HV \P:,N7OTI]I22YI" M49_L\3KNB1P,[8+8\N-',RA@%'E^NQU+ J@HH)0%U(1QIH=I]IZ29E#;>=:(4<2SPP M-#$&9 J$5JZDQ0UF6UWKI%^U8WR8U#2VA1EY:#9U$'JLHM30TKR]T?RXW]6= M;4]G&WC2'K.U+:J;U]0;>E(Y?1VC8/!4=R=%]W8I=E)R5CA5.=\(0DA.;WZB MT>,L]O9MKB:ZN*\G[XI.IT-WFXKQ^NJ7\DXX2:@?#NHF#)WK?S[TU M)8+5+(7@S6%?Q'E(MMFD'Y7*%#%.R[2NN)^V>X3B-,QH=B%(JD84M".;'Q.( M-))'Y>!C6O4=-1[K>#%X.^0)?K2]FG'/\XYHEZN\!BE#Q>2661]5=[?XNFZS M^+ +DX,*R2O/7UB.[G=U8?*CI6M>;H>2U$?!VHK@W1-F!A@WZ==&_5G'-.]U ME R7<8FM\UZ4Q67OJEDQT#8N2_Y!#DSJE1+&#>3V&2G$O4,9"83K36.U&$/U M&4&>H&X[.4D&;KK*,>9@Q[B3%%!SU1O[<1=<&5:DI=U%0-AXLV<,OX.%R67: MX27-D7&N9*YA4T^-L=24,T'6KMR-(D4-$A%53[#T%G(H. = MIHMH1\9E>Q$MWCGIGO$/ZED567K:CYU)T7?TZESZ?$I?TNE?@_FP@E;%%.GH M=@GX-5(R$N#9R,Y,.;ZD&AIKN-&[@CYXMWZ^Q49L;0E=)V9]V581_ZTNI#NP M&E]+M]7F/2ZC*^J*H0^+:CT'&B5E>4WGTGG\7UT/.XZ4PCS'8V29+>,RUE;: MUFW-]F*[;P2D6[7T"GN8B&GM8@=1QV6CP=']5](^W8=UM!1<1\6DO1HT[B>0 M$UK*.[(!"A9Z C0HNK_UGWMC'./ =%W6[U#7L%G8*C#BEJAB/0-?-BE&:1%S M=?A.[,2/E4&_\M&H7KQ3=*,T@)"W50LP163IO],U;BT>B-^UULKE07"^-6G5 M#:RV)!OQ#^F&(,HD[2R-!UC8M[HZ=9* 4FI"/-=V1@;7GFW-J'(7@F'G-N>X M,@K4.<_HB>(U6X772Z3(V$&K1=;!0TSB CYVLJ,:%__\JP^M'I_J5)_'R'3Z M3@F1:F]A%TEIV?WWT+=MI3?M[;B'ZNC]61T/(-&;8^[=4WN@]9XL\KF5!:;[ M-(U"SLL?H8]TOCKJ036L?XU M'FA?\#<'H*$/-?R7K5$$/?J+O9ZCX>I M,;"1R5%@.$6B9UN)0W.$.1$(%,%[O<6CN#Y*&IMZEQ72,9'.I)$R,E/DE+I2 M\'AY59-%)]FD0M7NT4@W%U>)AVIF^!2G\7:_%1=Q@>#LQ_2L@?+("=>0GI># MZ."Y%ZE7%IQIFR0OTC/E.9D0[1Z2&!N17G)7<1X&B6PG8A/JEL\S![G9=UZB M9O"[C#+#+OQ[?YU4$N6QXV@)_2X/T9%#Z])U2Q%(DH<)H=;?:@(GQN&%B/3X MAJQY;IVD(W K%BY\]-L/"_#+#N!DG;&MO86 ).MV9,8DC 'F[*.K88;:*=41 MHHZ1)$R<.-S(\VY>.5P#/E67JS2X&*C4W8[P]M#QKO#0;?L=H^D62\+#B==] MNQRO:V"GZ'25_I:"D[++$=8^>ES\:GVF8S0=(XEY./&X[Q;D<77L5#VNU-]2 M<%+W.,S:,X];;;"UN7"[%F%WF#88.7A@Y05F," \EN&&W8 J^&*'/A<%GHI7 M4O;>^J9-=W0)HJ-38,_ZM$JCI>!KKMUKCR_<0YCE[/,+8 MG?H)6T:PCY$AG#\P.%/X3-Z2YZY&FB>*)T4R\@![CK$D)X7B11F/O6\4Z3%7 M'%;T,E"5<](Z<\"X\S=5?'!98]>T#I;]A>0=HE*DZUA;>=U^GC&R(B.'A%9KRT8TDCLX$_R9Q=IZ12@L)N^?E-1>V0O#OU^Y,QU44.S"3V6 M;&[HJP.Y^0[[EC0^6_#[H)MY3YK\'YDEK&=2@[B?[:(]C]$AQT)&; /]ZWD5 M=5S[(%1_2N?IOI>+M))M1CM>*[4 MW[N@4GK3NQ.J3-HQ^K^-.Z*Z@*IZL;T[H[. I^RO,UXB55*0ZF52#>(30?VE M7R[5AU775VU<-IT)0@-_G>'VJ8J25&^AJM.>!NPO_5:J-J::WFKCENH\^.G[ MZ@S75I54I'B/3IWV1%!_X==9M3'5=54+M^GFP<_ 5:>_4R>K(NU[KYH,W(/^ M&[L':P:TAA-;O1<[(ZA:[CSO15E9;;GPXRE0_FUS M<=-6DX$CB/]Y\U;-;55NX!HH?EEH*WJWSM57]5UAD+^ 38+>!HY=]9C5JU.B0F^=RK0?T)[AQ6;!Q03?;YRH M^=B366EM%W9W68R-?Q.Z# MY!K /];H0RE)U$[PY.T\_3(E,&L#G@?]\Q.?SP M:DW\Y6;J7NTO"VNYF5JP!X0_N!L#>?J9VM"?U6D[BMN3^/3X3.VS5VO;@>Q< M[<"SY\%<=J[VP;OOB4SKS><FT% I,E!G +(!0$;E#4S*R"I;C[ZX?WF=H*L0;-8FTCJ MYK#> "P'H(( (0GI+2-D 5B8UD/:UKJU/KP$&3S#)*-SM-W!-&?'+UE&&).L MXMFA^@A/-*[>@BRZW6^?R)7 RU_W6(SKE(2L^!7>8=WGTH>0CKAKGJ YD<;) M\2<5 SP1.4!8DQ4$E;#@Z0#RVN?XR3,(B,0@I2*34 2IT#@,<:G!CHCMPWFJ M6]M$[E&?X@'PA_ %1OL$KC>C \G[1O(8/"5*I8(6F>K'<&M"V)_GA6@DMC-? MI9Q!73Q0EP^<'1H?+'M74&?]F8HYTFEVJ@6 ?8-#SC#]8HPKF<>NG$0L$B!O M@RU3^\M5/9:$@9/BDV:>D4_$QHSV6P%XBD MU'5,5GS37+>,TF_&;%LJ[S#Q& %9R!8:P_7R?3X5YB3Y+;J*33I*'.>59QG+GZ(J[U16.UNEK"^6BL_>NW M#F5XI=FVR5I:N]VB]#J-]B'=GM.=>:ZX4!N@H#E_]U)TL@3#W/!*2[!C*>H< M;"E#']9.95K'FO?GEM.X),6_-'.JH\EXO%P5+&5=C$X*S!3M2ZW.X2=(#PH4#A+^L=&8W\@EF"B+XU]!)U M4/U!6 #&0W;=-E5 & <(2>O,6S"X?PDNH [(7 M1[3*SFSB%UP7<*JU>;7!S M&'E'N3MP2HE@.U(M0Z0#5#Q/G-FB3:G,Y9+H+=]^%.9I6Z:S\#KE1G9QI,3X MBU:$-=/A6EQON@]]IVZ]8:QRE@Y:[8L7E,7_@-$DLUH_\QF"5)\P#CH4TYZG M.5W](+X<)74$]P^?\0\EXX5/9J.696-N&P;MB[,B!^&+YX%7$F;G9^1:15%, MOA(DL\:P(3%FM,-^L5P=C.>P0"[ M!'&55#Q:Q<64[<*#V: -V0A?_1!]4?9B+43Q:,1D)%?1F91+B4D\];[>%WF! M/25.GUG,G20N]3.?P=;ZA'&UU^2&4^.W\- T:DHVPM,P2E^IA98[&>;/;K1ELA^^SFM;QA.QE?Q24V2] M9N8@4]8-W9=J4@[S9D)@V@V(BFREH[BG<\2.+C@?BB KCHZ3CA<9)^ ,/LY9?O, OC MW#A1VOFFV__?WK7UUFTCX;_"QQ9PLDV:8G=?%G!B9Q' C0/;:1$$^Z!S#AT+ M*XNNI./8^^N7I.XZNI#4D!SIY*5HG)@SP_GF$SDS) ]CK!*W,(KFW]U;&F9[ MD;QQF>@<$^\OQ'K4<0.?=^+K'D5T][?;7 7^?_3I(4S60MMC. .D[4$'K@E3 MMFB[H:E*>G0MZ_'S>"@NVZOQ\SP7L\REN#CR37>G\>[\Z8%N^?_>,/$CK]ED M=9W\1:^JCFX >4)R?62I;!\_YG^@A6HD8T3\2!VJ2_J":",8\+.BAX)C02OX M!Z@ MSCT4QI ;IC\\8+3X8??L,Y5_>7>X5,2U@YP7,X;5PE%M69,15OYN8-7 M#4JI1(H5:Z0!<"1XM5ISG( ^-O8=//?:FSUSQL"0 M:ODX-:RM)GP54X.#EY7IM@!9D-/KACX_(GAJ$._$6??!E/G*Z+?4'A\#:VKF M$>5:FGKE885JR**8V R]D&1LX/OC0BH\)5=&K)>5>VH3:'A96S>/>-?4U2LW M+[_4: O5D'QMA(AC0S \9_>6,,U9>ZV)HVZ=R33-N?*2*)8\_5Q-,1>D4(/] M1[5U9G XK<%BK@M@" 1O]5JH71/T<[\JV<,K*JZXCDH\)R4AG%)E66$;]#N,5PL M[S<^9C])/!]9XT\66V*5:I]]F;PO-]J7R7F^T\9&,C#*>N(<".7M4= +10IZ M,49!V])$PA)2Y6W$'XK4S;%Q$FAT05$4'!"=/+(N3-E,6[O1SE@,V?9:>]/L M6KV9&P2WZCI((U>R24,X$=+%(?4VM]J",X*+ RF4A!;QQ[ 0MP M;@V@D?4C1BQM)(Q+9,/A^&IA?18-,S]P2$X#;=_!-'>UU''KA(H#HNUE;)Q MNWPQ/GD4 L21\C*WS%"F;ZP"SLZYQ#X?KA9<5L\>UFB5&B]LR5UT-XA[#=LS M[W0)/::%O\_]L%9..8_6:B#B/+N8 UQ^3GEQO?@"7AXVU.V2WM*6>=,+^=-O MWQ)Y#YJ_9> ,)3'W#@XH[912'Y>5&O"*=*=ML:/@.%I4>VN&K:PR7N5"-ZR] M#$$:G":IOO[W)RS,-VR?9Q=<47?,NZDO_8A#WG^*U]"&BG=$>I!*=<-: 9* M(NUUO>66%)P>U+:076$,201@-]P<^>YM;@]Y%@8MNIML#O1G=XT9H\=9=QB4 M5>Y/3BEHX>'3-ZF5K2?6Q*J,EHNXT:_%U&$&L=A2=-QZ(06V7!+Z MYNL=TM 8^3T*>I.?+_[.PL=P1^.=8'*/E->G#!J8'BH'3X#58GQ7B,F7+:ND MOQ'DV6/!(2>N'F7V.;% ;JDZ$;I[[!3SMMUIQO-9)=:EV?.'.,T2621)+[,[FMSHM(<$M;V$"8,(AFWJ*^%(916U7>^G"RYRC4[ M(&:7NN;!R>W]+>JZ?B[Z7-H=#.H/J>'0$R^UC.EMA6AN[BB)JS?75#J:"F;I M7-[2X)D3_BO;:"];/U)9B_N))7R\,/NYY)T3P4*9J+Z'N^B9__N0CRND"C9K M=.>3(!5J\=GB'"?O&N2,1VE&=OQKN^@R/'#(.:2K:8BZ*-9?<9E)*.3+)@2^"E$6NR#7YK. B7!F526+XR I"M%O_(W?M;W;9XQ7 MB%R,F9EIX/&I!.*+7/J<<"/L>$VKU7RV/7B:=L[3_S>8_E<9;#-^ME.K9U M9TR>53V^B?(#T,:)I-P:%:PN[.-?W>:%Z_O?HQ9&%CY0TPDA5%+7OA 8!J>3 MM<" =X\!B'X(M[Y:$&91L-"-;??!I?&4B\[K24C6!O;K4N/[*/AGJ8YF8OTM MP4K;#D^':^9CL+3+=.[ED]NA,_[=K_J;,)7 M57'6Q77-&6M'3F'+Y[(=YID M,;QQG/U(ZN*FH>FMLT<1M\MJ_5D4)1J;@)<:#4U:"T4.=RG]X$K V/7>7@3" MG=@S>]76%(14<>F+,06CKK^MUHR#.["E:")D-\X>G/SHV-"-"[?-'&;L=)0Q MX*T%1"W45E,E&GW.">L'15MIC!&E:82#=TX&/BI'V9N"[!-B!)8?J,?1_C+[ MFX(HC^ EQ6K"6FOHK5EG>(PTWQS;ZJLHB^^YUQ:R]-+3&.,72,<"?_1U;)U M>B'@LDE( R@_X.ZOM4@8Z&*AM;Y42[U5LP8?MAI457 MX@$#9W:I'0IL9GU(XKZ#0@,NN>_.!?4K.G1'- UK50EV@E#>$%$&DHB?I%*@ MN#Y'7)V3HH@/;>\RLSE>ABMM_RS$M3I?(4,7Y*+AO;$/4Q!8-E1CY!+*<65588\,_A(DPUK7RVH]'FTLL9[QS@ ;Z^#B&KL'4=^V?PK+@:T(?:;RGV*YT'/8%FYPF=/,>-:;\\I;(\7UM9/BVBG(_W'&>.N.NC]B# MB';!6'%*C6XUG1YNUEV:4\-;N.&T$"J_H0VQI)"++59T7,H,YG8![HLZGCOM M]YROH/LWC6D21%RKT]U]&(?\(\N_RX_4..P4!S3WG)( ^- KQ,K(:PO&&GQZ MKF5&,[P(-T9M#YX.>M!7$)Y&,J;HKG^-7&BG$X6J(YK[3TT"?!S>L(S[4%8% M7AS6[7!$GJ8_F=FL+L-W1?!5(LG@SK80ZZWT/_9$4]V)I?IPFCM=7)?RU75# M6K*OS[Z3H/&D596,NJV,D,_-HB@[.@3U[/*[+D!<'%D_OW^(V#.EUS1Y#+>T MW[8JD23-2.6GIOGW8IO\D65?:'9%M^Q;'/Z/:ET]:5$)\X^!-:7@O_V?XZ0: M/8_OGB6 C&/^'3DI6@>*O@(<*P/[,&3./+M:R!5+EE)+4J@YO'*ICUCGNI)\ MD=KZ-S+%QO4E7&%2:^QXIV%MYO-#3IS=BQ^)?Z?UI+9KS1"BMU=3[RQ:WB+T MHKQ%**FU*VYE6SFWCF/;!>&.(..X<.R2FLN#F]P0TK3$8Y':]=:K]5IUFH7W M07M_E,H-TA%-"%AU?NI9Y5IYD&>5WT5\IWMY^Z?<(V?I97(E2#W-#RF?[9,P M_J;Y'++&B(8)"F4)5M(,4KHH0W\OY!-. XG4H+R5="=U*+Z!&+($^EYF9G-M MWAA_.")'NI3>E7W^1)-MF*KML&<*F--L;2#08A=]'S0%89.MQ',/F&FI%08$ MS\8( W&-$;X'8HA3>IC DFSOD+ LVR/".(=G"Z7>1&2V7$ MF0JI#5\+T[,PW48LY0N0TXVHDVXSG=V\\I#FVQ=%$:#KOE)F?@PD1ZD02VJY MY&LI&4D;@*YWF>$4NT!J.WJ*X+D)-I%6<7QLE!D=>H.C6FB1E*QY>4L*:>0R MR>%(ODJ)2*"GX"ZF/H%X71.!>$6/]R ;9-J]SA7)>>J&Z?7611C3#QF]3V<' M>F,D8$15(SL->"&52+&8H_[0?U.1WYE-W+Z:9@ E-[F+)\-#G--C ?L)_!#9 M]./PR[AK7-FK4W$&>,30C05UF M+AON;64_";J)%U%+;U;B%FMHWTT)?9Z4-;3<_3V^!YP'9]DL91=+P0LR3#UD M"]F ,>MC)3#\8JGA-8!JR>+.#7"?DG!+^0Q*R:/LK)P[GB'!,)5L+-%*9KFZ M:*[L6WD0^H@LBE2(R0EXHM%O!ML,R">\-#KL"NF7\"$>,. M].!K54C@-ZXQ62CX!])<8-Y:,% 4'E@L/V]$*BCV;?F&9U[>41AB 3!_YW\.(!#A>T( 5]S& MD #*>_JV'P8._B;#>M;4='D!FTX=L+XS85?T/@C%DN8=BV7GVCZ(+L);]?L< MYHJ![=%5%.N\;_=[=W>2E)J1;:T:B;AN@0-B9Z/#5O7S]!O"A M%E3.TF&#-R]?OW+!!L FJK !%^F #?BO@:T.6H.!@ZP>W ,G".&X6:''D=.\ MT)U3]$[3X8;7O[W\[1G[3,>\_UUZ4(Q>%@JM<#P[MI M9^@PQ2T7@((H]!PZT)(P.K,+<)X.7?SZZ\M?0.G"H9U#I9^.B4*L_37%^_ 1 M;$G1' OZXU2/[7Y!<Z$XK=85H;C=^ V<&5D2IK"2'3/B]< MAT]0M- 8"AIDU=#N22$-GU!SPJ$#)RFA,YO(G:5#"']W10C -JKP 1?I@ [$ MFWE@A- <#!QE]> >2$$(QTT+/8Z<)H;NG*)WFE:1XM7?7;$#M)E*_""$VF>( MJ=I,<2;7QPQ!+B9*@PAA=IG MB(\A7&]#'.$3>WM#CQ$ERZ$XH=H=II1I>OWGY#R?4 &VE"C,( MF3"VC5[!T>[E.&BT!'KCX8&EH7B5\T;=O0NZ=:1]UV+^&D5^WXC->ZM\-T*. MAFJWZ]5B4[#O>2B"6>GN,M5&8:F>XSL%K[=W=+>/. FOZTC?8[NGO//U7B@8Q]_E6]O#T/$F% 6AY;T;Z\%UJR^6UWL)K QUFI MG\!94T-2JTA*'8E0DC2T%+]4ZMDXYH3J>F%+(&1V7;PNP$4>L6;G+>YY4WMA M&+]>+K =E,R.-:8+7^N!5>1(J14*4H)4AAY MZNUS_P"G3Z%+ZAI7PQOJQM1R1G"KX"@EG,'1UK3C5HPI8')[^SRXE/LJE,;! M>!^#>WK&Q+YX/FTUQX+&23VV,P(Y(4(H9AKI<=XD%W0G$KNC)J)2B"-?15WF9_5+.:,#V)8%!@;U$KYIA)(4GDM>7E/!8:JC9*;F/+, MH75)DZ-J?]17(C1RG7"%&?MF15V+\HOO*[N@*K3\$WW/XCFA/#*"Z?T*0R/: MN3!!2NO,+X8(GG8-4YLPG&YH/3V5^T #W4B,B%KZ:\>HQD+BBJ99$HIWNZ64 MSW&8I5?7G^T]T<8'MT"?I3GG]P\1>Z94&G,I7R:W9TKAGLOB 70]H^R\E\5B MKF(6;B+:_I:HDZ_R4#/>6AH?V@8/5 ))]].G!C]G3V,I.I!ISB9R9T40?L*8 MJSR]9_M8Z_EA(('>@VI][\QG#ZUSY\#"*^]EI'XK$#&K@4 M8],WJP (<-HP5VWNWN=]&(M[02]HD-+TFN,RO0F>3N/=[T$89U3^W>4F"K]) M3<25KS1.U>_Q-!S=<+%N),W*?JK0A$12E1.2"F5(%CP1ON0B][4^A-4*B9_INS[_=:E\^&#D0 ->7 MZP#J+6P+K-?(KY%.'@K5R&[/OXZYX?$7ZM)N20EB!$QS'TP-"9\-!22B!1%2EDX(F'2.TQUQK!Z(AIS@I]N@#Z# M]?L QD:!=8:MVO_2 F.XW#\U:WC],1$>0,7]T^TVV=/=979'DXLPV(21W*!K ME@0G1C'< 8R.:F5]7T@D3(@D42T3PX)=S55,??+PNJ657BQ$N61AD# HJ$# MDZ+YUKC9#5V8'#88&P5P-7YA[T! W[+\ EMOOX*SQK9(%U#]][8=,[)54O8) M\B1J$WOY@=TB(TIN6:*60UVT_86+RXQ:K@*1.A"N!.%:D(8:I*$'*10!MM]7 MCK%UO%(I=Q[&,H^X(YM]1F*6D8<@!'@)#L5L]..BB02!C!HGM4:D5(EPG4BA ME+]9L443@2R%I9(F;O?9/J%SV4)MIW!%P_O-GFLC#'S/\I+A[E/ 167O6)JI MO^>D,)+ATG1R9"N[AI;4G+ZE7!Z60C#9"LD8=A#J+F1Z$^HB;5\?5+ZB$5> M:Y%DSS=)$*?!5B+\[7/K;\PO = 2 ''T6D.@W2/]A3@BY9&F*N+D3OMO414. MYJ&C]W2^ME,6B83(,@BL<(':+.D6,W1&-?>UNA3X4&_Y#D?@&KB2F4_F02#HB3P@7BF&_HN8KICY[>/W2JG@, M.@6RY&'?IFC$'$5K7*X>+TP*']-C@2\Y+NP50097&PAK(G%XN7D#51=QX M;&II"%PD<914:^-0(:.V&,NB/J.XN/QL@W"@-.I=KU'-'W"W_I?_L/P1_\\F M2.F__@]02P,$% @ "HMM3_N"ULK#5@ >N,& !4 !B:6]C+3(P,3DP M.3,P7W!R92YX;6SM?5ESY+AVYOM$S'_0E%_L\%27I-H[W':DMK)$:4L977[ MSDL'12*5O,TDLKFHE/WK!^ &,I,+#@B"3)">F-M5*O'@X -P<'#6?_N/U[5S M]((\W\;N+V].?CI^V;#O9##_WSX^V_'/W/V/'S]92]OUL1,&9'3_)Q.OWQV]?9N2/O>0 M0?_AZ,((T%'T?S\?G1Z??'U[.3^?'SEV/T M9'P]^6"<6D\GGSY\^?3EY/C3L?GYT^>G/*=XL_7LYU5P],_FOT0LDOFZ+G(< MM#VZLEW#-6W#.7I,9_I_CZY=\Z>CF>, M62/7C_[ZRYL<>J]/GO,3]I[?G1X?OW^7_O:;Y-=?]W[_Q_OHMT^^?OWZ+OK7 M[%=]N^P7"=F3=_]S>_-HKM#:>$N6BNP"DP[@VS_[T0]OL!FM$0=?1Y6_0?_V M-OVUM_1';T].W[X_^>G5M]X0-(Z.8CP\[* 'M#RB__W^<%T8\\G&)MH$T1ZB M"W#\]?WQ._J+[Q9HO7'(#KJ))QQ16GEH^&G\!XQ2Y>;V/&TB.1_G?F6I=N8 ?;:W>)O76$:Q/##X30[Q!"U;/9 M>&0/ND'TVW3^A0_0:X!<"UDI&3J!3N8;,92RY&"S,'\ZGD\&C+:/C\R?GO'+ M.PO9T8CT#Q$X;X]/DLWS3^1'OZ=C!,@S8CEE!,9YZ'F$A2(J#MW,V$M_Z!A/ MR/GE33.-=UTQG8SP@#;8"XA$?B2K$_HPIJMH=,;TXXK(O7.\WACN%L9J\;S,[7_7 7/G9/8SHC2<8XL;M>(WG1V*F641\>K?8W*%.O_/WD!8K*/0 M-<-46J"Y=^_A%SN^^N$L[]'HFFFZIG-O@7^X0OSF/^^:U>0_Y+Y%)T+,%@ET MQN[">+VVR#5B+^U8X8,=_P8BG;%-U&SLD8LO&BW:A^Z4[+7A.&>A3\2^#WP0['S:J>#RSHF$,V=3[M0%>-7 MT97M$[WT[\CP+EV+FIFXU<;*[[N3"60\SW"NR3/\]6$B.C>QYVQ^8">;9^, MY0:0UU7YMQTP2<0*%7V/V_43=GBYV_FHPQLJWE"QQ+LB/^,^VS4$.F>7[O\6 MS.8^[Y#5&!+@,:_XN ,V9V08*\+$,;BO^)V/NE3S""=@U2[ZI@OAC5^0-WNB MDL+D5N)V/BJRE;=]SCRS0-+PS)0<^>.>X;-HRDY^X]W&H-?#6W-E.YGFL_3P MNI279#1G;XY"GS"#-Y1MPZ'_ MAI:(7$S633SO2C8C'HDJZZ/H-X<,Q\X>9WA\'"<>%2*)X?)UW+CLW2D9,B?O M)V1V5 .&S>=Q8K.CV65XG(Y4VI;KX0R6D0K=BD<4PT6ZT"7,/.$#0*;Z(9R! M\WZD$8MFLN#!!DX(Y7(Q2#/#(ZO(Q7 ^\&X#)*1 MRMW]X.D4DI.Q.M[* ]X9+*,6M,54!0;*2 7L96VJ20;/6#UPZ;NI/'V(P:- M^/[;NSUTB.[]A[RLMD@UHR:%<^R2]X^/K#/#H6F#Y,B@( L1JDUHXZ318RY; M$X>-02]IS,O2$^B10O]M\^&L8D#7Y 3^.E/=B-@DA__?F,;3[9C!S;R9ZX5 MV?Y6V"%;R;_\,R2[AR(//YMKA E"#45LR(O"3N6.?>&;5V[Y\;&)F^*G*$9,BL>:BIFE1OP M5\,)N4+:JK]5P?%]*N_%F"[]O)^S# G8XZ&B:K_8 97S5"X264_5&N2:1$Y" MMTXE&17SR,EWP6M!#9\7R6Y]H#]PY H@W41)"_S'<;!P;>4DQ%J)8<>-<]JD2#SN$&A7U--1MR]$CF3Q0T6OH UY M.%Z^;JBMA< U#U;($YX!%SD5\[IV7\A8V-L"=T_Q.Y62_ &9R'ZAHI@,W4*> ME]-1HZGX*Y@^0G]?^8D4N6HJ"*AY[R<&T?DR*WAWC^.0,K&7/P^]WDS^0M/& MC2O%$@H^:.DIX=OI>/?PL:#YTPF69BG*X/HTP;5_7;*8\>,)'FYUB*$VB:8R M-9CA\T4Z/IC:0P:"C^B-5__@88'X>DMX*'K %S"#46_)WT[MRL>HR[\"=#BL M=38KAIW>%P&']:]$(]NU4[*(=KT%&QBM*K,T TQO$<8'6*4'@L5TZZW$PO95 MD^^(H3;)+K ;D8$G7\,]//#J',0LG%Z^T-=!O>"(#& 0ZGT-2'T0E,:-L.!T MO6\*T71P@2P/0^Z4@"EY=+"C#3O?;HC&J MMFC7W0_^S:#2W,4$@VH_N)OAI+>V"\.))Y _0TYS;QT,.9[$#H;<),;J$WLR MI#KPX>F@:30G=#$$Y=\#>PCVG75X'P&]0H%M&EG5]S8IB*4$AYN/6&17;:*5 M4 ,3/CJ*4\9B#JY]/V2+)32)E$0O_,_"8$4.^E\MYY GHW@>9#?/O6C'6Y&R M=H^\B"?!^5234Y_@U^JP-)+J:S[P(U-'I:]9B!V<)DKJ9R/C^/!2G$)/!Z<: M\BZ=[ITGY.*X?[!U[U31!7ZIB->]FT47V)67_-6TY(X,2WRC^J=[=PR)(-:( M/TU;:4@';T_V:=IL0SIPY8)/?DN.0133RG[BSY=)& !V8V_BFO"Q(K]DOZ ; M[/O?72.T[("]5H#VKA8C#+5M3OX MF>';9AON$P)]\"[R2JRFH6(&OR$:^X^LV0O9T,])'=?Y,MD!K:Q(8-(]SG>/ M&_ N!!(>TEQ%=BV;J/D7^(?[@$/7B@J6^^3^X9F"*&7E*R:\ M'JJ*+-#Q%L9KDN!XAERTA%5EK"2ACG^*UQ51H..HL9"<4:;,G*$E]E#&)/(O M7\GI):HPT:N][351?Z+86O(ET9$(?\]1*5KD"V#0$1M*]BQ1$]/ V9C)9#5! M^[>:B)#D2 [RM6N%9J2EINFW!>+\U7*XZ:G9N?'Z"N"\]VFO.T3DJN4@IF). M\R(/4'E=^KD:?Z\?1&9*\+%!7I!#HZ2S@5FTT!(U9F8+Q_( MZ"ZT=G'APS[.KX@(K::A9N=$<*7:#AWX-SM8G8=^0"2A=_EJ.F'T5O():S[1 MRHU7V'X2(*].W\S,9B(+5TFB=ZMST^1PRP5B/B.]K?< '*M/,3/6Z^VE;)2% MN%)4LUI.>GO"(1 UW,2L$H_>;EL(9(VJ&*LEB\:#QKO$A\>R[J5I_H. M4S!"KM^BGY9EB\I7=P]L/XFZY3,(/\J[.O3:9CSA&0S%Z2(1CNG)0/RDM^(L M'$DE@.[N_ORBMUV@0VBK(PTS<+_JK7T##G]U&"H#2V_+<6,P;PU:.X?V5'.G M31NHLN#R#"P53IN>,RRBF9=VI&Z13%%-=+!Y$R4LJPBH:1/&OO?Q[XY][)P> M9B=SE;RK">VM"(><6?\(_:A"X@(WUQI[0*9C^+Z]M,WH9'!'2;8=IJNY[=DA M 7%*[<<0ZZR:2U[\OL$ND1]$G:-/WOFR+$V9>RIPPAWSS]U\78RND@YSV?;P M*_='#.G&@47(0RE/:1;<]TB\ARY"CUQB1!NSBCW.+CH/ M,B>W2[#WE:15@\ [4^\YX0.1%9IM! M]3]1=/3B5X6:9P/B#P#?#L@ MF]5[L4T4SXGHI?C9C:APZR;J>%&RFZ2^$ _S;:BXR-J-[:+(]0SC>O]K(0WP MOPPW-+SMX@=>K'#HDW6[C&S(R,V:(RV(QN8;)MV)MXA:E+F50#'B0O.XI?&K MN8'N""Z29B%"6M):U TUIT9^Q\&1S&F],."1A&9XA9X\P,# 60E25[!6G2Y/ MJWD\HDT0?5]R2!_0L^W3 !CRCO.0&'$U@EZCJ"O<<5P":.JU>)U?W5O750Z;XN0Z;\\#&@] XSXQ-F MN%'P,KST[JQ4?W&55U%-+U:&D=X=SQHQ JE0+.%?;Y'%O;,:U&.&UW02H<\D MAIW>)Y3C>JQ^+Q>OQE-]06JT.V"8L815X]!;D@',4%C,F,:0U+S'*AS)-M95 M!JO>5X< K&(F> :HYO<)'%!!YPPKUR._+^F!(RK!BTB4, \,+#@RGFAX_ MGZ4;/P\6IN[C^<92;0EP?.%AIET48=(.Q,9 98:BWOFZ[;ES%?%>US_3,U40'6X2JA&65W4.13Z\$(MX@$=QE7ZOLO"C$\LZG0@DM=+$HA?P+ M%A("ST%$37+7AAP#N@&)$I#LOVMWB;UU+#!%@OIY22I)SB$,T/]/+Z,7PZ$' MC=E=Z3_,Z',Z_X/<;Y+-'7? NK#]#?8-YYN'PPWMRF/[9ES/'%FLG#DH[T9Y^6JN#/<9/9#+Z7*Y1,"NAHHY M4U0T,!+6U+Y&E("S[7=R>5^S8(F9&=@OX&H^$*IJ.D)NC&VBC5#=E2HE1+6$ M54JK(:)Z#E&\^05Z$N8_1T %[_'"HQNZY>^)2F#:&_I0C[F!S*&!D(JYD$UM M(F1%S3^H 8SR,U^F%FO(9)HHJ9Y-,O+E*_),&]BYN9Z.D"9:#D_.HD/$+01V M :+#DL!"SI'8YVWBR'? $ M.0GV,S=F0MG2 %FXS8B#7C\SFYFF%TIEI%8OW,Z=XC MNKIMI2&7]#:D?H[_AOMFNQCHP0O6S_:[7E:=GK\1O]7V1=82^)#@<= M)5Z*RDK%GNT&OX,,]Q44A%ZEU5)F2]O;>R_\G09X2(D5)EQC+[#_BJ8Y7T:I MSO,E423Y+PXN,BI6_P)M/&3:L8?%M?(L0;9 +1GE):1IC@9Y?4<*(8NY6&!. MS5]$TG8SOCYM;52_"26^A'M?H5P5LP5= [<+#3&QUSJBX9V/)#ZD8%-I>^R\#6 M._Y?"=@\CY\,\(_R!/HP.Z^K$B953V&&]"2T9>#,:T#)U4>1)X&'>=;+1+'AY6+$3>0)U'##R M>009OO*$Z3CPW7,M,R@GZ0D$ ;"Q+XYA8 MQ2.]%7QI!EWNZ+#NLF27AA*@-N:?83E*(PE/M@462B%A)=+TUDS; 9N)UMHT(H:EWIJI M?"S+TLO&4H9.#IH-F8<,3-WM(G+@K$A&93#*4T3' N--,2JBLDL%J@TPM VCJ JX*P5>BHKM=Z<)=QRD"4WZUB4/HQ+X 1_W-5RSFEQX\R\,_>B M\.6[D/8WRWZ:CF'Q\"I"M9LZ/T06S)?IOYQC7V:YGS+:JBMB[42:0S92+1D5 M\\AM["YE#)0GU_+=8B09"0B=#H#L&Y[D0H"Q/*IU'[_AK-Q4<]^3I MD[-,)[_%?\C;#:*DIB7K.536':&LCP)D[PF15S?ON"U$CJ&$7V2=P&=92ZR_ M^G^Y*T54$:@@IF2=ZJYYUB7KW' <:AF]-,Q5\7=!Z]A^,+&J",_/7F2XWM%? MDO-Q'WH4_V"!$^$=]S#GED*BY-5D:/-UIN)?1%Z*T4D25[[A? N-*!>7/ _]T(LO M/3>R3/OD_;2VPS6@F&0;ZD(SZ7 :@YK#.?T;E3[)B ]H;=@N5373\*M"ZRU(9:77<$'^ZA/,R&&]1?3RX%X('E)**K-1-IYC M)P-1DHD0,MA/*02Q/ L__O&(N>3_/ZGXU.!7<9'4.'>LK#@TI1_K[@^ M(]$ER77.4+WWL$O^:";G&'A:@(15S/76,,G3'WG;?*H2?+%JR2BRQ):G7=%M M=('IG0VTQ3:3ZW5>9UO*"G0'\Y>%;KHJ"H-\9+4,:LI"^ M;8$*3.7WO5D*X'N^EDQO\X#N\!HB*N:0C O?SCL?JN U;EY,BW]AEQP@^(ZI M(*#T#;3# _A.;B"D9"Z(UJN9%=VU\!U42T;A^8W&%18_A:^5[J0\ \*[:)^( MP!Q\+\CQ3_ZVRSOYT>^WMFNOPS7_/BGYJ#/>C% 1/M0.D7&7$)0IK MAL2)GENC2JG'I<\*UE7E>)1H%!^ #(W1W^;5+_BB*/F@/TB5EA!<;ZYANTGO MV[O&T(4Y[7$,*CV%LL#!*S? %@_?)_V!JC5HXT;C.VNY]$'KC57OO,"5CA6& MC]XRJOG@U7C*BH?NB[8@-7L7?UL=^T"37.XEL?(LF8R>E\4M1'&^=W'%Q3-8-/<%B:DE=1$ MRK.^!IH#URCG*M(ABO),7P-B?3I)_D1"DV%8M7>]%1'1!"0,2*1B6([= E*6 M"L>JCNM]>=8D$>+NTB/'TF= $KJ[^;5==!8X4/@$LZR[:"IP> BFOR64\U4A M6B&2M2D8\P.7_19?9= .FSL+43Y .'T&X)E*UC8X86M(M+(>%EGC/ MJPS"#CKI'M@] .QYEB+W_GAZ,31UMLNP.M&AH2/MP>M@/_308H5H5I+A;L]" MG[9A]W,]QUWKS/!MLJ/NFGGV(I]%=6$O6?#M?^*QB./ M"Q\[MA7]I82?E.\+Y)N>'>U1PG@N=I=\;)+9+ AP9PZP"U3'C*BM:IPR(%)' MIXY*[P*08XI8V9JR\%(%][5"27IC_QG:%ID' > ;)G,GV)G(<[_3_PT,VV6] M)3E%)X#B(&0E#[^*BI$%Y/:V#><"AT_![ F'09X?(4D'H3J)K1[$%F2!=)5! M-%F"2.@XVYRY#8!RIX'*(&1-%8]"K9W*:>640(C )-45SQ91$+L?MF[5*B8 M"A9 7E:51]7" 47B.CK#E1QJ*$P")E1QI^2!\F&S)H* M*,,IL-!2@L#H*NER564ZF%'G(UOG^3++ALF,LT*21]* O8LHN#*,!-O)4B\-5 9A(BKXE'D750DT>8YQ$%)A7BZ0$^YC2\B M;ZHH]"Y &J:&^1="5QD0.>"A&DWQHT&<\(0ED0-]@WP?H2QT@]PM^> $F!(" M)*CB>,>#BASKW2][/\X54\%@W'4]S5$XR!F9K$7=L\CU17S3]40&<=HK6%1Q M668\1"$XV=A)>&$4?1,%ND;LBT'DJ)\L#+Y%.>22$EH^5(O4LO M25!AB3M$5SF8"X[+0J3W>\MSRD,^8H.0BPVL"CUW:DFV>O[ *2NQU@0KY*6A MNP4?B9 IAH-:[Y(),&4LOGBZ"IL[%-Q@W[]'7@(*E;A &5-+8Q"BI9Q#%4Y: MPZ.UJ.C(T9A"NE0-$26.YIWAA5S.E31ZEQ^-T\-<*Z&K@* 'Q@[2>H"TK!4! M +DF/ :%@](@A$4=GPJ.6\WP@@J+*&4E+9MY>!*1.$#"O8LA,2"P^.KJ*K"2 M]R,M*+?-%RP%2JLF,H,0595,*CBY56.W%%(@LBHD5!5#(D*IF5;O M/R(Y11>%@]*4R:(PDX5W491>BH-'#7KHQM+M'K#G1*4S@U+O&FZPC0B_L1F. M"@HQ#%K+C9I?=*_C%HPBY!6%?!A)>&RD,PCI6,TE_ #[ M7I [O.1ONP>7_"B[BZ.KV$*NCZP\#W#!)D!T2C8=4[*IP ;15;8E"3@BXJSL MTT%(L )C0@5V63;ZGQG_Q7=+[M1U*6IT=3-L1U[$H20BL4I]/Y-]A]IHVOJK9#3LD37*#V M [69WSGM\TC;H7<\/?%Q6IXO5EX[&BC6SEN?)2ZJ4WZKS/Q6(/ACL<9FSF1/I?X(:.HG+^0 M%;>CC'+=6_G9.V!"A?K+V"_G]P$1R6";0=*$+>I^.OMA>%822"'PJNYLZ+[P M2BHC1+Q%K,XC"<:\$43!#M?QS^3"U6;D(>RN/,_=;RB>T::B)X.RJLLO>B)C MDXSE::P&_39";"R/:_7G 'S[CN5YWN522%(/'AB MW68BQ]B#D*!R9R:B,,[6V N2*-;X1@!K0V;'DS"380-;7S_Y-C/"4A9J\,,1\$W*25>!KV]$[*)I&0T3\\;AP;=*5QD5-5G2]YG41WBS\+@Q6Y M0?Y"7">3BTP_ZT/?!0S-<^Q2?*D=C6ZDDW:+U41;Z#$-E\[DND#7 5K[W$*T MU1A*UA$Y3ASF<6MX?R :\D%%H.NC6[1^0AYHW1IIJ9C1M4ON9I3E8MPDMM4+ M3.4Y9#H-A'J%9_O>-1;8\^?T/QU_AXHR3H(JY+0B[ MY!EKQ6]+^%3*OU>R*M8_0C^NH7N%O9JJ/U"9!B2L2$.(S&,=:@<)_2ES=$R9 MH^WV"C-9G>KKY&A[4K&P8!E+Q(J8(,=-=Q"#[Y/6\-7>X!BL=##8OF@)FZQ# MO:.'%@_KJ7:PE>OIN.25P/(V]-Q 52\I7/J6R] @U,>(1O'5S="8- 8>C:'6 MO%(4.1^T Q-BJFK&+#6N9:B]UW,+PHR5&&)C9=!]T!(Z6:>WO7V>(:VG[BK- M2X+;^'88RGKF0'>!08D /FX TU\B3)P%#.:BBHD#[_B0R'2$&B/]T3F<&8@ >C M-%'J:I_>>]@*S6AY4P!A9ZN&0,<\S[UD0,CI*O^V[Y9 $FXIA4$P)4W?A)H4 M5U/IW03-,47.!D#ZQYJ -CBN.X:ZAXTT"B_<*%-U#PWANY,P_\6I>U (-V!- M^A(+?M!33,& XE!Y&6!Z^A1%Y'K9XV4,\44USSW<^ 8=0]A1\QL>-U@7QA". MQ(]2C4E(]T@EJ%SB-^\QY$8IT4O=-JTLP Q0Z>7R7I#WA+5V[MS1JNV#=>Z4 M<3<6YTYA[I-SA]_@>^#9Y97NE#6!B:8L[>^<[QL:,N#81%QMP6X6&%DE.9=1 MP,E\N? ,UR?2>K[\1AY(F3$#GD_.27 \Z2'4N(V2:PH)5%=V?= #-)-77X=9C4).JED9[%='!>FL=PO3:\+9$B*]NS M[@TOV,;>U<7*"!Y0PO0MIK0-]^28_"(.#"?G-2!TTQ\E=6NH1$'V"STA]!]7 MR/:2/DKW1/+0D9]5N7F&,;T#]1/U#)Z20LPN'=.+IOM@^W\P)D#%BNOIJ"DI MO<,!R)'$0T5A^<[<)A&NV%E"0\DZD)LB*F!0Q!$^C09"0H9>VN\/6;'1P"3W M--!'4?6Y$"^W9'J4""UBDO[1>C&B,P/DBX>4$(]G3HC./>S[] ^/*QLY%I"U M&@J=E>A%F] S5X:/9L\>BBK*G-,#@;P-E> TY KF& $0[&I.N^-!'"7EWRHI MJVXX]'45787D!A2HI5Y.H)?[Y RYYHJH W_ ?=[-M/J9T3;C ^KK;J:E9$;) M*T?&;=-$JI<5HO4R)6RW/)F>=AIE0<(F8V3Z60]H[EX5!26.73([8!\$\7-JZ*[#Y=S7]*L=G?EQ*_N'ES( M588!UZ_NCEPI1W-'!1N+-XU;L:U%;U+NEV"%;9P\=2MQRJ MY-9[-!AJ>I[6-@I'M4^+5<(=&6K\#X.;DA";3WHG/'-X@^L0*WBO&6;2 MS'%PU&9M'ITL_F1@(=IB2<".X?L9%G/OP7Y>!?X">6MN9NM(R./I\I6&N_KH MWK/SBY<.=[ZB+9&NW<*OM9N"V(A",R[?H%0Q]>]0,%^F/TO:P_A)K-4"QZS, MET1:1Q7U.>(T7SXB,_2BX+=SPW%HE8-+PUP5?Q?DZFH_ MF- .F*5U&M*QTNT6"X'[T*,K$B0K %YP4?)*XBMHVXV8CXO0BQL8V-B*92#K M(3-?QG\.;*(QLI4 !6*T'*EW-.[0C^B?Y,TZ1U'.OHV$R"-VY&_99LIBLC=\ MV]%\ J17"(W0QH_\.#2] GK--1IFMJ?M!UFRJJ ]J'YX9 M#CTB1,-$@.E+&49H1>?!"GEWV+VFGDOD!V?(H+?T>>A19\&-;3S9#O>[%TJQ MY0L0!3MC7+L6>@J01;,4+T)$4WIM=^ZBOY-_%G@' NEW.1O9W*LY-1$/M$GU M#>:;0L6':@IZ42<$LBX-CS:U]&>F&:[#R QY@9:V:0,+>S534_)N,?P5Z/$1 M_;[03LX[>&X-UWB.'M3^/1%4_@VX/"DG-37Y#)D:)) AL_]QF_="JD22LQR: M$23INXK@%$G>76T3F'G8>ASQ6Z@EY_*Y:L1"-K8JLZ9*?'KPW5U#1,UKS7XA M(I4(A1A'^ 2J* B^T- RI![S]"T.W!^5W_=FX1+(HJLCT]L\P#ETU414S"$9 M%[Z==SY4P6O^2 P3?,14$U/B^4K-_D0?N1J28J X_YF[100#D MK9Z(JGH-R6+%C8FBRGI&5/P2OH-YJ"F95?CDDP>8X6US'(%W=#61KFI^W!JO MU!'.OXM*/NJ,M]A)#^2M^%%G]5]H=!F,L$GG?(%*=R2^T!,:IHK9(5TM];9 M(&"E[$$T5=F%" ?T/U1E>2&GDVHK F4.FBCU']3.-U4LLE2ZESX0/A!X[RSJ M7O:@7%;A$DFI>S&#JML$E]YGNI$]SHZ6%;3L\7 )^G#%=Z\3)\/NLI MO60>P?RLYYJ&23D 3?%9C"PI@? _CZKBJ_)4/LR MH;:/6DU850K^IG(V>2.J\O ^S"!AWG")AE@TTW O=N:(F09J'K+/FY] MMR1&.L/HHYX8M=%Y(?'Q&8Z?-,81EGF BZ[A/$:?)XSV,.+)9,D0_"R],Z(& M".XD,S&P%!3&.QBP8,EK#,.O$X9"&.ZG+V:8?M$S0*,%IH"45H;B=)GLB$6 M^&-%,Q33<,&6VQ1H:(M M&9Z:!OJTVYSU97L8=GHZ*B7MQ>9*3AF0FAJQ6P#)7\:+@3B9=@1!W*_EEH&J M:>>2%J V%_9CX$UW"Z?+'5+7D<$[73\E05FYBJ 94IKZ^3K8B,W%8!FHTN^; M%^0]X4.%%5Q1. /RX_2DJ3)>[A2.9I!-5K5=S9NC!G@&WZ?)N^L[0 MG.[ADGN8L_I_AJ+\J-8-]HDJ]8(6FJ/)T4&"H2Q=$SK\2UNT20D#=7KGM'[G ME'6T80!/I@TNHZ] )Z4,XR^3I6,'8XG=N3*4)Y\E%\I)&[<4MO?'$VRE9CA@ MJ[X,S_>3H[?>ZU/6KC%#[Y."![O"5J8T.8&[\:3HAFUC]"/[Y/A+KA-A 2:]E* MJWDEB\:(72#?].Q(%'.#S$%)5H,GMOF@6Z"*2N\-(J-_3-2,[!!!-H<(]3&T M3Y:S=@-N9S6^ILM#;[%7+ @2.;"L2&Z#>]%Q4%+\.:>X)1 Y*9VW,TG M/V>V+NZ4!,P%R0^PC>C46KQD?0^VM?C43'MJICTUTQ9I.NE%U)'' MJJ_$)^(;_7-DCTB?F-Q6FII=3TTLE<\BJ2D8#GVTCXZ7 ZF$6M9R MD MMW;L,0G:N2!\PC1'KK ^8IKT)!:XO8!\P3=L8 L]H;?//4^W0$6C^>:*G M+!=M=ZEG)J5@*]2IE^"N\ 7T$M2TIIBHDC2U#Y37/E#3PDLF85 MMSV%4\= J1T#IPXJI6XVAH_> @MX"J^HD=8*/!C,I,6@=]BT[6!!+2LB??)9;Q\B-SCM$E5T;WLG MYP#SE^$^^:QG*638Y<%31$[7)H$PI& )CZR-G?3+X4"5%'A]]Q/->]OS(==4 MTOWDJ]Z> LZ7!*"*^\E7O5^JP'TE4+A=TZJB<'476JM=?CC=P3T5Y%0./YZ4 M8)%7;&VQ\.-)(1:O?L1Z&XY<-G949?U$NN0\-#TZ^T6>,FH,MY$+2MYZ>@RP M20J">A7*#Q<\3)6FBZ8'FC;1!(L\SK;"FKNY(4=7L+]!!\VD#@M"KI==15EE MW9MNP/9A0^5M!I;>(7:JBS2T%:GS! %?@>%;8,RH36+3+HW^E1E- MG>AL]X6!'QBN152\:S<@FIYOF[!*N#"B4R5/"94\I\K /54&KEB/2S^PU]2H MMA\*(=!CBI.:6'W/G#%Z/YYC@>]#C]SN/LH=ZOC-Q\U]BQ'TK.XMY[S<8==7>H!?DO(=7(:XEHW0> M.?."G_WP/VWD&40OW\(%&I"PTKF>;?<9B:"'"CI>BKVM9%[U;+$[FTCV-;\K M#_T9(M>4M#_WR"G>E66LM-B2U>0.Y84&KBXK<5"E&#%[KR]2F;:>3N_N$:YI MEKHP6Z_B6&KM1)U/&4AL7(J_+,*R[;\92)A=RES=@6*J/C*5JKJI3 M7ZOPW@3F5 ;9UM_4JZBM39UO-F M$:RSK6F0G&"=;J=7!WW]"XG&UGW3=.]7Y6=-=]XU1/::_D1$_E<;LH MCSN.0HF2RN-^TOOX"L@]GKB?K#",YGU#U%A1Y,2+96NBJ<;=;7Q?;EV$(AL9 M^IW5MER,8A7:E([37(GM%O,68=AL ?2^3;M= ,XH?E8^?)+SK>1\VW*H[Z7; M<@968*?;[!V4\=EBO?WBIO$3K6,>%0;[' MV>(7B#"YMET"3/:!7\@M9]4>9&7\2F-BN(G![:>H(.HM'9&:'AE:$FR#R8KBCW;K!])!=%1"4WS"65$:W8 M!Q(6/Q6$V"Q\#OV@9)1BL5.1PP"GKD)V[DKL2"#^BAVB+1 -= O/S^ DV,?< M:!TEDY:N)7=P^XF54>MC5E3[PJ$;/!@!(&D.0JW/M;JP7VR+:*AR9E='M9]9 MYFP^,J970JZ/>2T(\_#TISHJ?;>]58%DI]SUP\Q= M%WZY<">YP>A-^6O*\]=@"Z1[:IK0]A>)!-4/NNXC035/,!.(B(+>T[KGF+4] MOM7:V5@2QAIUW :TQI8/QO&RJ4&L]$$VEB2PMM!5/]49@GK?&.T0+#/EZ)XJ M)G?OY4U[NJ>5R4&NPMH[EBPT414/[AL82Q:0"*)@EU$&YH<)S'TP8>[#*;^E M$DNH'SF#\LL$9>G#6#R\( MTFQ[*: ]<4! *B\#7\S4C'.J3MX+E0HT87M+# M6@<2Q"T#,5B0&<-4>@>:D6"Z$_S^04%7/(7AOV>&0_.+'E<(!7%(J4]@0U9( M[YU\5IUKS4S3"U$^!%LHUE?BB(,([)4Q'P6^O_VQST./GBF(XZ^&B K_Y3Q8 M(4_*1)HHJ9C-12(D'LB(Y^2_=B PD1HB*N:00$C55)\&J=L^;28OOK.J""F< MRQEVB3AO<3IV"2CD_5?#C$2>./-[%-3N(L-K)9CV*"CD?E^,B(164;>D[LM(#?7Y9^AO:%JY1T"3:>>CJ+5"=>A0U-X+Q!1"TP[:;]'=(9( M.R77\AI[@?U7]/-*AH&+*&G,7M?ZFX=]4#!6$R4E/72P2PY*&)DTKBFTST05 M],%3J24CUD?'=JF>>$.>:*E*R,U5 P$5N$;#DO>4=;W>>/@EKOX)AK6.BE@/ M1;PF[USD95N-;+M'O Q^D/*7.U\])2\H[QGPTTN'RKHL&-;1G(QW>=>SO3]2F6. M;3B/Y"?Q:169NJ0!>S?'RP4.0_<&"U'0.^\?=/(PG\1@7F&]8U!%L:NY,AAT M>K>%AT+'JS9D^+U78#L^(/QXE$*&W23R]O9>]8N P2;=[7/0L'$][UC,RW15 M@)25/?SDWQ>2A#^J.\F^5KC+2+GBF#AXYUO0&2X2?_=AG23NWL MW<)AKF88ZWT5\;L!]O';\UNP4$&]5>XVH.VYJC+0/NNM9[3I+G=(,NTFR[6%7$YC @G?UUJ^%<&N*3&'@33<#OSJ2P^VK_,MA3]7K-X!O M9EEV/)-K=XF]=?*ZD!.KQT%\J&%Y=:PKB?=B;SU8B%?^N]:^YQOD^PCMO4&Y MV0(2'*.O_-[81B^G!4Z:44B)*H%0[=4_2@[A!ON&(R=V)$=-256B]-U[ ZE0 M6O>UHB@GFL]LN\^/-&S=\"S_^X8\\=$I300_A==/XR2H8FXTS7:^G%GQ]0R? M2OGW2E;%^D?H!W&?7.S=H1\,5;+=7?)',S&Q *M> 0DK/3?<];&JOIPB(,88 M ;&["W0OM]5P;K#P81]+L2TQX8J;[H6QE-RJO54Q6!'0O;P6_W$M4P''4M>H M1GGF\(JD[L3V7J._< 'YDY6 MDA!+E"IOK+FQO>T](I+*X@:=@Y*21#^Q3J'\^ L.T-O<(1TD6Z( &4I)W2 M*\2/ZJE>A+10&[],$:,KA'[9$%<(^;,U-7$0/$&M'3BI*7+%99?@#8YK%E'V M_)0_H">NB5A?^VQ?'1?<6#=JW7.Y_IUP_U7)QRIXIB:%8$O3F[!+;3/@/C,5 M!)0ZHW9X #O:&@B)22%LN.D^G+N WE9U7RO9Q84C!-\0Y=^KYQRZ"O+L;\!J7.[Q1G#6@513 8_&"C -3Q7BV?O@[:8\3W_<:.I@KF[ M]=YC]:8>7&N*8AB-3U, J:,YDR,KD*&W?&^ 81\W#M/S6(JS<&,'\44P\/2. MJ@-OO+(/JIU/71:X.4@8&QV3##&]@Q*E;+P]5W,797ZT0*]U< )#5KKV,K X M4#G8-H>_,$2E&T(.%5'>J"E6]$=Z']5#A:XQ%HYA-JG2N7:*0G&1#$N]G[LP M+&$QL@Q#!<]AA5'@47* Q,HBW/0&$>/=S*T"5VET8\R7WWT4I;+,G\C +K*N MWX54CJ0*SA;B1VTQB)*\[0VBFK'[' W^&XJZ%ELSN!Y8;)ZK)&96 F#\Y M]G.DC]UB-UB19\W?D<$?62E,7^9L8EO]18B^T_B3I'R*^SRC3XYG!%J9%B/( MG%&$E;.E)4 SJ[!8#;=FHC+Y3BV(UZY/QG B8[8D[FM)RYR#A/,M0%DP*2KG M]8N"KQ;X*G2M_/CL '*S#R7;&OU\/OCEZP:Y/G\R42.=J>XCE+\^>B121 K' MAN@=\^4Y$5DTTA>6A-A,3/7[I(5V6$M&+(TFLLGLV^T:$VAVO^NM(R(\%:R6 M3*\U/VDY*7@F"!>Y7N=UMJ6L0/-"N,A-=4&GNJ '5Q?4]X+\V:X ;\6/NN+M@3[#8)P5/NF4+]Z]N/-!B[N=.Y=M_QME M';&%BL'N?MF_1[1\*K@,6MWSSRHW(-[;V[KGEI6??5PB>73/%ZN2SKCT?M ] M&:P)C>)-SC)UI(&=57#^41/([F/) MHX-817@PS%MUQA)L"+&884Y+G](@PX$=U'(;+D-$3XVKUN*-.+PK+#6GKK6!V\"B[> NJ8]/,'PKC9BA)%U"'=.J@@0LI M;"QB#3\[G3!C*>L$2&G_9/ M'C!^S6&J#+T1WQ!"X8P7N19E"C((3_7JTQBC]FBND!4Z:+YD$$7_$EOO6]3J %$>4-4. M/KY;Y=;.BK;9GX6!6N<_ 0GY5.F\LF/^RCT4/"^;G:Y9 >M0YU4#P#KI6Z'VNEA MPP>\A\>BIJ;]7I3KJ>T''J2BVF):G6BJ=]@U92NK>9J]Z:NPB7&3ZE%K%9L1 M!S'!?ND[&[E('VXLY:4W::Y2S::\L(]"<85NZF:]-7_.1J&ZMH"P4?B.0GD5 M !!^+8]&?:5_3S*9Y*BEE02'J6[NLRM3C:0=?UKKC3$1]8H5+_-U7ZM6;]/N MAX!"MEQD>HYM=@ MS/1L/2/+.=\E-2>'];;6.#FA6?;PQ2,4Q6 &W7N-TU^$H=N[%5E_W+&>Q3K= MA_44U3/)C%-2U:NU'78/'=1#*\O$N H#\L])Z<5"6B(+_B9(%3>4I AHF3P, M\CDG9X93_RVACF@9"]]=*\D"0=;EJTE^-@;@5PVD.;\8(,W-DB)\0'-^E\9OFAE,[QVJ6*"15@8NWMA,=2/4NBC"B;)1M+\2PC_4/5-/.#J9[G#ZQL MEME0ZN8HK,9('[+%G%-E@I<#06>C^#"]A6JV#M#LD7<9MB @X=[F*FC[::8U MA!D)VWJ A(L,C! ]2R#J [06,UD>$Z2M"6>T<.$13_JF7^E!L^=]RP#=;J4Q$'-XRC_ M-MH+%-0+QVI3&0-5G@3]&H/JHF?:3TQC6//QSWH+3*Y+X=A(9^+;V#I'I.H5P \ M"Y]AP.MI>Q@2\/G@+-:2>;I;N\8]C[:>C\3!H,TB1D?14GL(D-\5BJ=_T5., MBV;<OZ%?'=3]=J)I!32E&)K_BA=I);UI%)?AR;<;!Q$(3*<<\-?73GXQ[6[Q-XZ&OP!.729%[BJ M5D^K^C-RQQY2W1E),U,<$VKA,9 M698=3R:'GI!**4Q_$&HCG'N1*_MQ1;;Q_BB>9[C/D;9ZMF6_DFS)V0_#LZX, MV_O5<$):&3=<1]O/I[5>3:+%7F%OB6Q:5/&!*+7[%-5#ZO.^R^D+L$6=$4_ 4U3N3_G98\OXN5X<[C 'AFM1*\#SLQ?9U8CN230# MWS8C0=>]3)7!H[*=^]0\P2?P)JF85F[BX,W<&Y]B^YMJ(.D@KO5 5MVSZ0Z( M_N$[$?+^+>(]U%"* GO']X+_WQJOM,PS/^,E'W7&6UR"&LA; M\:.N>'N@^Q3&6>&33OF:O=I<-KV=#U3(I[(]_O#XG1])3D*#UA*2(_]KE]?= M )@<]'TW3]]%R#-MWWAR=M@'O2.ZY.(0=G)N-_2W4VN8&L=(]7T;_ZL]> M#-NA&X$\'K^1;T&&]^YX"^QM X>NJ>O!!8Q:O]+7OA\BZ=F-[A1*\R@<> M-%;IZ6#6QN2U#;2*=L' 2.O:('Q4RVM2/E(WW(FN0?[!=T[Q@N?XW= MCD8?].ZYL5UT': U*%Q!QFA*K;;,) !_$]40&<3*^E5@1_^S(#,D[PRZ%>^, M-;K -%-"ZEH+C:\".38^Y\N]XD,A27;M6J$9X1.+1J 1J^IS(5[NL-N2G1H* M*E:2OHV)"@C?O#L?*N05NN<*GPFM\N('7JQPZ!-U>;&RO0 AM^0^ BX\C*@* M?,4E61\R*!T3NAV*WRFY9[*>A>(2?T&?MZ#+1=Z@*C!B@1/S99[-)+"6NE;] M/9.44+!?VY%Z#PZ4!!7N9*^P.#J]&^'*/].X2D0Q2/5.4BH5Z"6HI)<,PT7/ M!MX-US(6TB,8:%^T!JW3\UG0*(O'\U1;1,NT[WU,]@[G>[WO@?+W$VY^W#& M/HP8H$9T/N@MVSL54SO&EJ*@^J MIN7&*=RUW8W5&=1\RW9I-<5P!>D+O9@+ 7V!K8T MY0$UK&K?)+@4+D9U--A82OP-;$$:(QO9NDQ2J]>#LANTRTI?'4\+([8P'86D MLY71V]8VS"/3(B.#+=S(WY>2;"H-24BL-)K>%5([L:OL)*<5K:V?M,.R/'D/ MEZ0.9KM*TSX@5>F5N#3!DZ&AYQEK0J.8BLO0&+DRVU+ 0].S,]P_ZWDF!ZJK M2BD&P-9NY(XFA49W&>4TV+J-7)E5^PJ!5Y/)%NJ+](?\0$K<=;M4'1938DNC MI_9TH M343XL6ZVODY:AZJ:"%--+U^=41;78WBM3/H;KM>%MR:.?Z! MO+72XBHRN>ZE,-XYK8;K.,B:>XG$H7\DL[&)].#DG3N-;AC,]H)SY!#T4Q?Z MT( 5Y.X0BC#!C^*I2@$BQ-X@$NY;>Y)VYILX!6E5;G-@5[8Q\Y0]GREY3>9$U/:JX1I=W!+Y^T@$$]Y'A[>0,X. NU:/:$_J"%L#0)G M;:7U8>#;?..KK_''S],A(#RL87H4>6+AX\ M#JW->\M3>0.#18#Z(>R6XLWWS<.^F@IV=<,? F[#DD]3V1ZD?=F>[I(^.N@? MN(FE8V!XP5#\=L-;DE+AUV%OPH'%(W2P( *7=!<-^X;99'MX!Z!45\P6Y%1> MU,>T("T?/JR C?3@COBJN'2G99'PM&>E=#JZTJ=UDF'C8LLD_9*?-"_9!E]6 M@$;OM(4!+A/0!9*ME*;I-@->*;!SD-6NT3M<]&!OJ3W5[\ND4@Q1]>,\9E\Z MTC3T7SW5P5FL.,ZD;_ M5Y\AC*Q"RZ1S*%PM.9&\V>*=3$J(6LDH,^X]6\53 M!=7$>L]LR:7Z?/>C-)\+1-A<1^!D"4&%9 [_NTL0.G,,\X]'TO*%;>\OA$\Y+@!].HZ,-4 9SS(25C!3B>EVQE]':6'<3*E%E1.@Q, MU'B!>C ALJ!$!=7J6^KL6YQ%B^15J4NQDWL!$M$L4P79*]GIZ)[3YB"*0S:.\%?>EK* M8@V)WX,HC]$XWUP(^X&L$(QCM=YZ?G%0; YY4)(,S/IAGY#:$-FA'A(PTX>] M1OK>,L.58.4*#7]=F&'PJ]4XM7_S"VZ2Y/AXWP(4C=@6.\;PX=;E0C&)6&'K3\$VX@-(@5;M/6L=,J MQW7CJT".C<\9&UGQX10C.<5(3C&24XSDH"*6=F24[K&2]3)=2DF9NNM*]P!, M)NG=]VX@SUN M'!$.+#)9NIH_:8_J0XE806+-#6P'*4[!T7ML.36WAAS8N83%P;+*TU-ZZ)!6 M$1YOSHH;2\^XGC36#C56R"']HL#>V7N*UN5R2>#QD_*0>_^<. L7. 8^6@.? M_&V] 18,VT5,SH&W+)<7((%S.+%O>E<1H!.4O"T^(DJ"A8 M#Q&%9$5XN4 OR,$;NF^$9\9%3L6\:) -$;&&@WSX+$H^5L'SM4NN%92)\1O* M(SGB\*C!!D(]S@4:#%A+9@IFAB#Y@O12;0,KXM2:=UMA>$.9+)K[$;J]6^&%X5/YEJ\9M578__V MN6/XOKVT(XQV/FM5N+9C+@818-#5'$5**$7DY\N,#^^!QOOLQN:5=?2]L9?\ M!1[;#B-4'FJ'>M38X!YYT?FN8"BW#MQS:S<,7Z$Q>3-,^FYW.;ML"'5SBEM7 M=#RK;!!5\XJCGKN<5#J"ON=+4=Q"@8^$#>!D>6FUDACU1_8B],@ P%IW$))B M9?[HE1?OU#RU*^Q%0[>7!N(#R%R#?0;:+D$91=U.0X\SVG].B,[G1FVL7S(X M/(IDYT,ET2^Q%DQ>8M@E^CD\]*."@))XB-3,LL.##XWE:"#4VPD !VO445&X M\VE\=2PB[W" V,M,),R"FV3O=A/HY#'?NHTE$H+C!&#N(SN64 <^$8@;Q?58 M8A?JKSM<>15W&'! GEU/>#@(P8YAD[K%ZM2,4'C5VL.;%>\.*S(-L ("/X+0 M)QESH.G=(!*(H/BKG &J>_$I.9NRU%3318V:0P<1:J+KL,'HX++>@5NQK567 M%?@80_F=[L%-/0%C*;G1/:)E%]*7210VT8.("@(:'IM?==[FN^'.=@@3P^EYGD M 2?/I[09I:I-=+WL"\.3UM-L'F#R^DY>W\GK"X_92D[2;W:P*ARR.[(9^;<& M/RVY7%[2,E%P>K^P7:3LS3TM&S&.1 M. X]**.IL' M]*ZM(3)%5TW155-T52]F.%A8Q[@BJYK%7A->8XNMXKGP,."2'DN1%RFXY10P M5JUEA*X;,&YY]9HA-\++H HYSB<4PVZ$CFWHKLN_D\?2SU0*<#DKR%B*4LG! M+6_C8H&ETP71B%S!BCGJ<&8H#G"06?8O"24]B.=7[1FB=Q*)Y MN;R.4E@T+UTF*4R[.;2 2J_+SSV;5I];J$AL!7AV=(CWP\A'ZT4/5S#U(;Q$%=R%]:,V7C\@,R5FSD7]N. ZRSK8B2$@; M2DD?)3>P+=L)J?;->+I\-9V0[.\K(@'I>S6,S\%\>6EX5.ORT]R9?86.IP63 MM#$%$/*]((<.^=LN,N1'O]\2W7(=KODCF$H^ZHPWXU6 M^)'7?'V0$\ZC+/" M)YWRQ1O[M/.!4%S6Z,R[1W'4/(ZMZW>#2]Y7NL6%-:!1?PF.)^.I>=9!G.1E++)ET^U:3 M8@(Q\+%%T+O"81>+(,'>W&&ASN'Y6HK"Z8)W-0BZT>\29;+H@8^(^O*<-2KX M&ZZWI]/9#]^-,%OCT 59:20-.+E8.G"QP VUV"7;-K")UG.?BMG(80XORM)( M2J'A.1I7V&Y>^%II@98\ \+%6?:)*#$ 5_>>!UB JXFHF$-#4W?^>300$FO2 MM!_- G1MU5 0=K6Q8]["WU9-I+];XLY8([@$::9U /?>V;:< %0B=#HN%#"P%2P2\FK=OAR[>@0'7O0)08R;1/:: W]RT[VHKV,3&XE:N ML29B@.%S+![?P6OO-R5>^ ]ZKTF77GA)GB"V%'HEWE$ET@[6*,YE+1VK.L/@@@W#+"DY!Q&)]9;N&:Z(;9/C(OR7RG,R#_H",^V@XR%\8K_,G MQWZ.QKDWMA%3%X#,8?$!A"SPHL.=AQX5')U/*QNG_>S2<0@YE4@8:%5*Z7,SOB5 MA_X,R>G>SI=Q8T_;3#8,]\JU&*&+&?UW:'CDHG&VR2C$15MJ ]J'YX9#CTO MCRN$ -.7,HP*'&C44.%>VE>+.*991T5H7\Y,TPN1-0]6R+NQC2?;B10PH .V M@8H*?//K>D,YI1((['NMH]+7+* NTVH:8TQJ'G(R^/@2KCN2I6#?>!4%-?%R ME6^5=M5X@(1[MRN( 8&;5W$LKNZ&<]"4\:8?, (9;YIZ>P5SO#1UXHKF_^EM MUVT6'\TJY5C\78V*>0-:^VXO/3-M <\QS/=XU#T;%WX:ZXP 8W&K4 .$676/;ESMPO/<'W#C$ZFO "1%B,,(CI$A'\19]H# MLM=/(=D*T=6-XQ E,FQ XR2Q#RC%S$%)33)K*7#[IY,KG[6)EI@#$STCX\S& M 3)7+G;P,Y$>UZX)=6#64U&--=QQ6?9UCSO$/]OF_P7JPH1059O$R<=9BUQ- MT !]KK"(AZJ95N^J"/=T2U,U0:LW%C=5N].#Q<2"[JZN%@*X M&Q)4+67+B8 M3RW0W6VFZ@"7VJ_U]KUQ:]:8_T7 L.OU@9O\"_V?)_)(__?_#U!+ 0(4 Q0 M ( J+;4].E]#EXVH! "FM(0 1 " 0 !B:6]C+3(P M,3DP.3,P+GAM;%!+ 0(4 Q0 ( J+;4]^'Q<.1AL '!& 0 1 M " 1)K 0!B:6]C+3(P,3DP.3,P+GAS9%!+ 0(4 Q0 ( J+;4\" M\K)M* \ &_O 5 " 8>& 0!B:6]C+3(P,3DP.3,P7V-A M;"YX;6Q02P$"% ,4 " *BVU/8$.Q@(W !I"@0 %0 M@ 'BE0$ 8FEO8RTR,#$Y,#DS,%]D968N>&UL4$L! A0#% @ "HMM3T=M MUOZZBP K90( !4 ( !%\T! &)I;V,M,C Q.3 Y,S!?;&%B M+GAM;%!+ 0(4 Q0 ( J+;4_[@M;*PU8 'KC!@ 5 " M 019 @!B:6]C+3(P,3DP.3,P7W!R92YX;6Q02P4& 8 !@"* 0 ^J\" # end XML 50 R36.htm IDEA: XBRL DOCUMENT v3.19.3

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)

Sep. 30, 2019

Dec. 31, 2018

Fixed Assets

Machinery and equipment $ 2,845,053 $ 2,818,583

Furniture and office equipment 156,987 157,391

Computer equipment and software 1,552,981 1,437,408

Leasehold improvements 570,174 570,173

Financed equipment 2,573,955

Construction in process 325,550 116,640

Total fixed assets, gross 5,450,745 7,674,150

Less accumulated depreciation and amortization (4,125,490) (4,934,728)

Total fixed assets, net 1,325,255 2,739,422

Accrued Liabilities

Accrued payroll 458,750 255,426

Accrued vacation 566,811 535,682

Accrued bonuses 636,167 712,574

Accrued sales commissions 81,101 62,767

Current portion of deferred rent 158,342

Accrued other 104,155 203,602

Total accrued liabilities $ 1,846,984 $ 1,928,393

XML 51 R32.htm IDEA: XBRL DOCUMENT v3.19.3

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended 12 Months Ended

Mar. 19, 2019

Mar. 11, 2019

Feb. 12, 2019

Jan. 18, 2019

Sep. 20, 2018

Aug. 13, 2018

Jan. 30, 2018

May 31, 2019

May 31, 2018

Feb. 29, 2016

Sep. 30, 2019

Jun. 30, 2019

Mar. 31, 2019

Sep. 30, 2018

Jun. 30, 2018

Mar. 31, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Feb. 28, 2019

Liquidity And Managements Plans [Line Items]

Cash $ 6,539,444 $ 6,539,444 $ 3,423,373

Accumulated deficit (239,981,882) (239,981,882) (220,457,578)

Net loss (5,691,762) $ (7,816,012) $ (5,916,787) $ (6,047,784) $ (6,153,101) $ (6,357,143) (19,424,558) $ (18,558,028) $ (24,600,000)

Aggregate net interest-bearing indebtedness 1,900,000 1,900,000

Aggregate net interest-bearing indebtedness due within one year 909,000 909,000

Other non-interest bearing current liabilities 3,000,000 3,000,000

Unconditional purchase commitment aggregate amount $ 1,062,500 $ 154,000 $ 154,000

Unconditional purchase commitment payment terms Quarterly

Unconditional purchase commitment period May 31, 2020

Proceeds from issuance of common stock, net of issuance costs $ 7,500,000 $ 2,000,000

Proceeds from exercise of common stock warrants $ 4,800,000 $ 2,513,172 $ 0

Public offering, number of common stock and warrants issued 642,438

Stock price $ 1.37 $ 2.25 $ 3.285

Exercise price of unregistered warrants $ 1.25 $ 1.20 $ 4.53 $ 1.20

Aggregate units sold under right offering 11,587

Shares issued in offering 5,950,000 990,000

Warrant exercisable for share of common stock 1 1

Net proceeds from issuance of units, net of issuance expenses $ 2,200,000 $ 10,100,000

Class of warrant or rights, term 5 years 6 months 5 years 5 years

Proceeds from warrant exercise inducement, net $ 2,337,298

Pre-funded Warrants [Member]

Liquidity And Managements Plans [Line Items]

Issuance of warrants to purchase shares of common stock 120,000

Exercise price of unregistered warrants $ 3.275

Change in exercise price of warrants 0.01

May 2019 Warrant Exercise Inducement Offering [Member]

Liquidity And Managements Plans [Line Items]

Proceeds from warrant exercise inducement, net 2,300,000

Other Warrant Exercises [Member]

Liquidity And Managements Plans [Line Items]

Proceeds from exercise of common stock warrants 2,500,000

Warrant [Member]

Liquidity And Managements Plans [Line Items]

Proceeds from exercise of common stock warrants $ 2,500,000

Aggregate warrants sold under right offering 2,549,140

Common Stock [Member]

Liquidity And Managements Plans [Line Items]

Preferred Stock convertible into common stock 4,149,445 5,985

Common Stock [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]

Liquidity And Managements Plans [Line Items]

Issuance of warrants to purchase shares of common stock 4,200,000

Series A Preferred Stock [Member]

Liquidity And Managements Plans [Line Items]

Shares issued in offering 11,587

Preferred Stock convertible into common stock 471,393

Follow-on Public Offering [Member]

Liquidity And Managements Plans [Line Items]

Proceeds from issuance of common stock, net of issuance costs $ 592,000 $ 6,600,000 $ 13,300,000

Proceeds from exercise of common stock warrants $ 0 0

Proceeds from gross exercise of common stock warrants outstanding $ 1,300,000

Exercisable warrant available price per share $ 1.20

Exercisable warrant available price per share expiration period 2023-01

Public offering, number of common stock and warrants issued 1,095,153

Stock price $ 1.20 $ 1.20 $ 13.50

Exercise price of unregistered warrants $ 1.25 $ 1.20 $ 3.16 $ 4.53 $ 1.20

Shares issued in offering 6,250,000

Class of warrant or rights, term 5 years 6 months 5 years 5 years 5 years 5 years

Purchase of common stock by underwriters to cover overallotments, number of shares 538,867

Shelf Registration Statement [Member]

Liquidity And Managements Plans [Line Items]

Shelf registration statement expiration period May 31, 2021

Minimum public float limit for offering $ 75,000,000

Private Placement [Member]

Liquidity And Managements Plans [Line Items]

Exercise price of unregistered warrants $ 3.16

Warrant exercisable for share of common stock 1

Class of warrant or rights, term 5 years

Over-allotment Option [Member] | Warrant [Member]

Liquidity And Managements Plans [Line Items]

Shares issued in offering 915,000

Minimum [Member]

Liquidity And Managements Plans [Line Items]

Unconditional purchase commitment, quarterly payment amount $ 62,500

Exercise price of unregistered warrants $ 1.25

Minimum [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]

Liquidity And Managements Plans [Line Items]

Exercise price of unregistered warrants 1.20

Maximum [Member]

Liquidity And Managements Plans [Line Items]

Exercise price of unregistered warrants 1.20

Maximum [Member] | Pre-funded Warrants [Member]

Liquidity And Managements Plans [Line Items]

Issuance of warrants to purchase shares of common stock 120,000

Maximum [Member] | Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]

Liquidity And Managements Plans [Line Items]

Exercise price of unregistered warrants $ 1.25

Maximum [Member] | Follow-on Public Offering [Member]

Liquidity And Managements Plans [Line Items]

Issuance of warrants to purchase shares of common stock 6,250,000 1,095,153

Maximum [Member] | Shelf Registration Statement [Member]

Liquidity And Managements Plans [Line Items]

Aggregate offering price $ 50,000,000

Maximum [Member] | Over-allotment Option [Member]

Liquidity And Managements Plans [Line Items]

Issuance of warrants to purchase shares of common stock 937,500

X

- Definition
Aggregate net interest-bearing indebtedness.
+ References
No definition available.
+ Details

Name: bioc_AggregateNetInterestBearingIndebtedness

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate net interest bearing indebtedness due within one year.
+ References
No definition available.
+ Details

Name: bioc_AggregateNetInterestBearingIndebtednessDueWithinOneYear

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Aggregate number of units sold pursuant to right offering.
+ References
No definition available.
+ Details

Name: bioc_AggregateNumberOfUnitsSoldPursuantToRightOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of warrants issued pursuant to right offering.
+ References
No definition available.
+ Details

Name: bioc_AggregateNumberOfWarrantsIssuedPursuantToRightOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate offering price.
+ References
No definition available.
+ Details

Name: bioc_AggregateOfferingPrice

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Class of warrant or right, exercise price of warrants or rights change in exercise price.
+ References
No definition available.
+ Details

Name: bioc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsChangeInExercisePrice

Namespace Prefix: bioc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Class of warrant or rights, term.
+ References
No definition available.
+ Details

Name: bioc_ClassOfWarrantOrRightsTerm

Namespace Prefix: bioc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Liquidity and managements plans.
+ References
No definition available.
+ Details

Name: bioc_LiquidityAndManagementsPlansLineItems

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Other non interest bearing current liabilities.
+ References
No definition available.
+ Details

Name: bioc_OtherNonInterestBearingCurrentLiabilities

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Proceeds from gross warrant exercises outstanding.
+ References
No definition available.
+ Details

Name: bioc_ProceedsFromGrossWarrantExercisesOutstanding

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of common stock net of issuance costs.
+ References
No definition available.
+ Details

Name: bioc_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of units net of issuance expenses related to rights offering.
+ References
No definition available.
+ Details

Name: bioc_ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Public float, minimum limit for offering.
+ References
No definition available.
+ Details

Name: bioc_PublicFloatMinimumLimitForOffering

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Shares available for public offering.
+ References
No definition available.
+ Details

Name: bioc_SharesAvailableForPublicOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued to underwriters under over allotment options.
+ References
No definition available.
+ Details

Name: bioc_SharesIssuedToUnderwritersUnderOverAllotmentOptions

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Shelf registration statement expiration period.
+ References
No definition available.
+ Details

Name: bioc_ShelfRegistrationStatementExpirationPeriod

Namespace Prefix: bioc_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Unconditional purchase commitment frequency of periodic payment.
+ References
No definition available.
+ Details

Name: bioc_UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Unconditional purchase commitment quarterly payment amount.
+ References
No definition available.
+ Details

Name: bioc_UnconditionalPurchaseCommitmentQuarterlyPaymentAmount

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Warrants exercisable exercise price per share.
+ References
No definition available.
+ Details

Name: bioc_WarrantsExercisableExercisePricePerShare

Namespace Prefix: bioc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Warrants exercisable exercise price per share expiration period .
+ References
No definition available.
+ Details

Name: bioc_WarrantsExercisableExercisePricePerShareExpirationPeriod

Namespace Prefix: bioc_

Data Type: xbrli:gYearMonthItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of currency on hand as well as demand deposits with banks or financial institutions. Includes other kinds of accounts that have the general characteristics of demand deposits. Excludes cash and cash equivalents within disposal group and discontinued operation.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 20
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631418-115840

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.1)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 946
-SubTopic 210
-Section 45
-Paragraph 21
-URI http://asc.fasb.org/extlink&oid=118262064&loc=SL116631419-115840
+ Details

Name: us-gaap_Cash

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The cash inflow from issuance of rights to purchase common shares at predetermined price (usually issued together with corporate debt).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromIssuanceOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cumulative amount of the reporting entity's undistributed earnings or deficit.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30)(a)(3))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 210
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-03(a)(23)(a)(4))
-URI http://asc.fasb.org/extlink&oid=119400593&loc=d3e572229-122910

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_RetainedEarningsAccumulatedDeficit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
End date of the unrecognized unconditional purchase obligation, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_PrefundedWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantExerciseInducementOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_OtherWarrantExercisesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_CommonStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantExerciseInducementOfferingAndOtherWarrantExercisesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=bioc_FollowOnPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=bioc_ShelfRegistrationStatementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 52 R23.htm IDEA: XBRL DOCUMENT v3.19.3

Balance Sheet Details (Tables)
9 Months Ended

Sep. 30, 2019

Organization Consolidation And Presentation Of Financial Statements [Abstract]

Schedule of Fixed Assets and Accrued Liabilities
The following provides certain balance sheet details:

December 31,

September 30,

2018

2019

Fixed Assets

Machinery and equipment

$

2,818,583

$

2,845,053

Furniture and office equipment

157,391

156,987

Computer equipment and software

1,437,408

1,552,981

Leasehold improvements

570,173

570,174

Financed equipment

2,573,955

—

Construction in process

116,640

325,550

Total fixed assets, gross

7,674,150

5,450,745

Less accumulated depreciation and amortization

(4,934,728

)

(4,125,490

)

Total fixed assets, net

$

2,739,422

$

1,325,255

Accrued Liabilities

Accrued payroll

255,426

458,750

Accrued vacation

535,682

566,811

Accrued bonuses

712,574

636,167

Accrued sales commissions

62,767

81,101

Current portion of deferred rent

158,342

—

Accrued other

203,602

104,155

Total accrued liabilities

$

1,928,393

$

1,846,984

X

- Definition
Tabular disclosure of condensed balance sheet, including, but not limited to, balance sheets of consolidated entities and consolidation eliminations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher SEC
-Name Regulation S-X (SX)
-Number 210
-Section 3
-Paragraph i
-Subsection 10
+ Details

Name: srt_ScheduleOfCondensedBalanceSheetTableTextBlock

Namespace Prefix: srt_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_OrganizationConsolidationAndPresentationOfFinancialStatementsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 53 R27.htm IDEA: XBRL DOCUMENT v3.19.3

Net Loss per Common Share (Tables)
9 Months Ended

Sep. 30, 2019

Earnings Per Share [Abstract]

Schedule of Anti-Dilutive Securities Excluded from Computations of Diluted Weighted-Average Shares
The following potentially dilutive securities have been excluded from the computations of diluted weighted-average shares outstanding for the periods presented, as they would be anti-dilutive:

For the three and nine months ended

September 30,

2018

2019

Preferred warrants outstanding (number of common stock equivalents)

17

—

Common warrants outstanding

4,814,927

15,197,249

RSUs outstanding

360

360

Convertible preferred stock outstanding (number of common stock equivalents)

2,560,727

471,393

Common options outstanding

114,641

2,797,656

Total anti-dilutive common share equivalents

7,490,672

18,466,658

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of securities (including those issuable pursuant to contingent stock agreements) that could potentially dilute basic earnings per share (EPS) in the future that were not included in the computation of diluted EPS because to do so would increase EPS amounts or decrease loss per share amounts for the period presented, by antidilutive securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_ScheduleOfAntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

EXCEL 54 Financial_Report.xlsx IDEA: XBRL DOCUMENT begin 644 Financial_Report.xlsx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end XML 55 R46.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation - Additional Information (Detail)
3 Months Ended 9 Months Ended

Jun. 17, 2019

shares

Jun. 28, 2018

shares

Sep. 30, 2019

USD ($)

shares

Sep. 30, 2018

Sep. 30, 2019

USD ($)

Plan

shares

Sep. 30, 2018

Apr. 30, 2019

shares

Dec. 31, 2018

USD ($)

shares

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Number of equity incentive plans | Plan 2

Total Shares Outstanding 2,797,656 2,797,656 195,820

Unrecognized share-based compensation expense, weighted-average recognition period 3 years 2 months 12 days

Minimum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Estimated forfeitures rate 0.00% 0.00% 0.00% 0.00%

Maximum [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Estimated forfeitures rate 8.00% 8.00% 8.00% 8.00%

Stock Options [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Intrinsic value of options outstanding | $ $ 0 $ 0 $ 0

Intrinsic value of options exercisable | $ 0 0 0

Intrinsic value of options vested and unvested expected to vest | $ 0 0 $ 0

RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Intrinsic value shares, RSUs outstanding | $ 400 400

Intrinsic value amount, RSUs unvested and vested expected to vest | $ $ 400 $ 400

RSUs outstanding 360 360 360

Stock Options and RSUs [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Unrecognized share-based compensation expense, stock options | $ $ 2,545,000 $ 2,545,000

2013 Equity Incentive Plan [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized 124,211 124,211

Common stock, shares authorized 2,578,229

2013 Equity Incentive Plan [Member] | Non-inducement Shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized 3,064,098 3,064,098

Increase in number of shares of common stock authorized for issuance 2,800,000 146,666

Stock options and RSUs issued 2,711,095

Total Shares Outstanding 2,650,970 2,650,970

Common stock, shares authorized 353,003 353,003

2013 Equity Incentive Plan [Member] | Inducement shares [Member]

Share Based Compensation Arrangement By Share Based Payment Award [Line Items]

Total stock options and RSUs authorized 118,368 118,368

Stock options and RSUs issued 117,534

Total Shares Outstanding 118,368 118,368

Common stock, shares authorized 0 0

X

- Definition
Share based compensation arrangement by share based payment award fair value assumptions expected forfeiture rate.
+ References
No definition available.
+ Details

Name: bioc_ShareBasedCompensationArrangementByShareBasedPaymentAwardFairValueAssumptionsExpectedForfeitureRate

Namespace Prefix: bioc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award number of equity incentive plans.
+ References
No definition available.
+ Details

Name: bioc_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfEquityIncentivePlans

Namespace Prefix: bioc_

Data Type: xbrli:integerItemType

Balance Type: na

Period Type: duration

X

- Definition
Share based compensation arrangement by share based payment award options unvested and expected to vest outstanding aggregate intrinsic value.
+ References
No definition available.
+ Details

Name: bioc_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsUnvestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of cost not yet recognized for nonvested award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognized

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Weighted-average period over which cost not yet recognized is expected to be recognized for award under share-based payment arrangement, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_EmployeeServiceShareBasedCompensationNonvestedAwardsTotalCompensationCostNotYetRecognizedPeriodForRecognition1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of non-vested equity-based payment instruments, excluding stock (or unit) options, that validly exist and are outstanding as of the balance sheet date.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(2)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardEquityInstrumentsOtherThanOptionsNonvestedNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of additional shares authorized for issuance under share-based payment arrangement.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfAdditionalSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of shares authorized for issuance under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (a)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAuthorized

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
The difference between the maximum number of shares (or other type of equity) authorized for issuance under the plan (including the effects of amendments and adjustments), and the sum of: 1) the number of shares (or other type of equity) already issued upon exercise of options or other equity-based awards under the plan; and 2) shares (or other type of equity) reserved for issuance on granting of outstanding awards, net of cancellations and forfeitures, if applicable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardNumberOfSharesAvailableForGrant

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which the current fair value of the underlying stock exceeds the exercise price of options outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount by which current fair value of underlying stock exceeds exercise price of fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingAggregateIntrinsicValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Number of shares issued under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardSharesIssuedInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Intrinsic value of outstanding award under share-based payment arrangement. Excludes share and unit options.
+ References
No definition available.
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardEquityInstrumentsOtherThanOptionsAggregateIntrinsicValueOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
Amount of difference between fair value of the underlying shares reserved for issuance and exercise price of vested portions of options outstanding and currently exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsExercisableIntrinsicValue1

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_EmployeeStockOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=us-gaap_RestrictedStockUnitsRSUMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_AwardTypeAxis=bioc_StockOptionsAndRestrictedStockUnitsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_PlanNameAxis=bioc_TwoThousandThirteenEquityIncentivePlanMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=bioc_NonInducementSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_VestingAxis=bioc_InducementSharesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 56 Show.js IDEA: XBRL DOCUMENT // Edgar(tm) Renderer was created by staff of the U.S. Securities and Exchange Commission. Data and content created by government employees within the scope of their employment are not subject to domestic copyright protection. 17 U.S.C. 105. var Show={};Show.LastAR=null,Show.showAR=function(a,r,w){if(Show.LastAR)Show.hideAR();var e=a;while(e&&e.nodeName!='TABLE')e=e.nextSibling;if(!e||e.nodeName!='TABLE'){var ref=((window)?w.document:document).getElementById(r);if(ref){e=ref.cloneNode(!0); e.removeAttribute('id');a.parentNode.appendChild(e)}} if(e)e.style.display='block';Show.LastAR=e};Show.hideAR=function(){Show.LastAR.style.display='none'};Show.toggleNext=function(a){var e=a;while(e.nodeName!='DIV')e=e.nextSibling;if(!e.style){}else if(!e.style.display){}else{var d,p_;if(e.style.display=='none'){d='block';p='-'}else{d='none';p='+'} e.style.display=d;if(a.textContent){a.textContent=p+a.textContent.substring(1)}else{a.innerText=p+a.innerText.substring(1)}}} XML 57 R42.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail)

Sep. 30, 2019

USD ($)

Long-term portion of lease liability:

Finance $ 1,032,243

Total $ 1,032,243

X

- Definition
Long-term portion of lease liability.
+ References
No definition available.
+ Details

Name: bioc_LongTermPortionOfLeaseLiabilityAbstract

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating and finance lease liability noncurrent.
+ References
No definition available.
+ Details

Name: bioc_OperatingAndFinanceLeaseLiabilityNoncurrent

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Present value of lessee's discounted obligation for lease payments from finance lease, classified as noncurrent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918627-209977
+ Details

Name: us-gaap_FinanceLeaseLiabilityNoncurrent

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 58 R4.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Statements of Operations and Comprehensive Loss (Unaudited) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Income Statement [Abstract]

Net revenues $ 1,529,262 $ 761,591 $ 3,744,824 $ 2,390,772

Costs and expenses:

Cost of revenues 2,832,735 2,481,916 8,105,422 7,616,473

Research and development expenses 1,163,546 1,089,746 3,535,116 3,179,612

General and administrative expenses 1,700,380 1,793,720 5,058,525 5,441,354

Sales and marketing expenses 1,462,335 1,404,192 4,451,628 4,473,908

Total costs and expenses 7,158,996 6,769,574 21,150,691 20,711,347

Loss from operations (5,629,734) (6,007,983) (17,405,867) (18,320,575)

Other income/ (expense):

Interest expense (62,028) (63,764) (187,575) (230,677)

Warrant inducement and other income (expenses) 23,963 (1,831,116) (6,037)

Total other income/ (expense): (62,028) (39,801) (2,018,691) (236,714)

Loss before income taxes (5,691,762) (6,047,784) (19,424,558) (18,557,289)

Income tax expense (739)

Net loss and comprehensive loss (5,691,762) (6,047,784) (19,424,558) (18,558,028)

Deemed dividend related to warrants down round provision (636,370) (99,743) (636,370)

Net loss attributable to common shareholders $ (5,691,762) $ (6,684,154) $ (19,524,301) $ (19,194,398)

Weighted-average shares outstanding used in computing net loss per share attributable to common shareholders:

Basic 23,018,235 2,767,440 17,807,298 2,322,749

Diluted 23,018,235 2,759,614 17,807,298 2,320,111

Net loss per common share:

Basic $ (0.25) $ (2.42) $ (1.10) $ (8.26)

Diluted $ (0.25) $ (2.42) $ (1.10) $ (8.27)

X

- Definition
Deemed dividend related to warrants down round provision.
+ References
No definition available.
+ Details

Name: bioc_DeemedDividendRelatedToWarrantsDownRoundProvision

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Warrant inducement and other income (expenses).
+ References
No definition available.
+ Details

Name: bioc_WarrantInducementAndOtherIncomeExpenses

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate cost of goods produced and sold and services rendered during the reporting period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.2)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostOfRevenue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Total costs of sales and operating expenses for the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_CostsAndExpenses

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_CostsAndExpensesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EarningsPerShareAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period per each share of common stock or unit outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256
+ Details

Name: us-gaap_EarningsPerShareBasic

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The amount of net income (loss) for the period available to each share of common stock or common unit outstanding during the reporting period and to each share or unit that would have been outstanding assuming the issuance of common shares or units for all dilutive potential common shares or units outstanding during the reporting period.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 55
-Paragraph 52
-URI http://asc.fasb.org/extlink&oid=117327953&loc=d3e4984-109258

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1252-109256

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(23))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 5: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 6: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 7
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1337-109256

Reference 7: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(21))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 8: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 60B
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=117326831&loc=SL5780133-109256

Reference 9: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(19))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263
+ Details

Name: us-gaap_EarningsPerShareDiluted

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
The aggregate total of expenses of managing and administering the affairs of an entity, including affiliates of the reporting entity, which are not directly or indirectly associated with the manufacture, sale or creation of a product or product line.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.4)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_GeneralAndAdministrativeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of income (loss) from continuing operations, including income (loss) from equity method investments, before deduction of income tax expense (benefit), and income (loss) attributable to noncontrolling interest.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 940
-SubTopic 20
-Section 25
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=68072869&loc=d3e41242-110953

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(10))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(8))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(15))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_IncomeStatementAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of current income tax expense (benefit) and deferred income tax expense (benefit) pertaining to continuing operations.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (h)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(h))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 740
-SubTopic 20
-Section 45
-Paragraph 2
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=109238882&loc=d3e38679-109324
+ Details

Name: us-gaap_IncomeTaxExpenseBenefit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of the cost of borrowed funds accounted for as interest expense.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 20
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6450988&loc=d3e26243-108391

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 835
-SubTopic 30
-Section 45
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=114775744&loc=d3e28555-108399

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 280
-SubTopic 10
-Section 50
-Paragraph 22
-Subparagraph (d)
-URI http://asc.fasb.org/extlink&oid=115929826&loc=d3e8736-108599

Reference 4: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (210.5-03(11))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04.9)
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260
+ Details

Name: us-gaap_InterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount, after deduction of tax, noncontrolling interests, dividends on preferred stock and participating securities; of income (loss) available to common shareholders.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-SubTopic 10
-Section 50
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=109234566&loc=d3e22694-107794

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 11
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1377-109256
+ Details

Name: us-gaap_NetIncomeLossAvailableToCommonStockholdersBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate amount of income or expense from ancillary business-related activities (that is to say, excluding major activities considered part of the normal operations of the business).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03.7)
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227
+ Details

Name: us-gaap_NonoperatingIncomeExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_NonoperatingIncomeExpenseAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The net result for the period of deducting operating expenses from operating revenues.
+ References
No definition available.
+ Details

Name: us-gaap_OperatingIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate costs incurred (1) in a planned search or critical investigation aimed at discovery of new knowledge with the hope that such knowledge will be useful in developing a new product or service, a new process or technique, or in bringing about a significant improvement to an existing product or process; or (2) to translate research findings or other knowledge into a plan or design for a new product or process or for a significant improvement to an existing product or process whether intended for sale or the entity's use, during the reporting period charged to research and development projects, including the costs of developing computer software up to the point in time of achieving technological feasibility, and costs allocated in accounting for a business combination to in-process projects deemed to have no alternative future use.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 985
-SubTopic 20
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6501960&loc=d3e128462-111756

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 730
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6420194&loc=d3e21568-108373
+ Details

Name: us-gaap_ResearchAndDevelopmentExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount, excluding tax collected from customer, of revenue from satisfaction of performance obligation by transferring promised good or service to customer. Tax collected from customer is tax assessed by governmental authority that is both imposed on and concurrent with specific revenue-producing transaction, including, but not limited to, sales, use, value added and excise.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130543-203045

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 606
-SubTopic 10
-Section 50
-Paragraph 5
-URI http://asc.fasb.org/extlink&oid=118956577&loc=SL49130545-203045
+ Details

Name: us-gaap_RevenueFromContractWithCustomerExcludingAssessedTax

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
The aggregate total amount of expenses directly related to the marketing or selling of products or services.
+ References
No definition available.
+ Details

Name: us-gaap_SellingAndMarketingExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The average number of shares or units issued and outstanding that are used in calculating diluted EPS or earnings per unit (EPU), determined based on the timing of issuance of shares or units in the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 16
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1505-109256
+ Details

Name: us-gaap_WeightedAverageNumberOfDilutedSharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of [basic] shares or units, after adjustment for contingently issuable shares or units and other shares or units not deemed outstanding, determined by relating the portion of time within a reporting period that common shares or units have been outstanding to the total time in that period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 45
-Paragraph 10
-URI http://asc.fasb.org/extlink&oid=117326831&loc=d3e1448-109256

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_WeightedAverageNumberOfSharesOutstandingBasic

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

XML 59 R8.htm IDEA: XBRL DOCUMENT v3.19.3

The Company, Business Activities and Basis of Presentation
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

The Company, Business Activities and Basis of Presentation
1. The Company, Business Activities and Basis of Presentation

The Company and Business Activities

The Company was founded in California in May 1997 and effected a reincorporation to Delaware in July 2013. The Company is an early stage molecular oncology diagnostics company that develops and commercializes proprietary circulating tumor cell, or CTC, and circulating tumor DNA, or ctDNA, assays utilizing a standard blood sample, or liquid biopsy. The Company’s current and planned assays are intended to provide information to aid healthcare providers to identify specific oncogenic alterations that may qualify a subset of cancer patients for targeted therapy at diagnosis, progression or for monitoring in order to identify specific resistance mechanisms. Sometimes traditional procedures, such as surgical tissue biopsies, result in tumor tissue that is insufficient and/or unable to provide the molecular subtype information necessary for clinical decisions. The Company’s assays, performed on blood, have the potential to provide more contemporaneous information on the characteristics of a patient’s disease when compared with tissue biopsy and radiographic imaging. Additionally, commencing in October 2017, the Company’s pathology partnership program, branded as Empower TC^TM, provides the unique ability for pathologists to participate in the interpretation of liquid biopsy results and is available to pathology practices and hospital systems throughout the United States. Further, sales to laboratory supply distributors of the Company’s proprietary blood collection tubes commenced in June 2018, which allow for the intact transport of liquid biopsy samples for research use only, or RUO, from regions around the world.

The Company operates a clinical laboratory that is CLIA-certified (under the Clinical Laboratory Improvement Amendment of 1988) and CAP-accredited (by the College of American Pathologists), and manufactures cell enrichment and extraction microfluidic channels, related equipment and certain reagents to perform the Company’s diagnostic assays in a facility located in San Diego, California. CLIA certification and accreditation are required before any clinical laboratory may perform testing on human specimens for the purpose of obtaining information for the diagnosis, prevention, treatment of disease, or assessment of health. The assays the Company offers are classified as laboratory developed tests under the CLIA regulations.

Basis of Presentation

The accompanying unaudited condensed financial statements and notes are prepared in accordance with accounting principles generally accepted in the United States of America, or GAAP, and on the basis that the Company will continue as a going concern (see Note 2). The accompanying unaudited condensed financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

On July 6, 2018, the Company’s stockholders approved, and the Company filed, an amendment to the Company’s Certificate of Amendment of Certificate of Incorporation to effect a one-for-thirty reverse stock split of the Company’s outstanding common stock. As such, all references to share and per share amounts in these unaudited condensed financial statements and accompanying notes have been retroactively restated to reflect the one-for-thirty reverse stock split, except for the authorized number of shares of the Company’s common stock of 150,000,000 shares, which was not affected by the one-for-thirty reverse stock split.

The unaudited condensed financial statements included in this Form 10-Q have been prepared in accordance with the U.S. Securities and Exchange Commission, or SEC, instructions for Quarterly Reports on Form 10-Q. Accordingly, the condensed financial statements are unaudited and do not contain all the information required by GAAP to be included in a full set of financial statements. The balance sheet at December 31, 2018 has been derived from the audited financial statements at that date but does not include all of the information and footnotes required by GAAP for a complete set of financial statements. The audited financial statements for the year ended December 31, 2018, filed with the U.S. Securities and Exchange Commission, or SEC, with our Annual Report on Form 10-K on March 29, 2019 include a summary of our significant accounting policies and should be read in conjunction with this Form 10-Q. In the opinion of management, all material adjustments necessary to present fairly the results of operations for such periods have been included in this Form 10-Q. All such adjustments are of a normal recurring nature. The results of operations for interim periods are not necessarily indicative of the results of operations for the entire year.

Certain prior period balances have been reclassified to conform to the current period presentation. Such reclassifications had no effect on net loss.

Revenue Recognition and Accounts Receivable

The Company's commercial revenues are generated from diagnostic services provided to patient’s physicians and billed to third-party insurance payers such as managed care organizations, Medicare and Medicaid and patients for any deductibles, coinsurance or copayments that may be due. Commencing on January 1, 2018, the Company recognizes revenue in accordance with ASC 606, Revenue from Contracts with Customers, or ASC 606, which requires that an entity recognize revenue when it transfers promised goods or services to customers in an amount that reflects the consideration to which the entity expects to be entitled to in exchange for those goods or services. The Company adopted the provisions of ASC 606 using the modified retrospective application method applied to all contracts, which did not impact amounts previously reported by the Company, nor did it require a cumulative effect adjustment upon adoption, as the Company’s method of recognizing revenue under ASC 606 was analogous to the method utilized immediately prior to adoption. Accordingly, there is no need for the Company to disclose the amount by which each financial statement line item was affected as a result of applying the new standard and an explanation of significant changes.

Contracts

For its commercial revenues, while the Company markets directly to physicians, its customer is the patient. Patients do not enter into direct agreements with the Company, however, a patient’s insurance coverage requirements would dictate whether or not any portion of the cost of the tests would be patient responsibility. Accordingly, the Company establishes contracts with commercial insurers in accordance with customary business practices, as follows:

•

Approval of a contract is established via the order and accession, which are submitted by the patient’s physician.

•

The Company is obligated to perform its diagnostic services upon receipt of a sample from a physician, and the patient and/or applicable payer are obligated to reimburse the Company for services rendered based on the patient’s insurance benefits.

•

Payment terms are a function of a patient’s existing insurance benefits, including the impact of coverage decisions with CMS and applicable reimbursement contracts established between the Company and payers, unless the patient is a self-pay patient, whereby the Company bills the patient directly after the services are provided.

•

Once the Company delivers a patient’s assay result to the ordering physician, the contract with a patient has commercial substance, as the Company is legally able to collect payment and bill an insurer and/or patient, regardless of payer contract status or patient insurance benefit status.

•

Consideration associated with commercial revenues is considered variable and constrained until fully adjudicated, with net revenues recorded to the extent that it is probable that a significant reversal will not occur.

The Company’s development services revenues are supported by contractual agreements and generated from assay development services provided to entities, as well as certain other diagnostic services provided to physicians, and revenues are recognized upon delivery of the performance obligations in the contract.

Performance Obligations

A performance obligation is a promise in a contract to transfer a distinct good or service, or a bundle of goods or services, to the customer. For its commercial and development services revenues, the Company’s contracts have a single performance obligation, which is satisfied upon rendering of services, which culminates in the delivery of a patient’s assay result(s) to the ordering physician or entity. The duration of time between accession receipt and delivery of a valid assay result to the ordering physician or entity is typically less than two weeks. Accordingly, the Company elected the practical expedient and therefore, does not disclose the value of unsatisfied performance obligations.

Transaction Price

The transaction price is the amount of consideration that the Company expects to collect in exchange for transferring promised goods or services to a customer, excluding amounts collected on behalf of third parties, such as sales taxes. The consideration expected from a contract with a customer may include fixed amounts, variable amounts, or both. The Company’s gross commercial revenues billed, and corresponding gross accounts receivable, are subject to estimated deductions for such allowances and reserves to arrive at reported net revenues, which relate to differences between amounts billed and corresponding amounts estimated to be subsequently collected, and is deemed to be variable although the variability is not explicitly stated in any contract. Rather, the implied variability is due to several factors, such as the payment history or lack thereof for third-party payers, reimbursement rate changes for contracted and non-contracted payers, any patient co-payments, deductibles or compliance incentives, the existence of secondary payers and claim denials. The Company estimates the amount of variable consideration using the most likely amount approach to estimating variable consideration for third-party payers, including direct patient bills, whereby the estimated reimbursement for services are established by payment histories on CPT codes for each payer, or similar payer types. When no payment history is available, the value of the account is estimated at Medicare rates, with additional other payer-specific reserves taken as appropriate. Collection periods for billings on commercial revenues range from less than 30 days to several months, depending on the contracted or non-contracted nature of the payer, among other variables. The estimates of amounts that will ultimately be realized from commercial diagnostic services for non-contracted payers require significant judgment by management.

The Company limits the amount of variable consideration included in the transaction price to the unconstrained portion of such consideration. Revenue is recognized up to the amount of variable consideration that is not subject to a significant reversal until additional information is obtained or the uncertainty associated with the additional payments or refunds is subsequently resolved. Differences between original estimates and subsequent revisions, including final settlements, represent changes in the estimate of variable consideration and are included in the period in which such revisions are made. The Company monitors its estimates of transaction price to depict conditions that exist at each reporting date. If the Company subsequently determines that it will collect more consideration than it originally estimated for a contract with a customer, it will account for the change as an increase in the estimate of the transaction price in the period identified as an increase to revenue. Similarly, if the Company subsequently determines that the amount it expects to collect from a customer is less than it originally estimated, it will generally account for the change as a decrease in the estimate of the transaction price as a decrease to revenue, provided that such downward adjustment does not result in a significant reversal of cumulative revenue recognized. Revenue recognized from changes in transaction prices was not significant during the three and nine months ended September 30, 2018 and 2019.

Allocate Transaction Price

For the Company’s commercial revenues, the entire transaction price is allocated to the single performance obligation contained in a contract with a customer. For the Company’s development services revenues, the contracted transaction price is allocated to each single performance obligation contained in a contract with a customer as performed.

Point-in-time Recognition

The Company’s single performance obligation is satisfied at a point in time, and that point in time is defined as the date a patient’s successful assay result is delivered to the patient’s ordering physician or entity. The Company considers this date to be the time at which the patient obtains control of the promised diagnostic assay service.

Contract Balances

The timing of revenue recognition, billings and cash collections results in accounts receivable recorded in the Company’s condensed balance sheets. Generally, billing occurs subsequent to delivery of a patient’s test result to the ordering physician or entity, resulting in an account receivable.

Practical Expedients

The Company does not adjust the transaction price for the effects of a significant financing component, as at contract inception, the Company expects the collection cycle to be one year or less.

The Company expenses sales commissions when incurred because the amortization period is one year or less, which are recorded within sales and marketing expenses.

The Company incurs certain other costs that are incurred regardless of whether a contract is obtained. Such costs are primarily related to legal services and patient communications. These costs are expensed as incurred and recorded within general and administrative expenses.

Disaggregation of Revenue and Concentration of Risk

The composition of the Company’s net revenues recognized during the three and nine months ended September 30, 2018 and 2019, disaggregated by source and nature, are as follows:

For the three months ended September 30,

For the nine months ended September 30,

2018

2019

2018

2019

Net revenues from contracted payers*

$

325,097

$

476,101

$

1,019,857

$

1,447,421

Net revenues from non-contracted payers

373,018

956,140

1,201,869

2,080,018

Development services revenues

63,476

37,981

159,606

125,169

Kits and Blood Collection Tubes (BCT)

—

59,040

9,440

92,216

Total net revenues

$

761,591

$

1,529,262

$

2,390,772

$

3,744,824

*Includes Medicare and Medicare Advantage, as reimbursement amounts are fixed.

For the three months ended September 30,

For the nine months ended September 30,

2018

2019

2018

2019

Net commercial revenues recognized upon delivery

$

698,115

$

1,432,241

$

2,221,726

$

3,527,439

Development services revenues recognized upon delivery

63,476

37,981

159,606

125,169

Kits and Blood Collection Tubes (BCT)

—

59,040

9,440

92,216

Total net revenues

$

761,591

$

1,529,262

$

2,390,772

$

3,744,824

Concentrations of credit risk with respect to revenues are primarily limited to geographies to which the Company provides a significant volume of its services, and to specific third-party payers of the Company’s services such as Medicare, insurance companies, and other third-party payers. The Company’s client base consists of many geographically dispersed clients diversified across various customer types.

The Company's third-party payers that represent more than 10% of total net revenues in any period presented, as well as their related net revenue amount as a percentage of total net revenues, during the three and nine months ended September 30, 2018 and 2019 were as follows:

For the three months ended September 30,

For the nine months ended September 30,

2018

2019

2018

2019

Medicare and Medicare Advantage

40

%

32

%

39

%

40

%

Blue Cross Blue Shield

9

%

25

%

14

%

20

%

United Healthcare

6

%

8

%

15

%

9

%

The Company's third-party payers that represent more than 10% of total net accounts receivable, and their related net accounts receivable balance as a percentage of total net accounts receivable, at December 31, 2018 and September 30, 2019 were as follows:

December 31, 2018

September 30, 2019

Blue Cross Blue Shield

22

%

25

%

Medicare and Medicare Advantage

17

%

17

%

United Healthcare

15

%

13

%

Recent Accounting Pronouncements

In February 2016, the FASB issued authoritative guidance, which changes several aspects of the accounting for leases, including the requirement that all leases with durations greater than twelve months be recognized on the balance sheet. The guidance is effective for annual and interim reporting periods in fiscal years beginning after December 15, 2018. Effective January 1, 2019, the Company adopted the guidance and elected the optional transition method to account for the impact of the adoption with a cumulative-effect adjustment in the period of adoption and did not restate prior periods. The Company also elected the practical expedient package as permitted under the transition guidance. As of January 1, 2019, the Company recorded a right-of-use asset and liability upon adoption of the guidance (See Note 7).

In August 2017, the FASB issued authoritative guidance that expands and refines hedge accounting for both nonfinancial and financial risk components and align the recognition and presentation of the effects of the hedging instrument and the hedged item in the financial statements. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early application is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures because the Company does not currently hold any financial instruments accounted for as a hedging activity.

In February 2018, the FASB issued authoritative guidance allowing a reclassification from accumulated other comprehensive income to retained earnings for stranded tax effects resulting from a tax bill, “H.R.1, An Act to Provide for Reconciliation Pursuant to Titles II and V of the Concurrent Resolution on the Budget for Fiscal Year 2018,” or the Tax Cuts and Jobs Act, enacted on December 22, 2017. These amendments eliminate the stranded tax effects resulting from the Tax Cuts and Jobs Act. However, because these amendments only relate to the reclassification of the income tax effects of the Tax Cuts and Jobs Act, the underlying guidance that requires that the effect of a change in tax laws or rates be included in income from continuing operations is not affected. This guidance also requires certain disclosures about stranded tax effects. This guidance is effective for fiscal years beginning after December 15, 2018, and interim periods within those fiscal years. Early adoption is permitted. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 which did not have a material impact on its financial statements or disclosures because the Company does not currently maintain any stranded tax effects in accumulated other comprehensive income.

In June 2018, the FASB issued authoritative guidance simplifying the accounting for nonemployee stock-based compensation and largely aligning such compensation with the accounting requirements for employee stock-based awards. For public companies, this guidance is effective for fiscal years beginning after December 15, 2018, including interim periods within that fiscal year. The Company adopted this guidance for the fiscal year beginning on January 1, 2019 and determined that the adoption of this guidance does not have a material impact on its financial statements or disclosures.

In November 2018, the FASB issued authoritative guidance clarifying the interaction between Collaborative Arrangements (Topic 808) and Revenue from Contracts with Customers (Topic 606) to address diversity in practice related to how companies account for collaborative arrangements. For public companies, this guidance is effective for fiscal years beginning after December 15, 2019, including interim periods within that fiscal year. Early adoption is permitted, but no earlier than an entity’s adoption date of Revenue from Contracts with Customers (Topic 606). The Company currently intends to adopt this guidance upon the effective date and does not anticipate that the adoption of this guidance will have a material impact on its financial statements or disclosures.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for the general note to the financial statements for the reporting entity which may include, descriptions of the basis of presentation, business description, significant accounting policies, consolidations, reclassifications, new pronouncements not yet adopted and changes in accounting principles.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 810
-URI http://asc.fasb.org/topic&trid=2197479

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 275
-URI http://asc.fasb.org/topic&trid=2134479

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 250
-URI http://asc.fasb.org/topic&trid=2122394

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-URI http://asc.fasb.org/topic&trid=2122369
+ Details

Name: us-gaap_OrganizationConsolidationBasisOfPresentationBusinessDescriptionAndAccountingPoliciesTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 60 R22.htm IDEA: XBRL DOCUMENT v3.19.3

Fair Value Measurement (Tables)
9 Months Ended

Sep. 30, 2019

Fair Value Disclosures [Abstract]

Assumptions Used for Determining Fair Values of Common Stock Warrants The fair value of the warrants was estimated using a Monte Carlo simulation valuation model using Geometric Brownian Motion, incorporating anticipated future financing events, with the following assumptions:

Beginning stock price

$

10.17

Exercise price

$

15.00

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.48

%

Expected life (in years)

5.00

Expected volatility

99.00

%

The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:

Beginning stock price

$

3.89

Exercise price

$

4.53

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.75

%

Expected life (in years)

5.00

Expected volatility

128.69

%

The fair value of the warrants was estimated using a Black-Scholes model, incorporating the following assumptions:

Beginning stock price

$

2.92

Exercise price

$

3.16

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.77

%

Expected life (in years)

5.50

Expected volatility

130.7

%

The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price

$

1.05

Exercise price

$

1.20

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.49

%

Expected life (in years)

5.00

Expected volatility

147.7

%

The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price

$

1.12

Exercise price

$

1.25

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.44

%

Expected life (in years)

5.50

Expected volatility

140.0

%

The fair value of the warrants was estimated using a Black-Scholes model with the following assumptions:

Beginning stock price

$

1.29

Exercise price

$

1.31

Expected dividend yield

0.00

%

Discount rate-bond equivalent yield

2.05

%

Expected life (in years)

5.50

Expected volatility

145.9

%

X

- Definition
Tabular disclosure of input and valuation technique used to measure fair value and change in valuation approach and technique for each separate class of asset and liability measured on recurring and nonrecurring basis.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 820
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (bbb)
-URI http://asc.fasb.org/extlink&oid=117815213&loc=d3e19207-110258
+ Details

Name: us-gaap_FairValueAssetsAndLiabilitiesMeasuredOnRecurringAndNonrecurringBasisValuationTechniquesTableTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_FairValueDisclosuresAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 61 R26.htm IDEA: XBRL DOCUMENT v3.19.3

Common Stock Warrants Outstanding (Tables)
9 Months Ended

Sep. 30, 2019

Equity Classified Warrants [Abstract]

Summary of Equity-Classified Common Stock Warrant Activity
A summary of equity-classified common stock warrant activity for the nine months ended September 30, 2019 is as follows:

Average

Weighted

Remaining

Number of

Average Exercise

Contractual

Shares

Price Per Share

Term in Years

Outstanding at December 31, 2018

4,694,927

$

8.55

4.4

Issued

14,662,226

$

1.23

Exercised

(4,155,430

)

1.20

Expired

(4,474

)

953.06

Outstanding at September 30, 2019

15,197,249

$

3.08

4.5

Schedule of Equity-Classified Common Stock Warrants, Outstanding
Further information about equity-classified common stock warrants outstanding at September 30, 2019 is as follows:

Weighted

Weighted

Average

Average

Total Shares

Contractual

Exercise Price

Outstanding

Life (in years)

$

1.24

11,601,949

4.7

$

4.21

3,311,578

3.9

$

25.50

8,208

3.2

$

33.00

96,999

2.1

$

45.00

47,821

2.9

$

75.00

71,995

3.0

$

117.00

38,772

1.6

$

140.00

19,339

0.4

$

424.80

588

4.6

15,197,249

X

- Definition
Equity classified warrants.
+ References
No definition available.
+ Details

Name: bioc_EquityClassifiedWarrantsAbstract

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Schedule of common stock warrants activity.
+ References
No definition available.
+ Details

Name: bioc_ScheduleOfCommonStockWarrantsActivityTableTextBlock

Namespace Prefix: bioc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- Definition
Tabular disclosure of warrants or rights issued. Warrants and rights outstanding are derivative securities that give the holder the right to purchase securities (usually equity) from the issuer at a specific price within a certain time frame. Warrants are often included in a new debt issue to entice investors by a higher return potential. The main difference between warrants and call options is that warrants are issued and guaranteed by the company, whereas options are exchange instruments and are not issued by the company. Also, the lifetime of a warrant is often measured in years, while the lifetime of a typical option is measured in months. Disclose the title of issue of securities called for by warrants and rights outstanding, the aggregate amount of securities called for by warrants and rights outstanding, the date from which the warrants or rights are exercisable, and the price at which the warrant or right is exercisable.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 50
-Section S99
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6784392&loc=d3e188667-122775
+ Details

Name: us-gaap_ScheduleOfStockholdersEquityNoteWarrantsOrRightsTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 62 R47.htm IDEA: XBRL DOCUMENT v3.19.3

Stock-Based Compensation - Summary of Stock Option Activity (Detail) - $ / shares
9 Months Ended 12 Months Ended

Sep. 30, 2019

Dec. 31, 2018

Disclosure Of Compensation Related Costs Sharebased Payments [Abstract]

Number of Shares Outstanding, Beginning Balance 195,820

Number of Shares, Granted 2,664,129

Number of Shares, Cancelled/forfeited/expired (62,293)

Number of Shares Outstanding, Ending Balance 2,797,656 195,820

Number of Shares, Vested and unvested expected to vest, Ending Balance 2,701,017

Weighted Average Exercise Price Per Share, Outstanding, Beginning Balance $ 41.41

Weighted Average Exercise Price Per Share, Granted 0.91

Weighted Average Exercise Price Per Share, Cancelled/forfeited/expired 6.43

Weighted Average Exercise Price Per Share, Outstanding, Ending Balance 3.62 $ 41.41

Weighted Average Exercise Price Per Share, Vested and unvested expected to vest, Ending Balance $ 3.71

Weighted Average Remaining Contractual Term in Years, Outstanding 9 years 6 months 7 days 9 years 2 months 12 days

Weighted Average Remaining Contractual Term in Years, Vested and unvested expected to vest 9 years 6 months 7 days

X

- References
No definition available.
+ Details

Name: us-gaap_DisclosureOfCompensationRelatedCostsSharebasedPaymentsAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The number of shares under options that were cancelled during the reporting period as a result of occurrence of a terminating event specified in contractual agreements pertaining to the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(3)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsForfeituresInPeriod

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Gross number of share options (or share units) granted during the period.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of options outstanding, including both vested and non-vested options.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)-(ii)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees can acquire the shares reserved for issuance under the stock option plan.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(i)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of fully vested and expected to vest options outstanding that can be converted into shares under option plan. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingNumber

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted-average exercise price, at which grantee can acquire shares reserved for issuance, for fully vested and expected to vest options outstanding. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Weighted average price at which grantees could have acquired the underlying shares with respect to stock options that were terminated.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsForfeituresInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average per share amount at which grantees can acquire shares of common stock by exercise of options.
+ References
No definition available.
+ Details

Name: us-gaap_ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for option awards outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents the reported fact of one year, five months, and thirteen days.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsOutstandingWeightedAverageRemainingContractualTerm2

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Weighted average remaining contractual term for fully vested and expected to vest options outstanding, in 'PnYnMnDTnHnMnS' format, for example, 'P1Y5M13D' represents reported fact of one year, five months, and thirteen days. Includes, but is not limited to, unvested options for which requisite service period has not been rendered but that are expected to vest based on achievement of performance condition, if forfeitures are recognized when they occur.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (e)(1)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901
+ Details

Name: us-gaap_SharebasedCompensationArrangementBySharebasedPaymentAwardOptionsVestedAndExpectedToVestOutstandingWeightedAverageRemainingContractualTerm1

Namespace Prefix: us-gaap_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

XML 63 R43.htm IDEA: XBRL DOCUMENT v3.19.3

Leases - Schedule of Lease Expense (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2019

Finance lease cost

Amortization of right-of-use assets $ 134,472 $ 364,401

Interest on lease liabilities 62,026 187,574

Operating lease cost 318,005 954,015

Total $ 514,503 $ 1,505,990

X

- Definition
Finance leases cost.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeasesCostAbstract

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Operating and finance lease cost.
+ References
No definition available.
+ Details

Name: bioc_OperatingAndFinanceLeaseCost

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of interest expense on finance lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseInterestExpense

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of amortization expense attributable to right-of-use asset from finance lease.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 45
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77888419&loc=SL77918638-209977

Reference 3: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971
+ Details

Name: us-gaap_FinanceLeaseRightOfUseAssetAmortization

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Amount of single lease cost, calculated by allocation of remaining cost of lease over remaining lease term. Includes, but is not limited to, single lease cost, after impairment of right-of-use asset, calculated by amortization of remaining right-of-use asset and accretion of lease liability.
+ References
Reference 1: http://www.xbrl.org/2003/role/exampleRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 55
-Paragraph 53
-URI http://asc.fasb.org/extlink&oid=77888399&loc=SL77918982-209971

Reference 2: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 842
-SubTopic 20
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77888426&loc=SL77918686-209980
+ Details

Name: us-gaap_OperatingLeaseCost

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

XML 64 R9.htm IDEA: XBRL DOCUMENT v3.19.3

Liquidity and Going Concern Uncertainty
9 Months Ended

Sep. 30, 2019

Accounting Policies [Abstract]

Liquidity and Going Concern Uncertainty
2. Liquidity and Going Concern Uncertainty

As of September 30, 2019, cash totaled $6.5 million and the Company had an accumulated deficit of $240.0 million. For the year ended December 31, 2018 and the nine months ended September 30, 2019, the Company incurred net losses of $24.6 million and $19.4 million. At September 30, 2019, the Company had aggregate net interest-bearing indebtedness of $1.9 million, of which $909,000 was due within one year, in addition to $3.0 million of other non-interest-bearing current liabilities. Additionally, in February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020, under which $154,000 remained outstanding at September 30, 2019 (see Note 11). These factors raise substantial doubt about the Company’s ability to continue as a going concern for the one-year period following the date that these financial statements were issued. The accompanying financial statements and notes have been prepared assuming that the Company will continue as a going concern. The accompanying financial statements and notes do not include any adjustments to reflect the possible future effects on the recoverability and classification of assets or the amounts and classification of liabilities that may result from the possible inability of the Company to continue as a going concern.

While the Company is currently in the commercialization stage of operations, the Company has not yet achieved profitability and anticipates that it will continue to incur net losses for the foreseeable future. Historically, the Company’s principal sources of cash have included proceeds from the issuance of common and preferred stock, proceeds from the exercise of warrants to purchase common stock, proceeds from the issuance of debt, and revenues from laboratory services. The Company’s principal uses of cash have included cash used in operations, payments relating to purchases of property and equipment and repayments of borrowings. The Company expects that the principal uses of cash in the future will be for continuing operations, hiring of sales and marketing personnel and increased sales and marketing activities, funding of research and development, capital expenditures, and general working capital requirements. The Company expects that, as revenues grow, sales and marketing and research and development expenses will continue to grow, albeit at a slower rate and, as a result, the Company will need to generate significant growth in net revenues to achieve and sustain income from operations.

On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering, with approximately $1.3 million in gross warrant proceeds remaining outstanding and available to be exercised at $1.20 per share, which is subject to down round adjustment, until their expiration in January 2023. Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 offering price per share in the February 2019 financing transaction.

In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of its common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as its public float is less than $75 million.

On August 13, 2018, the Company completed a rights offering pursuant to an effective registration statement. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock convertible into 471,393 shares of its common stock and 2,549,140 warrants, with each warrant exercisable for one share of its common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants.

On September 20, 2018, the Company completed a registered offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from the offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers in the concurrent registered offering a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date.

On January 18, 2019, the Company completed a registered offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses.

On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million from the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering. On March 11, 2019, the underwriters exercised their overallotment option for 538,867 shares of the Company’s common stock related to the February 12, 2019 follow-on offering, purchasing shares at $1.20 per share for net cash proceeds of approximately $592,000.

On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share.

In May 2019, the Company received net proceeds of approximately $2.3 million related to the May 2019 Warrant Exercise Inducement Offering as well as an additional $2.5 million from other warrant exercises. The warrants exercised had exercise prices ranging from $1.20 to $1.25 per share and the total number of shares of common stock issued upon exercises both in connection with the Warrant Exercise Inducement Offering and other warrant exercises was approximately 4.2 million shares.

Management’s Plan to Continue as a Going Concern

In order to continue as a going concern, the Company will need, among other things, additional capital resources. Until the Company can generate significant cash from operations, including assay revenues, management’s plans to obtain such resources for the Company include proceeds from offerings of the Company’s equity securities or debt, cash received from the exercise of outstanding common stock warrants, or transactions involving product development, technology licensing or collaboration. Management can provide no assurances that any sources of a sufficient amount of financing will be available to the Company on favorable terms, if at all.

X

- References
No definition available.
+ Details

Name: us-gaap_AccountingPoliciesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure when substantial doubt is raised about the ability to continue as a going concern. Includes, but is not limited to, principal conditions or events that raised substantial doubt about the ability to continue as a going concern, management's evaluation of the significance of those conditions or events in relation to the ability to meet its obligations, and management's plans that alleviated or are intended to mitigate the conditions or events that raise substantial doubt about the ability to continue as a going concern.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 205
-SubTopic 40
-URI http://asc.fasb.org/subtopic&trid=51888271
+ Details

Name: us-gaap_SubstantialDoubtAboutGoingConcernTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 65 R1.htm IDEA: XBRL DOCUMENT v3.19.3

Document and Entity Information - shares
9 Months Ended

Sep. 30, 2019

Nov. 08, 2019

Cover [Abstract]

Document Type 10-Q

Amendment Flag false

Document Period End Date Sep. 30, 2019

Document Fiscal Year Focus 2019

Document Fiscal Period Focus Q3

Trading Symbol BIOC

Entity Registrant Name BIOCEPT INC

Entity Central Index Key 0001044378

Current Fiscal Year End Date --12-31

Entity Filer Category Non-accelerated Filer

Entity Small Business true

Entity Emerging Growth Company true

Entity Ex Transition Period true

Entity Common Stock, Shares Outstanding 23,018,235

Document Quarterly Report true

Document Transition Report false

Entity File Number 001-36284

Entity Incorporation, State or Country Code DE

Entity Tax Identification Number 80-0943522

Entity Address, Address Line One 5810 Nancy Ridge Drive

Entity Address, City or Town San Diego

Entity Address, State or Province CA

Entity Address, Postal Zip Code 92121

City Area Code 858

Local Phone Number 320-8200

Title of 12(b) Security Common Stock, par value $.0001 per share

Security Exchange Name NASDAQ

Entity Shell Company false

Entity Current Reporting Status Yes

Entity Interactive Data Current Yes

X

- Definition
Boolean flag that is true when the XBRL content amends previously-filed or accepted submission.
+ References
No definition available.
+ Details

Name: dei_AmendmentFlag

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Area code of city
+ References
No definition available.
+ Details

Name: dei_CityAreaCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Cover page.
+ References
No definition available.
+ Details

Name: dei_CoverAbstract

Namespace Prefix: dei_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
End date of current fiscal year in the format --MM-DD.
+ References
No definition available.
+ Details

Name: dei_CurrentFiscalYearEndDate

Namespace Prefix: dei_

Data Type: xbrli:gMonthDayItemType

Balance Type: na

Period Type: duration

X

- Definition
Fiscal period values are FY, Q1, Q2, and Q3. 1st, 2nd and 3rd quarter 10-Q or 10-QT statements have value Q1, Q2, and Q3 respectively, with 10-K, 10-KT or other fiscal year statements having FY.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalPeriodFocus

Namespace Prefix: dei_

Data Type: dei:fiscalPeriodItemType

Balance Type: na

Period Type: duration

X

- Definition
This is focus fiscal year of the document report in CCYY format. For a 2006 annual report, which may also provide financial information from prior periods, fiscal 2006 should be given as the fiscal year focus. Example: 2006.
+ References
No definition available.
+ Details

Name: dei_DocumentFiscalYearFocus

Namespace Prefix: dei_

Data Type: xbrli:gYearItemType

Balance Type: na

Period Type: duration

X

- Definition
The end date of the period reflected on the cover page if a periodic report. For all other reports and registration statements containing historical data, it is the date up through which that historical data is presented. If there is no historical data in the report, use the filing date. The format of the date is CCYY-MM-DD.
+ References
No definition available.
+ Details

Name: dei_DocumentPeriodEndDate

Namespace Prefix: dei_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as an quarterly report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Form 10-Q
-Number 240
-Section 13
-Subsection a-13
+ Details

Name: dei_DocumentQuarterlyReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true only for a form used as a transition report.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Forms 10-K, 10-Q, 20-F
-Number 240
-Section 13
-Subsection a-1-
+ Details

Name: dei_DocumentTransitionReport

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The type of document being provided (such as 10-K, 10-Q, 485BPOS, etc). The document type is limited to the same value as the supporting SEC submission type, or the word 'Other'.
+ References
No definition available.
+ Details

Name: dei_DocumentType

Namespace Prefix: dei_

Data Type: dei:submissionTypeItemType

Balance Type: na

Period Type: duration

X

- Definition
Address Line 1 such as Attn, Building Name, Street Name
+ References
No definition available.
+ Details

Name: dei_EntityAddressAddressLine1

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the City or Town
+ References
No definition available.
+ Details

Name: dei_EntityAddressCityOrTown

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Code for the postal or zip code
+ References
No definition available.
+ Details

Name: dei_EntityAddressPostalZipCode

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the state or province.
+ References
No definition available.
+ Details

Name: dei_EntityAddressStateOrProvince

Namespace Prefix: dei_

Data Type: dei:stateOrProvinceItemType

Balance Type: na

Period Type: duration

X

- Definition
A unique 10-digit SEC-issued value to identify entities that have filed disclosures with the SEC. It is commonly abbreviated as CIK.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityCentralIndexKey

Namespace Prefix: dei_

Data Type: dei:centralIndexKeyItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate number of shares or other units outstanding of each of registrant's classes of capital or common stock or other ownership interests, if and as stated on cover of related periodic report. Where multiple classes or units exist define each class/interest by adding class of stock items such as Common Class A [Member], Common Class B [Member] or Partnership Interest [Member] onto the Instrument [Domain] of the Entity Listings, Instrument.
+ References
No definition available.
+ Details

Name: dei_EntityCommonStockSharesOutstanding

Namespace Prefix: dei_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Indicate 'Yes' or 'No' whether registrants (1) have filed all reports required to be filed by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or for such shorter period that registrants were required to file such reports), and (2) have been subject to such filing requirements for the past 90 days. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
No definition available.
+ Details

Name: dei_EntityCurrentReportingStatus

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if registrant meets the emerging growth company criteria.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityEmergingGrowthCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate if an emerging growth company has elected not to use the extended transition period for complying with any new or revised financial accounting standards.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Securities Act
-Number 7A
-Section B
-Subsection 2
+ Details

Name: dei_EntityExTransitionPeriod

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Commission file number. The field allows up to 17 characters. The prefix may contain 1-3 digits, the sequence number may contain 1-8 digits, the optional suffix may contain 1-4 characters, and the fields are separated with a hyphen.
+ References
No definition available.
+ Details

Name: dei_EntityFileNumber

Namespace Prefix: dei_

Data Type: dei:fileNumberItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicate whether the registrant is one of the following: Large Accelerated Filer, Accelerated Filer, Non-accelerated Filer. Definitions of these categories are stated in Rule 12b-2 of the Exchange Act. This information should be based on the registrant's current or most recent filing containing the related disclosure.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityFilerCategory

Namespace Prefix: dei_

Data Type: dei:filerCategoryItemType

Balance Type: na

Period Type: duration

X

- Definition
Two-character EDGAR code representing the state or country of incorporation.
+ References
No definition available.
+ Details

Name: dei_EntityIncorporationStateCountryCode

Namespace Prefix: dei_

Data Type: dei:edgarStateCountryItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant has submitted electronically every Interactive Data File required to be submitted pursuant to Rule 405 of Regulation S-T during the preceding 12 months (or for such shorter period that the registrant was required to submit such files).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation S-T
-Number 232
-Section 405
+ Details

Name: dei_EntityInteractiveDataCurrent

Namespace Prefix: dei_

Data Type: dei:yesNoItemType

Balance Type: na

Period Type: duration

X

- Definition
The exact name of the entity filing the report as specified in its charter, which is required by forms filed with the SEC.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityRegistrantName

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Boolean flag that is true when the registrant is a shell company as defined in Rule 12b-2 of the Exchange Act.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityShellCompany

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
Indicates that the company is a Smaller Reporting Company (SRC).
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntitySmallBusiness

Namespace Prefix: dei_

Data Type: xbrli:booleanItemType

Balance Type: na

Period Type: duration

X

- Definition
The Tax Identification Number (TIN), also known as an Employer Identification Number (EIN), is a unique 9-digit value assigned by the IRS.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Regulation 12B
-Number 240
-Section 12
-Subsection b-2
+ Details

Name: dei_EntityTaxIdentificationNumber

Namespace Prefix: dei_

Data Type: dei:employerIdItemType

Balance Type: na

Period Type: duration

X

- Definition
Local phone number for entity.
+ References
No definition available.
+ Details

Name: dei_LocalPhoneNumber

Namespace Prefix: dei_

Data Type: xbrli:normalizedStringItemType

Balance Type: na

Period Type: duration

X

- Definition
Title of a 12(b) registered security.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection b
+ Details

Name: dei_Security12bTitle

Namespace Prefix: dei_

Data Type: dei:securityTitleItemType

Balance Type: na

Period Type: duration

X

- Definition
Name of the Exchange on which a security is registered.
+ References
Reference 1: http://www.xbrl.org/2003/role/presentationRef
-Publisher SEC
-Name Exchange Act
-Number 240
-Section 12
-Subsection d1-1
+ Details

Name: dei_SecurityExchangeName

Namespace Prefix: dei_

Data Type: dei:edgarExchangeCodeItemType

Balance Type: na

Period Type: duration

X

- Definition
Trading symbol of an instrument as listed on an exchange.
+ References
No definition available.
+ Details

Name: dei_TradingSymbol

Namespace Prefix: dei_

Data Type: dei:tradingSymbolItemType

Balance Type: na

Period Type: duration

XML 66 R5.htm IDEA: XBRL DOCUMENT v3.19.3

Condensed Statements of Shareholders' Equity - USD ($)

Total

August 2018 Rights Offering [Member]

September 2018 Registered Direct Offering [Member]

January 2019 Financing Transaction [Member]

February 2019 Financing Transaction [Member]

January 2019 Financing Transaction Overallotment [Member]

March 2019 Financing Transaction [Member]

January 2018 financing transaction [Member]

Common Stock [Member]

Common Stock [Member]

September 2018 Registered Direct Offering [Member]

Common Stock [Member]

January 2019 Financing Transaction [Member]

Common Stock [Member]

February 2019 Financing Transaction [Member]

Common Stock [Member]

January 2019 Financing Transaction Overallotment [Member]

Common Stock [Member]

March 2019 Financing Transaction [Member]

Common Stock [Member]

January 2018 financing transaction [Member]

SeriesA Convertible Preferred Stock [Member]

SeriesA Convertible Preferred Stock [Member]

August 2018 Rights Offering [Member]

Additional Paid-in Capital [Member]

Additional Paid-in Capital [Member]

August 2018 Rights Offering [Member]

Additional Paid-in Capital [Member]

September 2018 Registered Direct Offering [Member]

Additional Paid-in Capital [Member]

January 2019 Financing Transaction [Member]

Additional Paid-in Capital [Member]

February 2019 Financing Transaction [Member]

Additional Paid-in Capital [Member]

January 2019 Financing Transaction Overallotment [Member]

Additional Paid-in Capital [Member]

March 2019 Financing Transaction [Member]

Additional Paid-in Capital [Member]

January 2018 financing transaction [Member]

Accumulated Deficit [Member]

Beginning balance at Dec. 31, 2017 $ 1,296,034 $ 118 $ 196,545,523 $ (195,249,607)

Beginning balance, shares at Dec. 31, 2017 1,181,179

Stock-based compensation expense 225,263 225,263

Shares and warrants issued, net of issuance costs $ 13,342,821 $ 110 $ 13,342,711

Shares and warrants issued, net of issuance costs, shares 1,095,153

Adjustment for presentation after reverse stock split $ 6,576 (6,576)

Net loss (6,357,143) (6,357,143)

Ending balance at Mar. 31, 2018 8,506,975 $ 6,804 210,106,921 (201,606,750)

Ending balance, shares at Mar. 31, 2018 2,276,332

Beginning balance at Dec. 31, 2017 1,296,034 $ 118 196,545,523 (195,249,607)

Beginning balance, shares at Dec. 31, 2017 1,181,179

Deemed dividends related warrants down round provision 636,370

Net loss (18,558,028)

Ending balance at Sep. 30, 2018 8,938,408 $ 394 $ 1 223,382,018 (214,444,005)

Ending balance, shares at Sep. 30, 2018 3,937,226 7,005

Beginning balance at Dec. 31, 2017 1,296,034 $ 118 196,545,523 (195,249,607)

Beginning balance, shares at Dec. 31, 2017 1,181,179

Net loss (24,600,000)

Ending balance at Dec. 31, 2018 3,042,519 $ 463 223,499,634 (220,457,578)

Ending balance, shares at Dec. 31, 2018 4,629,174 4,417

Beginning balance at Mar. 31, 2018 8,506,975 $ 6,804 210,106,921 (201,606,750)

Beginning balance, shares at Mar. 31, 2018 2,276,332

Stock-based compensation expense 173,694 173,694

Shares issued for restricted stock units $ 19 (19)

Shares issued for restricted stock units, shares 5,834

Net loss (6,153,101) (6,153,101)

Ending balance at Jun. 30, 2018 2,527,568 $ 6,823 210,280,596 (207,759,851)

Ending balance, shares at Jun. 30, 2018 2,282,166

Stock-based compensation expense 113,072 113,072

Shares and warrants issued, net of issuance costs $ 10,097,878 $ 2,247,674 $ 64 $ 1 $ 10,097,877 $ 2,247,610

Shares and warrants issued, net of issuance costs, shares 642,438 11,587

Deemed dividends related warrants down round provision 636,370 636,370 (636,370)

Shares issued upon conversion of preferred stock $ 101 (101)

Shares issued upon conversion of preferred stock, shares 1,012,622 (4,582)

Common stock reclassification $ (6,594) 6,594

Net loss (6,047,784) (6,047,784)

Ending balance at Sep. 30, 2018 8,938,408 $ 394 $ 1 223,382,018 (214,444,005)

Ending balance, shares at Sep. 30, 2018 3,937,226 7,005

Beginning balance at Dec. 31, 2018 3,042,519 $ 463 223,499,634 (220,457,578)

Beginning balance, shares at Dec. 31, 2018 4,629,174 4,417

Stock-based compensation expense 102,459 102,459

Shares issued upon exercise of common stock warrants 4,748 $ 1 4,747

Shares issued upon exercise of common stock warrants, shares 5,985

Shares and warrants issued, net of issuance costs $ 2,032,311 $ 6,602,735 $ 592,306 $ 7,553,793 $ 99 $ 625 $ 54 $ 595 $ 2,032,212 $ 6,602,110 $ 592,252 $ 7,553,198

Shares and warrants issued, net of issuance costs, shares 990,000 6,250,000 538,867 5,950,000

Deemed dividends related warrants down round provision 99,743 (99,743)

Shares issued upon conversion of preferred stock $ 50 (50)

Shares issued upon conversion of preferred stock, shares 503,438 (2,278)

Net loss (5,916,787) (5,916,787)

Ending balance at Mar. 31, 2019 14,014,084 $ 1,887 240,486,305 (226,474,108)

Ending balance, shares at Mar. 31, 2019 18,867,464 2,139

Beginning balance at Dec. 31, 2018 3,042,519 $ 463 223,499,634 (220,457,578)

Beginning balance, shares at Dec. 31, 2018 4,629,174 4,417

Deemed dividends related warrants down round provision 99,743

Net loss (19,424,558)

Ending balance at Sep. 30, 2019 7,705,458 $ 2,302 247,685,038 (239,981,882)

Ending balance, shares at Sep. 30, 2019 23,018,235 2,133

Beginning balance at Mar. 31, 2019 14,014,084 $ 1,887 240,486,305 (226,474,108)

Beginning balance, shares at Mar. 31, 2019 18,867,464 2,139

Stock-based compensation expense 224,641 224,641

Shares issued upon exercise of common stock warrants 4,845,722 $ 415 4,845,307

Shares issued upon exercise of common stock warrants, shares 4,149,445

Shares issued upon conversion of preferred stock, shares 1,326 (6)

Warrant inducement expense 1,831,116 1,831,116

Net loss (7,816,012) (7,816,012)

Ending balance at Jun. 30, 2019 13,099,551 $ 2,302 247,387,369 (234,290,120)

Ending balance, shares at Jun. 30, 2019 23,018,235 2,133

Stock-based compensation expense 297,669 297,669

Net loss (5,691,762) (5,691,762)

Ending balance at Sep. 30, 2019 $ 7,705,458 $ 2,302 $ 247,685,038 $ (239,981,882)

Ending balance, shares at Sep. 30, 2019 23,018,235 2,133

X

- Definition
Adjustment to additional paid in capital common stock reclassification.
+ References
No definition available.
+ Details

Name: bioc_AdjustmentToAdditionalPaidInCapitalCommonStockReclassification

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Adjustment to additional paid in capital, warrant inducement expense.
+ References
No definition available.
+ Details

Name: bioc_AdjustmentToAdditionalPaidInCapitalWarrantInducementExpense

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Deemed dividend related to warrants down round provision.
+ References
No definition available.
+ Details

Name: bioc_DeemedDividendRelatedToWarrantsDownRoundProvision

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Shares issued upon conversion of preferred stock shares.
+ References
No definition available.
+ Details

Name: bioc_SharesIssuedUponConversionOfPreferredStockShares

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued upon conversion of preferred stock value.
+ References
No definition available.
+ Details

Name: bioc_SharesIssuedUponConversionOfPreferredStockValue

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of increase to additional paid-in capital (APIC) for recognition of cost for award under share-based payment arrangement.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 12
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11149-113907

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5047-113901

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 20
-Section 55
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=118258462&loc=d3e11178-113907

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 35
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=116855982&loc=d3e4534-113899
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from a stock split in which per-share par value or stated value is not changed proportionately.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockSplit

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The portion of profit or loss for the period, net of income taxes, which is attributable to the parent.
+ References
Reference 1: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1A
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669619-108580

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 942
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.9-04(22))
-URI http://asc.fasb.org/extlink&oid=116637391&loc=SL114874048-224260

Reference 3: http://www.xbrl.org/2003/role/disclosureRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section 45
-Paragraph 1B
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118930883&loc=SL7669625-108580

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 944
-SubTopic 220
-Section S99
-Paragraph 1
-Subparagraph (SX 210.7-04(18))
-URI http://asc.fasb.org/extlink&oid=116637232&loc=SL114874131-224263

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 220
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SX 210.5-03(20))
-URI http://asc.fasb.org/extlink&oid=116634182&loc=SL114868664-224227

Reference 6: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 7: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 260
-SubTopic 10
-Section 50
-Paragraph 1
-URI http://asc.fasb.org/extlink&oid=6371337&loc=d3e3550-109257
+ Details

Name: us-gaap_NetIncomeLoss

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Number of shares issued which are neither cancelled nor held in the treasury.
+ References
No definition available.
+ Details

Name: us-gaap_SharesOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of shares issued during the period as a result of the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-30)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 3
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21475-112644

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Total number of shares issued during the period, including shares forfeited, as a result of Restricted Stock Awards.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
The gross value of stock issued during the period upon the conversion of convertible securities.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02.29-31)
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueConversionOfConvertibleSecurities

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Equity impact of the value of new stock issued during the period. Includes shares issued in an initial public offering or a secondary public offering.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Aggregate value of stock related to Restricted Stock Awards issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodValueRestrictedStockAwardGross

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Total of all stockholders' equity (deficit) items, net of receivables from officers, directors, owners, and affiliates of the entity which are attributable to the parent. The amount of the economic entity's stockholders' equity attributable to the parent excludes the amount of stockholders' equity which is allocable to that ownership interest in subsidiary equity which is not attributable to the parent (noncontrolling interest, minority interest). This excludes temporary equity and is sometimes called permanent equity.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 310
-SubTopic 10
-Section S99
-Paragraph 2
-Subparagraph (SAB Topic 4.E)
-URI http://asc.fasb.org/extlink&oid=27010918&loc=d3e74512-122707

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(31))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(30))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockholdersEquity

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

XML 67 R52.htm IDEA: XBRL DOCUMENT v3.19.3

Common Stock Warrants Outstanding - Equity-Classified Common Stock Warrants, Outstanding (Detail) - $ / shares
9 Months Ended

Sep. 30, 2019

Mar. 19, 2019

Feb. 28, 2019

Feb. 12, 2019

Dec. 31, 2018

Aug. 13, 2018

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 1.25 $ 1.20 $ 1.20 $ 4.53

Warrant [Member]

Class Of Warrant Or Right [Line Items]

Total Shares Outstanding 15,197,249 4,694,927

Weighted Average Exercise Price 1.24 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 1.24

Total Shares Outstanding 11,601,949

Weighted Average Contractual Life (in years) 4 years 8 months 12 days

Weighted Average Exercise Price 4.21 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 4.21

Total Shares Outstanding 3,311,578

Weighted Average Contractual Life (in years) 3 years 10 months 24 days

Weighted Average Exercise Price 25.50 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 25.50

Total Shares Outstanding 8,208

Weighted Average Contractual Life (in years) 3 years 2 months 12 days

Weighted Average Exercise Price 33.00 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 33.00

Total Shares Outstanding 96,999

Weighted Average Contractual Life (in years) 2 years 1 month 6 days

Weighted Average Exercise Price 45.00 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 45.00

Total Shares Outstanding 47,821

Weighted Average Contractual Life (in years) 2 years 10 months 24 days

Weighted Average Exercise Price 75.00 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 75.00

Total Shares Outstanding 71,995

Weighted Average Contractual Life (in years) 3 years

Weighted Average Exercise Price 117.00 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 117.00

Total Shares Outstanding 38,772

Weighted Average Contractual Life (in years) 1 year 7 months 6 days

Weighted Average Exercise Price 140.00 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 140.00

Total Shares Outstanding 19,339

Weighted Average Contractual Life (in years) 4 months 24 days

Weighted Average Exercise Price 424.80 [Member] | Warrant [Member]

Class Of Warrant Or Right [Line Items]

Weighted Average Exercise Price $ 424.80

Total Shares Outstanding 588

Weighted Average Contractual Life (in years) 4 years 7 months 6 days

X

- Definition
Class of warrant or right outstanding weighted average remaining contractual terms.
+ References
No definition available.
+ Details

Name: bioc_ClassOfWarrantOrRightOutstandingWeightedAverageRemainingContractualTerms

Namespace Prefix: bioc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightOutstanding

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceOneMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceTwoMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceThreeMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WeightedAverageExercisePriceFourMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceFiveMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceSixMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceSevenMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceEightMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_WarrantsWithExercisePriceNineMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 68 R56.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Feb. 29, 2016

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Loss Contingencies [Line Items]

Unconditional purchase commitment aggregate amount $ 1,062,500 $ 154,000 $ 154,000

Unconditional purchase commitment payment terms Quarterly

Unconditional purchase commitment period May 31, 2020

Total expense for sales tax and maintenance obligations 35,000 $ 25,000 $ 82,000 $ 75,000

Total amounts for future sales tax and maintenance obligations 306,426 306,426

Accrued Other Liabilities [Member]

Loss Contingencies [Line Items]

Sales tax and maintenance obligations incurred but not paid $ 71,000 $ 71,000 $ 69,000

Minimum [Member]

Loss Contingencies [Line Items]

Unconditional purchase commitment, quarterly payment amount $ 62,500

X

- Definition
Finance leases maintenance and sales tax obligation payments due.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDue

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Finance leases maintenance and sales tax obligation payments due current.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeasesMaintenanceAndSalesTaxObligationPaymentsDueCurrent

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Finance leases, sales tax and maintenance obligations expense.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeasesSalesTaxAndMaintenanceObligationsExpense

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Unconditional purchase commitment frequency of periodic payment.
+ References
No definition available.
+ Details

Name: bioc_UnconditionalPurchaseCommitmentFrequencyOfPeriodicPayment

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Unconditional purchase commitment quarterly payment amount.
+ References
No definition available.
+ Details

Name: bioc_UnconditionalPurchaseCommitmentQuarterlyPaymentAmount

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_LossContingenciesLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Amount of the unrecorded obligation to transfer funds in the future for fixed or minimum amounts or quantities of goods or services at fixed or minimum prices (for example, as in take-or-pay contracts or throughput contracts).
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationBalanceSheetAmount

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
End date of the unrecognized unconditional purchase obligation, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-SubTopic 10
-Section 50
-Paragraph 4
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=77896938&loc=d3e25336-109308
+ Details

Name: us-gaap_UnrecordedUnconditionalPurchaseObligationDate

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_BalanceSheetLocationAxis=bioc_AccruedOtherLiabilitiesMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 69 R10.htm IDEA: XBRL DOCUMENT v3.19.3

Sales of Equity Securities
9 Months Ended

Sep. 30, 2019

Equity [Abstract]

Sales of Equity Securities
3. Sales of Equity Securities

On January 30, 2018, the Company received net cash proceeds of approximately $13.3 million from the closing of a follow-on public offering of 1,095,153 shares of its common stock and warrants to purchase up to an aggregate of 1,095,153 shares of its common stock at a combined offering price of $13.50 per unit, with $1.4 million of costs directly associated with the offering recorded as an offset to additional paid-in capital under applicable accounting guidance. The warrants sold in this offering have an exercise price of $1.20 per share, which is subject to down round adjustment, are exercisable immediately and expire five years from the date of issuance. The aggregate estimated grant date fair value of $9.7 million was recorded as an offset to additional paid-in-capital upon the closing of this offering (see Note 4).

In May 2018, the SEC declared effective a shelf registration statement filed by the Company, which expires in May 2021. The shelf registration statement allows the Company to issue any combination of our common stock, preferred stock, debt securities and warrants from time to time for an aggregate initial offering price of up to $50 million, subject to certain limitations for so long as our public float is less than $75 million.

On August 13, 2018, the Company completed a rights offering. Pursuant to the rights offering, the Company sold an aggregate of 11,587 units consisting of an aggregate of 11,587 shares of Series A Preferred Stock and 2,549,140 warrants, with each warrant exercisable for one share of our common stock at an exercise price of $4.53 per share, resulting in net proceeds to the Company of approximately $10.1 million, after deducting expenses relating to the rights offering, including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. Each share of Series A Preferred Stock will be convertible, at the Company’s option at any time on or after the first anniversary of the closing of the Rights Offering or at the option of the holder at any time, into the number of shares of the Company’s common stock, par value $0.0001 per share determined by dividing the $1,000 stated value per share of the Series A Preferred Stock by a conversion price of $4.53 per share. In addition, the conversion price per share is subject to adjustment for stock dividends, distributions, subdivisions, combinations or reclassifications. Holders of Series A Preferred Stock shall be entitled to receive dividends (on an as-if-converted-to-common-stock basis) in the same form as dividends actually paid on shares of the common stock when, as and if such dividends are paid on shares of common stock. The Series A Preferred Stock have no voting rights. Upon the Company’s liquidation, dissolution or winding-up, whether voluntary or involuntary, holders of Series A Preferred Stock will be entitled to receive out of the assets, whether capital or surplus, of the Company the same amount that a holder of common stock would receive if the Series A Preferred Stock were fully converted (disregarding for such purpose any conversion limitations thereunder) to common stock, which amounts shall be paid pari passu with all holders of common stock. The Company is not obligated to redeem or repurchase any shares of Series A Preferred Stock.

On September 20, 2018, the Company completed an offering of 642,438 shares of the Company’s common stock and pre-funded warrants to purchase up to an aggregate of 120,000 shares of its common stock. The shares were sold at a purchase price of $3.285 per share and the pre-funded warrants were sold at a purchase price of $3.275 per pre-funded warrant which represents the per share purchase price for the shares less the $0.01 per share exercise price for each such pre-funded warrant. The net proceeds to the Company from this offering were approximately $2.2 million, after deducting expenses related to the offering including dealer-manager fees and expenses, and excluding any proceeds received upon exercise of any warrants. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share and pre-funded warrant purchased for cash in the offering. All warrants issued in this offering have an exercise price of $3.16 per share, are exercisable upon the six-month anniversary of issuance and expire five years from such date.

On January 18, 2019, the Company completed an offering of 990,000 shares of the Company’s common stock. The shares were sold at a purchase price of $2.25 per share and the net proceeds to the Company from this offering were approximately $2.0 million, after deducting expenses related to the offering including dealer-manager fees and expenses.

On February 12, 2019, the Company received net cash proceeds of approximately $6.6 million as a result of the closing of a follow-on public offering of 6,250,000 shares of its common stock and warrants to purchase up to an aggregate of 6,250,000 shares of its common stock at a combined offering price of $1.20 per unit. All warrants sold in this offering have an exercise price of $1.20 per share, are exercisable immediately and expire five years from the date of issuance. In addition, the Company sold warrants to purchase up to an aggregate of 937,500 shares of the Company’s common stock in connection with the partial exercise of the over-allotment option granted to the underwriters. Upon closing of the transaction, warrants to purchase 915,000 shares were issued pursuant to the placement agents’ partial exercise of their overallotment. Subsequent to the closing of this offering, no additional cash proceeds have been received from the exercise of warrants sold in this offering. On March 11, 2019, the underwriters exercised their overallotment option for 538,867 shares of the Company’s common stock related to the February 12, 2019 follow-on offering, purchasing shares at $1.20 per share for net cash proceeds of approximately $592,000.

Pursuant to the down round adjustment feature of the January 2018 warrants, the exercise price of these warrants was adjusted to the $1.20 price per share offering price in the February 2019 financing transaction.

On March 19, 2019, the Company received net cash proceeds of approximately $7.5 million as a result of completing a registered direct offering of 5,950,000 shares at a negotiated purchase price of $1.37 per share. In addition, in a concurrent private placement, the Company issued to purchasers a warrant to purchase one share of the Company’s common stock for each share purchased for cash in the offering. All warrants issued in this offering have an exercise price of $1.25 per share, are exercisable immediately upon issuance and expire 5.5 years following the date of issuance.

In May 2019, the Company received cash proceeds of approximately $2.5 million from the exercise of 2,086,479 February 2019 warrants at $1.20 per share.

On May 28, 2019, the Company entered into Warrant Exercise Agreements, or the Exercise Agreements, with certain of the holders of its existing warrants, or the Exercising Holders. Pursuant to the Exercise Agreements, the Exercising Holders and the Company agreed that, subject to any applicable beneficial ownership limitations, the Exercising Holders would cash exercise up to 20% of their Existing Warrants, or the Investor Warrants, into shares of common stock underlying such Existing Warrants, or the Exercised Shares. In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date. The New Warrants have an exercise price per share of $1.31. A total of 2,062,966 Investor Warrants were exercised contemporaneously with the execution of the Exercise Agreements resulting in total proceeds to the Company of $2.3 million, net of investment banking fees. The warrants issued in connection with the Exercise Agreement were considered inducement warrants and are classified in equity. The fair value of the warrants issued was approximately $1.8 million (see valuation assumptions in Note 4). The fair value of the inducement warrants of $1.8 million was expensed as warrant inducement expense in the accompanying consolidated statements of operations for the nine months ended September 30, 2019.

On July 15, 2019, the Company entered into amendments (the “Amendments”) to the Exercise Agreements. Pursuant to the Amendments, the period during which the Exercising Holders may elect to exercise for cash the Existing Warrants in exchange for new warrants to purchase common stock to be issued in an amount equal to 75% of the number of shares of common stock exercised under the Existing Warrants was extended from July 15, 2019 to July 31, 2019. There were no additional warrants exercised under the Amendments during the second or third quarter of 2019.

X

- Definition
Sales of equity securities.
+ References
No definition available.
+ Details

Name: bioc_SalesOfEquitySecuritiesDisclosureTextBlock

Namespace Prefix: bioc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_EquityAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 70 R14.htm IDEA: XBRL DOCUMENT v3.19.3

Leases
9 Months Ended

Sep. 30, 2019

Leases [Abstract]

Leases
7. Leases

Effective January 1, 2019, the Company adopted US GAAP accounting rules in ASC Topic 842, Leases (ASC 842), using the modified retrospective method. The Company elected to follow the package of practical expedients provided under the transition guidance within ASC 842, and accordingly, did not reassess whether any expired or existing contracts are or contain leases, did not reassess expired or existing leases, and did not reassess initial direct costs for any existing leases. Upon adoption, the Company recorded an operating lease right-of-use asset and an operating lease liability on the balance sheet. In addition, assets under equipment leases previously classified as capital leases within Property, Plant and Equipment on the Company’s balance sheet were reclassified to finance lease right-of-use assets upon adoption of the guidance. Right-of-use assets and obligations were recognized based on the present value of remaining lease payments over the lease term. As the Company’s operating lease does not provide an implicit rate, an estimated incremental borrowing rate was used based on the information available at the adoption date in determining the present value of lease payments. Operating lease expense is recognized on a straight-line basis over the lease term. Variable lease costs such as common area costs and other operating costs are expensed as incurred. Leases with an initial term of 12 months or less are not recorded on the balance sheet.

Finance Leases

The Company leases certain laboratory equipment under arrangements previously accounted for as capital leases, classified on the Company’s balance sheet as fixed assets and related lease liabilities and depreciated on a straight line basis over the lease term. Upon adoption of ASC 842, leased equipment previously classified as fixed assets totaling $1.4 million in net book value were reclassified to lease right-of-use assets in accordance with the guidance. The equipment under finance leases is depreciated on a straight-line basis over periods ranging from approximately 3 to 7 years. The total gross value of equipment capitalized under such lease arrangements was approximately $2,574,000 and $3,075,000 at December 31, 2018 and September 30, 2019, respectively. Total accumulated depreciation related to equipment under finance leases was approximately $1,135,000 and $1,500,000 at December 31, 2018 and September 30, 2019, respectively. Total depreciation expense related to equipment under finance leases during the three months ended September 30, 2018 and 2019 was approximately $115,000 and $134,000, and during the nine months ended September 30, 2018 and 2019 was approximately $271,000 and $365,000, respectively.

On January 31, 2019, the Company executed an equipment financing commitment with a third-party lender for total amount of approximately $149,000, which was funded by the lender on February 1, 2019. Under the terms of the equipment financing agreement, which was accounted for as a finance lease transaction, the principal balance plus interest for the equipment are to be repaid in full after 36 monthly installments of $5,013 totaling approximately $180,000 through February 2022.

In July 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $100,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 48 monthly installments of $2,706 totaling approximately $130,000 through May 2023.

In August 2019, an equipment financing commitment was executed with a third-party lender for total amount of approximately $245,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 36 monthly installments of $8,253 totaling approximately $297,000 through August 2022.

In September 2019, an additional equipment financing commitment was executed with a third-party lender for total additional amount of approximately $89,000, which was accounted for as a finance lease transaction with the principal balance plus interest for the equipment to be repaid in full after 60 monthly installments of $1,770 totaling approximately $106,000 through September 2024.

Operating Lease

The Company leases its primary laboratory and office facilities in San Diego, California. This lease is classified as an operating lease in accordance with the ASC 842 guidance. The average monthly cash payment for the operating lease is approximately $120,000 per month, and the lease term ends on July 31, 2020. The Company recorded a lease right-of-use asset and lease liability of $1,930,000 and $2,201,000, respectively, as of January 1, 2019, based on present value of payments and an incremental borrowing rate of 4.5%.

In addition, the Company reviews agreements at inception to determine if they include a lease, and when they do, uses its incremental borrowing rate or implicit interest rate to determine the present value of the future lease payments.

The following schedule sets forth the components of right-of-use lease assets as of December 31, 2018 and September 30, 2019 as follows:

December 31,

September 30,

2018

2019

Lease right-of-use assets:

Operating

$

—

$

1,035,210

Finance

—

1,575,039

Total

$

—

$

2,610,249

The following schedule sets forth the current portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

December 31,

September 30,

2018

2019

Current portion of lease liability:

Operating

$

—

1,193,255

Finance

—

776,030

Total

$

—

$

1,969,285

The following schedule sets forth the long-term portion of operating and finance lease liabilities as of December 31, 2018 and September 30, 2019:

December 31,

September 30,

2018

2019

Long-term portion of lease liability:

Operating

$

—

$

—

Finance

—

1,032,243

Total

$

—

$

1,032,243

The following schedule represents the components of lease expense for the three and nine months ended September 30, 2018 and 2019:

For the three months ended September 30,

For the nine months ended September 30,

2018

2019

2018

2019

Lease cost

Finance lease cost

Amortization of right-of-use assets

$

—

$

134,472

$

—

$

364,401

Interest on lease liabilities

—

62,026

—

187,574

Operating lease cost

—

318,005

—

954,015

Total

$

—

$

514,503

$

—

$

1,505,990

The following schedule sets forth the remaining future minimum lease payments outstanding under finance and operating leases, as well as corresponding remaining sales tax and maintenance obligation payments that are expensed as incurred and due within each respective year ending December 31, as well as the present value of the total amount of the remaining minimum lease payments, as of September 30, 2019:

Finance

Operating

Minimum

Maintenance and

Minimum

Lease

Sales Tax Obligation

Lease

Payments

Payments

Payments

2019 (remaining)

$

222,245

$

27,016

$

362,929

2020

764,533

89,136

855,136

2021

517,927

67,974

—

2022

405,318

57,260

—

2023

263,274

56,799

—

Thereafter

58,448

8,241

—

Total payments

2,231,745

306,426

1,218,065

Less amount representing interest

(423,472

)

—

(24,810

)

Present value of payments

$

1,808,273

$

306,426

$

1,193,255

The following schedule sets forth supplemental cash flow information related to operating and finance leases as of September 30, 2019:

For the three months ended

For the nine months ended

September 30, 2019

September 30, 2019

Other information

Operating cash flows from financing leases

$

62,026

$

187,574

Operating cash flows from operating leases

$

355,813

$

1,067,437

Financing cash flows from finance leases

$

101,139

$

378,389

The aggregate weighted average remaining lease term was 3.14 years on finance leases and 0.84 years on operating leases as of September 30, 2019. The aggregate weighted average discount rate was 20.30% on finance leases and 4.5% on operating leases as of September 30, 2019. During the nine months ended September 30, 2019, the Company added $583,000 of right of use assets in exchange for finance lease liabilities. In addition, upon adoption of the accounting guidance in ASC 842, $1.4 million of net machinery and equipment was reclassified to lease right-of-use assets related to assets under finance leases and $1.9 million of right-of-use facility lease was recorded under operating lease.

X

- Definition
Lessee, operating and finance leases.
+ References
No definition available.
+ Details

Name: bioc_LesseeOperatingAndFinanceLeasesTextBlock

Namespace Prefix: bioc_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

X

- References
No definition available.
+ Details

Name: us-gaap_LeasesAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

XML 72 R18.htm IDEA: XBRL DOCUMENT v3.19.3

Commitments and Contingencies
9 Months Ended

Sep. 30, 2019

Commitments And Contingencies Disclosure [Abstract]

Commitments and Contingencies
11. Commitments and Contingencies

In the normal course of business, the Company may be involved in legal proceedings or threatened legal proceedings. The Company is not party to any legal proceedings or aware of any threatened legal proceedings that are expected to have a material adverse effect on its financial condition, results of operations or liquidity.

In February 2016, the Company signed a firm, non-cancelable, and unconditional commitment in an aggregate amount of $1,062,500 with a vendor to purchase certain inventory items, payable in minimum quarterly amounts of $62,500 through May 2020. At September 30, 2019, a balance of approximately $154,000 remained outstanding under this purchase commitment.

During the three months ended September 30, 2018 and 2019, total expense recorded in the Company’s unaudited condensed statements of operations and comprehensive loss for sales tax and maintenance obligations associated with equipment financing arrangements was approximately $25,000 and $35,000, respectively, with approximately $75,000 and $82,000 recorded during the nine months ended September 30, 2018 and 2019, respectively. At December 31, 2018 and September 30, 2019, approximately $69,000 and $71,000, respectively, of such sales tax and maintenance obligations incurred but not paid were recorded in accrued other liabilities in the Company’s balance sheet (see Note 5). Future amounts totaling approximately $306,426 for sales tax and maintenance obligations associated with financed equipment were due under equipment financing arrangements at September 30, 2019, which will be expensed as incurred (see Note 7).

X

- References
No definition available.
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureAbstract

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
The entire disclosure for commitments and contingencies.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 450
-URI http://asc.fasb.org/topic&trid=2127136

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 440
-URI http://asc.fasb.org/topic&trid=2144648
+ Details

Name: us-gaap_CommitmentsAndContingenciesDisclosureTextBlock

Namespace Prefix: us-gaap_

Data Type: nonnum:textBlockItemType

Balance Type: na

Period Type: duration

XML 73 R37.htm IDEA: XBRL DOCUMENT v3.19.3

Balance Sheet Details - Additional Information (Detail) - USD ($)
3 Months Ended 9 Months Ended

Sep. 30, 2019

Sep. 30, 2018

Sep. 30, 2019

Sep. 30, 2018

Dec. 31, 2018

Disposal of fixed assets $ 0

Fixed assets acquired 297,877 $ 145,253

Financed equipment gross $ 2,573,955

Depreciation expense $ 240,207 $ 223,194 691,191 $ 580,366

ASC Topic 842 [Member]

Fixed assets acquired 350,000

Financed equipment gross 3,075,000 3,075,000 2,574,000

Accumulated depreciation related to financed equipment $ 1,500,000 $ 1,500,000 $ 1,135,000

X

- Definition
Finance lease lessee accumulated deprecation.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeaseLesseeAccumulatedDeprecation

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Finance leased assets gross.
+ References
No definition available.
+ Details

Name: bioc_FinanceLeasedAssetsGross

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: instant

X

- Definition
The amount of expense recognized in the current period that reflects the allocation of the cost of tangible assets over the assets' useful lives. Includes production and non-production related depreciation.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 360
-SubTopic 10
-Section 50
-Paragraph 1
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=6391035&loc=d3e2868-110229

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585
+ Details

Name: us-gaap_Depreciation

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash outflow associated with the acquisition of long-lived, physical assets that are used in the normal conduct of business to produce goods and services and not intended for resale; includes cash outflows to pay for construction of self-constructed assets.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 13
-Subparagraph (c)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3213-108585
+ Details

Name: us-gaap_PaymentsToAcquirePropertyPlantAndEquipment

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Amount of divestiture of long-lived, physical assets used in the normal conduct of business and not intended for resale. Examples include, but are not limited to, land, buildings, machinery and equipment, office equipment, furniture and fixtures, and computer equipment.
+ References
No definition available.
+ Details

Name: us-gaap_PropertyPlantAndEquipmentDisposals

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Details

Name: us-gaap_AdjustmentsForNewAccountingPronouncementsAxis=us-gaap_AccountingStandardsUpdate201602Member

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

XML 74 R33.htm IDEA: XBRL DOCUMENT v3.19.3

Sales of Equity Securities - Additional Information (Detail) - USD ($)
1 Months Ended 3 Months Ended 9 Months Ended

Jul. 15, 2019

May 30, 2019

May 28, 2019

Mar. 19, 2019

Mar. 11, 2019

Feb. 12, 2019

Jan. 18, 2019

Sep. 20, 2018

Aug. 13, 2018

Jan. 30, 2018

May 31, 2019

May 31, 2018

Sep. 30, 2019

Jun. 30, 2019

Sep. 30, 2019

Sep. 30, 2018

Feb. 28, 2019

Dec. 31, 2018

Class Of Stock [Line Items]

Net cash proceeds from sale of securities $ 7,500,000 $ 2,000,000

Stock price $ 1.37 $ 2.25 $ 3.285

Exercise price of warrants $ 1.25 $ 1.20 $ 4.53 $ 1.20

Class of warrant or rights, term 5 years 6 months 5 years 5 years

Issuance of warrants to purchase shares of common stock, grant date fair value $ 1,800,000 $ 6,000,000 $ 6,800,000 $ 2,000,000 $ 8,400,000 $ 9,700,000

Aggregate units sold under right offering 11,587

Public offering, number of shares issued 5,950,000 990,000

Warrant exercisable for share of common stock 1 1

Series A Preferred Stock convertible to common stock, conversion price $ 4.53

Net proceeds from issuance of units, net of issuance expenses $ 2,200,000 $ 10,100,000

Common stock, par value $ 0.0001 $ 0.0001 $ 0.0001 $ 0.0001

Public offering, number of common stock and warrants issued 642,438

Proceeds from exercise of common stock warrants $ 4,800,000 $ 2,513,172 $ 0

Warrant inducement expense $ 1,800,000 $ 1,800,000

Pre-funded Warrants [Member]

Class Of Stock [Line Items]

Issuance of warrants to purchase shares of common stock 120,000

Exercise price of warrants $ 3.275

Change in exercise price of warrants $ 0.01

Investor Warrants [Member]

Class Of Stock [Line Items]

Exercise price of warrants $ 1.31

Proceeds from exercise of common stock warrants $ 2,300,000

Number of warrant exercised 2,062,966 0 0

Cash exercise of warrants description In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date.

Fair value of warrants issued $ 1,800,000

Percentage of common stock exercised for exchange of new warrants 75.00%

Warrants exercisable date Jul. 31, 2019 Jul. 15, 2019

Warrant [Member]

Class Of Stock [Line Items]

Aggregate warrants sold under right offering 2,549,140

Proceeds from exercise of common stock warrants $ 2,500,000

Number of warrant exercised 2,086,479

Series A Preferred Stock [Member]

Class Of Stock [Line Items]

Public offering, number of shares issued 11,587

Preferred stock stated value per share $ 1,000

Maximum [Member]

Class Of Stock [Line Items]

Exercise price of warrants $ 1.20

Maximum [Member] | Pre-funded Warrants [Member]

Class Of Stock [Line Items]

Issuance of warrants to purchase shares of common stock 120,000

Maximum [Member] | Investor Warrants [Member]

Class Of Stock [Line Items]

Warrants exercisable percentage 20.00%

Minimum [Member]

Class Of Stock [Line Items]

Exercise price of warrants $ 1.25

Follow-on Public Offering [Member]

Class Of Stock [Line Items]

Net cash proceeds from sale of securities $ 592,000 $ 6,600,000 $ 13,300,000

Private offering, number of common stock and warrants issued 6,250,000 1,095,153

Stock price $ 1.20 $ 1.20 $ 13.50

Cost directly associated with offering $ 1,400,000

Exercise price of warrants $ 1.25 $ 1.20 $ 3.16 $ 4.53 $ 1.20

Class of warrant or rights, term 5 years 6 months 5 years 5 years 5 years 5 years

Issuance of warrants to purchase shares of common stock, grant date fair value $ 9,700,000

Public offering, number of shares issued 6,250,000

Public offering, number of common stock and warrants issued 1,095,153

Proceeds from exercise of common stock warrants $ 0 $ 0

Purchase of common stock by underwriters to cover overallotments, number of shares 538,867

Follow-on Public Offering [Member] | Maximum [Member]

Class Of Stock [Line Items]

Issuance of warrants to purchase shares of common stock 6,250,000 1,095,153

Shelf Registration Statement [Member]

Class Of Stock [Line Items]

Shelf registration statement expiration period May 31, 2021

Minimum public float limit for offering $ 75,000,000

Shelf Registration Statement [Member] | Maximum [Member]

Class Of Stock [Line Items]

Aggregate offering price $ 50,000,000

Private Placement [Member]

Class Of Stock [Line Items]

Exercise price of warrants $ 3.16

Class of warrant or rights, term 5 years

Warrant exercisable for share of common stock 1

Over-allotment Option [Member] | Warrant [Member]

Class Of Stock [Line Items]

Public offering, number of shares issued 915,000

Over-allotment Option [Member] | Maximum [Member]

Class Of Stock [Line Items]

Issuance of warrants to purchase shares of common stock 937,500

X

- Definition
Aggregate number of units sold pursuant to right offering.
+ References
No definition available.
+ Details

Name: bioc_AggregateNumberOfUnitsSoldPursuantToRightOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate number of warrants issued pursuant to right offering.
+ References
No definition available.
+ Details

Name: bioc_AggregateNumberOfWarrantsIssuedPursuantToRightOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Aggregate offering price.
+ References
No definition available.
+ Details

Name: bioc_AggregateOfferingPrice

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Cash exercise of warrants description.
+ References
No definition available.
+ Details

Name: bioc_CashExerciseOfWarrantsDescription

Namespace Prefix: bioc_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Class of warrant or right, exercise price of warrants or rights change in exercise price.
+ References
No definition available.
+ Details

Name: bioc_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRightsChangeInExercisePrice

Namespace Prefix: bioc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Class of warrant or rights, term.
+ References
No definition available.
+ Details

Name: bioc_ClassOfWarrantOrRightsTerm

Namespace Prefix: bioc_

Data Type: xbrli:durationItemType

Balance Type: na

Period Type: duration

X

- Definition
Conversion of preferred stock to common stock conversion price.
+ References
No definition available.
+ Details

Name: bioc_ConversionOfPreferredStockToCommonStockConversionPrice

Namespace Prefix: bioc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Percentage of common stock exercised for exchange of warrants.
+ References
No definition available.
+ Details

Name: bioc_PercentageOfCommonStockExercisedForExchangeOfWarrants

Namespace Prefix: bioc_

Data Type: num:percentItemType

Balance Type: na

Period Type: duration

X

- Definition
Preferred stock stated value per share.
+ References
No definition available.
+ Details

Name: bioc_PreferredStockStatedValuePerShare

Namespace Prefix: bioc_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Proceeds from issuance of common stock net of issuance costs.
+ References
No definition available.
+ Details

Name: bioc_ProceedsFromIssuanceOfCommonStockNetOfIssuanceCosts

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Proceeds from issuance of units net of issuance expenses related to rights offering.
+ References
No definition available.
+ Details

Name: bioc_ProceedsFromIssuanceOfUnitsNetOfIssuanceExpensesRelatedToRightsOffering

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Public float, minimum limit for offering.
+ References
No definition available.
+ Details

Name: bioc_PublicFloatMinimumLimitForOffering

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: instant

X

- Definition
Shares available for private offering.
+ References
No definition available.
+ Details

Name: bioc_SharesAvailableForPrivateOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares available for public offering.
+ References
No definition available.
+ Details

Name: bioc_SharesAvailableForPublicOffering

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Shares issued to underwriters under over allotment options.
+ References
No definition available.
+ Details

Name: bioc_SharesIssuedToUnderwritersUnderOverAllotmentOptions

Namespace Prefix: bioc_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Shelf registration statement expiration period.
+ References
No definition available.
+ Details

Name: bioc_ShelfRegistrationStatementExpirationPeriod

Namespace Prefix: bioc_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Unregistered warrants issued grant date fair value.
+ References
No definition available.
+ Details

Name: bioc_UnregisteredWarrantsIssuedGrantDateFairValue

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: credit

Period Type: duration

X

- Definition
Warrant inducement expense.
+ References
No definition available.
+ Details

Name: bioc_WarrantInducementExpense

Namespace Prefix: bioc_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Warrants exercisable percentage.
+ References
No definition available.
+ Details

Name: bioc_WarrantsExercisablePercentage

Namespace Prefix: bioc_

Data Type: num:percentItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of decrease in additional paid in capital (APIC) resulting from direct costs associated with issuing stock. Includes, but is not limited to, legal and accounting fees and direct costs associated with stock issues under a shelf registration.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770
+ Details

Name: us-gaap_AdjustmentsToAdditionalPaidInCapitalStockIssuedIssuanceCosts

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Line items represent financial concepts included in a table. These concepts are used to disclose reportable information associated with domain members defined in one or many axes to the table.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfStockLineItems

Namespace Prefix: us-gaap_

Data Type: xbrli:stringItemType

Balance Type: na

Period Type: duration

X

- Definition
Date the warrants or rights are exercisable, in CCYY-MM-DD format.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(3))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRighstDateFromWhichWarrantsOrRightsExercisable

Namespace Prefix: us-gaap_

Data Type: xbrli:dateItemType

Balance Type: na

Period Type: duration

X

- Definition
Exercise price per share or per unit of warrants or rights outstanding.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(4))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightExercisePriceOfWarrantsOrRights1

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which each warrant or right may be converted. For example, but not limited to, each warrant may be converted into two shares.
+ References
No definition available.
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByEachWarrantOrRight

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of securities into which the class of warrant or right may be converted. For example, but not limited to, 500,000 warrants may be converted into 1,000,000 shares.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 235
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.4-08.(i)(2))
-URI http://asc.fasb.org/extlink&oid=26873400&loc=d3e23780-122690
+ Details

Name: us-gaap_ClassOfWarrantOrRightNumberOfSecuritiesCalledByWarrantsOrRights

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: instant

X

- Definition
Face amount or stated value per share of common stock.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_CommonStockParOrStatedValuePerShare

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Amount of expense (income) related to adjustment to fair value of warrant liability.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 28
-Subparagraph (b)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3602-108585

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 480
-SubTopic 10
-Section 25
-Paragraph 13
-URI http://asc.fasb.org/extlink&oid=109262497&loc=d3e20148-110875
+ Details

Name: us-gaap_FairValueAdjustmentOfWarrants

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
The cash inflow associated with the amount received from holders exercising their stock warrants.
+ References
Reference 1: http://www.xbrl.org/2009/role/commonPracticeRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 230
-SubTopic 10
-Section 45
-Paragraph 14
-Subparagraph (a)
-URI http://asc.fasb.org/extlink&oid=118932676&loc=d3e3255-108585
+ Details

Name: us-gaap_ProceedsFromWarrantExercises

Namespace Prefix: us-gaap_

Data Type: xbrli:monetaryItemType

Balance Type: debit

Period Type: duration

X

- Definition
Price of a single share of a number of saleable stocks of a company.
+ References
No definition available.
+ Details

Name: us-gaap_SharePrice

Namespace Prefix: us-gaap_

Data Type: num:perShareItemType

Balance Type: na

Period Type: instant

X

- Definition
Number of new stock issued during the period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesNewIssues

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Definition
Number of share options (or share units) exercised during the current period.
+ References
Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 718
-SubTopic 10
-Section 50
-Paragraph 2
-Subparagraph (c)(1)(iv)(2)
-URI http://asc.fasb.org/extlink&oid=116856206&loc=d3e5070-113901

Reference 2: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.3-04)
-URI http://asc.fasb.org/extlink&oid=27012166&loc=d3e187085-122770

Reference 3: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(28))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 4: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 210
-SubTopic 10
-Section S99
-Paragraph 1
-Subparagraph (SX 210.5-02(29))
-URI http://asc.fasb.org/extlink&oid=6877327&loc=d3e13212-122682

Reference 5: http://fasb.org/us-gaap/role/ref/legacyRef
-Publisher FASB
-Name Accounting Standards Codification
-Topic 505
-SubTopic 10
-Section 50
-Paragraph 2
-URI http://asc.fasb.org/extlink&oid=109259400&loc=d3e21463-112644
+ Details

Name: us-gaap_StockIssuedDuringPeriodSharesStockOptionsExercised

Namespace Prefix: us-gaap_

Data Type: xbrli:sharesItemType

Balance Type: na

Period Type: duration

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_PrefundedWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_ClassOfWarrantOrRightAxis=bioc_InvestorWarrantsMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementEquityComponentsAxis=us-gaap_WarrantMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_StatementClassOfStockAxis=us-gaap_SeriesAPreferredStockMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MaximumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: srt_RangeAxis=srt_MinimumMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=bioc_FollowOnPublicOfferingMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=bioc_ShelfRegistrationStatementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_PrivatePlacementMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

X

- Details

Name: us-gaap_SubsidiarySaleOfStockAxis=us-gaap_OverAllotmentOptionMember

Namespace Prefix:

Data Type: na

Balance Type:

Period Type:

Balance Sheet Details - Schedule of Fixed Assets and Accrued Liabilities (Detail) - USD ($)	Sep. 30, 2019	Dec. 31, 2018
Fixed Assets
Machinery and equipment	$ 2,845,053	$ 2,818,583
Furniture and office equipment	156,987	157,391
Computer equipment and software	1,552,981	1,437,408
Leasehold improvements	570,174	570,173
Financed equipment		2,573,955
Construction in process	325,550	116,640
Total fixed assets, gross	5,450,745	7,674,150
Less accumulated depreciation and amortization	(4,125,490)	(4,934,728)
Total fixed assets, net	1,325,255	2,739,422
Accrued Liabilities
Accrued payroll	458,750	255,426
Accrued vacation	566,811	535,682
Accrued bonuses	636,167	712,574
Accrued sales commissions	81,101	62,767
Current portion of deferred rent		158,342
Accrued other	104,155	203,602
Total accrued liabilities	$ 1,846,984	$ 1,928,393

Liquidity and Going Concern Uncertainty- Additional Information (Detail) - USD ($)								1 Months Ended			3 Months Ended						9 Months Ended		12 Months Ended
	Mar. 19, 2019	Mar. 11, 2019	Feb. 12, 2019	Jan. 18, 2019	Sep. 20, 2018	Aug. 13, 2018	Jan. 30, 2018	May 31, 2019	May 31, 2018	Feb. 29, 2016	Sep. 30, 2019	Jun. 30, 2019	Mar. 31, 2019	Sep. 30, 2018	Jun. 30, 2018	Mar. 31, 2018	Sep. 30, 2019	Sep. 30, 2018	Dec. 31, 2018	Feb. 28, 2019
Liquidity And Managements Plans [Line Items]
Cash											$ 6,539,444						$ 6,539,444		$ 3,423,373
Accumulated deficit											(239,981,882)						(239,981,882)		(220,457,578)
Net loss											(5,691,762)	$ (7,816,012)	$ (5,916,787)	$ (6,047,784)	$ (6,153,101)	$ (6,357,143)	(19,424,558)	$ (18,558,028)	$ (24,600,000)
Aggregate net interest-bearing indebtedness											1,900,000						1,900,000
Aggregate net interest-bearing indebtedness due within one year											909,000						909,000
Other non-interest bearing current liabilities											3,000,000						3,000,000
Unconditional purchase commitment aggregate amount										$ 1,062,500	$ 154,000						$ 154,000
Unconditional purchase commitment payment terms																	Quarterly
Unconditional purchase commitment period																	May 31, 2020
Proceeds from issuance of common stock, net of issuance costs	$ 7,500,000			$ 2,000,000
Proceeds from exercise of common stock warrants								$ 4,800,000									$ 2,513,172	$ 0
Public offering, number of common stock and warrants issued					642,438
Stock price	$ 1.37			$ 2.25	$ 3.285
Exercise price of unregistered warrants	$ 1.25		$ 1.20			$ 4.53														$ 1.20
Aggregate units sold under right offering						11,587
Shares issued in offering	5,950,000			990,000
Warrant exercisable for share of common stock	1					1
Net proceeds from issuance of units, net of issuance expenses					$ 2,200,000	$ 10,100,000
Class of warrant or rights, term	5 years 6 months					5 years	5 years
Proceeds from warrant exercise inducement, net																	$ 2,337,298
Pre-funded Warrants [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock					120,000
Exercise price of unregistered warrants					$ 3.275
Change in exercise price of warrants					0.01
May 2019 Warrant Exercise Inducement Offering [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from warrant exercise inducement, net								2,300,000
Other Warrant Exercises [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants								2,500,000
Warrant [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from exercise of common stock warrants								$ 2,500,000
Aggregate warrants sold under right offering						2,549,140
Common Stock [Member]
Liquidity And Managements Plans [Line Items]
Preferred Stock convertible into common stock												4,149,445	5,985
Common Stock [Member] \| Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock								4,200,000
Series A Preferred Stock [Member]
Liquidity And Managements Plans [Line Items]
Shares issued in offering						11,587
Preferred Stock convertible into common stock						471,393
Follow-on Public Offering [Member]
Liquidity And Managements Plans [Line Items]
Proceeds from issuance of common stock, net of issuance costs		$ 592,000	$ 6,600,000				$ 13,300,000
Proceeds from exercise of common stock warrants			$ 0				0
Proceeds from gross exercise of common stock warrants outstanding							$ 1,300,000
Exercisable warrant available price per share							$ 1.20
Exercisable warrant available price per share expiration period							2023-01
Public offering, number of common stock and warrants issued							1,095,153
Stock price		$ 1.20	$ 1.20				$ 13.50
Exercise price of unregistered warrants	$ 1.25		$ 1.20		$ 3.16	$ 4.53	$ 1.20
Shares issued in offering			6,250,000
Class of warrant or rights, term	5 years 6 months		5 years		5 years	5 years	5 years
Purchase of common stock by underwriters to cover overallotments, number of shares		538,867
Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Shelf registration statement expiration period									May 31, 2021
Minimum public float limit for offering									$ 75,000,000
Private Placement [Member]
Liquidity And Managements Plans [Line Items]
Exercise price of unregistered warrants					$ 3.16
Warrant exercisable for share of common stock					1
Class of warrant or rights, term					5 years
Over-allotment Option [Member] \| Warrant [Member]
Liquidity And Managements Plans [Line Items]
Shares issued in offering			915,000
Minimum [Member]
Liquidity And Managements Plans [Line Items]
Unconditional purchase commitment, quarterly payment amount										$ 62,500
Exercise price of unregistered warrants								$ 1.25
Minimum [Member] \| Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]
Liquidity And Managements Plans [Line Items]
Exercise price of unregistered warrants								1.20
Maximum [Member]
Liquidity And Managements Plans [Line Items]
Exercise price of unregistered warrants								1.20
Maximum [Member] \| Pre-funded Warrants [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock					120,000
Maximum [Member] \| Warrant Exercise Inducement Offering and Other Warrant Exercises [Member]
Liquidity And Managements Plans [Line Items]
Exercise price of unregistered warrants								$ 1.25
Maximum [Member] \| Follow-on Public Offering [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock			6,250,000				1,095,153
Maximum [Member] \| Shelf Registration Statement [Member]
Liquidity And Managements Plans [Line Items]
Aggregate offering price									$ 50,000,000
Maximum [Member] \| Over-allotment Option [Member]
Liquidity And Managements Plans [Line Items]
Issuance of warrants to purchase shares of common stock			937,500

Stock-Based Compensation - Additional Information (Detail)			3 Months Ended		9 Months Ended
	Jun. 17, 2019 shares	Jun. 28, 2018 shares	Sep. 30, 2019 USD ($) shares	Sep. 30, 2018	Sep. 30, 2019 USD ($) Plan shares	Sep. 30, 2018	Apr. 30, 2019 shares	Dec. 31, 2018 USD ($) shares
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Number of equity incentive plans \| Plan					2
Total Shares Outstanding			2,797,656		2,797,656			195,820
Unrecognized share-based compensation expense, weighted-average recognition period					3 years 2 months 12 days
Minimum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate			0.00%	0.00%	0.00%	0.00%
Maximum [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Estimated forfeitures rate			8.00%	8.00%	8.00%	8.00%
Stock Options [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value of options outstanding \| $			$ 0		$ 0			$ 0
Intrinsic value of options exercisable \| $			0		0			0
Intrinsic value of options vested and unvested expected to vest \| $			0		0			$ 0
RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Intrinsic value shares, RSUs outstanding \| $			400		400
Intrinsic value amount, RSUs unvested and vested expected to vest \| $			$ 400		$ 400
RSUs outstanding			360		360			360
Stock Options and RSUs [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Unrecognized share-based compensation expense, stock options \| $			$ 2,545,000		$ 2,545,000
2013 Equity Incentive Plan [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			124,211		124,211
Common stock, shares authorized							2,578,229
2013 Equity Incentive Plan [Member] \| Non-inducement Shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			3,064,098		3,064,098
Increase in number of shares of common stock authorized for issuance	2,800,000	146,666
Stock options and RSUs issued					2,711,095
Total Shares Outstanding			2,650,970		2,650,970
Common stock, shares authorized			353,003		353,003
2013 Equity Incentive Plan [Member] \| Inducement shares [Member]
Share Based Compensation Arrangement By Share Based Payment Award [Line Items]
Total stock options and RSUs authorized			118,368		118,368
Stock options and RSUs issued					117,534
Total Shares Outstanding			118,368		118,368
Common stock, shares authorized			0		0

Leases - Schedule of Long-Term Portion of Operating and Finance Lease Liabilities (Detail)	Sep. 30, 2019 USD ($)
Long-term portion of lease liability:
Finance	$ 1,032,243
Total	$ 1,032,243

Leases - Schedule of Lease Expense (Detail) - USD ($)	3 Months Ended	9 Months Ended
Leases - Schedule of Lease Expense (Detail) - USD ($)	Sep. 30, 2019	Sep. 30, 2019
Finance lease cost
Amortization of right-of-use assets	$ 134,472	$ 364,401
Interest on lease liabilities	62,026	187,574
Operating lease cost	318,005	954,015
Total	$ 514,503	$ 1,505,990

Document and Entity Information - shares	9 Months Ended
Document and Entity Information - shares	Sep. 30, 2019	Nov. 08, 2019
Cover [Abstract]
Document Type	10-Q
Amendment Flag	false
Document Period End Date	Sep. 30, 2019
Document Fiscal Year Focus	2019
Document Fiscal Period Focus	Q3
Trading Symbol	BIOC
Entity Registrant Name	BIOCEPT INC
Entity Central Index Key	0001044378
Current Fiscal Year End Date	--12-31
Entity Filer Category	Non-accelerated Filer
Entity Small Business	true
Entity Emerging Growth Company	true
Entity Ex Transition Period	true
Entity Common Stock, Shares Outstanding		23,018,235
Document Quarterly Report	true
Document Transition Report	false
Entity File Number	001-36284
Entity Incorporation, State or Country Code	DE
Entity Tax Identification Number	80-0943522
Entity Address, Address Line One	5810 Nancy Ridge Drive
Entity Address, City or Town	San Diego
Entity Address, State or Province	CA
Entity Address, Postal Zip Code	92121
City Area Code	858
Local Phone Number	320-8200
Title of 12(b) Security	Common Stock, par value $.0001 per share
Security Exchange Name	NASDAQ
Entity Shell Company	false
Entity Current Reporting Status	Yes
Entity Interactive Data Current	Yes

Condensed Statements of Shareholders' Equity - USD ($)	Total	August 2018 Rights Offering [Member]	September 2018 Registered Direct Offering [Member]	January 2019 Financing Transaction [Member]	February 2019 Financing Transaction [Member]	January 2019 Financing Transaction Overallotment [Member]	March 2019 Financing Transaction [Member]	January 2018 financing transaction [Member]	Common Stock [Member]	Common Stock [Member] September 2018 Registered Direct Offering [Member]	Common Stock [Member] January 2019 Financing Transaction [Member]	Common Stock [Member] February 2019 Financing Transaction [Member]	Common Stock [Member] January 2019 Financing Transaction Overallotment [Member]	Common Stock [Member] March 2019 Financing Transaction [Member]	Common Stock [Member] January 2018 financing transaction [Member]	SeriesA Convertible Preferred Stock [Member]	SeriesA Convertible Preferred Stock [Member] August 2018 Rights Offering [Member]	Additional Paid-in Capital [Member]	Additional Paid-in Capital [Member] August 2018 Rights Offering [Member]	Additional Paid-in Capital [Member] September 2018 Registered Direct Offering [Member]	Additional Paid-in Capital [Member] January 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member] February 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member] January 2019 Financing Transaction Overallotment [Member]	Additional Paid-in Capital [Member] March 2019 Financing Transaction [Member]	Additional Paid-in Capital [Member] January 2018 financing transaction [Member]	Accumulated Deficit [Member]
Beginning balance at Dec. 31, 2017	$ 1,296,034								$ 118									$ 196,545,523								$ (195,249,607)
Beginning balance, shares at Dec. 31, 2017									1,181,179
Stock-based compensation expense	225,263																	225,263
Shares and warrants issued, net of issuance costs								$ 13,342,821							$ 110										$ 13,342,711
Shares and warrants issued, net of issuance costs, shares															1,095,153
Adjustment for presentation after reverse stock split									$ 6,576									(6,576)
Net loss	(6,357,143)																									(6,357,143)
Ending balance at Mar. 31, 2018	8,506,975								$ 6,804									210,106,921								(201,606,750)
Ending balance, shares at Mar. 31, 2018									2,276,332
Beginning balance at Dec. 31, 2017	1,296,034								$ 118									196,545,523								(195,249,607)
Beginning balance, shares at Dec. 31, 2017									1,181,179
Deemed dividends related warrants down round provision	636,370
Net loss	(18,558,028)
Ending balance at Sep. 30, 2018	8,938,408								$ 394							$ 1		223,382,018								(214,444,005)
Ending balance, shares at Sep. 30, 2018									3,937,226							7,005
Beginning balance at Dec. 31, 2017	1,296,034								$ 118									196,545,523								(195,249,607)
Beginning balance, shares at Dec. 31, 2017									1,181,179
Net loss	(24,600,000)
Ending balance at Dec. 31, 2018	3,042,519								$ 463									223,499,634								(220,457,578)
Ending balance, shares at Dec. 31, 2018									4,629,174							4,417
Beginning balance at Mar. 31, 2018	8,506,975								$ 6,804									210,106,921								(201,606,750)
Beginning balance, shares at Mar. 31, 2018									2,276,332
Stock-based compensation expense	173,694																	173,694
Shares issued for restricted stock units									$ 19									(19)
Shares issued for restricted stock units, shares									5,834
Net loss	(6,153,101)																									(6,153,101)
Ending balance at Jun. 30, 2018	2,527,568								$ 6,823									210,280,596								(207,759,851)
Ending balance, shares at Jun. 30, 2018									2,282,166
Stock-based compensation expense	113,072																	113,072
Shares and warrants issued, net of issuance costs		$ 10,097,878	$ 2,247,674							$ 64							$ 1		$ 10,097,877	$ 2,247,610
Shares and warrants issued, net of issuance costs, shares										642,438							11,587
Deemed dividends related warrants down round provision	636,370																	636,370								(636,370)
Shares issued upon conversion of preferred stock									$ 101									(101)
Shares issued upon conversion of preferred stock, shares									1,012,622							(4,582)
Common stock reclassification									$ (6,594)									6,594
Net loss	(6,047,784)																									(6,047,784)
Ending balance at Sep. 30, 2018	8,938,408								$ 394							$ 1		223,382,018								(214,444,005)
Ending balance, shares at Sep. 30, 2018									3,937,226							7,005
Beginning balance at Dec. 31, 2018	3,042,519								$ 463									223,499,634								(220,457,578)
Beginning balance, shares at Dec. 31, 2018									4,629,174							4,417
Stock-based compensation expense	102,459																	102,459
Shares issued upon exercise of common stock warrants	4,748								$ 1									4,747
Shares issued upon exercise of common stock warrants, shares									5,985
Shares and warrants issued, net of issuance costs				$ 2,032,311	$ 6,602,735	$ 592,306	$ 7,553,793				$ 99	$ 625	$ 54	$ 595							$ 2,032,212	$ 6,602,110	$ 592,252	$ 7,553,198
Shares and warrants issued, net of issuance costs, shares											990,000	6,250,000	538,867	5,950,000
Deemed dividends related warrants down round provision																		99,743								(99,743)
Shares issued upon conversion of preferred stock									$ 50									(50)
Shares issued upon conversion of preferred stock, shares									503,438							(2,278)
Net loss	(5,916,787)																									(5,916,787)
Ending balance at Mar. 31, 2019	14,014,084								$ 1,887									240,486,305								(226,474,108)
Ending balance, shares at Mar. 31, 2019									18,867,464							2,139
Beginning balance at Dec. 31, 2018	3,042,519								$ 463									223,499,634								(220,457,578)
Beginning balance, shares at Dec. 31, 2018									4,629,174							4,417
Deemed dividends related warrants down round provision	99,743
Net loss	(19,424,558)
Ending balance at Sep. 30, 2019	7,705,458								$ 2,302									247,685,038								(239,981,882)
Ending balance, shares at Sep. 30, 2019									23,018,235							2,133
Beginning balance at Mar. 31, 2019	14,014,084								$ 1,887									240,486,305								(226,474,108)
Beginning balance, shares at Mar. 31, 2019									18,867,464							2,139
Stock-based compensation expense	224,641																	224,641
Shares issued upon exercise of common stock warrants	4,845,722								$ 415									4,845,307
Shares issued upon exercise of common stock warrants, shares									4,149,445
Shares issued upon conversion of preferred stock, shares									1,326							(6)
Warrant inducement expense	1,831,116																	1,831,116
Net loss	(7,816,012)																									(7,816,012)
Ending balance at Jun. 30, 2019	13,099,551								$ 2,302									247,387,369								(234,290,120)
Ending balance, shares at Jun. 30, 2019									23,018,235							2,133
Stock-based compensation expense	297,669																	297,669
Net loss	(5,691,762)																									(5,691,762)
Ending balance at Sep. 30, 2019	$ 7,705,458								$ 2,302									$ 247,685,038								$ (239,981,882)
Ending balance, shares at Sep. 30, 2019									23,018,235							2,133

Sales of Equity Securities - Additional Information (Detail) - USD ($)											1 Months Ended		3 Months Ended		9 Months Ended
	Jul. 15, 2019	May 30, 2019	May 28, 2019	Mar. 19, 2019	Mar. 11, 2019	Feb. 12, 2019	Jan. 18, 2019	Sep. 20, 2018	Aug. 13, 2018	Jan. 30, 2018	May 31, 2019	May 31, 2018	Sep. 30, 2019	Jun. 30, 2019	Sep. 30, 2019	Sep. 30, 2018	Feb. 28, 2019	Dec. 31, 2018
Class Of Stock [Line Items]
Net cash proceeds from sale of securities				$ 7,500,000			$ 2,000,000
Stock price				$ 1.37			$ 2.25	$ 3.285
Exercise price of warrants				$ 1.25		$ 1.20			$ 4.53								$ 1.20
Class of warrant or rights, term				5 years 6 months					5 years	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value		$ 1,800,000		$ 6,000,000		$ 6,800,000		$ 2,000,000	$ 8,400,000	$ 9,700,000
Aggregate units sold under right offering									11,587
Public offering, number of shares issued				5,950,000			990,000
Warrant exercisable for share of common stock				1					1
Series A Preferred Stock convertible to common stock, conversion price									$ 4.53
Net proceeds from issuance of units, net of issuance expenses								$ 2,200,000	$ 10,100,000
Common stock, par value									$ 0.0001				$ 0.0001		$ 0.0001			$ 0.0001
Public offering, number of common stock and warrants issued								642,438
Proceeds from exercise of common stock warrants											$ 4,800,000				$ 2,513,172	$ 0
Warrant inducement expense													$ 1,800,000		$ 1,800,000
Pre-funded Warrants [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock								120,000
Exercise price of warrants								$ 3.275
Change in exercise price of warrants								$ 0.01
Investor Warrants [Member]
Class Of Stock [Line Items]
Exercise price of warrants			$ 1.31
Proceeds from exercise of common stock warrants			$ 2,300,000
Number of warrant exercised			2,062,966										0	0
Cash exercise of warrants description			In order to induce the Exercising Holders to cash exercise the Investor Warrants, the Exercise Agreements provided for the issuance of new warrants, or the New Warrants, with such New Warrants to be issued in an amount equal to 75% of the number of Exercised Shares underlying any Investor Warrants that was cash exercised by July 15, 2019. The New Warrants were exercisable upon issuance and terminate on the date that is five-years and six-months following the initial exercise date.
Fair value of warrants issued			$ 1,800,000
Percentage of common stock exercised for exchange of new warrants	75.00%
Warrants exercisable date	Jul. 31, 2019		Jul. 15, 2019
Warrant [Member]
Class Of Stock [Line Items]
Aggregate warrants sold under right offering									2,549,140
Proceeds from exercise of common stock warrants											$ 2,500,000
Number of warrant exercised											2,086,479
Series A Preferred Stock [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued									11,587
Preferred stock stated value per share									$ 1,000
Maximum [Member]
Class Of Stock [Line Items]
Exercise price of warrants											$ 1.20
Maximum [Member] \| Pre-funded Warrants [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock								120,000
Maximum [Member] \| Investor Warrants [Member]
Class Of Stock [Line Items]
Warrants exercisable percentage			20.00%
Minimum [Member]
Class Of Stock [Line Items]
Exercise price of warrants											$ 1.25
Follow-on Public Offering [Member]
Class Of Stock [Line Items]
Net cash proceeds from sale of securities					$ 592,000	$ 6,600,000				$ 13,300,000
Private offering, number of common stock and warrants issued						6,250,000				1,095,153
Stock price					$ 1.20	$ 1.20				$ 13.50
Cost directly associated with offering										$ 1,400,000
Exercise price of warrants				$ 1.25		$ 1.20		$ 3.16	$ 4.53	$ 1.20
Class of warrant or rights, term				5 years 6 months		5 years		5 years	5 years	5 years
Issuance of warrants to purchase shares of common stock, grant date fair value										$ 9,700,000
Public offering, number of shares issued						6,250,000
Public offering, number of common stock and warrants issued										1,095,153
Proceeds from exercise of common stock warrants						$ 0				$ 0
Purchase of common stock by underwriters to cover overallotments, number of shares					538,867
Follow-on Public Offering [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock						6,250,000				1,095,153
Shelf Registration Statement [Member]
Class Of Stock [Line Items]
Shelf registration statement expiration period												May 31, 2021
Minimum public float limit for offering												$ 75,000,000
Shelf Registration Statement [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Aggregate offering price												$ 50,000,000
Private Placement [Member]
Class Of Stock [Line Items]
Exercise price of warrants								$ 3.16
Class of warrant or rights, term								5 years
Warrant exercisable for share of common stock								1
Over-allotment Option [Member] \| Warrant [Member]
Class Of Stock [Line Items]
Public offering, number of shares issued						915,000
Over-allotment Option [Member] \| Maximum [Member]
Class Of Stock [Line Items]
Issuance of warrants to purchase shares of common stock						937,500